As filed with the U.S. Securities and Exchange Commission on January 10, 2022

Registration Number 333-261616

  

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

___________________

AMENDMENT NO. 1 TO
FORM S-1
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933

___________________

Innovative Eyewear, Inc.

(Exact Name of Registrant as Specified in its Charter)

___________________

Florida

 

5995

 

84-2794274

(State or other jurisdiction of
incorporation or organization)

 

(Primary Standard Industrial
Classification Code Number)

 

(I.R.S. Employer
Identification No.)

8101 Biscayne Blvd., Suite 705

Miami, Florida, 33138

(786) 785-5178
(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

___________________

Harrison Gross

Chief Executive Officer 8101 Biscayne Blvd., Suite 705

Miami, Florida, 33138

(786) 785-5178
(Name, Address, Including Zip Code, and Telephone Number, Including Area Code, of Agent for Service)

___________________

with Copies to:

Barry I. Grossman, Esq.
Sarah W. Williams, Esq.
Ellenoff Grossman & Schole LLP
1345 Avenue of the Americas
New York, NY 10105
Phone: (212) 370
-1300
Fax: (212) 370
-7889

 

Leslie Marlow, Esq.
Hank Gracin, Esq.
Patrick J. Egan, Esq.
Gracin & Marlow, LLP
405 Lexington Avenue, 26
th Floor
New York, NY 10174
Phone: (212) 907
-6457
Fax: (212) 208
-4657

___________________

Approximate date of commencement of proposed sale to public:

As soon as practicable after the effective date hereof.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer    ☐

 

Accelerated filer    ☐

 

Non-accelerated filer    ☒

 

Smaller reporting company    ☒

           

Emerging growth company    ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

 

CALCULATION OF REGISTRATION FEE

Title of each class of securities to be registered

 

Proposed
maximum
aggregate
offering
price
(1)

 

Amount of
registration
fee
(2)

Units consisting of:

 

 

   

 

 

 

(i) Shares of common stock, par value $0.00001 per share(3)

 

$

17,250,000.00

 

$

 1,599.08

 

(ii) Warrants to purchase shares of common stock(4)

 

 

 

 

 

Common stock issuable upon exercise of the Warrants

 

$

17,250,000.00

 

$

1,599.08

 

Representative’s warrant(4)

 

 

 

 

 

Common stock underlying the Representative’s warrant(5)

 

$

1,138,500.00

 

$

105.54

 

Total

 

$

35,638,500.00 

 

$

3,303.70

(6)

____________

(1)      Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the “Securities Act”).

(2)      Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price.

(3)      Includes shares of common stock which may be issued on exercise of a 45-day option granted to the underwriters to cover over-allotments, if any.

(4)      No separate registration fee required pursuant to Rule 457(g) under the Securities Act.

(5)      Estimated solely for the purposes of calculating the registration fee pursuant to Rule 457(g) under the Securities Act. We have agreed to issue, upon the closing of this offering, representative’s warrants to Maxim Group LLC (or its designees) entitling it to purchase up to 6% of the aggregate shares of Common Stock in this offering. We have calculated the proposed maximum aggregate offering price of the common stock underlying the representative’s warrants by assuming that such warrants are exercisable at a price per share equal to 110% of the price per share sold in this offering.

(6)      Fee previously paid.

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission, acting pursuant to Section 8(a), may determine.

 

 

The information contained in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

PRELIMINARY PROSPECTUS

 

SUBJECT TO COMPLETION

 

DATED JANUARY 10, 2022

Innovative Eyewear, Inc.

2,857,142 Units consisting of
2,857,142 Shares of Common Stock and
2,857,142 Warrants to purchase 2,857,142 Shares of Common Stock

This is a firm commitment underwritten public offering by Innovative Eyewear, Inc., a Florida corporation (the “Company”) of units (the “Units”), each of which consisting of one share of the Company’s common stock, par value $0.00001 per share and one warrant (the “Warrant”) to purchase one share of common stock. Prior to this offering, there has been no public market for our Common Stock or Warrants, comprising the Units. We anticipate that the initial public offering price of our Units will be between $4.25 and $6.25, and the number of Units offered hereby is based upon an assumed offering price of $5.25 per Unit, the midpoint of such estimated price range.

The Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The Warrants and common stock are immediately separable and will be issued separately in this offering. Each Warrant offered hereby is immediately exercisable on the date of issuance at an exercise price of $           per Warrant (which shall not be less than 100% of the public offering price per Unit) and will expire five years from the date of issuance. The Warrants will be exercisable, at the option of the holder, in whole or in part. Each Warrant entitles the holder thereof to purchase one share of common stock, and the Warrants are not exercisable for a fractional share. A holder of a Warrant may not exercise any portion of a Warrant to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% of our outstanding shares of common stock after exercise, as such ownership percentage is determined in accordance with the terms of the Warrants, except that upon notice from the holder to us, the holder may waive such limitation up to a percentage, not in excess of 9.99%. The Warrants will not be listed for trading. To better understand the terms of the Warrants, you should carefully read the “Description of Capital Stock” section of this prospectus.

We have applied to have our shares of common stock listed on the Nasdaq Capital Market (“NASDAQ”) under the symbol “LUCY”. No assurance can be given that our application will be approved. If our common stock is not approved for listing on NASDAQ, we will not consummate this offering. There is no established trading market for any of the Warrants, and we do not expect a market to develop. We do not intend to apply for a listing for any of the Warrants on any securities exchange or other nationally recognized trading system. Without an active trading system, the liquidity of the Warrants will be limited.

We are an emerging growth company under the Jumpstart our Business Startups Act of 2012, or JOBS Act, and, as such, may elect to comply with certain reduced public company reporting requirements for this prospectus and future filings. See “Summary — Implications of Being an Emerging Growth Company.”

Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on page 14.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

Per Unit

 

Total

Initial public offering price

 

$

   

$

 

Underwriting discounts and commissions(1)

 

$

   

$

 

Proceeds to us, before expenses

 

$

   

$

 

____________

(1)       Does not include the reimbursement of certain expenses of the underwriters and warrants that we have agreed to issue to the representative of the underwriters as additional compensation. We refer you to “Underwriting” beginning on page 106 for additional information regarding underwriters’ compensation.

We have granted a 45-day option to the representative of the underwriters to purchase up to 428,571 additional shares of common stock at a price of $           per share and/or up to an additional 428,571 Warrants to purchase up to 428,571 shares of Common Stock at a price per Warrant of $0.01, in any combination thereof, less, in each case, the underwriting discounts and commissions, solely to cover over-allotments, if any. If the representative of the underwriters exercises the option in full, the total underwriting discounts and commissions will be $         and the additional proceeds to us, before expenses, from the over-allotment option exercise will be $        .

The underwriters expect to deliver the securities comprising the Units to purchasers on or about        , 2022.

Sole Book-Running Manager

Maxim Group LLC

The date of this prospectus is        , 2022

 

 

 

 

 

 

Table of Contents

 

Page

Prospectus Summary

 

2

The Offering

 

9

Summary of Financial Information

 

11

Cautionary Note Regarding Forward-Looking Statements

 

13

Risk Factors

 

14

Use of Proceeds

 

40

Dividend Policy

 

41

Capitalization

 

42

Dilution

 

44

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

47

Business

 

59

Management

 

76

Executive Compensation

 

80

Principal Stockholders

 

87

Certain Relationships and Related Party Transactions

 

89

Description of Capital Stock

 

91

Shares Eligible For Future Sale

 

95

Certain U.S. Federal Income Tax Considerations

 

97

Underwriting

 

105

Experts

 

112

Legal Matters

 

112

Where You Can Find More Information

 

112

Index to Financial Statements

 

F-1

i

About this Prospectus

We and the underwriters have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by us or on our behalf or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted or where the person making the offer or sale is not qualified to do so or to any person to whom it is not permitted to make such offer or sale. The information contained in this prospectus is current only as of the date on the front cover of the prospectus. Our business, financial condition, results of operations and prospects may have changed since that date.

Persons who come into possession of this prospectus and any applicable free writing prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus and any such free writing prospectus applicable to that jurisdiction. See “Underwriting” for additional information on these restrictions.

Industry and Market Data

Unless otherwise indicated, information in this prospectus concerning economic conditions, our industry, our markets and our competitive position is based on a variety of sources, including information from third-party industry analysts and publications and our own estimates and research. Some of the industry and market data contained in this prospectus are based on third-party industry publications. This information involves a number of assumptions, estimates and limitations.

The industry publications, surveys and forecasts and other public information generally indicate or suggest that their information has been obtained from sources believed to be reliable. None of the third-party industry publications used in this prospectus were prepared on our behalf. The industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of factors, including those described in “Risk Factors” in this prospectus. These and other factors could cause results to differ materially from those expressed in these publications.

Trademarks

This prospectus contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus may appear without the ® or TM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent possible under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by any other companies.

1

Prospectus Summary

This summary highlights certain information appearing elsewhere in this prospectus. Because it is only a summary, it does not contain all of the information that you should consider before investing in our securities and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus. Before you decide to invest in our securities, you should read the entire prospectus carefully, including “Risk Factors” beginning on page 14 and the financial statements and related notes included in this prospectus.

Unless the context indicates otherwise, as used in this prospectus, the terms “we,” “us,” “our,” “the Company,” “Innovative Eyewear” and “our business” refer to Innovative Eyewear, Inc.

This prospectus includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this prospectus are the property of their respective owners.

Our Company

Innovative Eyewear develops and sells cutting-edge eyeglasses and sunglasses, which are designed to allow our customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. The Company was founded by Lucyd Ltd. (the “Parent”), a portfolio company of Tekcapital. Tekcapital is a U.K. based university intellectual property accelerator. Tekcapital builds portfolio companies around new technologies. Innovative Eyewear licensed the exclusive rights to the Lucyd® brand (“Lucyd”), from Lucyd Ltd., which includes the exclusive use of all of Lucyd Ltd.’s intellectual property, including our main product, Lucyd Lyte® glasses (“Lucyd Lyte”).

In January 2021, Innovative Eyewear fully launched its first commercial product, Lucyd Lyte. This initial product embodies our goal of creating smart eyewear for all day wear that looks like and is priced similarly to designer eyewear, but is also light weight and comfortable, and enables the wearer to remain connected to their digital lives. The product was initially launched with six styles. In September 2021, an additional six styles were added. These twelve styles are each available with 56 different lens types, resulting in 668 variations of products currently available.

Lucyd Lyte glasses enable the wearer to listen to music, take and make calls, and use voice assistants to perform many common smartphone tasks hands-free. Some of the many things our customers can do with their Lucyd Lyte glasses include:

1.      “Send a voice message to (contact)”: this command begins the recording of an audio message to be sent to named contact.

2.      “Send a text to (contact)”: begins recording of a speech-to-text message to be sent by SMS to named contact.

3.      “Call (contact)”: speed-dials the named contact.

4.      “Send $___ to (contact)”: this command allows our user to send money to a contact via Venmo or Apple Pay. Follow the digital assistant’s prompts to confirm.

5.      “Check my messages”: this command reads out our user’s latest incoming text messages and offers a prompt to reply to each. Close out the digital assistant to end the readout.

6.      “Check my mailbox”: this command announces the number of unread emails, and reads them out with a prompt to continue after each one. In the prompt after each one, our customers can tell their digital assistant “Reply” and dictate an email response to the previous email.

7.      “Find (cuisine type) food nearby”: this command reads through a list of nearby restaurants and their ratings, and prompts our user for directions or to call after each one.

8.      “Call me an Uber”: this command prompts our user on which type of Uber ride they want, then asks to confirm to send a car to our user’s location.

9.      “What time is it?”: announces the current time.

2

10.    “Play (song/album/artist)”: this command begins playing the requested song, album or artist via Apple Music.

11.    “Get me directions to (location)”: this command begins navigating on phone, with audible directions on glasses.

12.    “Take a memo”: this command begins recording a speech-to-text memo in Notes. Say “Read my Notes” to play back.

We believe that our Upgrade Your Eyewear® approach will set the pace and pave the way for the future of the eyewear industry (“Upgrade Your Eyewear”). We also believe that traditional frames, no matter how attractive, do not possess the functionality many eyeglass wearers need and want. Smart eyewear is part of a fast-growing, technology-enhanced ecosystem, consisting of traditional eyewear, electronic in-ear devices (“hearables”) and digital assistants. Lucyd Lyte sits at the intersection of these market drivers. We view proper eyewear design and construction as a core competency for competing in this new sector. Understanding the technological capabilities of hearables and digital assistants, and our ability to effectively integrate these technologies into eyewear, is a critical element for our long-term success in the eyewear market.

Additionally, we believe smart eyewear should also enable customers to freely interact with social media. While digital assistants, once enabled, can provide some of this interaction, we believe that the ability to receive and send social media posts with your voice will greatly enhance ease of use of these platforms on the go. To facilitate this, Innovative Eyewear has developed a full stack social media application called Vyrb™ (“Vyrb”) which enables the user to receive and send posts through Lucyd Lyte smart glasses with your voice. The application launched out of beta in December 2021, and we are aiming to roll out software upgrades to Vyrb in the fourth quarter of 2022, which are currently planned to include new features like: monetization, ad-buying modules, an itemized upgrade system, and content selling capabilities for social media creators.

Innovative Eyewear believes that Vyrb will enhance the utility of current and future Lyte glasses by enabling users to keep their smart phones in their pockets and still be able to hear and make social media posts on Vyrb, which other Vyrb users will be able hear. Additionally, Vyrb offers Lucyd Lyte users external social sharing features, which allow posts made on Vyrb to be exported to other platforms such as Facebook, Twitter and Instagram. The app can also be

3

used with its visual interface on a phone or tablet, and does not require Lucyd Lyte or another “hearable” to function; however, we believe it enhances Lucyd Lyte and other hearables by enabling new voice commands that can be used through virtual assistants, such as Siri, and allowing users to interact with Vyrb and other social media platforms without looking at their phone or tablet.

Additionally, we are designing Vyrb to host audiobooks, podcasts and entire music albums on the platform. With Vyrb, Lucyd Lyte customers will be able to hear their social media feeds, post messages, hold gatherings and musical performances, and enjoy social media with the authenticity of their own voice: all through their eyewear and without taking their phone out of their pocket.

Our Market Opportunity

According to Statista, the total addressable market for eyewear in the U.S. is projected to be $28.3 billion in 2021. The market for digital assistants like Siri, Google Voice, Bixby and Alexa has grown rapidly in North America, and had $2.5 billion in revenue in 2020. In the U.S., our primary market, the hearables market is projected to be $5.1 billion in 2021. We view the popularity of hearables and digital assistants as important catalysts for the smart eyewear market.

The common denominator among markets for the hearables and digital assistant is that they facilitate real-time access to digital data, whether it is through music, calls, navigational directions, or information, among other uses. The combination of hearables and digital assistants provides a transparent, ergonomic interface between the users and their digital lives. At Innovative Eyewear, we are dedicated to a touch-free interface and untethering your eyes from your smartphone’s screen, all with the simplicity and elegance of our carefully designed eyewear.

The synergistic fusion of these three markets enables, in our view, an opportunity to create a completely new experience of connected eyewear, which smoothly delivers the functionality of both optical glasses and headphones, eliminating the need for either on its own. Nevertheless, we believe that several orthodoxies of the eyewear industry still hold, namely: if you want to sell a lot of eyewear, it should be attractive, comfortable (e.g., light weight, which we believe to be approximately 1 oz.) and cost roughly the same as traditional eyewear. This is what we sought to achieve, and in our view accomplished with the introduction of Lucyd Lyte eyewear.

____________

1         https://www.statista.com/outlook/cmo/eyewear/united-states

          https://www.grandviewresearch.com/industry-analysis/intelligent-virtual-assistant-industry

          https://www.globenewswire.com/news-release/2021/07/29/2270984/0/en/Global-Wireless-Headphones-Market-to-
Reach-45-7-Billion-by-2026.html

4

Our Business Strategy

When we started Innovative Eyewear, we believed that there were no attractive smart glasses that addressed the basic consumer need for good looking designer glasses that were comfortable, lightweight, and provided the functionality of hearables, and priced around the same as regular glasses. To meet this need, we decided to create products that we believed addressed all of these areas.

All of our products are designed in Miami, manufactured in China and sold through multiple ecommerce channels, including on our website (Lucyd.co), BestBuy.com, DickSportingGoods.com and Amazon.com, or through optical retailers (such as, but not limited to, Metro Optics Eyewear). We believe this capital light approach is highly scalable and efficient in the deployment of resources.

Since we understand that customers are particular about what they wear on their faces, and because customers come in every shape, size and design sensibility, we aim to continuously introduce new models in an effort to offer a wide variety of designs for myriad applications.

Competition

The smart eyewear industry in which we operate is highly competitive and rapidly evolving. While we believe that our products, which are an amalgam of optical quality eyeglasses and Bluetooth audio technology, provide a unique, designer format that is feature rich and competitively priced, we face competition from many different entities currently and likely will in the future. Our competitors’ products may have attributes and structural capabilities that we are unable to currently duplicate. Specifically, these may include:

Experience in designing, producing, and selling smart eyewear and consumer electronic products.    All of our key competitors have significantly longer experience designing and selling smart eyewear. As a result they are likely to have better developed design, manufacturing and production experience.

Brand awareness and marketing know-how.    Most of our competitors have storied brands that they can leverage to accelerate market awareness and encourage early adopters to evaluate and purchase their products.

Channel development and product placement.    Many of our competitors have long-standing relationships with retail and ecommerce distribution channels which gives them an advantage for market penetration, certainly in the near-term and perhaps over time as well.

Captive retail distribution.    At least one of our competitors has their own company-owned retail distribution channel which enhances their ability to bring smart eyewear to a large audience at an incremental cost.

Financial resources.    All of our competitors have significantly greater financial resources which they can put in harness towards research and development and sales and marketing to develop and sell an enhanced product at a favorable price.

Our Competitive Strengths

A Unique Solution to a Common Problem.    We believe that the distraction created by smartphones originates in two forms: (1) via headphones or earbuds, where the user is deprived of full audible situational awareness; and, (2) via the visual interface of the phone, which distracts the user completely from their surroundings. Many of our competitors have relatively bulky speakers enclosed within the temples, while Lucyd Lyte’s speakers and temples are thin, which allows them to look similar to traditional designer glasses.

Affordable Price Point.    The manufacturer’s suggested retail price for Lucyd Lyte eyewear starts at $149. Most of our U.S. based competitors are significantly more expensive, starting at $249 or higher.

Quality. All of our frames can be outfitted in-house or by optical resellers with any combination of the following: prescription, sunglass, readers and blue light formats. Our frame fronts are made with what we believe are high quality optical materials to ensure easy lens fitting by any optician.

5

Customizable Product Offering.    There are 56 lens types available for Lucyd Lyte, making it one of the most customizable smart eyewear in the world. Innovative Eyewear has a long-standing partnership with a high-quality optical lab in Boston to produce prescription and custom lenses for our frames quickly and affordably. Our contract with a third-party lab also allows us to offer direct fulfillment to our customers.

Comfort.    At just 1.0-1.45 ounces, our eyewear has a feather-light fit, suitable for all day vision correction.

Long battery life.    At 6.5-8 hours of playback per charge, Lucyd eyewear outpaces most if not all of the competition on battery life.

Capital light business model.    All of our products are sold through multiple ecommerce channels, including on our website (Lucyd.co), BestBuy.com, DickSportingGoods.com and Amazon.com, or through optical or other retailers that maintain traditional brick and mortar retail stores (such as, but not limited to, Metro Optics Eyewear and Marca Eyewear Group, Inc.). We believe this capital light approach is highly scalable and efficient in the deployment of resources. We view “capital light” as being more efficient, by obviating the need to build factories and retail stores, but rather contract with both.

Multi-channel approach.    We sell our products both through multiple online channels and multiple categories of brick-and-mortar retail stores. We believe this multi-channel approach provides us with an advantage against our competitors who either solely sell their products online or in brick-and-mortar retail stores.

Experienced management team.    We have an experienced board of directors with more than 80 years of combined experience in the eyewear industry and a management team with substantial experience with operating eyewear and technology companies.

Risks Associated with our Business

Our business and ability to execute our business strategy are subject to a number of risks of which you should be aware before you decide to buy our common stock. In particular, you should carefully consider the following risks, which are discussed more fully in the section entitled “Risk Factors” in this prospectus:

•        The optical industry is highly competitive, and if we do not compete successfully, our business may be adversely impacted.

•        We have a history of losses, and we may be unable to achieve or sustain profitability.

•        The reports of our independent registered public accounting firm for the fiscal years ended December 31, 2019 and 2020 contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.

•        We have limited experience in scaling a smart eyewear business. If we are unable to manage our expected growth effectively, our brand, and financial performance may suffer, which may have a material adverse effect on our business, financial condition, and operating results.

•        Increases in component costs, shipping costs, long lead times, supply shortages, and supply changes could disrupt our supply chain; factors such as wage rate increases and inflation can have a material adverse effect on our business, financial condition, and operating results.

•        We currently derive all of our revenue from sales of our glasses. A decline in sales of our eyewear would negatively affect our business, financial condition, and results of operation.

•        We face significant risks due to our dependency on foreign supply and manufacturing chains, geopolitical and economic changes, and changes in public perception about internationally sourced and manufactured products.

•        We rely on a limited number of contract manufacturers and logistics partners for our products. A loss of any of these partners could negatively affect our business.

•        If we fail to cost-effectively retain our existing customers or to acquire new customers, our business, financial condition, and results of operations would be harmed.

6

•        Eyeglasses are regulated as medical devices by the FDA, and our failure, or the failure of any third-party manufacturer or optical laboratory, to obtain and maintain the necessary marketing authorizations for our products could have a material adverse effect on our business.

•        Our profitability and cash flows may be negatively affected if we are not successful in managing our supply chain and customer demands for product deliveries.

•        If we fail to maintain and enhance our brand, our ability to engage or expand our base of customers will be impaired, and our business, financial condition, and results of operations may suffer.

•        We rely heavily on our information technology systems, as well as those of our third-party vendors, business partners, and service providers, for our business to effectively operate and to safeguard confidential information; any significant failure, inadequacy, interruption, or data security incident could adversely affect our business, financial condition, and operations.

•        Our multichannel channel business faces distinct risks, and our failure to successfully manage it could have a negative impact on our profitability.

•        The COVID-19 pandemic has had, and may in the future continue to have, a material adverse impact on our business.

•        If we fail to adapt and respond effectively to rapidly changing technology, evolving industry standards and changing customer needs or requirements, our solutions may become less competitive.

•        We depend on highly skilled personnel to grow and operate our business, and if we are unable to hire, retain, and motivate our personnel, we may not be able to grow effectively.

•        A decline in sales of our eyewear would negatively affect our business, financial condition, and results of operations.

•        We could be adversely affected by product liability, product recall or personal injury issues.

•        We license our technology from Lucyd Ltd., the majority stockholder of the Company, and our inability to maintain this license could materially affect our business, financial condition, and operating results.

•        Failure to adequately maintain and protect our intellectual property and proprietary rights could harm our brand, devalue our proprietary content, and adversely affect our ability to compete effectively.

•        We may incur costs to defend against, face liability or for being vulnerable to intellectual property infringement claims brought against us by others.

•        We face risks associated with suppliers from whom our products are sourced and are dependent on a limited number of suppliers.

•        Our projects could be hindered due to our dependence on third parties to complete many of our contracts.

•        We depend on search engines, social media platforms, digital application stores, content-based online advertising, and other online sources to attract consumers to and promote our website and our mobile applications, which may be affected by third-party interference beyond our control; and, as we grow, our the cost of acquiring new customers may continue to rise and become uneconomical.

•        Our directors, executive officers and principal stockholders will continue to have substantial control over our company after this offering, which could limit your ability to influence the outcome of key transactions, including a change of control.

Corporate Information

We were initially organized as a limited liability company under the laws of the State of Florida on August 15, 2019. We converted the Company from a Florida limited liability company into a Florida corporation on March 25, 2020. Our principal executive office is located at 8101 Biscayne Blvd., Suite 705, Miami, FL, 33126, and our phone number

7

is (786) 785-5178. We maintain a website at www.lucyd.co. Following the effectiveness of the registration statement of which this prospectus is a part, we intend to announce material information to the public through filings with the SEC, the investor relations page of our website, as well as press releases, public conference calls, and investor conferences.

The reference to our website is intended to be an inactive textual reference only. The information contained on, or that can be accessed through, our website is not part of this prospectus and investors should not rely on such information in deciding whether to purchase shares of our common stock.

Our “Lucyd” logo, the Lucyd Lyte name and the slogan “Upgrade your Eyewear” and our other registered or common law trademarks mentioned in this prospectus are the exclusive licensed property of Innovative Eyewear Inc. Other trade names, trademarks, and service used in this prospectus are the property of their respective owners.

Implications of Being an Emerging Growth Company

We qualify as an “emerging growth company” as defined under the Securities Act of 1933, as amended (the “Securities Act”). As a result, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements that are otherwise applicable to public companies. These provisions include, but are not limited to:

•        being permitted to present only two years of audited financial statements and only two years of related “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in this prospectus;

•        not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (or the Sarbanes-Oxley Act);

•        reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and

•        exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.

In addition, an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this extended transition period. We will remain an emerging growth company until the earliest to occur of: (i) our reporting $1.07 billion or more in annual gross revenues; (ii) the end of fiscal year 2026; (iii) our issuance, in a three year period, of more than $1 billion in non-convertible debt; and (iv) the end of the fiscal year in which the market value of our common stock held by non-affiliates exceeded $700 million on the last business day of our second fiscal quarter.

We have elected to take advantage of certain of the reduced disclosure obligations and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than the information you might receive from other public reporting companies in which you hold equity interests.

To the extent that we continue to qualify as a “smaller reporting company,” as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, after we cease to qualify as an “emerging growth company,” certain of the exemptions available to us as an “emerging growth company” may continue to be available to us as a smaller reporting company, including: (1) not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act; (2) scaled executive compensation disclosures; and (3) the ability to provide only two years of audited financial statements, instead of three years.

8

The Offering

Units offered by us

 

2,857,142 Units, assuming a public offering price of $5.25 per Unit, the midpoint of the initial public offering price range reflected on the cover page of this prospectus. Each Unit will consist of one share of common stock and one Warrant to purchase one share of common stock. The Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The shares of common stock and Warrants are immediately separable and will be issued separately in this offering.

Common stock outstanding immediately before this offering

 


6,113,220 shares of common stock

Common stock to be outstanding after this offering(1)

 


8,970,362 shares of common stock (or 9,398,933 shares of common stock if the underwriters exercise their option to purchase additional shares of common stock and/or additional Warrants in full, and assuming in each case no exercise of the Warrants).

Option to purchase additional shares of common stock and/or Warrants

 


We have granted to the underwriters an option exercisable for a period of 45 days from the date of this prospectus to purchase an aggregate of up to an additional 428,571 shares of common stock at the initial public offering price per share less the underwriting discounts and commissions and/or up to 428,571 additional Warrants to purchase up to 428,571 shares of common stock, in any combination thereof.

Use of proceeds

 

We estimate that the net proceeds to us from this offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately $13 million, based on the assumed initial public offering price of $5.25 per share, which is the midpoint of the price range set forth on the cover page of this prospectus. Approximately $13 million of the net proceeds received by us from this offering will be used for (i) sales and marketing, (ii) expanding our inventory, (iii) updating and producing our in-store displays, (iv) development of new styles and sizes of our smart eyewear and (v) working capital and general purposes. We may also use a portion of the net proceeds to acquire, license and invest in complementary products, technologies or additional businesses; however, we currently have no agreements or commitments to complete any such transaction. See “Use of Proceeds.”

Description of the Warrants

 

The Warrants will have an exercise price of $         per share of common stock (which shall not be less than 100% of the public offering price per Unit), will be immediately exercisable and will expire five years from the date of issuance. Each Warrant is exercisable for one share of common stock, subject to adjustment in the event of stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting our common stock. A holder may not exercise any portion of a Warrant to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% of our outstanding shares of common stock after exercise, as such ownership percentage is determined in accordance with the terms of the Warrants, except that upon notice from the holder to us, the holder may waive such limitation up to a percentage, not in excess of 9.99%. This prospectus also relates to the offering of the common stock issuable upon exercise of the Warrants. To better understand the terms of the Warrants, you should carefully read the “Description of Capital Stock” section of this prospectus. You should also read the form of Warrant, which is filed as an exhibit to the registration statement that includes this prospectus.

9

Concentration of ownership

 

Upon completion of this offering, our executive officers and directors, and Lucyd Ltd. will beneficially own, in the aggregate, approximately 55% of the outstanding shares of our common stock.

Nasdaq Symbol and Trading

 

We have applied to list our common stock on the Nasdaq Capital Market under the ticker symbol “LUCY.” No assurance can be given that our application will be approved. We do not intend to apply for a listing for any of the Warrants on any securities exchange or other nationally recognized trading system.

Risk Factors

 

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 14 and the other information in this prospectus for a discussion of the factors you should consider carefully before you decide to invest in our Common Stock and warrants.

Lock-Up

 

In connection with this offering, we, our directors, executive officers, and certain stockholders holding one percent (1%) or more of our common stock have agreed not to offer, issue, sell, contract to sell, encumber, grant any option for the sale of or otherwise dispose of any of our securities for a period of six (6) months following the closing of the offering of the shares. See “Underwriting” for more information.

Representative’s warrants

 

We will issue to Maxim Group LLC, as the representative of the underwriters, upon closing of this offering compensation warrants entitling the underwriters or their designees to purchase up to six percent (6%) of the aggregate number of shares of our Common Stock that we issue to investors in this offering. The warrants are exercisable for a four-and-one-half year period commencing 180 days following the commencement of sales of the common stock in this offering. The warrants will have an exercise price per share equal to 110% of the public offering price of our shares of Common Stock offered hereby. See “Underwriting — Representative’s Warrants.”

____________

(1)      The number of shares of our common stock to be outstanding immediately after this offering is based on shares of our common stock outstanding as of January 5, 2022, which gives effect to the conversion of outstanding convertible promissory notes, (the “Notes”), into 53,930 shares of common stock, and exclude:

•        2,332,500 shares of common stock issuable upon exercise of stock options, at a weighted average exercise price of $2.59 per share; and

•                     shares of our common stock reserved for future issuance under our 2021 Equity Incentive Plan (which is equal to 20% of our issued and outstanding common stock immediately after the consummation of this offering, less the number of outstanding option grants).

Unless otherwise indicated, this prospectus reflects and assumes the following:

•        Conversion of the Notes upon the closing of this offering into an aggregate of 53,930 shares of our common stock at an assumed conversion price of $5.25 per share, which is the assumed offering price;

•        No exercise of the Warrants included in the Units offered hereby; and

•        No exercise by the underwriters of its over-allotment option; and

•        No exercise of the Representative’s warrants.

10

Summary of Financial Information

The following tables present our summary financial data and should be read together with our financial statements and accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” appearing elsewhere in this prospectus. The summary financial data for the years ended December 31, 2020 and 2019 are derived from our audited annual financial statements, which are included elsewhere in this prospectus. The unaudited summary financial data as of September 30, 2021 and for the nine months ended September 30, 2021 have been derived from our unaudited interim financial statements, which are included elsewhere in this prospectus, and include all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of our financial position and results of operations for these periods.

Statement of Operations Data:

 

Nine months
ended
September 30,
2021

 

Year ended
December 31,
2020

 

Nine months
ended
September 30,
2020

   

(unaudited)

 

(audited)

 

(unaudited)

Revenues, net

 

415,185

 

 

56,997

 

 

33,592

 

Less: Cost of Goods Sold

 

(332,378

)

 

(74,266

)

 

(34,783

)

Gross Profit (Loss)

 

82,807

 

 

(17,269

)

 

(1,191

)

     

 

   

 

   

 

Operating expenses:

   

 

   

 

   

 

General & administrative

 

(883,356

)

 

(316,115

)

 

(210,509

)

Impairment expense

 

 

 

(112,329

)

 

(112,329

)

Sales and marketing

 

(903,795

)

 

(152,731

)

 

(98,789

)

Related party management fee

 

(84,975

)

 

(130,000

)

 

(102,475

)

Research and development

 

(36,121

)

 

(36,894

)

 

(30,822

)

Total Operating Expenses

 

(1,908,247

)

 

(748,069

)

 

(554,924

)

     

 

   

 

   

 

Other Income

 

 

 

2,120

 

 

 

Interest Expense

 

(33,654

)

 

(4,966

)

 

 

Total Other Income/(Expense)

 

(33,654

)

 

(2,846

)

 

 

     

 

   

 

   

 

Net Loss

 

(1,859,094

)

 

(768,184

)

 

(556,115

)

     

 

   

 

   

 

Weighted average number of shares outstanding

 

5,033,823

 

 

2,960,289

 

 

2,602,987

 

Earnings per share, basic and diluted

 

(0.37

)

 

(0.26

)

 

(0.21

)

Cash Flow Data:

 

Nine months
ended
September 30,
2021

 

Nine months
ended
September 30,
2020

   

(unaudited)

 

(unaudited)

Net cash flows from operating activities

 

(810,446

)

 

(3,672

)

Net cash flows from investing activities

 

(87,246

)

 

(29,634

)

Net cash flows from financing activities

 

935,725

 

 

62,769

 

Net Change in Cash

 

38,033

 

 

29,463

 

11

Balance Sheet Data:

 

As of
September 30,
2021

 

As of
December 31,
2020

   

(unaudited)

 

(audited)

Non Current Assets

 

150,241

 

 

69,213

 

Current Assets

 

546,223

 

 

141,803

 

Current Liabilities

 

(665,593

)

 

(765,853

)

Total Equity/(Deficit)

 

30,871

 

 

(554,837

)

12

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this prospectus may contain “forward-looking statements” within the meaning of the federal securities laws. Our forward-looking statements include, but are not limited to, statements about us and our industry, as well as statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. Additionally, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. We intend the forward-looking statements to be covered by the safe harbor provisions of the federal securities laws. Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, as well as statements in future tense, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to significant risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to:

•        our lack of operating history;

•        our expected use of proceeds from this offering and relationships with our current customers;

•        our expectations regarding the time during which we will be an emerging growth company under the JOBS Act;

•        our estimates regarding future revenue, expenses and needs for additional financing;

•        our ability to compete in our industry;

•        our ability to expand the number of retail stores that sell our products;

•        our ability to expand the production of our products;

•        the impact of governmental laws and regulation;

•        difficulties with certain vendors, suppliers and distributors we rely on or will rely on;

•        failure to maintain our corporate culture as we grow and changes in consumer recognition of our brand;

•        changes in senior management, loss of one or more key personnel or an inability to attract, hire, integrate and retain highly skilled personnel;

•        the ability of our product to perform in a safe and efficient manner; and

•        our ability to adapt and respond effectively to rapidly changing technology, evolving industry standards and changing customer needs or requirements.

The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with. Forward-looking statements necessarily involve risks and uncertainties, and our actual results could differ materially from those anticipated in the forward-looking statements due to a number of factors, including those set forth under the section of this prospectus entitled “Risk Factors” elsewhere in this prospectus. The factors set forth under the “Risk Factors” section and other cautionary statements made in this prospectus should be read and understood as being applicable to all related forward-looking statements wherever they appear in this prospectus. The forward-looking statements contained in this prospectus represent our judgment as of the date of this prospectus. We caution readers not to place undue reliance on such statements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained above and throughout this prospectus.

13

Risk Factors

Any investment in our securities involves a high degree of risk. You should carefully consider the risks described below, which we believe represent certain of the material risks to our business, together with the information contained elsewhere in this prospectus, before you make a decision to invest in our securities. Please note that the risks highlighted here are not the only ones that we may face. For example, additional risks presently unknown to us or that we currently consider immaterial or unlikely to occur could also impair our operations. If any of the following events occur or any additional risks presently unknown to us actually occur, our business, financial condition and operating results may be materially adversely affected. In that event, the trading price of our securities could decline and you could lose all or part of your investment.

Risks Relating to Our Business, Strategy and Industry

The optical industry is highly competitive, and if we do not compete successfully, our business may be adversely impacted.

We compete directly with large, integrated optical players that sell both at the retail level and online such as Ray-Ban® that have multiple products, well regarded brands and retail banners, as well as established and well-regarded consumer electronics companies such as Bose®. This diversified and capable competition takes place both in physical retail locations as well as online, for smart glasses. To compete effectively, we must continue to create, invest in, or acquire, advanced technology, incorporate this technology into our products, obtain regulatory approvals in a timely manner where required, and process and successfully market our products.

Most if not all of our competitors have significantly greater financial and operational resources, longer operating histories, greater brand recognition, and broader geographic presence than we do. As a result, they may be able to outmaneuver us in the marketplace and offer capable products at more competitive prices, which may adversely affect our business. They also are able to spend far more than we do for advertising. We may be at a substantial disadvantage to larger competitors with greater economies of scale. If our costs are greater compared to those of our competitors, the pricing of our products may not be as attractive, thus depressing sales or the profitability of our products and services. Our competitors may expand into markets in which we currently operate and we remain vulnerable to the marketing power and high level of customer recognition of these larger competitors and to the risk that these competitors or others could attract our customer base. Some of our competitors are vertically integrated and are also engaged in the manufacture and distribution of glasses and many of our competitors operate under a variety of brands and price points. These competitors can advantageously leverage this structure to better compete and access the market with significant market power could to make it more difficult for us to compete. We purchase some of our product components from suppliers who may be affiliates of one or more competitors or may compete with ourselves in the future.

We may not continue to be able to successfully compete against existing or future competitors. Our inability to respond effectively to competitive pressures, improved performance by our competitors, and changes in the retail and ecommerce markets could result in lost market share and have a material adverse effect on our business, financial condition, and results of operations.

We have a history of losses, and we may be unable to achieve or sustain profitability.

We had a net loss of $768,184 for the year ended December 31, 2020 and $1,859,094 for the nine months ended September 30, 2021 and have in the past had net losses. As of September 30, 2021, we had an accumulated deficit of $3,238,742. Because we have a short operating history it is difficult for us to predict our future operating results. We will need to generate and sustain increased revenue and manage our costs to achieve profitability. Even if we do, we may not be able become or increase our profitability.

Our ability to generate profit depends on our ability to strengthen and expand our brand, continue to provide exciting products customers love, expand sales and improve margins. We are aiming to achieve profitability in the next two years, and between now and then we plan to efficiently invest in the business to bring it to scale by:

•        enhancing our products with new designs, functionality, and technology to widen our appeal and delight customers in a wide variety of demographic groups; and,

14

•        investing in our product development, supply chain and sales and marketing capabilities to leverage external resources as efficiently as possible to ensure that smart glasses are affordable for the majority of the world’s population who need them.

However, we may not succeed in any of the foregoing, and the planned investments may not result in profitability.

The reports of our independent registered public accounting firm for the fiscal years ended December 31, 2019 and 2020 contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern.

Due to the uncertainty of our ability to meet our current operating and capital expenses, in their report on our audited annual financial statements as of and for the years ended December 31, 2019 and December 31, 2020, our independent auditors included an explanatory paragraph regarding concerns about our ability to continue as a going concern. Substantial doubt about our ability to continue as a going concern may materially and adversely affect the price per share of our common stock and we may have a more difficult time obtaining financing. Further, the perception that we may be unable to continue as a going concern may impede our ability to raise additional funds or operate our business due to concerns regarding our ability to discharge our contractual obligations.

We have limited experience in the smart eyewear space. If we are unable to manage our growth effectively, our brand “Lucyd”, and our financial performance may suffer, which may have a material adverse effect on our business, financial condition, and operating results.

The smart eyewear industry is newly emerging. Whilst our directors have more than 80 years of combined experience in the eyewear industry, the smart eyewear market presents numerous new challenges. To effectively manage these challenges and continue to grow, we must continue to invest in the design of new frames and technology, expand our product line and effectively integrate several new technologies into eyewear. Achieving this could strain our existing resources, and we could experience ongoing operating difficulties in managing our business and bringing it to scale. Failure to scale could harm our competitive position and future success, including our ability to retain and recruit personnel and to effectively execute our corporate objectives.

Our ability to generate net revenue will depend upon many factors, some of which we may have no control over.

The industry for stylish, affordable smart glasses, is rapidly evolving and may not develop as we expect. Even if our net revenue continues to increase, our net revenue growth rates may decline in the future as a result of a variety of factors, including macroeconomic factors, increased competition, and the maturation of our business. As a result, you should not rely on our net revenue growth rate for any prior period as an indication of our future performance. Overall growth of our net revenue will depend on a number of factors, including our ability to:

•        Increase exogenous distribution of our products in optical stores, big box retailers, specialty retailers and through multiple ecommerce channels;

•        Price our products so that we are able to attract new customers, and expand our relationships with existing customers;

•        Accurately forecast our net revenue and plan our operating expenses accordingly;

•        Successfully compete with other companies that are currently in, or may in the future enter, the smart eyewear industry or the markets in which we compete, and respond to developments from these competitors such as pricing changes and the introduction of new products and features, noting that most, if not all, of our competitors have stronger balance sheets and larger staffs to devote to their products;

•        Comply with existing and new laws and regulations applicable to our business;

•        Develop new product offerings, with services and features, including in response to new trends, competitive dynamics, or the needs of customers;

•        Successfully identify and acquire or invest in businesses, products, or technologies that we believe could complement or expand our business;

•        Avoid interruptions or disruptions in our supply chain from natural disasters and political uncertainty;

15

•        Provide customers with a high-quality experience and customer service and support that meets their needs;

•        Hire, integrate, and retain talented sales, customer experience, product design, and development and other personnel;

•        Effectively manage growth of our business, personnel, and operations;

•        Effectively manage our costs related to our business and operations; and,

•        Enhance our reputation and the value of the Lucyd brand.

Because we have a limited history operating our business, it is difficult to evaluate our current business and future prospects, including our ability to plan for and model future growth. Our limited operating experience combined with the rapidly evolving nature of the market in which we sell our products and services, substantial uncertainty concerning how these markets may develop, and other economic factors beyond our control, reduces our ability to accurately forecast quarterly or annual revenue. Failure to manage our future growth effectively could have an adverse effect on our business, financial condition, and operating results.

We also expect to continue to expend substantial financial and other resources to grow our business, and we may fail to allocate our resources in a manner that results in increased net revenue growth in our business. Additionally, we may encounter unforeseen operating expenses, difficulties, complications, delays, and other unknown factors that may result in losses in future periods. If our net revenue growth does not meet our expectations in future periods, our business, financial condition, and results of operations may be harmed, and we may not achieve or sustain profitability in the future.

Increases in component costs, shipping costs, long lead times, supply shortages, and supply changes could disrupt our supply chain and factors such as wage rate increases and inflation can have a material adverse effect on our business, financial condition, and operating results.

Meeting customer demand partially depends on our ability to obtain timely and adequate delivery of components for our products and services. All of the components that go into the manufacturing of our products and services are sourced from a limited number of third-party suppliers predominantly in the U.S., and China. Our contract manufacturers purchase and provide many of these components on our behalf, including sun lenses, demo lenses, hinge and chip sets and other electronic components, and we do not have long-term arrangements with most of our component suppliers. We are therefore subject to the risk of shortages and long lead times in the supply of these components and the risk that our suppliers discontinue or modify components used in our products. In addition, the lead times associated with certain components are lengthy and may preclude rapid changes in design, quantities, and delivery schedules. Our ability to meet temporary unforeseen increases in demand has been, and may in the future be, impacted by our reliance on the availability of components from these suppliers. We may in the future experience component shortages, and the predictability of the availability of these components may be limited, which may be heightened in light of the ongoing COVID-19 pandemic. In the event of a component shortage or supply interruption from suppliers of these components, we may not be able to develop alternate sources in a timely manner. Developing alternate sources of supply for these components may be time-consuming, difficult, and costly, and we may not be able to source these components on terms that are acceptable to us, or at all, which may undermine our ability to fill our orders in a timely manner. Any interruption or delay in the supply of any of these parts or components, or the inability to obtain these parts or components from alternate sources at acceptable prices and within a reasonable amount of time, would harm our ability to timely ship our products to our customers.

In addition, substantially all of our components are shipped directly from our contract manufacturers to our warehouse facility in Miami or to a third party optical laboratory in the United States, where lenses are cut and mounted into frames. These laboratories process most of the glasses ordered by our customers. Once processed at the laboratories, the finished products are then sorted and shipped using third-party carriers to our customers. Our eyeglasses are also shipped directly to our third-party distribution center in the United States for shipment directly to our customers and resellers. We depend in large part on the orderly operation of this distribution process, which depends, in turn, on adherence to shipping schedules and effective management of our optical laboratory network and third-party distribution center. Increases in transportation costs (including increases in fuel costs), issues with overseas shipments,

16

supplier-side delays, as well as reductions in the transportation capacity of carriers, labor strikes or shortages in the transportation industry, disruptions to the national and international transportation infrastructure, and unexpected delivery interruptions or delays also have the potential to derail our distribution process.

Moreover, volatile economic conditions may make it more likely that our suppliers and logistics providers may be unable to timely deliver supplies, or at all, and there is no guarantee that we will be able to timely locate alternative suppliers of comparable quality at an acceptable price. In addition, international supply chains may be impacted by events outside of our control, including but not limited to the COVID-19 pandemic, and limit our ability to procure timely delivery of supplies or finished goods and services. We face additional risks related to the manufacturing facility we contract with in China and suppliers in China, including port of entry risks such as longshoremen strikes, import restrictions, foreign government regulations, trade restrictions, customs, and duties.

We source components from suppliers located in China. Effective September 1, 2019, the U.S. government implemented a 15% tariff on specified products imported into the U.S. from China and effective February 14, 2020, the 15% tariff was reduced to 7.5%. In June 2020, the U.S. government granted a temporary exclusion for plastic and metal frames with a retroactive effective date of September 1, 2019, and such exclusion expired in September 2020. Given the recent change in the U.S. presidential administration, there is uncertainty whether there will be, and the resulting impacts of, any changes to U.S. government trade policy. If we are unable to mitigate the full impact of the enacted tariffs or if there is a further escalation of tariffs, costs on a significant portion of our products may increase further and our financial results may be negatively affected. While it is too early to predict how the current and future China tariffs will impact our business, our financial results may also be impacted by any resulting economic slowdown.

The inability to fulfill, or any delays in processing, customer orders through third party optical laboratory optical laboratory could result in the loss of customers, issuances of refunds or credits, and may also adversely affect our income and reputation. The success of our retail and e-commerce sales depends on the timely receipt of products by our customers and any repeated, intermittent or long-term disruption in, or failures of, the operations of our distribution center and/or optical laboratories could result in lower sales and profitability, a loss of loyalty to our brands, and excess inventory.

Furthermore, increases in compensation, wage pressure, and other expenses for our employees, may adversely affect our profitability. Increases in minimum wages and other wage and hour regulations can exacerbate this risk. These cost increases may be the result of inflationary pressures which could further reduce our sales or profitability. Increases in other operating costs, may increase our cost of products sold or selling, general, and administrative expenses. Our competitive price model and pricing pressures in the optical retail industry may inhibit our ability to reflect these increased costs in the prices of our products, in which case such increased costs could have a material adverse effect on our business, financial condition, and results of operations.

We currently derive all of our revenue from sales of our glasses. A decline in sales of our eyewear would negatively affect our business, financial condition, and results of operations.

We derive all of our revenue from the sale of one product line, our Lucyd Lyte smart eyewear. Our glasses are sold in highly competitive markets with limited barriers to entry. Introduction by competitors of comparable products at lower price points, a maturing product lifecycle, a decline in consumer spending, or other factors could result in a material decline in our revenue. Because we derive most of our revenue from the sale of our glasses, any material decline in sales of our glasses would have a material adverse impact on our business, financial condition, and operating results.

We face significant risks due to our dependency on foreign supply and manufacturing chains, geopolitical and economic changes, and changes in public perception about internationally sourced and manufactured products.

Since our component materials are sourced in China, our production may face additional risks such as, but not limited to: increased shipping costs, imposition of additional import or trade restrictions, increased custom duties and tariffs, legal or economic restrictions on our supplier and manufacturer’s ability to meet our needs, unforeseen delays in customs clearance of goods, transportation delays, issues with ports of entry, new and adverse foreign government regulations, political instability, war, natural disasters, and overall economic uncertainty. Our overseas sourcing and manufacturing could also suffer due to health-related concerns surrounding infectious diseases, such the ongoing COVID-19 pandemic. Public opinion about internationally sourced and manufactured products could be changed by negative press, which could have an impact on our customers’ confidence and satisfaction, and could also have a negative impact on our public image and brand perception.

17

If we fail to cost-effectively retain our existing customers or to acquire new customers, our business, financial condition, and results of operations would be harmed.

The growth of our business is dependent upon our ability to continue to grow by cost-effectively retaining our existing customers and adding new customers. Although we believe that many customers originate from word-of-mouth and paid and non-paid referrals, we expect to continue to expend resources and run marketing campaigns to acquire additional customers, all of which could impact our overall profitability. If we are not able to continue to expand our customer base, or fail to retain customers, our net revenue will grow slower than expected or decline.

The growth of our e-commerce channel is critical to our continued customer retention and growth. Historically, consumers have been slower to adopt online shopping for glasses than e-commerce offerings in other industries such as consumer electronics and apparel. Improving upon the consumer in-store experience through an online platform is difficult due to broad consumer demands on selection, quality, convenience, and affordability. Changing traditional optical retail habits is difficult, and if consumers and retailers do not embrace smart eyewear as we expect, our business and operations could be harmed.

Our ability to attract new customers and increase net revenue from existing customers also depends in large part on our ability to enhance and improve our existing products and to introduce new products and services, in each case, in a timely manner. We also must be able to identify and originate styles and trends as well as to anticipate and react to changing consumer demands in a timely manner. The success of new and/or enhanced products and services depends on several factors, including their timely introduction and completion, sufficient demand, and cost-effectiveness. New products that we develop may not be well received and could negatively impact our financial performance.

Our number of customers may decline materially or fluctuate as a result of many factors, including, among other things:

•        the quality, consumer appeal, price, and reliability of products and services offered by us;

•        intense competition in the optical retail industry by better financed participants;

•        negative publicity related to our brand or brand influencers;

•        the impact of the COVID-19 pandemic or a future outbreak of disease or similar public health concern;

•        customer dissatisfaction with changes we make to our products and services.

In addition, if we are unable to provide high-quality support to customers or help resolve issues in a timely and acceptable manner, our ability to attract new customers and retain customers could be adversely affected. If our number of customers declines or fluctuates for any of these reasons among others, our business would suffer.

Our profitability and cash flows may be negatively affected if we are not successful in managing our inventory balances and inventory shrinkage.

Efficient inventory management is a key component of our business success and profitability. To be successful, we must maintain sufficient inventory levels to meet our customers’ demands without allowing those levels to increase to such an extent that the costs to hold the goods unduly impact our financial results. We must balance the need to maintain inventory levels that are sufficient to ensure competitive lead times against the risk of inventory obsolescence because of changing customer requirements, fluctuating commodity prices, changes to our products, product transfers, or the life cycle of our products. If we fail to adequately forecast demand for any product, or fail to determine the optimal product mix for production purposes, we may face production capacity issues in processing sufficient quantities of a given product. If our buying and distribution decisions do not accurately predict customer trends or spending levels in general or if we inappropriately price products, we may have to record potential write-downs relating to the value of obsolete or excess inventory. Conversely, if we underestimate future demand for a particular product or do not respond quickly enough to replenish our best performing products, we may have a shortfall in inventory of such products, likely leading to unfulfilled orders, reduced net revenue, and customer dissatisfaction. In addition, because we source components from suppliers located in China, our inventory management may be impacted by enactment or further escalation of tariffs, import restrictions, foreign government regulations, trade restrictions, customs, and duties.

18

Maintaining adequate inventory requires significant attention and monitoring of market trends, local markets, developments with suppliers, and our distribution network, and it is not certain that we will be effective in our inventory management.

If we fail to maintain and enhance our brand, our ability to engage or expand our base of customers will be impaired, and our business, financial condition, and results of operations may suffer.

Maintaining and enhancing our appeal and reputation as a stylish, innovative, and coveted brand is critical to attracting and expanding our relationships with customers. The successful promotion of our brand and the market’s awareness of our products and services will depend on a number of factors, including our marketing efforts, ability to continue to develop our products and services, and ability to successfully differentiate our offerings from competitive offerings. We expect to invest substantial resources to promote and maintain our brand, but there is no guarantee that our brand development strategies will enhance the recognition of our brand or lead to increased sales. The strength of our brand will depend largely on our ability to provide stylish, technologically enhanced products and quality services at competitive prices. Brand promotion activities may not yield increased net revenue, and even if they do, the increased net revenue may not offset the expenses we incur in promoting and maintaining our brand and reputation. In order to protect our brand, we also plan to expend substantial resources to register and defend our trademarks and to prevent others from using the same or substantially similar marks. Despite these efforts, we and Lucyd Ltd. may not always be successful in protecting the trademarks we license from Lucyd Ltd. Our trademarks may be diluted, and we may suffer harm to our reputation, or other harm to our brand. If our efforts to cost-effectively promote and maintain our brand are not successful, our results of operations and our ability to attract and engage customers, partners, and employees may be adversely affected.

Unfavorable publicity regarding our products, customer service, or privacy and security practices could also harm our reputation and diminish confidence in, and the use of, our products and services. In addition, negative publicity related to key brands that we have partnered with may damage our reputation, even if the publicity is not directly related to us. If we fail to maintain, protect, and enhance our brand successfully or to maintain loyalty among customers, or if we incur substantial expenses in unsuccessful attempts to maintain, protect, and enhance our brand, we may fail to attract or increase the engagement of customers, and our business, financial condition, and results of operations may suffer.

We rely heavily on our information technology systems, as well as those of our third-party vendors, business partners, and service providers, for our business to effectively operate and to safeguard confidential information; any significant failure, inadequacy, interruption, or data security incident could adversely affect our business, financial condition, and operations.

We rely heavily on our in-house information technology and enterprise resource planning systems for many functions across our operations, including managing our supply chain and inventory, processing customer transactions in our stores, allocating lens processing jobs to the appropriate laboratories, our financial accounting and reporting, compensating our employees, and operating our website, mobile applications and in-store systems. Our ability to effectively manage our business and coordinate the manufacturing, sourcing, distribution, and sale of our products depends significantly on the reliability and capacity of these systems. We are critically dependent on the integrity, security, and consistent operations of these systems, which are highly reliant on the coordination of our internal business and engineering teams. We also collect, process, and store sensitive and confidential information, including our proprietary business information and that of our customers, employees, suppliers, and business partners. The secure processing, maintenance, and transmission of this information is critical to our operations.

Our systems may be subject to damage or interruption from power outages or damages, telecommunications problems, data corruption, software errors, network failures, acts of war or terrorist attacks, fire, flood, global pandemics, and natural disasters; our existing safety systems, data backup, access protection, user management, and information technology emergency planning may not be sufficient to prevent data loss or long-term network outages. In addition, we may have to upgrade our existing information technology systems or choose to incorporate new technology systems from time to time in order for such systems to support the increasing needs of our expanding business. Costs and potential problems and interruptions associated with the implementation of new or upgraded systems and technology or with maintenance or adequate support of existing systems could disrupt or reduce the efficiency of our operations.

19

Our systems and those of our third-party service providers and business partners may be vulnerable to security incidents, attacks by hackers, acts of vandalism, computer viruses, misplaced or lost data, human errors or other similar events. If unauthorized parties gain access to our networks or databases, or those of our third-party service providers or business partners, they may be able to steal, publish, delete, use inappropriately, or modify our private and sensitive third-party information including personal health information, credit card information, and personal identification information. In addition, employees may intentionally or inadvertently cause data or security incidents that result in unauthorized release of personal or confidential information. Because the techniques used to circumvent security systems can be highly sophisticated, change frequently, are often not recognized until launched against a target, and may originate from less regulated and remote areas around the world, we may be unable to proactively address all possible techniques or implement adequate preventive measures for all situations.

Security incidents compromising the confidentiality, integrity, and availability of this information and our systems could result from cyber-attacks, computer malware, viruses, social engineering (including spear phishing and ransomware attacks), credential stuffing, supply chain attacks, efforts by individuals or groups of hackers and sophisticated organizations, including state-sponsored organizations, errors or malfeasance of our personnel, and security vulnerabilities in the software or systems on which we rely. We anticipate that these threats will continue to grow in scope and complexity over time and such incidents have occurred in the past, and may occur in the future, resulting in unauthorized, unlawful, or inappropriate access to, inability to access, disclosure of, or loss of the sensitive, proprietary and confidential information that we handle.

We also rely on a number of third-party service providers to operate our critical business systems, provide us with software, and process confidential and personal information, such as the payment processors that process customer credit card payments, which expose us to security risks outside of our direct control and our ability to monitor these third-party service providers’ data security is limited. These service providers could experience a security incident that compromises the confidentiality, integrity, or availability of the systems they operate for us or the information they process on our behalf. Cybercrime and hacking techniques are constantly evolving, and we or our third-party service providers may be unable to anticipate attempted security breaches, react in a timely manner, or implement adequate preventative measures, particularly given the increasing use of hacking techniques designed to circumvent controls, avoid detection, and remove or obfuscate forensic artifacts. While we have taken measures designed to protect the security of the confidential and personal information under our control, we cannot assure you that any security measures that we or our third-party service providers have implemented will be effective against current or future security threats. Moreover, we or our third-party service providers may be more vulnerable to such attacks in remote work environments, which have increased in response to the COVID-19 pandemic.

A security breach may also cause us to breach our contractual obligations. Our agreements with certain customers, business partners, or other stakeholders may require us to use industry-standard or reasonable measures to safeguard personal information. We also may be subject to laws that require us to use industry-standard or reasonable security measures to safeguard personal information. A security incident could lead to claims by our customers, business partners, or other relevant stakeholders that we have failed to comply with such legal or contractual obligations. In addition, our inability to comply with data privacy obligations in our contracts or our inability to flow down such obligations to our vendors, collaborators, other contractors, or consultants may cause us to breach our contracts. As a result, we could be subject to legal action or our customers or business partners could end their relationships with us. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages.

In addition, any such access, disclosure or other loss or unauthorized use of information or data, whether actual or perceived, could result in legal claims or proceedings, regulatory investigations or actions, and other types of liability under laws that protect the privacy and security of personal information, including federal, state and foreign data protection and privacy regulations, violations of which could result in significant penalties and fines in the EU and United States. In addition, although we seek to detect and investigate all data security incidents, security breaches, and other incidents of unauthorized access to our information technology systems and data can be difficult to detect and any delay in identifying such breaches or incidents may lead to increased harm and legal exposure of the type described above.

The cost of investigating, mitigating, and responding to potential security breaches and complying with applicable breach notification obligations to individuals, regulators, partners, and others can be significant. Further, defending a suit, regardless of its merit, could be costly, divert management attention, and harm our reputation. The successful

20

assertion of one or more large claims against us that exceed available insurance coverage, or the occurrence of changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, could adversely affect our reputation, business, financial condition, revenues, results of operations, or cash flows. Any material disruption or slowdown of our systems or those of our third-party service providers and business partners, could have a material adverse effect on our business, financial condition, and results of operations. Our risks are likely to increase as we continue to expand, grow our customer base, and process, store, and transmit increasing amounts of proprietary and sensitive data.

Our e-commerce and multichannel channel business faces distinct risks, and our failure to successfully manage it could have a negative impact on our profitability.

As an e-commerce and multichannel retailer, we encounter risks and difficulties frequently experienced by businesses with significant online and in-store sales. The successful operation of our business as well as our ability to provide a positive shopping experience that will generate orders and drive subsequent visits depends on efficient and uninterrupted operation of our e-commerce order-taking and fulfillment operations. If we are unable to allow real-time and accurate visibility to product availability when customers are ready to purchase, quickly and efficiently fulfill our customers’ orders using the fulfillment and payment methods they demand, provide a convenient and consistent experience for our customers regardless of the ultimate sales channel, or effectively manage our online sales, our ability to compete and our results of operations could be adversely affected. Risks associated with our e-commerce and multichannel business include:

•        uncertainties associated with our websites, mobile applications and in-store virtual try-on kiosks including changes in required technology interfaces, website downtime and other technical failures, costs and technical issues as we upgrade our systems software, inadequate system capacity, computer viruses, human error, security breaches, legal claims related to our systems operations, and fulfillment;

•        our partnership with select third-party apps, through which we sell a portion of our products, are subject to changes in their technology interfaces, website downtime and other technical failures, costs, and issues;

•        disruptions in internet service or power outages;

•        reliance on third parties for computer hardware and software, as well as delivery of merchandise to our customers;

•        rapid technology changes;

•        credit or debit card fraud and other payment processing related issues;

•        cybersecurity and consumer privacy; and

•        natural disasters or adverse weather conditions.

In addition, we must keep up to date with competitive technology trends, including the use of new or improved technology, creative user interfaces, virtual and augmented reality, and other e-commerce marketing tools such as paid search and mobile application, among others, which may increase our costs and which may not increase sales or attract customers. Our competitors, most of whom have significantly greater resources than we do, may also be able to benefit from changes in e-commerce technologies, which could harm our competitive position.

The COVID-19 pandemic has had, and may in the future continue to have, a material adverse impact on our business.

The COVID-19 pandemic and the travel restrictions, quarantines, other and related public health measures and actions taken by governments and the private sector have adversely affected global economies, financial markets, and the overall environment for our business, and the extent to which it may continue to impact our future results of operations and overall financial performance remains uncertain. The global macroeconomic effects of the pandemic, including the Delta variant and other new variants may persist for an indefinite period of time, even after the initial waves of the pandemic have subsided.

21

COVID-19 and related governmental reactions have had and may continue to have a negative impact on our financial condition, business, and results of operations due to the occurrence of some or all of the following events or circumstances, among others:

•        our inability to manage our business effectively due to key employees becoming ill or being unable to travel to our third-party suppliers’, contract manufacturers’, logistics providers’, and other business partners’ inability to operate worksites at full capacity or at all, including manufacturing facilities and shipping and fulfillment centers, due to employee illness or reluctance to appear at work, or “stay-at-home” regulations;

•        longer wait times and delayed responses to customer support inquiries and requests;

•        our inability to meet consumer demand and delays in the delivery of our products to our customers, resulting in reputational harm and damaged customer relationships;

•        decrease in consumer discretionary spending;

•        inventory shortages caused by a combination of increased demand that has been difficult to predict with accuracy, and longer lead-times and component shortages in the manufacturing of our products, due to work restrictions related to COVID-19, shut-down, or disruption of international suppliers, import/export conditions such as port congestion, and local government orders;

•        interruptions in manufacturing, receiving and making shipments of our products; and

•        disruptions of the operations of our third-party suppliers, which could impact our ability to purchase components at efficient prices and in sufficient amounts.

The scope and duration of the pandemic, including the current resurgences as a result of the Delta variant in various regions in the United States and globally and other future resurgences, the pace at which government restrictions are lifted or whether additional actions may be taken to contain the virus, the impact on our customers and suppliers, the speed and extent to which markets fully recover from the disruptions caused by the pandemic, and the impact of these factors on our business, will depend on future developments that are highly uncertain and cannot be predicted with confidence. It is possible that changes in economic conditions and steps taken by the federal government and the Federal Reserve in response to the COVID-19 pandemic could lead to higher inflation than we had anticipated, which could in turn lead to an increase in our costs of products and services and other operating expenses. In addition, to the extent COVID-19 continues, it may adversely affect our operations, because people like to try on glasses in stores and in a pandemic, they may be less likely to do so.

Please see “Results of Operations” for more details on the potential impact of the COVID-19 pandemic and associated economic disruptions, and the actual operational and financial impacts that we have experienced to date.

If we fail to adapt and respond effectively to rapidly changing technology, evolving industry standards and changing customer needs or requirements, our solutions may become less competitive.

Our success depends on our customers’ willingness to adopt and use our products, as well as our ability to adapt and enhance our products. To attract new customers and increase revenue from existing customers, we need to continue to enhance and improve our products and to meet customer needs at prices that customers are willing to pay. Such efforts will require adding new features, expanding related applications and responding to technological advancements, which will increase our research and development costs. If we are unable to develop solutions that address customers’ needs or enhance and improve our platform in a timely manner, we may not be able to increase or maintain market acceptance of our products. Further, we may make changes to our products that customers do not find useful. We may also face unexpected problems or challenges in connection with new applications or feature introductions.

Moreover, many competitors expend a considerably greater amount of funds on their research and development programs, and those that do not may be acquired by larger companies that would allocate greater resources to competitors’ research and development programs. If we fail to compete effectively with the research and development programs of competitors, our business could be harmed. Our ability to grow is also subject to the risk of future disruptive technologies. If new technologies emerge that are able to deliver smart eyewear products at lower prices, more efficiently, more conveniently or more securely, such technologies could adversely affect our ability to compete.

22

We depend on highly skilled personnel to grow and operate our business, and if we are unable to hire, retain, and motivate our personnel, we may not be able to grow effectively.

Our success and future growth depend largely upon the continued services of our management team, including our Chief Executive Officer Harrison Gross. From time to time, there may be changes in our executive management team resulting from the hiring or departure of our executives. Our executive officers are employed on an at-will basis, which means they may terminate their employment with us at any time. The loss of one or more of our executive officers, or the failure by our executive team to effectively work with our employees and lead our company, could harm our business. We do not maintain key person life insurance with respect to any member of management or other employee.

In addition, our future success will depend, in part, upon our continued ability to identify and hire skilled employees with the skills and technical knowledge that we require, including software design and programming, eyewear design, marketing, merchandising, operations, and other key management skills and knowledge. Such efforts will require significant time, expense, and attention as there is intense competition for such individuals.

Certain technological advances, greater availability of, or increased consumer preferences for, vision correction alternatives to prescription eyeglasses or contact lenses, and future drug development for the correction of vision-related problems may reduce the demand for our products and adversely impact our business and profitability.

Technological advances in vision care, including the development of new or improved products, as well as future drug development for the correction of vision-related problems, could significantly change how vision care may be conducted and make our existing products less attractive or even obsolete. The greater availability and acceptance, or reductions in the cost, of vision correction alternatives to prescription eyeglasses and contact lenses, such as corneal refractive surgery procedures, including radial keratotomy, photorefractive keratotomy, or PRK, and LASIK, may reduce the demand for our products, lower our sales, and thereby adversely impact our business and profitability.

We could be adversely affected by product liability, product recall or personal injury issues.

We could be adversely impacted by the supply of defective products, including the infiltration of counterfeit products into the supply chain or product mishandling issues. Product liability or personal injury claims may be asserted against us with respect to any of the products we sell or services we provide.

If the products that we sell, including those that we process, package, or label, are defective or otherwise result in product liability or personal injury claims against us, our business could be adversely affected and we could be subject to adverse regulatory action. If our products or services do not meet applicable governmental safety standards or our customers’ expectations regarding quality or safety, we could experience lost sales and increased costs, be exposed to legal and reputational risk, and face fines or penalties which could materially adversely affect our financial results.

Refunds, cancellations, and warranty claims could harm our business.

We allow our customers to return our products, subject to our refund policy, which allows any customer to return our products for any reason within the first 7 days of their purchase and receive a full refund. At the time of sale, we establish a reserve for returns, based on historical experience and expected future returns, which is recorded as a reduction of sales. If we experience a substantial increase in refunds, our cancellation reserve levels might not be sufficient and our business, financial condition, and results of operations could be harmed.

We expect a number of factors to cause our results of operations and operating cash flows to fluctuate on a quarterly and annual basis, which may make it difficult to predict our future performance.

Our results of operations could vary significantly from quarter to quarter and year to year because of a variety of factors, many of which are outside of our control. As a result, comparing our results of operations on a period-to-period basis may not be meaningful. In addition to other risk factors discussed in this section, factors that may contribute to the variability of our quarterly and annual results include:

•        our ability to accurately forecast and achieve net revenues and appropriately plan our expenses;

•        changes to financial accounting standards and the interpretation of those standards, which may affect the way we recognize and report our financial results;

23

•        the effectiveness of our internal controls;

•        the early-stage nature of our business and the need to scale our operations and,

•        the impact of the COVID-19 pandemic on our business.

The impact of one or more of the foregoing and other factors may cause our results of operations to vary significantly. As such, quarter-to-quarter and year-over-year comparisons of our results of operations may not be meaningful and should not be relied upon as an indication of future performance.

We may require additional capital to support the growth of our business, and this capital might not be available on acceptable terms, if at all.

We have funded our operations since inception primarily through net proceeds from the sale of convertible loan notes and common stock sales through two registered crowdfunds and cash flows generated from operating activities. We cannot be certain when, or if, our operations will generate sufficient cash to fully fund our ongoing operations or the growth of our business. We intend to continue to make investments to support the development of our products and services and will require additional funds for such development. We may need additional funding for marketing expenses and to develop and expand sales resources, develop new products and improve existing products with new features or enhance our products and services with new technology, improve our operating infrastructure, or acquire complementary businesses and technologies. Accordingly, we might need or may want to engage in future equity or debt financings to secure additional funds. Additional financing may not be available on terms favorable to us, if at all. If adequate funds are not available on acceptable terms, we may be unable to invest in future growth opportunities, which could harm our business, financial condition, and results of operations. In particular, the ongoing COVID-19 pandemic has caused disruption in the credit and financial markets in the United States and worldwide, which may reduce our ability to access capital and negatively affect our liquidity in the future. If we are unable to obtain adequate financing or financing on terms satisfactory to us, our ability to develop our products and services, support our business growth, and respond to business challenges could be significantly impaired, and our business may be adversely affected.

If we incur additional debt, the debt holders would have rights senior to holders of common stock to make claims on our assets, and the terms of any additional debt could include restrictive covenants that restrict our operations, including our ability to pay dividends on our common stock. Furthermore, if we issue additional equity securities, stockholders will experience dilution, and the new equity securities could have rights senior to those of our common stock. Because our decision to issue securities in the future will depend on numerous considerations, including factors beyond our control, we cannot predict or estimate the amount, timing, or nature of any future issuances of debt or equity securities. As a result, our stockholders bear the risk of future issuances of debt or equity securities reducing the value of our common stock and diluting their interests.

The occurrence of any of these foregoing risks could adversely affect our business, financial condition, and results of operations and expose us to unknown risks or liabilities.

Eyeglasses are regulated as medical devices by the FDA, and our failure, or the failure of any third-party manufacturer or optical laboratory, to obtain and maintain the necessary marketing authorizations for our products could have a material adverse effect on our business.

We are a FDA registered eyewear importer and we also engage in certain manufacturing, packaging, shipping and labeling activities that subject us to direct oversight by the FDA under the FDCA and its implementing regulations. The FDA regulates, among other things, with respect to medical devices: design, development and manufacturing, testing, labeling, content, and language of instructions for use and storage; clinical trials; product safety; establishment registration and device listing; marketing, sales and distribution; premarket clearance, classification and approval; recordkeeping procedures; advertising and promotion; recalls and field safety corrective actions; post market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury; post-market approval studies; and product import and export. The regulations to which we are subject are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs, or lower than anticipated sales. The FDA enforces its regulatory requirements through, among other means, periodic unannounced inspections. Failure to comply with applicable regulations could jeopardize our or our contract manufacturers’ ability to manufacture and

24

sell our products and result in FDA enforcement actions such as: warning letters; fines; injunctions; civil penalties; termination of distribution; recalls or seizures of products; delays in the introduction of products into the market; total or partial suspension of production; refusal to grant future clearances or approvals; withdrawals or suspensions of clearances or approvals, resulting in prohibitions on sales of our products; and in the most serious cases, criminal penalties.

We are subject to rapidly changing and increasingly stringent laws, regulations, contractual obligations, and industry standards relating to privacy, data security, and data protection. The restrictions and costs imposed by these laws and other obligations, or our actual or perceived failure to comply with them, could subject us to liabilities that adversely affect our business, operations, and financial performance.

We collect, process, store, and use a wide variety of data from current and prospective customers, including personal information, such as home addresses and geolocation, and health information related to their ophthalmic prescriptions. These activities are regulated by a variety of federal, state, local, and foreign privacy, data security, and data protection laws and regulations, which have become increasingly stringent in recent years.

Domestic privacy and data security laws are complex and changing rapidly. Many states have enacted laws regulating the online collection, use, and disclosure of personal information and requiring that companies implement reasonable data security measures. Laws in all states and U.S. territories also require businesses to notify affected individuals, governmental entities, and/or credit reporting agencies of certain security incidents affecting personal information. These laws are not consistent, and compliance with them in the event of a widespread data breach is complex and costly.

Further, the California Consumer Privacy Act (CCPA) took effect on January 1, 2020. The CCPA gives California residents expanded rights related to their personal information, including the right to access and delete their personal information, and receive detailed information about how their personal information is used and shared. The CCPA also created restrictions on “sales” of personal information that allow California residents to opt-out of certain sharing of their personal information and may restrict the use of cookies and similar technologies for advertising purposes. Our e-commerce platform, including our websites and mobile applications, rely on these technologies and could be adversely affected by the CCPA’s restrictions. The CCPA prohibits discrimination against individuals who exercise their privacy rights, provides for civil penalties for violations, and creates a private right of action for data breaches that is expected to increase data breach litigation. Additionally, a new California ballot initiative, the California Privacy Rights Act, or CPRA, was recently passed in California. The CPRA will restrict use of certain categories of sensitive personal information that we handle; further restrict the use of cross-context behavioral advertising techniques on which our products may rely in the future; establish restrictions on the retention of personal information; expand the types of data breaches subject to the private right of action; and establish the California Privacy Protection Agency to implement and enforce the new law, as well as impose administrative fines. The majority of the CPRA’s provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes will likely be required. Similar laws have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. Compliance with such laws could be difficult and costly to achieve and we could be subject to fines and penalties in the event of non-compliance.

Additionally, we are subject to certain health information privacy and security laws as a result of the health information that we receive in connection with our products and services. These laws and regulations include not be adequate to indemnify us for the full extent of our potential liabilities.

Our business could be adversely impacted by changes in the internet and mobile device accessibility of users. Companies and governmental agencies may restrict access to our products and services, our mobile applications, website, application stores, or the internet generally, which could negatively impact our operations.

Our business depends on customers accessing our products and services via a mobile device or a personal computer, and the internet. We may operate in jurisdictions that provide limited internet connectivity. Internet access and access to a mobile device or personal computer are frequently provided by companies with significant market power that could take actions that degrade, disrupt, or increase the cost of consumers’ ability to access our products and services. In addition, the internet infrastructure that we and our customers rely on in any particular geographic area may be

25

unable to support the demands placed upon it and could interfere with the speed and availability of our products and services. Any such failure in internet or mobile device or computer accessibility, even for a short period of time, could adversely affect our results of operations.

Governmental agencies in any of the countries in which we or our customers are located could block access to or require a license for our mobile applications, website, or the internet generally for a number of reasons, including security, confidentiality, or regulatory concerns. In addition, companies may adopt policies that prohibit their employees from using our products and services. If companies or governmental entities block, limit, or otherwise restrict customers from accessing our products and services, our business could be negatively impacted, the number of customers could decline or grow more slowly, and our results of operations could be adversely affected.

We could incur significant liabilities related to, and significant costs in complying with, environmental, health, and safety laws and regulations.

Our operations are subject to various national, state, and local environmental, health, and safety laws and regulations that govern, among other things, the health and safety of our employees and the end-users of our products and the materials used in, and the recycling of, our products and their packaging. Non-compliance with, or liability related to, these laws and regulations, which tend to become more stringent over time, could result in substantial fines or penalties, injunctive relief, civil, or criminal sanctions, and could expose us to costs of investigation or remediation, as well as tort claims for property damage or personal injury.

In addition, a number of governmental authorities, both in the United States and abroad, have considered, and are expected to consider, legislation aimed at reducing the amount of plastic non-recyclable waste. Programs have included banning certain types of products, mandating certain rates of recycling and/or the use of recycled materials, imposing deposits or taxes on single-use plastic bags, paper bags, reusable bags, and packaging materials. Such legislation, as well as voluntary initiatives, aimed at reducing the level of plastic wastes could result in increased cost of packaging for our products or otherwise require us to alter our current packaging and bagging practices. Additional regulatory efforts addressing other environmental or safety concerns in the future could similarly impact our business, financial condition, and results of operations.

From time to time, we may be subject to legal proceedings, regulatory disputes, and governmental inquiries that could cause us to incur significant expenses, divert our management’s attention, and materially harm our business, financial condition, and operating results.

From time to time, we may be subject to claims, lawsuits, government investigations, and other proceedings involving products liability, competition and antitrust, intellectual property, privacy, false advertising, consumer protection, securities, tax, labor and employment, commercial disputes, and other matters that could adversely affect our business operations and financial condition. As we grow, we may see a rise in the number and significance of these disputes and inquiries. Litigation and regulatory proceedings may be protracted and expensive, and the results are difficult to predict. Certain of these matters include speculative claims for substantial or indeterminate amounts of damages and include claims for injunctive relief. Additionally, our litigation costs could be significant. Adverse outcomes with respect to litigation or any of these legal proceedings may result in significant settlement costs or judgments, penalties and fines, or require us to modify our products or services, all of which could negatively affect our revenue growth. The results of litigation, investigations, claims, and regulatory proceedings cannot be predicted with certainty, and determining reserves for pending litigation and other legal and regulatory matters requires significant judgment. There can be no assurance that our expectations will prove correct, and even if these matters are resolved in our favor or without significant cash settlements, these matters, and the time and resources necessary to litigate or resolve them, could harm our business, financial condition, and results of operations.

Risks Related to Intellectual Property

We license our technology from Lucyd Ltd., the majority stockholder of the Company, and our inability to maintain this license could materially affect our business, financial condition, and operating results.

All our current intellectual property is licensed from Lucyd Ltd., the majority stockholder of the Company, pursuant to a license agreement we entered into with Lucyd Ltd. on April 1, 2020 (the “License Agreement”). Pursuant to the License Agreement, we acquired an exclusive, worldwide license that is royalty-free, fully paid up, and perpetual

26

license for the exclusive use of certain assets of Lucyd Ltd. related to Innovative Eyewear current products and trademarks. There can be no assurance that the license will not be terminated by Lucyd Ltd. and if we are unable to continue to license the technology (because of, for example, intellectual property infringement claims brought by third-parties against us or against Lucyd Ltd.) then our business, financial condition and operating results would be adversely affected. If we are unable to continue the License Agreement, our ability to continue developing, designing, manufacturing, distributing, and selling our products would be limited and may require us to stop selling our products. If the License Agreement is terminated for any reason, we may be forced to acquire or develop alternative technology, which we may be unable to do in a commercially feasible manner, if at all, and may require us to use alternative technology of lower quality or performance standards. This could, in turn, limit, delay or disrupt our ability to offer new or competitive solutions and could also increase our costs, which could adversely affect our margins, market share, business, financial condition, and operating results. Please see “Business—Material Agreements” for a more complete description of the License Agreement.

Failure to adequately maintain and protect our intellectual property and proprietary rights could harm our brand, devalue our proprietary content, and adversely affect our ability to compete effectively.

Our success depends to a significant degree on Lucyd Ltd.’s ability to obtain, maintain, protect, and enforce our licensed intellectual property rights, including those in our proprietary technologies, know-how, and brand. To protect our rights to our intellectual property, we rely on a combination of patent, trademark, copyright and trade secret laws, domain name registrations, confidentiality agreements, and other contractual arrangements with our employees, affiliates, clients, strategic partners, and others. However, the protective steps we have taken and plan to take may be inadequate to deter misappropriation or other violation of or otherwise protect our intellectual property rights. We may be unable to detect the unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Effective patent, trademark, copyright, and trade secret protection may not be available to us or available in every jurisdiction in which we offer or intend to offer our services. Failure to adequately protect our intellectual property could harm our brand, devalue our proprietary technology and content, and adversely affect our ability to compete effectively. Further, even if we are successful, defending our intellectual property rights could result in the expenditure of significant financial and managerial resources, which could adversely affect our business, financial condition, and results of operations.

If we fail to protect our intellectual property rights adequately, our competitors may gain access to our licensed intellectual property and proprietary technology and develop and commercialize substantially identical offerings or technologies. Any patents, trademarks, copyrights, or other intellectual property rights that we have or may obtain may be challenged or circumvented by others or invalidated or held unenforceable through administrative process, including re-examinationinter partes review, interference and derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings), or litigation. There can be no assurance that our patent applications will result in issued patents and we may be unable to obtain or maintain patent protection for our technology. In addition, any patents issued from pending or future patent applications or licensed to us in the future may not provide us with claims sufficiently broad to provide meaningful competitive advantages or may be successfully challenged by third parties. There is also no guarantee that our pending trademark applications for any mark will proceed to registration; our pending applications may be opposed by a third party prior to registration; and even those trademarks that are registered could be challenged by a third party, including by way of revocation or invalidity actions. For example, we have registrations in a number of foreign countries in which we are not currently offering goods or services, and those registrations could be subject to invalidation proceedings if we cannot demonstrate use of the marks by the applicable use deadlines in those countries. In addition, because patent applications in the United States are currently maintained in secrecy for a period of time prior to issuance, and patent applications in certain other countries generally are not published until more than 18 months after they are first filed, and because publication of discoveries in scientific or patent literature often lags behind actual discoveries, we cannot be certain that we were the first creator of inventions covered by our pending patent applications or that we were the first to file patent applications on such inventions. To maintain a proprietary market position in foreign countries, we may seek to protect some of our proprietary inventions through foreign counterpart patent applications. Statutory differences in patentable subject matter may limit the protection we can obtain on some of our inventions outside of the United States. The diversity of patent laws may make our expenses associated with the development and maintenance of intellectual property in foreign jurisdictions more expensive than we anticipate. We probably will not be able to obtain the same patent protection in every market in which we may otherwise be able to potentially generate revenue. Further, the laws of some foreign countries may not be as protective of intellectual property rights as those in the United States, and mechanisms for enforcement

27

of intellectual property rights may be inadequate. Moreover, policing unauthorized use of our technologies, trade secrets, and intellectual property may be difficult, expensive, and time-consuming. Despite our precautions, it may be possible for unauthorized third parties to copy our offerings and capabilities and use information that we regard as proprietary to create offerings that compete with ours. Third parties may apply to register our trademarks or other trademarks similar to our trademarks in jurisdictions before us, thereby creating risks relating to our ability to use and register our trademarks in those jurisdictions. In addition, there could be potential trade name or trademark ownership or infringement claims brought by owners of other rights, including registered trademarks, in our marks or marks similar to ours. Any claims of infringement, brand dilution, or consumer confusion related to our brand (including our trademarks) or any failure to renew key license agreements on acceptable terms could damage our reputation and brand identity and substantially harm our business and results of operations. The value of our intellectual property could diminish if others assert rights in or ownership of our trademarks and other intellectual property rights, or trademarks that are similar to our trademarks. We may be unable to successfully resolve these types of conflicts to our satisfaction. In some cases, litigation or other actions may be necessary to protect or enforce our trademarks and other intellectual property rights.

We generally enter into confidentiality and invention assignment agreements with our employees and consultants, as well as confidentiality agreements with other third parties, including suppliers and other partners. However, we cannot guarantee that we have entered into such agreements with each party that has or may have had access to our proprietary information, know-how, and trade secrets. Moreover, no assurance can be given that these agreements will be effective in controlling access to our proprietary information or the distribution, use, misuse, misappropriation, reverse engineering, or disclosure of our proprietary information, know-how, and trade secrets. Further, these agreements may not prevent our competitors from independently developing technologies that are substantially equivalent or superior to our offerings and capabilities. These agreements may be breached, and we may not have adequate remedies for any such breach.

We may be required to spend significant resources to monitor and protect our intellectual property rights. Litigation may be necessary in the future to enforce our intellectual property rights and to protect our trade secrets. Litigation brought to protect and enforce our intellectual property rights could be costly, time-consuming, and distracting to management, and could result in the impairment or loss of portions of our intellectual property rights. Further, our efforts to enforce our intellectual property rights may be met with defenses, counterclaims, and countersuits attacking the validity and enforceability of our intellectual property rights, and if such defenses, counterclaims, or countersuits are successful, we could lose valuable intellectual property rights. Further, any changes in law or interpretation of any such laws, particularly intellectual property laws, may impact our ability to protect, register, or enforce our intellectual property rights. Our inability to protect our proprietary technology against unauthorized copying or use, as well as any costly litigation or diversion of our management’s attention and resources, could delay further sales or the implementation of our offerings and capabilities, impair the functionality of our offerings and capabilities, delay introductions of new offerings, result in our substituting inferior or more costly technologies into our offerings, or injure our reputation.

Domain names generally are regulated by internet regulatory bodies, and the regulation of domain names is subject to change. Regulatory bodies have and may continue to establish additional top-level domains, appoint additional domain name registrars, or modify the requirements for holding domain names. We may not be able to, or it may not be cost-effective to, acquire or maintain all domain names that utilize the name “Lucyd Ltd.” or “Innovative Eyewear” in all of the countries in which we currently conduct or intend to conduct business. If we lose the ability to use a domain name, we could incur significant additional expenses to market our products within that country, including the development of new branding. This could substantially harm our business, results of operations, financial condition and prospects.

We may incur costs to defend against, face liability or for being vulnerable to intellectual property infringement claims brought against us by others.

Third parties may assert claims against us alleging that we infringe upon, misappropriate, dilute or otherwise violate their intellectual property rights, particularly as we expand our business and the number of products we offer. These risks have been amplified by the increase in third parties whose sole or primary business is to assert such claims. We may be particularly vulnerable to such claims, as companies having a substantial online presence are frequently subject to litigation based on allegations of infringement or other violations of intellectual property rights. As we gain an increasingly high public profile, the possibility of intellectual property rights claims against us grows. Our competitors and others may now and in the future have significantly larger and more mature patent portfolios than us.

28

We rely on contracts and releases for ownership of copyrighted materials and the right to use images of individuals on our webpage and marketing material, and we may be subject to claims that we did not properly obtain rights, consent, a release, or permission to use certain content or imagery. Many potential litigants have the ability to dedicate substantial resources to the assertion of their intellectual property rights. Any claim of infringement by a third party, even those without merit, could cause us to incur substantial costs defending against the claim, could distract our management from our business, could require us to cease use of such intellectual property, and could create ongoing obligations if we are subject to agreements or injunctions (stipulated or imposed) preventing us from engaging in certain acts. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, we risk compromising our confidential information during this type of litigation. Our defense of any claim, regardless of its merit, could be expensive and time consuming and could divert management resources. We cannot predict the outcome of lawsuits and cannot ensure that the results of any such actions will not have an adverse effect on our business, financial condition, or results of operations. Successful infringement claims against us could result in significant monetary liability or prevent us from selling some of our products. In addition, resolution of claims may require us to redesign or rebrand our products, license rights from third parties on potentially unfavorable terms, cease using certain brand names or other intellectual property rights altogether, make substantial payments for royalty or license fees, legal fees, settlement payments or other costs or damages, or admit liability. Such outcomes could encourage others to bring claims against us. To the extent we seek a license to continue offerings or operations found or alleged to infringe third-party intellectual property rights, such a license may be non-exclusive, and therefore our competitors may have access to the same technology licensed to us. In the event we are required to develop alternative, non-infringing technology, this could require significant time (during which we would be unable to continue to offer our affected offerings), effort and expense, and may ultimately not be successful. Any of these events could harm our business and cause our results of operations, liquidity, and financial condition to suffer.

Risks Related to Our Dependence on Third Parties

We face risks associated with suppliers from whom our products are sourced and are dependent on a limited number of suppliers.

We purchase all of the inputs for our products, including eyeglass frames, temples with electronics embedded within them, prescription lenses, sun lenses, demo lenses, hinges, packaging materials and other components, parts, and raw materials, directly or indirectly from domestic and international suppliers. For our business to be successful, our suppliers must be willing and able to provide us with inputs in substantial quantities, in compliance with regulatory requirements, at acceptable costs and on a timely basis. Our ability to obtain a sufficient selection or volume of inputs on a timely basis at competitive prices could suffer as a result of any deterioration or change in our supplier relationships or events that adversely affect our suppliers.

We typically do not enter into long-term contracts with our suppliers and, as such, we operate without significant contractual assurances of continued supply, pricing or access to inputs. Any of our suppliers could discontinue supplying us with desired inputs in sufficient quantities or offer us less favorable terms on future transactions for a variety of reasons. The benefits we currently experience from our suppliers relationships could be adversely affected if our suppliers:

•        discontinue selling products to us;

•        raise their prices;

•        increase lead times for products and/or key components

We also source inputs directly from suppliers outside of the United States, including China. Global sourcing and foreign trade involve numerous factors and uncertainties beyond our control including increased shipping costs, the imposition of additional import or trade restrictions, including legal or economic restrictions on overseas suppliers’ ability to produce and deliver inputs, increased custom duties and tariffs, unforeseen delays in customs clearance of goods, more restrictive quotas, loss of a most favored nation trading status, currency exchange rates, transportation delays, port of entry issues and foreign government regulations, political instability, and economic uncertainties in the countries from which we or our suppliers source our products.

Additionally, sourcing could be impacted by current and future travel restrictions and/or the shut-down of certain businesses globally due to the COVID-19 pandemic.

29

We rely on a limited number of contract manufacturers and logistics partners for our products. A loss of any of these partners could negatively affect our business.

We rely on a limited number of third-party suppliers and contract manufacturers for the components that go into the manufacturing of our products. In particular, our frames are provided by a single supplier. We also assemble and fulfill glasses at a single third-party optical laboratory. Our reliance on a limited number of contract manufacturers and logistics partners for our products increases our risks of being unable to deliver our products in a timely and cost-effective manner. In the event of interruption from any of our contract manufacturers or our own fulfillment capabilities, we may not be able to increase capacity from other sources or develop alternate or secondary sources without incurring material additional costs and substantial delays.

Our business could be adversely affected if one or more of our manufacturers is impacted by a natural disaster, an epidemic such as the current COVID-19 outbreak, or other interruption at a particular location. In particular, the current COVID-19 outbreak has caused, and will likely continue to cause, interruptions in the development, manufacturing (including the sourcing of key components), and shipment of our products, which could adversely impact our revenue, gross margins, and operating results.

Additionally, we do not own or operate a warehouse or a warehouse management company or system, and we currently rely on a single third-party warehouse. Because a significant percentage of our products are stored in and shipped out of the single third-party warehouse, we face significant risks such as, but not limited to: our operations could be disrupted and our inventory could be destroyed by earthquakes, floods, fires or other natural disasters or other events outside of our control, or the control of our third-party warehouse. Our dependence on a single third-party warehouse also exposes us to the risk that the warehouse may experience operational disruptions due to security or computer viruses, software and hardware failure, power interruptions and other system failures. If we encounter problems with our third-party warehouse, we may be unable to meet customer expectations, manage our inventory and fulfillment capacity, complete sales, fulfill orders in a timely fashion, and our ability to achieve objectives for operating efficiencies could be adversely affected, all of which could harm our reputation and our relationship with our customers.

Our projects could be hindered due to our dependence on third parties to complete many of our contracts.

In the current economic environment, third parties may find it difficult to obtain sufficient financing to help fund their operations. The inability to obtain financing could adversely affect a third party’s ability to provide materials, equipment or services which could have a material adverse impact on our business, financial condition, and results of operations. In addition, a failure by a third party subcontractor, supplier or manufacturer to comply with applicable laws, regulations or client requirements could negatively impact our business and, for government clients, could result in fines, penalties, suspension or even debarment being imposed on us, which could have a material adverse impact on our business, financial condition, and results of operations.

We depend on search engines, social media platforms, digital application stores, content-based online advertising, and other online sources to attract consumers to and promote our website and our mobile applications, which may be affected by third-party interference beyond our control and as we grow our customer acquisition costs may continue to rise.

Our success depends in part on our ability to attract consumers to our website, mobile applications, and retail partners to convert them into customers in a cost-effective manner. We depend, in large part, on search engines, social media platforms, digital application stores, content-based online advertising, and other online sources for traffic to our website, mobile applications, and select application partners.

With respect to search engines, we are included in search results as a result of both paid search listings, where we purchase specific search terms that result in the inclusion of our advertisement, and free search listings, which depend on algorithms used by search engines. For paid search listings, if one or more of the search engines or other online sources on which we rely for purchased listings modifies or terminates its relationship with us, our expenses could rise, we could lose consumers and traffic to our website could decrease, any of which could have a material adverse effect on our business, financial condition, and results of operations.

30

We plan to rely primarily on third-party insurance policies to insure our operations-related risks. If our insurance coverage is insufficient for the needs of our business or our insurance providers are unable to meet their obligations, we may not be able to mitigate the risks facing our business, which could adversely affect our business, financial condition, and results of operations.

We procure third-party insurance policies or plan to procure policies to cover various operations-related risks including employment practices liability, workers’ compensation, property and business interruptions, cybersecurity and data breaches, crime, directors’ and officers’ liability, and general business liabilities. We rely on a limited number of insurance providers, and should such providers discontinue or increase the cost of coverage, we cannot guarantee that we would be able to secure replacement coverage on reasonable terms or at all. If our insurance carriers change the terms of our policies in a manner not favorable to us, our insurance costs could increase. Further, if the insurance coverage we maintain is not adequate to cover losses that occur, or if we are required to purchase additional insurance for other aspects of our business, we could be liable for significant additional costs. Additionally, if any of our insurance providers becomes insolvent, it would be unable to pay any operations-related claims that we make.

General Risk Factors

Failure to establish and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act could have a material adverse effect on our business and stock price.

We are not currently required to comply with the rules of the SEC implementing Section 404 of the Sarbanes-Oxley Act and therefore are not required to make a formal assessment of the effectiveness of our internal control over financial reporting for that purpose. Upon becoming a publicly traded company, we will be required to comply with the SEC’s rules implementing Sections 302 and 404 of the Sarbanes-Oxley Act, which will require management to certify financial and other information in our quarterly and annual reports and provide an annual management report on the effectiveness of controls over financial reporting. Though we will be required to disclose changes made in our internal controls and procedures on a quarterly basis, we will not be required to make our first annual assessment of our internal control over financial reporting pursuant to Section 404 until the year following our first annual report required to be filed with the SEC. As an “emerging growth company,” as defined in the JOBS Act, we may take advantage of certain temporary exemptions from various reporting requirements, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes Oxley Act (and the rules and regulations of the Securities and Exchange Commission thereunder). Once we no longer qualify as an “emerging growth company” under the JOBS Act and lose the ability to rely on the exemptions related thereto discussed above and depending on our status as per Rule 12b-2 of the Securities Exchange Act of 1934, as amended, our independent registered public accounting firm may also need to attest to the effectiveness of our internal control over financial reporting under Section 404.

Based on the number of personnel available to serve the Company’s accounting function, management believes we are not able to adequately segregate responsibility over financial transaction processing and reporting. Further, the Company does not have a formal internal control environment in place and operating effectively. As such, we have identified these issues as material weaknesses in our internal control over financial reporting and we may identify additional material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our financial statements. If our remediation of such material weaknesses is not effective, or if we fail to develop and maintain an effective system of internal controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable laws and regulations could be materially and adversely affected and the market price of our common stock could be negatively affected, which could require additional financial and management resources.

Changes in tax treatment of companies engaged in e-commerce may adversely affect the commercial use of our sites and our financial results.

Due to the global nature of the Internet, it is possible that various states or foreign countries might attempt to impose additional or new regulation on our business or levy additional or new sales, income, or other taxes relating to our activities. Tax authorities at the international, federal, state, and local levels are currently reviewing the appropriate treatment of companies engaged in e-commerce and digital services. New or revised international, federal, state, or local tax regulations or court decisions may subject us or our customers to additional sales, income and other taxes. For example, on June 21, 2018, the U.S. Supreme Court rendered a 5-4 majority decision in South Dakota v. Wayfair Inc.,

31

17-494 where the Court held, among other things, that a state may require an out-of-state seller with no physical presence in the state to collect and remit sales taxes on goods the seller ships to consumers in the state, overturning existing court precedent. Other new or revised taxes and, in particular, digital taxes, sales taxes, VAT, and similar taxes could increase the cost of doing business online and decrease the attractiveness of selling products over the Internet. New taxes and rulings could also create significant increases in internal costs necessary to capture data and collect and remit taxes. Any of these events could have a material adverse effect on our business, financial condition, and operating results.

An overall decline in the health of the economy and other factors impacting consumer spending, such as recessionary conditions, governmental instability, inclement weather, and natural disasters, may affect consumer purchases, which could reduce demand for our products and harm our business, financial conditions, and results of operations.

Our business depends on consumer demand for our products and, consequently, is sensitive to a number of factors that influence consumer confidence and spending, such as general economic conditions, consumer disposable income, energy and fuel prices, recession and fears of recession, unemployment, minimum wages, availability of consumer credit, consumer debt levels, conditions in the housing market, interest rates, tax rates and policies, inflation, consumer confidence in future economic conditions and political conditions, war and fears of war, inclement weather, natural disasters, terrorism, outbreak of viruses or widespread illness, and consumer perceptions of personal well-being and security.

We are an “emerging growth company,” and we cannot be certain if the reduced reporting and disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.

We are an “emerging growth company,” as defined in the JOBS Act, and we may take advantage of certain exemptions from reporting requirements that are applicable to other public companies that are not “emerging growth companies,” including the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Pursuant to Section 107 of the JOBS Act, as an emerging growth company, we have elected to use the extended transition period for complying with new or revised accounting standards until those standards would otherwise apply to private companies. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make our common stock less attractive to investors. In addition, if we cease to be an emerging growth company, we will no longer be able to use the extended transition period for complying with new or revised accounting standards.

We will remain an emerging growth company until the earliest of: (1) the last day of the fiscal year following the fifth anniversary of our listing; (2) the last day of the first fiscal year in which our annual gross revenue is $1.07 billion or more; (3) the date on which we have, during the previous rolling three-year period, issued more than $1 billion in non-convertible debt securities; and (4) the date on which we are deemed to be a “large accelerated filer” under the rules of the SEC.

We cannot predict if investors will find our common stock less attractive if we choose to rely on these exemptions. For example, if we do not adopt a new or revised accounting standard, our future results of operations may not be comparable to the results of operations of certain other companies in our industry that adopted such standards. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock price may be more volatile.

If our estimates or judgments relating to our critical accounting policies prove to be incorrect, our results of operations could be adversely affected.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes appearing elsewhere in this prospectus. We base our estimates on short duration historical experience and on various other assumptions that we believe to be reasonable under the circumstances, as provided in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Estimates.” The results

32

of these estimates form the basis for making judgments about the carrying values of assets, liabilities, and equity, and the amount of revenue and expenses. Significant estimates and judgments involve: revenue recognition, including revenue-related reserves; legal contingencies; valuation of our common stock and equity awards; income taxes; and sales and indirect tax reserves. Our results of operations may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions, which could cause our results of operations to fall below the expectations of securities analysts and investors, resulting in a decline in the market price of our common stock.

Our current insurance coverage may not be adequate, and we may not be able to obtain insurance at acceptable rates, or at all.

We currently have General Liability and Product Liability policies covering our business. These policies may not provide sufficient coverage in the face of significant claims or multiple claims. Claims exceeding our insurance coverage could create significant increases in internal costs. This even could have a material adverse effect on our business, financial condition, and operating results.

We may decide to pursue strategic acquisitions to accelerate our growth. These potential acquisitions may not be successful. We may not be able to successfully integrate future acquisitions or generate sufficient revenues from future acquisitions, which could cause our business to suffer.

If we buy a company or a division of a company, there can be no assurance that we will be able to profitably manage such business or successfully integrate such business without substantial costs, delays or other operational or financial problems. There can be no assurance that the businesses we acquire in the future will achieve anticipated revenues and earnings. Additionally:

•        the key personnel of the acquired business may decide not to work for us;

•        changes in management at an acquired business may impair its relationships with employees and customers;

•        we may be unable to maintain uniform standards, controls, procedures and policies among acquired businesses;

•        we may be unable to successfully implement infrastructure, logistics and systems integration;

•        we may be held liable for legal claims (including environmental claims) arising out of activities of the acquired businesses prior to our acquisitions, some of which we may not have discovered during our due diligence, and we may not have indemnification claims available to us or we may not be able to realize on any indemnification claims with respect to those legal claims;

•        we will assume risks associated with deficiencies in the internal controls of acquired businesses;

•        we may not be able to realize the cost savings or other financial benefits we anticipated; and

•        our ongoing business may be disrupted or receive insufficient management attention.

Future acquisitions may require us to obtain additional equity or debt financing, which may not be available on attractive terms. Moreover, to the extent an acquisition transaction financed by non-equity consideration results in additional goodwill, it will reduce our tangible net worth, which might have an adverse effect on our credit and bonding capacity.

Risks Relating to Our Securities and this Offering

Our directors, executive officers and principal stockholders will continue to have substantial control over our company after this offering, which could limit your ability to influence the outcome of key transactions, including a change of control.

Upon completion of this offering, our executive officers, directors and principal stockholders and their affiliates will own 4,922,115 shares of our common stock, or approximately 55% of the outstanding shares of our common stock, based on the number of shares outstanding as of the date of this prospectus and assuming the sale of 2,857,142 Units in this offering at an assumed initial public offering price of $5.25 per Unit, which is the midpoint of the price range set forth on the cover page of this prospectus, and underwriters’ over-allotment option is not exercised. As a result,

33

these stockholders will be able to exercise a significant level of control over all matters requiring stockholder approval, including the election of directors and the approval of mergers, acquisitions or other extraordinary transactions. They may also have interests that differ from yours and may vote in a way with which you disagree and which may be adverse to your interests. This concentration of ownership may have the effect of delaying, preventing or deterring a change of control of our company, could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company and might ultimately affect the market price of our common stock.

There is no existing market for our securities and we do not know if one will develop to provide you with adequate liquidity. Even if a market does develop following this offering, the prices in the market may not exceed the offering price.

Prior to this offering, there has not been a public market for our securities. We cannot assure you that an active trading market for our common stock will develop following this offering, or if it does develop, it may not be maintained. You may not be able to sell your shares quickly or at the market price if trading in our common stock is not active. There is no established trading market for any of the Warrants, and we do not expect a market to develop. We do not intend to apply for a listing for any of the Warrants on any securities exchange or other nationally recognized trading system. Without an active trading system, the liquidity of the Warrants will be limited. The initial public offering price for the Units will be determined by negotiations between us and representatives of the underwriters and may not be indicative of prices that will prevail in the trading market following the completion of this offering. Consequently, you may not be able to sell shares of our common stock or Warrants at prices equal to or greater than the price you pay in this offering.

The market price of our securities is likely to be highly volatile, and you could lose all or part of your investment.

The trading price of our common stock and Warrants is likely to be volatile. This volatility may prevent you from being able to sell your shares of common stock or Warrants at or above the price you paid in this offering. The market price of our securities could be subject to wide fluctuations in response to a variety of factors, which include:

•        actual or anticipated fluctuations in our quarterly or annual operating results;

•        publication of research reports by securities analysts about us or our competitors or our industry;

•        the public’s reaction to our press releases, our other public announcements and our filings with the SEC;

•        our failure or the failure of our competitors to meet analysts’ projections or guidance that we or our competitors may give to the market;

•        additions and departures of key personnel;

•        strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;

•        the passage of legislation or other regulatory developments affecting us or our industry;

•        speculation in the press or investment community;

•        changes in accounting principles;

•        terrorist acts, acts of war or periods of widespread civil unrest;

•        natural disasters and other calamities; and

•        changes in general market and economic conditions.

In addition, the stock market has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of companies. Broad market and industry factors may negatively affect the market price of our common stock and Warrants, regardless of our actual operating performance. In the past, securities class action litigation has often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management’s attention and resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation.

34

Our trading price and trading volume could decline if securities or industry analysts do not publish research about our business, or if they publish unfavorable research.

Equity research analysts do not currently provide coverage of our common stock, and we cannot assure that any equity research analysts will adequately provide research coverage of our common stock after the listing of our common stock on the NASDAQ. To the extent equity research analysts do provide research coverage of our common stock, we will not have any control over the content and opinions included in their reports. The trading price of our common stock could decline if one or more equity research analysts downgrade our stock or publish other unfavorable commentary or research. If one or more equity research analysts cease coverage of our company, or fail to regularly publish reports on us, the demand for our common stock could decrease, which in turn could cause our trading price or trading volume to decline.

We do not intend to pay dividends for the foreseeable future.

We have never declared or paid any cash dividends on our capital stock, and we do not intend to pay any cash dividends in the foreseeable future. We expect to retain future earnings, if any, to fund the development and growth of our business. Any future determination to pay dividends on our capital stock will be at the discretion of our board of directors. Accordingly, you must rely on the sale of your common stock after price appreciation, which may never occur, as the only way to realize any future gain on your investment.

Our quarterly operating results may fluctuate significantly and could fall below the expectations of securities analysts and investors due to the introduction of technologically more advanced products, seasonality and other factors, some of which are beyond our control, resulting in a decline in our stock price.

Our quarterly operating results may fluctuate significantly because of several factors, including:

•        labor availability and costs for hourly and management personnel;

•        changes in interest rates;

•        macroeconomic conditions, both nationally and locally;

•        changes in consumer preferences and competitive conditions;

•        expansion to new markets;

•        weather conditions in the regions we operate;

•        increases in infrastructure costs; and

•        fluctuations in commodity prices.

Unanticipated fluctuations in our quarterly operating results could result in a decline in our stock price.

Our failure to meet the continued listing requirements of NASDAQ could result in a de-listing of our common stock.

If after listing we fail to satisfy the continued listing requirements of NASDAQ, such as the corporate governance requirements or the minimum closing bid price requirement, NASDAQ may take steps to de-list our common stock. Such a de-listing would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a de-listing, we would take actions to restore our compliance with NASDAQ’s listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, prevent our common stock from dropping below the NASDAQ minimum bid price requirement or prevent future non-compliance with NASDAQ’s listing requirements.

If our shares are delisted from NASDAQ and become subject to the penny stock rules, it would become more difficult to trade our shares.

The Securities and Exchange Commission (“SEC”) has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than

35

$5.00, other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. If we do not obtain or retain a listing on NASDAQ and if the price of our common stock is less than $5.00, our common stock will be deemed a penny stock. The penny stock rules require a broker-dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing specified information. In addition, the penny stock rules require that before effecting any transaction in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive (i) the purchaser’s written acknowledgment of the receipt of a risk disclosure statement; (ii) a written agreement to transactions involving penny stocks; and (iii) a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common stock, and therefore stockholders may have difficulty selling their shares.

Our management will have broad discretion in how we use the net proceeds of this offering and might not use them effectively.

Our management will have considerable discretion over the use of proceeds from this offering. You will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used in a manner which you may consider most appropriate. Our management might spend a portion or all of the net proceeds from this offering in ways that our stockholders do not desire or that might not yield a favorable return. The failure by our management to apply these funds effectively could harm our business. Furthermore, you will have no direct say on how our management allocates the net proceeds of this offering. Until the net proceeds are used, they may be placed in investments that do not produce significant income or that may lose value.

Future sales by our common stock may adversely affect the market price of our securities and our ability to raise funds in new offerings.

Sales of our common stock in the public market following this offering or at the conclusion of any required lock-up periods could lower the market price of our common stock and Warrants. Sales may also make it more difficult for us to sell equity securities or equity-related securities in the future at a time and price that our management deems acceptable or at all. Of the 6,059,290 shares of common stock outstanding as of January 5, 2022, 381,469 shares are, or will be, freely tradable without restriction immediately after the consummation of this offering, and approximately 755,706 of these shares, representing shares not held by our “affiliates,” generally may be resold under SEC Rule 144 beginning 90 days from the effectiveness of the registration statement of which this prospectus forms a part, subject to any lock-up agreements entered into between such stockholder and Maxim Group LLC.

Additionally, we intend to register shares of common stock that are reserved for issuance under our 2021 Equity Incentive Plan. For more information, see the section entitled “Shares Eligible for Future Sale — Registration Statements on Form S-8.”

Sales of substantial amounts of our common stock in the public market after this offering, or the perception that such sales will occur, could adversely affect the market price of our common stock and make it difficult for us to raise funds through securities offerings in the future. Of the shares to be outstanding after this offering, the shares offered by this prospectus will be eligible for immediate sale in the public market without restriction by persons other than our affiliates.

The Warrants offered by this prospectus may not have any value.

The Warrants offered by this prospectus will be exercisable for five years from the date of initial issuance at an initial exercise price of $               per share (which shall not be less than 100% of the public offering price per Unit). There can be no assurance that the market for shares of our common stock will ever equal or exceed the price of the Warrants. In the event that the price per share of our common stock does not exceed the exercise price of the Warrants during the period when the Warrants are exercisable, the Warrants may not have any value.

36

A Warrant does not entitle the holder to any rights as a holder of our shares of common stock until the holder exercises the Warrant for a share of common stock.

Until you acquire a share of common stock upon exercise of your Warrants, your Warrants will not provide you any rights as a holder of common stock. Upon exercise of your Warrants, you will be entitled to exercise the rights of a holder of common stock only as to matters for which the record date occurs after the exercise date.

Since the warrants are executory contracts, they may have no value in a bankruptcy or reorganization proceeding.

In the event a bankruptcy or reorganization proceeding is commenced by or against us, a bankruptcy court may hold that any unexercised warrants are executory contracts that are subject to rejection by us with the approval of the bankruptcy court. As a result, holders of the warrants may, even if we have sufficient funds, not be entitled to receive any consideration for their warrants or may receive an amount less than they would be entitled to if they had exercised their warrants prior to the commencement of any such bankruptcy or reorganization proceeding.

We may amend the terms of the warrants in a way that may be adverse to holders with the approval by the holders of a majority of the then outstanding warrants.

Our warrants will be issued in physical certificated form under a warrant agreement. The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision. All other modifications or amendments, including any amendment to increase the exercise price of the warrants or shorten the exercise period of the warrants, shall require the written consent of the registered holders of a majority of the then outstanding warrants.

Our outstanding warrants may have an adverse effect on the market price of our Common Stock and make it more difficult to effect a business combination.

We will be issuing warrants to purchase shares of Common Stock as part of this Offering. To the extent we issue shares of Common Stock to effect a future business combination, the potential for the issuance of a substantial number of additional shares upon exercise of these Warrants could make us a less attractive acquisition vehicle in the eyes of a target business. Such securities, when exercised, will increase the number of issued and outstanding shares of common stock and reduce the value of the shares issued to complete the business combination. Accordingly, our Warrants may make it more difficult to effectuate a business combination or increase the cost of acquiring a target business. Additionally, the sale, or even the possibility of sale, of the shares of common stock underlying the Warrants could have an adverse effect on the market price for our securities or on our ability to obtain future financing. If and to the extent these warrants are exercised, you may experience dilution to your holdings.

You will experience immediate and substantial dilution as a result of this offering and may experience additional dilution in the future.

You will incur immediate and substantial dilution as a result of this offering. After giving effect to the sale by us of 2,857,142 Units in this offering at a public offering price of $5.25 per Unit (the mid-point of the range appearing on the front cover of this prospectus), and after deducting underwriting commissions and estimated offering expenses payable by us, investors in this offering can expect an immediate dilution of $3.68 per share at the assumed public offering price. Additionally, to the extent that these warrants, or options we will grant to our officers, directors and employees, are ultimately exercised, you will sustain future dilution. We may also acquire new businesses or finance strategic alliances by issuing equity, which may result in additional dilution to our stockholders. Following the completion of this offering, our board of directors has the authority, without action or vote of our stockholders, to issue all or any part of our authorized but unissued shares of common stock, including shares issuable upon the exercise of options, or shares of our authorized but unissued preferred stock. Issuances of common stock or voting preferred stock would reduce your influence over matters on which our stockholders vote and, in the case of issuances of preferred stock, would likely result in your interest in us being subject to the prior rights of holders of that preferred stock. See the section entitled “Dilution.”

37

We will incur significant increased costs as a result of operating as a public company and our management will be required to devote substantial time to new compliance initiatives.

As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC and NASDAQ, has imposed various requirements on public companies. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, we anticipate that compliance with these rules and regulations will increase our legal, accounting and financial compliance costs substantially. A number of those requirements will require us to carry out activities we have not done previously. For example, we will create new board committees and adopt new internal controls and disclosure controls and procedures. In addition, these rules and regulations may make our activities related to legal, accounting and financial compliance more difficult, time-consuming and costly and may also place undue strain on our personnel, systems and resources. Furthermore, if we identify any issues in complying with those requirements (for example, if we or our auditors identify a material weakness or significant deficiency in our internal control over financial reporting), we could incur additional costs rectifying those issues, and the existence of those issues could adversely affect us, our reputation or investor perceptions of us. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition and results of operations. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain our current levels of such coverage. We estimate the additional costs we may incur to respond to these requirements to range from $350,000 to $500,000 annually, although unforeseen circumstances could increase actual costs. These increased costs will require us to divert a significant amount of money that we could otherwise use to expand our business and achieve our strategic objectives. Advocacy efforts by stockholders and third parties may also prompt additional changes in governance and reporting requirements, which could further increase our costs.

An investment in our company may involve tax implications, and you are encouraged to consult your own advisors as neither we nor any related party is offering any tax assurances or guidance regarding our company or your investment.

An investment in our company generally, involves complex federal, state and local income tax considerations. Neither the Internal Revenue Service nor any State or local taxing authority has reviewed the transactions described herein, and may take different positions than the ones contemplated by management. You are strongly urged to consult your own tax and other advisors prior to investing, as neither we nor any of our officers, directors or related parties is offering you tax or similar advice, nor are any such persons making any representations and warrants regarding such matters.

Unanticipated changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax returns could adversely affect our financial condition and results of operations.

We will be subject to income taxes in the United States, and our domestic tax liabilities will be subject to the allocation of expenses in differing jurisdictions. Our future effective tax rates could be subject to volatility or adversely affected by a number of factors, including:

•        changes in the valuation of our deferred tax assets and liabilities;

•        expected timing and amount of the release of any tax valuation allowances;

•        tax effects of stock-based compensation;

•        costs related to intercompany restructurings; or

•        changes in tax laws, regulations or interpretations thereof.

In addition, we may be subject to audits of our income, sales and other transaction taxes by federal, state and local authorities. Outcomes from these audits could have an adverse effect on our financial condition and results of operations.

38

Anti-takeover provisions in our charter documents and Florida law could discourage, delay or prevent a change in control of our company and may affect the trading price of our common stock.

The anti-takeover provisions of the Florida Business Corporation Act may discourage, delay or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder, even if a change in control would be beneficial to our existing stockholders. Our second amended and restated articles of incorporation and our bylaws, upon the consummation of this offering, may discourage, delay or prevent a change in our management or control over us that stockholders may consider favorable. For example, our board of directors has the right to issue preferred stock without stockholder approval that could be used to dilute a potential hostile acquirer. As a result, you may lose your ability to sell your stock for a price in excess of the prevailing market price due to these protective measures, and efforts by stockholders to change the direction or management of the company may be unsuccessful. In addition, our second amended and restated articles of incorporation and bylaws will:

•        provide that vacancies on our board of directors, including newly created directorships, may be filled only by a majority vote of directors then in office;

•        provide that special meetings of stockholders may only be called by our board of directors or a majority of our stockholders;

•        place restrictive requirements (including advance notification of stockholder nominations and proposals) on how special meetings of stockholders may be called by our stockholders;

•        not provide stockholders with the ability to cumulate their votes; and

•        provide that either a majority of our board of directors or a majority of our stockholders may amend our second amended and restated bylaws.

39

Use of Proceeds

We estimate that the net proceeds from the sale of the Units we are offering will be approximately $13.0 million based on an assumed offering price of $5.25 per Unit (which represents the mid-point of the estimated range of the initial public offering price shown on the front cover of this prospectus). If the underwriters fully exercise the over-allotment option to purchase additional shares of common stock and/or Warrants, based on an assumed offering price of $5.25 per Unit, the net proceeds we sell will be approximately $15.1 million. “Net proceeds” is what we expect to receive after deducting the underwriting discount and commission and estimated offering expenses payable by us.

The principal purposes of this offering are to increase our financial flexibility, create a public market for our common stock and to facilitate our access to the public equity markets. We intend to use the net proceeds of this offering primarily for (i) sales and marketing, (ii) expanding our inventory, (iii) updating and producing our in-store displays, (iv) development of new styles and sizes of our smart eyewear and (v) working capital and general purposes.

We anticipate an approximate allocation of the use of net proceeds as follows:

Use of Net Proceeds

 

$
(in millions)*

 

%

Inventory

 

3,902,128

 

30

Sales & Marketing

 

3,902,128

 

30

Product Development

 

2,601,419

 

20

Working Capital

 

1,951,064

 

15

Capital Expenditures

 

650,355

 

5

Total

 

13,007,094

 

100

____________

*        Assuming the over-allotment option is not exercised.

While we expect to use the net proceeds for the purposes described above, the amounts and timing of our actual expenditures will depend upon numerous factors, including the aggregate amount raised in this offering. The expected net proceeds from the sale of the shares offered hereby, if added to our current cash and cash equivalents is anticipated to be sufficient to fund our operations for at least the next 12 months. In the event that our plans change, our assumptions change or prove to be inaccurate, or the net proceeds of this offering are less than as set forth herein or otherwise prove to be insufficient, it may be necessary or advisable to reallocate proceeds or curtail expansion activities, or we may be required to seek additional financing or curtail our operations. As a result of the foregoing, our success will be affected by our discretion and judgment with respect to the application and allocation of the net proceeds of this offering.

Each $1.00 increase (decrease) in the assumed initial public offering price of $5.25 per Unit (the midpoint of the estimated price range set forth on the cover page of this prospectus) would increase (decrease) the net proceeds to us from this offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, by approximately $2,628,571, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. We may also increase or decrease the number of shares we are offering. An increase (decrease) of 1,000,000 in the number of Units we are offering would increase (decrease) the net proceeds to us from this offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, by approximately $4,830,000, assuming the initial public offering price stays the same. An increase of 1,000,000 in the number of Units we are offering, together with a $1.00 increase in the assumed initial public offering price of $5.25 per Unit (the midpoint of the estimated price range set forth on the cover page of this prospectus), would increase the net proceeds to us from this offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, by approximately $8,378,571. A decrease of 1,000,000 in the number of Units we are offering, together with a $1.00 decrease in the assumed initial public offering price of $5.25 per Unit (the midpoint of the estimated price range set forth on the cover page of this prospectus), would decrease the net proceeds to us from this offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, by approximately $5,907,538. We do not expect that a change in the offering price or the number of Units by these amounts would have a material effect on our intended uses of the net proceeds from this offering, although it may impact the amount of time prior to which we may need to seek additional capital.

Pending their use, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.

40

Dividend Policy

We have never declared or paid any cash dividends on our equity interests and we do not anticipate paying any cash dividends in the foreseeable future. The payment of dividends, if any, in the future is within the discretion of our board of directors and will depend on our earnings, capital requirements and financial condition and other relevant facts. We currently intend to retain all future earnings, if any, to finance the development and growth of our business.

41

Capitalization

The following table sets forth our cash and equivalents and capitalization as of September 30, 2021:

•        on an actual basis;

•        on a pro forma basis to give effect to (i) the issuance of 253,166 shares of common stock, at a conversion price per share of $3.56, upon the partial conversion of the Notes in the amount of $901,270.96 (including the outstanding interest thereon) on November 16, 2021, (ii) the issuance of an aggregate of 4,447 shares of common stock, at a price per share of $3.56, pursuant to the Company’s Regulation CF offering, and (iii) the conversion upon the closing of this offering of the remaining outstanding Notes in the principal amount of $283,134 into an aggregate of 53,930 shares of common stock at an assumed conversion price of $5.25 per share, which is the assumed offering price; and

•        on a pro forma as adjusted basis to additionally give effect to the sale of 2,857,142 Units in this offering, assuming an initial public offering price of $5.25 per Unit (the mid-point of the price range set forth on the cover page of this prospectus), after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.

The information set forth in the table below is illustrative only and will be adjusted based on the actual initial public offering price and other terms of this offering as determined at pricing. You should read the information in this table together with our audited financial statements and related notes and unaudited interim condensed financial statements and related notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” appearing elsewhere in this prospectus.

 

As of September 30, 2021

   

Actual

 

Pro Forma

 

Pro Forma,
as adjusted

   

(unaudited)

 

(unaudited)

 

(unaudited)

Cash and cash equivalents

 

$

65,056

 

 

$

65,056

 

 

$

13,072,150

 

Related party convertible note

 

 

420,104

 

 

 

 

 

 

 

   

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

 

 

 

 

Common stock (50,000,000 shares authorized, 5,801,677 and 4,131,469 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively at par value $0.00001).

 

 

58

 

 

 

61

 

 

 

90

 

Preferred stock, $0.00001 par value per share; 15,000,000 shares authorized, is 0 issued or outstanding as of September 30, 2021 and December 31, 2020

 

 

 

 

 

 

 

 

 

 

Additional paid-in capital

 

 

3,294,841

 

 

 

4,495,074

 

 

 

17,502,140

 

Stock subscription receivable

 

 

(25,286

)

 

 

(25,286

)

 

 

(25,286

)

Accumulated deficit

 

 

(3,238,742

)

 

 

(3,238,742

)

 

 

(3,238,742

)

Total stockholders’ equity

 

 

30,871

 

 

 

1,231,107

 

 

 

14,238,201

 

Total capitalization

 

 

450,975

 

 

 

1,231,107

 

 

 

14,238,201

 

42

The number of shares of our common stock to be outstanding upon completion of this offering is based on 5,801,667 shares of our common stock outstanding as of September 30, 2021, and excludes:

•        2,332,500 shares of common stock issuable upon exercise of stock options, at a weighted average exercise price of $2.59 per share;

•        253,166 shares of common stock, at a conversion price per share of $3.56, upon the partial conversion of Notes in the amount of $901,270.96 and 53,930 shares of common stock issuable upon conversion of the remaining Notes in the amount of $283,134 at an assumed conversion price of $5.25 per share, which is the assumed offering price;

•                 shares of common stock issuable upon the exercise of the warrants to purchase shares of our common stock issued to the underwriters in connection with this offering; and

•                 shares of our common stock reserved for future issuance under our 2021 Equity Incentive Plan (which is equal to 20% of our issued and outstanding common stock immediately after the consummation of this offering, less the number of outstanding option grants).

Each $1.00 increase (decrease) in the assumed initial public offering price of $5.25 per Unit (the midpoint of the estimated price range set forth on the cover page of this prospectus) would increase (decrease) the amount of cash, additional paid-in capital, total stockholders’ equity (deficit) and total capitalization on a pro forma as adjusted basis by approximately $2,628,571, assuming the number of Units, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of one million Units offered by us would increase (decrease) cash, total stockholders’ equity (deficit) and total capitalization on a pro forma as adjusted basis by approximately $4,830,000, assuming the assumed initial public offering price of $5.25 per Unit (the midpoint of the estimated price range set forth on the cover page of this prospectus) remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. Each one million Unit increase in the number of Units offered by us together with a concomitant $1.00 increase in the assumed initial public offering price of $5.25 per Unit (the midpoint of the estimated price range set forth on the cover page of this prospectus) would increase each of cash and total stockholders’ (deficit) equity by approximately $8,378,574 after deducting underwriting discounts and commissions and any estimated offering expenses payable by us. Conversely, each one million Unit decrease in the number of Units offered by us together with a concomitant $1.00 decrease in the assumed initial public offering price of $5.25 per Unit (the midpoint of the estimated price range set forth on the cover page of this prospectus) would decrease each of cash and total stockholders’ (deficit) equity by approximately $5,907,138 after deducting underwriting discounts and commissions and any estimated offering expenses payable by us. The pro forma as adjusted information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing.

43

Dilution

If you purchase the Units in this offering, your interest will be diluted immediately to the extent of the difference between the assumed public offering price of $5.25 per Unit (the mid-point of the range appearing on the front cover of this prospectus) and the as adjusted net tangible book value per share of our common stock immediately upon the consummation of this offering. As of September 30, 2021, we had a historical net tangible book value of $(108,708), or $(0.02) per share of common stock. Our historical net tangible book value per share represents total tangible assets less total liabilities, divided by the number of shares of our common stock outstanding as of September 30, 2021.

Our pro forma net tangible book value as of September 30, 2021 was $1,091,528, or $0.18 per share of our common stock. Pro forma net tangible book value represents the amount of our total tangible assets less our total liabilities, after giving effect to (i) the issuance of 253,166 shares of common stock, at a price per share of $3.56, upon the partial conversion of the principal and interest in the amount of $901,270.96 on the Notes on November 16, 2021, (ii) the issuance of an aggregate of 4,447 shares of common stock, at a price per share of $3.56, pursuant to the Company’s receipt of $15,831 from the Regulation CF offering, and (iii) the conversion upon the closing of this offering of amount remaining principal and interest in the amount of $283,134 on the Notes into an aggregate of 53,930 shares of common stock at a conversion price of $5.25 per share.

After giving effect to our sale of 2,857,142 Units in this offering at an assumed public offering price of $5.25 per share of common stock included in each Unit, and after deducting underwriters’ commissions and estimated offering expenses, but assuming no exercise of the Warrants included in the Units offered hereby or the warrants issued to the Representative of the underwriters, our pro forma as adjusted net tangible book value as of September 30, 2021 would have been $14,098,626, or $1.57 per share of common stock. This represents an immediate increase in net tangible book value of $1.39 per share of common stock to existing stockholders and an immediate dilution in net tangible book value of $3.68 per share to purchasers of Units in this offering.

The following table illustrates this dilution on a per share of common stock basis assuming the underwriters do not exercise their option to purchase additional shares of common stock:

Assumed public offering price per Unit

 

 

 

 

 

$

5.25

Net tangible book value per share as of September 30, 2021

 

$

(0.02

)

 

 

 

Pro forma net tangible book value per share

 

$

 

 

 

 

0.18

Pro forma increase in net tangible book value per share attributable to new investors

 

$

 

 

 

 

1.39

Pro forma as adjusted net tangible book value per share as of September 30, 2021, after giving effect to the offering

 

$

 

 

 

 

1.57

Dilution per share to new investors in the offering

 

 

 

 

 

$

3.68

The dilution information discussed above is illustrative only and may change based on the actual initial public offering price and other terms of this offering.

A $1.00 decrease in the assumed initial public offering price of $5.25 per Unit (the midpoint of the price range set forth on the cover page of this prospectus) would decrease our pro forma as adjusted net tangible book value as of September 30, 2021 after this offering by approximately $2,628,571, or approximately $0.29 per share, and would increase dilution to investors in this offering to approximately $3.97 per share, assuming that the number of Units offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting the estimated underwriting discount and estimated offering expenses payable by us. A $1.00 increase in the assumed initial public offering price of $5.25 per Unit (the midpoint of the price range set forth on the cover page of this prospectus) would decrease our pro forma as adjusted net tangible book value as of September 30, 2021 after this offering by approximately $2,628,571, or approximately $0.29 per share, and would decrease dilution to investors in this offering to approximately $3.39 per share, assuming that the number of Units offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting the estimated underwriting discount and estimated offering expenses payable by us. We may also increase or decrease the number of Units we are offering. An increase of 1,000,000 in the number of Units we are offering would increase our pro forma as adjusted net tangible book value as of September 30, 2021 after this offering by approximately $4,830,000, or approximately $0.33 per share, and would decrease dilution to investors in this offering to approximately $3.35 per share, assuming the assumed initial public offering price per Unit remains the same, after deducting the estimated underwriting discount and estimated offering expenses payable by us. A decrease

44

of 1,000,000 in the number of Units we are offering would decrease our pro forma as adjusted net tangible book value as of September 30, 2021 after this offering by approximately $4,830,000, or approximately $0.41 per share, and would increase dilution to investors in this offering to approximately $4.09 per share, assuming the assumed initial public offering price per Unit remains the same, after deducting the estimated underwriting discount and estimated offering expenses payable by us.

If the underwriters exercise their option in full to purchase 428,571 additional shares of common stock and/or Warrants in this offering at the assumed offering price of $5.25 per Unit, the pro forma net tangible book value per share after this offering would be $1.72 per share of common stock, the increase in the pro forma as adjusted net tangible book value per share to existing stockholders would be $1.54 per share of common stock and the dilution to new investors purchasing securities in this offering would be $3.53 per share of common stock.

The following charts illustrate our pro forma proportionate ownership, upon completion of this offering by present stockholders and investors in this offering, compared to the relative amounts paid by each. The charts reflect payment by present stockholders as of the date the consideration was received and by investors in this offering at the public offering price. The charts further assume no changes in net tangible book value other than those resulting from the offering.

 

Shares Purchased

 

Total Consideration

 

Average Price

   

Amount
(#)

 

Percent
(%)

 

Amount
($)

 

Percent
(%)

 

Per Share
($)

Existing stockholders

 

6,113,220

 

68

%

 

4,067,358

 

21

%

 

$

0.67

New investors

 

2,857,142

 

32

%

 

15,000,000

 

79

%

 

$

5.25

Total

 

8,970,362

 

100.0

%

 

19,067,358

 

100.0

%

 

$

2.13

The number of shares of our common stock outstanding before and after this offering reflected in the tables and discussion above are based on (i) 6,113,220 shares of common stock outstanding as of the date of this prospectus (including the issuance of 253,166 shares of common stock, at a price per share of $3.56, upon the partial conversion of the Notes on November 16, 2021, the issuance of an aggregate of 4,447 shares of common stock, at a price per share of $3.56, pursuant to the Company’s Regulation CF offering, and the conversion upon the closing of this offering of amount remaining on the Notes into an aggregate of 53,930 shares of common stock at a conversion price of $5.25 per share), and (ii) 8,970,362 shares of common stock outstanding on a pro forma as adjusted basis after giving effect to this offering and exclude, as of that date, the following:

•        2,332,500 shares of common stock issuable upon exercise of stock options, at a weighted average exercise price of $2.59 per share;

•                     shares of common stock issuable upon the exercise of the warrants to purchase shares of our common stock issued to the underwriters in connection with this offering; and

•                     shares of our common stock reserved for future issuance under our 2021 Equity Incentive Plan (which is equal to 20% of our issued and outstanding common stock immediately after the consummation of this offering, less the number of outstanding option grants).

45

The table below assumes the underwriters’ exercise their over-allotment option in full:

 

Shares Purchased

 

Total Consideration

 

Average Price

   

Amount
(#)

 

Percent
(%)

 

Amount
($)

 

Percent
(%)

 

Per Share
($)

Existing stockholders

 

6,113,220

 

65%

 

4,067,358

 

19%

 

$

0.67

New investors

 

3,285,713

 

35%

 

17,250,000

 

81%

 

$

5.25

Total

 

9,398,933

 

100.0%

 

21,317,358

 

100.0%

 

$

2.27

The number of shares of our common stock outstanding before and after this offering reflected in the tables and discussion above are based on 6,113,220 shares of common stock outstanding as of the date of this prospectus (including the issuance of 253,166 shares of common stock, at a price per share of $3.56, upon the partial conversion of the Notes on November 16, 2021, the issuance of an aggregate of 4,447 shares of common stock, at a price per share of $3.56, pursuant to the Company’s Regulation CF offering, and the conversion upon the closing of this offering of amount remaining on the Notes into an aggregate of 53,930 shares of common stock at a conversion price of $5.25 per share), and (ii) 9,398,933 shares of common stock outstanding on a pro forma as adjusted basis after giving effect to this offering and exclude, as of that date, the following:

•        2,332,500 shares of common stock issuable upon exercise of stock options, at a weighted average exercise price of $2.59 per share;

•                     shares of common stock issuable upon the exercise of the warrants to purchase shares of our common stock issued to the underwriters in connection with this offering; and

•                     shares of our common stock reserved for future issuance under our 2021 Equity Incentive Plan (which is equal to 20% of our issued and outstanding common stock immediately after the consummation of this offering, less the number of outstanding option grants).

46

Management’s Discussion and Analysis of
F
inancial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with the section titled “Summary of Financial Information” and our financial statements and related notes included elsewhere in this prospectus. Data as of and for the periods ended December 31, 2019 and 2020 has been derived from our audited financial statements appearing at the end of this prospectus. Data as of and for the nine months ended September 30, 2020 and 2021 has been derived from our unaudited condensed financial statements appearing at the end of this prospectus. Results for any interim period should not be construed as an inference of what our results would be for any full fiscal year or future period. This discussion and other parts of this prospectus contain forward-looking statements, such as those relating to our plans, objectives, expectations, intentions, and beliefs, which involve risks and uncertainties. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the sections titled “Special Note Regarding Forward-Looking Statements” and “Risk Factors” included elsewhere in this prospectus.

Overview

We develop and sell smart eyeglasses and sunglasses, which are designed to allow our customers to remain connected to their digital lives, while also offering vision correction and protection. Our flagship product, Lucyd Lyte, enables the wearer to listen to music, take and make calls, and use voice assistants to perform many common smartphone tasks hands-free. Innovative Eyewear owns the exclusive rights to the Lucyd brand and the Lyte product line.

Our mission is to Upgrade Your Eyewear. Our smart eyewear is a fusion of headphones with glasses, bringing vision correction and protection together with digital connectivity and clear audio, while also offering a solution for listening to music outdoors (as compared to in-ear headphones). The convenience of having a Bluetooth headset and comfortable glasses in one, especially for those who are already accustomed to all-day eyewear use, offers a lifestyle upgrade at a price similar to traditional prescription eyewear.

After the full launch of Lucyd Lyte in January 2021, we had strong interest and demand from customers in the U.S., and have since sold thousands of our smart eyewear. In order to meet the growing demand for our products, and in an effort to expand our reach, we have engaged over 100 optical resellers. All of our products are designed in Miami, manufactured in Asia, and currently sold through two major sales channels:

(1)    ecommerce primarily via our website (Lucyd.co) and Amazon; and,

(2)    a growing network of independent eyewear stores.

We apply a manufacturer suggested retail price (“MSRP”) of $149 (for our standard frames) to $179 (for our titanium frames) for non-prescription, polarized sunglass and blue light blocking glasses across all of our online channels, with our wholesale pricing offering volume discounts to these prices. Please refer to discussion in the Components of Results of Operations for more details regarding our pricing structure.

We are gearing-up to expand these channels with national eyewear chains, big box retail stores (electronics, sporting goods, general merchandise) and specialty retail stores.

We view this business model as being more efficient with regards to the deployment of capital, by electing not to build our own manufacturing facilities and Company-owned retail distribution, but rather contract with existing sources of production and consumer facing retail distribution.

Impact of COVID-19 on Our Business

On March 11, 2020, the World Health Organization officially declared the outbreak of the COVID-19 virus a “pandemic.” This contagious disease outbreak has continued to spread across the globe and is impacting worldwide economic activity and financial markets. In light of the uncertain and rapidly evolving situation relating to the spread of COVID-19, we took precautionary measures intended to minimize the risk of the virus to our employees, by following the CDC guidelines. Specifically, we set up a system that enabled our employees to work remotely when it was beneficial for them or when they felt ill. Additionally, precautionary measures that have been adopted may negatively affect our ability to sell our products. For example, reducing the marketplace traction at trade shows, and

47

retail store traffic for our re-sellers, and the fulfillment of customer orders with customized lenses, shipping delays and other operations of our suppliers and fulfillment partners. Additionally, our product is manufactured in China and shipped from China on a regular basis. We have not experienced substantial delays in manufacturing or shipping due to COVID-19, however, we are exposed to such risk in the future as a potential impact of COVID-19. More generally, the outbreak of COVID-19 could adversely affect economies and financial markets globally, potentially leading to an economic downturn, which could decrease consumer spending and adversely affect demand for our products. It is not possible at this time to estimate the impact that COVID-19 could have on our business, as the impact will depend on future developments, which are highly uncertain and cannot be predicted.

Key Factors Affecting Performance

Expansion of retail points of purchase

Our future depends in large part on our ability to place Lucyd Lyte in optical stores as well as sporting goods stores and other specialty stores. To address this we assembled a team with decades of experience in the eyewear industry and are offering a strong co-op marketing program. We currently have 12 different styles available and plans to continuously increase this number over time.

Retail store client retention and re-orders

Our ability to sustain and increase revenue depends in large part on our ability to receive re-orders from stores, either directly or through our wholesale distributors. To support our sales to retail stores directly, we offer a strong co-op marketing program that includes free and paid store display materials. As part of this strategy, we are launching a digital try-on kiosk for our resellers to help educate their in-store customers about Lucyd Lyte and enable customers to try them on in a contact-less manner, to mitigate customer contact with viral pathogens.

Investing in business growth

We believe that people care about what they wear on their faces, and because we understand that customers have diverse preferences about the shape, size and design of their eyewear, we aim to continuously invest in the design and development of new models in an effort to provide the consumer with a wide selection of styles, colors and finishes.

We also intend to invest in co-op marketing with retail stores, expansion of our sales and marketing team (including influencers) to broaden our brand awareness and online presence. We will also increase our general and administrative expenses in the foreseeable future to cover the additional costs for finance, compliance, supply chain, quality assurance and investor relations as we grow as a public company.

Key Performance Indicators

Store Count (B2B)

We believe that one of the key indicators for our business is the number of retail stores onboarded to sell Lucyd Lyte. We started onboarding our first retail stores in June 2021. Currently, we have over 180 retail stores selling Lucyd Lyte primarily in the United States and Canada.

Based on the existing demand for our products, current distribution and recently consummated supply agreements, we anticipate that our products will be available in a significant number of new third-party retail locations in 2022.

Re-order ratio (B2B)

Many of the retail stores that placed initial stocking orders, either directly or through our wholesale distributors, have also placed follow-on orders in the few short months since launching our wholesale business in June 2021. As of September 30, 2021, 58% of stores have re-ordered our product. We expect this number to gradually increase as we roll out our co-op marketing program and introduce our virtual try-on kiosks into retail stores, to facilitate customer education and product sell-through.

48

Number of online orders (B2C)

For our ecommerce business, we track the number of online orders as an indicator of the success of our online marketing efforts. Through September 30 2021, we received total of over 3000 orders from customers online. We believe that the addition of a virtual try on widget, as well as further investment in brand awareness, product ambassadors and influencer campaigns, will enable continued growth of online orders in the foreseeable future. We expect to allocate a significant portion of our advertising expenditures towards influencer marketing programs.

Components of Results of Operations

Net Revenue

Our revenue is generated from the sales of prescription and non-prescription optical glasses, sunglasses and shipping charges, which are charged to the customer, associated with these purchases. We sell products through our retail store resellers, distributors and on our own website Lucyd.co and on Amazon.

We apply a manufacturer suggested retail price (“MSRP”) of $149 (for our standard frames) to $179 (for our titanium frames) for non-prescription, polarized sunglass and blue light blocking glasses across all of our online channels. Only U.S. consumers enjoy free USPS first class postage, with faster delivery options available for extra cost, for sales processed through our website and on Amazon. For Amazon sales, shipping is free for U.S consumers while international customers pay shipping charges. Any costs associated with fees charged by the online platforms (Shopify for Lucyd.co website and Amazon) are not recharged to customers. We charge applicable state sales taxes in addition to the MSRP for both online channels and all other marketplaces on which sell.

Our wholesale pricing for eyewear sold to retail store partners and distributors includes volume discounts to the MSRP, due to the nature of large quantity orders. The pricing includes shipping charges, while excluding any state sales tax charges applicable. Due to the nature of wholesale retail orders, no e-commerce fees are applicable.

Our prescription lens price currently ranges from $35 to $275, which is charged in addition to the MSRP. Glasses with prescription lenses are only available through our website Lucyd.co, while our sales through Amazon and to our retail partners only include non-prescription glasses.

Cost of Goods Sold

Cost of goods sold includes the costs incurred to acquire materials, assemble, and sell our finished products.

For retail sales placed on one of our eCommerce channels these costs include (i) product costs held at the lesser of cost and net realizable value and inclusive of inventory reserves, (ii) freight, import, and inspection costs, (iii) optical laboratory costs for RX glasses, (iv) merchant fees, (v) fees paid to 3rd party eCommerce platforms (vi) and cost of shipping the product to the consumer.

For wholesale sales these costs include (i) product costs stated at the lesser of cost and net realizable value and inclusive of inventory reserves, (ii) freight, import, and inspection costs, (iii) and credit card fees.

When consumers place their orders directly on our online store, our cost of goods sold on a per-unit basis is approximately 8% lower than when consumers place their orders directly from 3rd parties’ platforms.

We expect our cost of goods sold to fluctuate as a percentage of net revenue primarily due to product mix, customer preferences and resulting demand, customer shipping costs, and management of our inventory and merchandise mix.

Over time we expect our total cost of goods sold on a per unit basis to decrease as a result of an increase in scale. Increase in scale is achieved as a result of increase in volumes from both business to consumer and business to business (retail store) orders. We continue to expand our products with line extensions and new models and broaden our presence in retail stores carrying our products.

Gross Profit and Gross Margin

We define gross profit as net revenues less cost of goods sold. Gross margin is gross profit expressed as a percentage of net revenues. Our gross margin may fluctuate in the future based on a number of factors, including the cost at which we can obtain, transport, and assemble our inventory, the rate at our vendor network expands, and how effective we can be at controlling costs, in any given period.

49

We anticipate our cost of goods sold, on a per unit basis, will decrease with scale, and this will likely have a positive impact on our gross margins.

Operating Expenses

Our operating expenses consist primarily of:

•        general & administrative expenses that include primarily consulting and payroll expenses, IT & software, legal, stock compensation expense, postage and non-customer product shipping and other administrative expense;

•        sales and marketing expenses including cost of online and TV advertising, marketing agency fees, influencers, trade shows and other initiatives;

•        related party management fee for a range of back-office services provided by Lucyd Ltd.;

•        research and development expenses related to (i) development of new styles and features of our smart eyewear (ii) development and improvement of our ecommerce website (iii) development of our Vyrb social media app for wearables.

Interest and Other Income, Net

Interest and other income, net, consists primarily of interest expense paid on convertible note loan due to the Parent.

Provision for Income Taxes

Provision for income taxes consists of income taxes related to foreign and domestic federal and state jurisdictions in which we conduct business, adjusted for allowable credits, deductions, and valuation allowance against deferred tax assets.

Results of Operations

Comparison of nine months ended September 30, 2021 (unaudited) to nine months ended September 30, 2020 (unaudited)

 

Nine months ended
September 30,

     

Change
between the
nine months
ended
September 30,
2020 and 2021

   
   

2021

     

2020

 

Revenues, net

 

415,185

 

 

100

%

 

33,592

 

 

100

%

 

381,593

 

 

1,136

%

Less: Cost of Goods Sold

 

(332,378

)

 

80

%

 

(34,783

)

 

104

%

 

(297,595

)

 

856

%

Gross Profit

 

82,807

 

 

20

%

 

(1,191)

 

 

(4

)%

 

83,998

 

 

7,053

%

     

 

   

 

   

 

   

 

   

 

   

 

Operating expenses:

   

 

   

 

   

 

   

 

   

 

   

 

General & administrative

 

(883,356

)

 

213

%

 

(210,509

)

 

627

%

 

(672,847

)

 

320

%

Impairment expense

 

 

 

0

%

 

(112,329

)

 

334

%

 

112,329

 

 

 

Sales and marketing

 

(903,795

)

 

218

%

 

(98,789

)

 

294

%

 

(805,006

)

 

815

%

Related party management fee

 

(84,975

)

 

20

%

 

(102,475

)

 

305

%

 

17,500

 

 

(17

)%

Research and development

 

(36,121

)

 

9

%

 

30,822

)

 

92

%

 

(5,299

)

 

17

%

Total Operating Expenses

 

(1,908,247

)

 

460

%

 

(554,924

)

 

1,652

%

 

(1,353,323

)

 

244

%

     

 

   

 

   

 

   

 

   

 

   

 

Other (Expense):

   

 

   

 

   

 

   

 

   

 

   

 

Interest Expense

 

(33,654

)

 

8

%

 

 

 

0

%

 

(33,654

)

 

 

Total Other (Expense)

 

(33,654

)

 

8

%

 

 

 

0

%

 

(33,654

)

 

 

     

 

   

 

   

 

   

 

   

 

   

 

Net Loss

 

(1,859,094

)

 

448

%

 

(556,115

)

 

1,655

%

 

(1,302,979

)

 

234

%

50

Revenue

Our revenues during the nine months ended September 30, 2021 were $415,185 as compared to revenues of $33,592 during the nine months ended September 30, 2020. Our revenue is generated entirely from sales of eyewear products, namely smart frames, lenses and accessories. The increase in revenue was due to the launch of Lucyd Lytes, in January 2021, as compared to our limited sales of our beta products, which we do not consider a comparable benchmark to our 2021 sales.

For nine months ending September 30, 2021, approximately 49% of sales were processed on our online store (Lucyd.co), 32% on Amazon and 19% to retail store partners. This sales channel mix impacted our revenue for the period, due to the fact we charge additional $35 to $275 for our prescription lenses available only on Lucyd.co. For nine months ended September 30, 2021, we generated $306,409 of revenue from sales of nonprescription frames and $108,776 was generated from sales of frames with prescription lenses. All sales generated on Amazon.com during the period of $130,841 represent non-prescription frames as we only offer prescription lenses through our website. Out of $201,437 in online sales generated through Lucyd.co, $108,776 related to frames with prescription lenses with $92,661 of glasses sold with non-prescription frames. Our website sales have remained the most material portion of our sales to date, aided by higher price compared to retail store pricing as well as additional revenue recorded due to sales of prescription lenses.

We expect that the online portion of our sales will gradually decrease on a percentage basis, but remain an important component of our total sales as we onboard more retail stores. We pursued growth in retail store segment in the third quarter of 2021, growing our retail store presence to over 100 stores as of September 30, 2021.

Cost of goods sold

Our total cost of goods sold increased to $332,378 for the nine month period ended September 30, 2021 as compared to $34,783 for the nine month period ended September 30, 2020. This increase mirrors the increase in underlying sales and the launch of our Lucyd Lyte in January 2021. These items included, but weren’t limited to, the cost of frames of $173,098, cost of prescription lenses incurred with our third-party vendor of $108,451, affiliate referral fees, sales commission expense, ecommerce platform fees of $46,915 and quality assurance costs related to our products sold of $3,600 for the nine month period ended September 30, 2021. Out of $332,378 of our total cost of goods sold for the nine months ended September 30, 2021, $172,483 related to orders with prescription lenses, while $159,895 pertained to non-prescription orders.

For nine months ending September 30, 2021, approximately 49% of sales were processed on our online store (Lucyd.co), 32% on Amazon and 19% to retail store partners. This sales channel mix impacted our cost of goods sold, as the cost of prescription lenses attributable to our Lucyd.co sales increased our cost of goods sold through Lucyd.co while not impacting cost of goods sold for sales realized through Amazon or retail store partners.

Over time, we expect retail stores to become our primary sales channel as we onboard new stores. Consequently, we expect cost of prescription lens, offered only as part of our website sales and not to retail stores, to gradually decrease as a percentage of our overall cost of goods sold.

As we anticipate growth in both wholesale and ecommerce channel sales in our fourth quarter of 2021 and going forward, we also expect corresponding growth in total cost of goods sold, primarily from product related costs.

Gross profit

Our gross profit increased to $82,807 for the nine month period ended September 30, 2021 as compared to ($1,191) for the nine month period ended September 30, 2020. This increase was due to the difference in the price of Lucyd Lytes versus our previous beta products. We expect that gross profits for the remainder of fiscal year ended 2021 and for fiscal year 2022 to improve slightly, primarily due to economies of scale from large anticipated orders. As we expect retail stores to become our primary sales channel as we onboard new stores, we also expect our overall gross margin to approximate that of the wholesale channel, where no e-commerce platform fees or prescription lens cost apply and volume related price discounts are included.

51

Operating expenses

Our operating expenses increased to $1,908,247 for the nine month period ended September 30, 2021 as compared to $554,924 for the nine month period ended September 30, 2020. This increase was primarily due to the expansion of our business following launch of Lucyd Lyte in January 2021 and included, but was not limited to, the following:

General and administrative expenses

Our general and administrative expenses increased to $883,356 for the nine month period ended September 30, 2021 as compared to $554,924 for the nine month period ended September 30, 2020. This increase was primarily due to an increase of stock option awards, resulting from increase in our staffing, from $41,875 to $564,637. Also as a result of Company’s growth and increased used of consultants, consulting fees increased from $46,943 to $209,330.

Sales and marketing expenses

Our sales and marketing expenses increased to $903,795 for the nine month period ended September 30, 2021 as compared to $98,789 for the nine month period ended September 30, 2020. The increase was primarily due to our multi-prong sales and marketing approach, launched in 2021, including the costs of online advertising of $355,780, TV advertising of $111,297, trade shows of $59,956 and SEO management of $59,177. We also hired four sales & marketing staff, and booked $130,137 in related stock compensation expense for the period.

We anticipate these costs to further increase as we continue to invest in and build our brand, expand the number of ecommerce platforms we sell our products on and invest in retail store co-op marketing programs to help educate our in-store customers about Lucyd Lytes, and increase our brand’s physical presence and role in the eyewear industry.

Related party management fee

Our related party management fee was $84,975 for the nine month period ended September 30, 2021 as compared to $102,475 for the nine month period ended September 30, 2020. The management fees are related to the management services agreement between us and an affiliate of our Parent.

Research and development costs

Our research and development costs increased to $36,121 for the nine month period ended September 30, 2021 as compared to $30,822 for the nine month period ended September 30, 2020. The increase was primarily attributable to the increased cost of new frame development by $2,820, the cost of website development by $1,731 and the cost of Vyrb app development of $748.

Impairment Expense

During the nine months period ended September 30, 2021, no impairment charges were required based on management’s analysis of long-lived assets.

The following tables set forth our statement of operations in dollar amounts and as a percentage of total revenue for each period presented (dollars in millions):

 

Year ended
December 31,
2020

     

Period ended
December 31,
2019

     

2020 vs 2019

   

Revenues, net

 

56,997

 

 

100

%

 

4,821

 

 

100

%

 

52,176

 

 

1,082

%

Less: Cost of Goods Sold

 

(74,266

)

 

130

%

 

(7,735

)

 

160

%

 

(66,531

)

 

860

%

Gross (Deficit)

 

(17,269

)

 

(30

)%

 

(2,914

)

 

(60

)%

 

(14,355

)

 

493

%

     

 

   

 

   

 

   

 

   

 

   

 

Operating expenses

   

 

   

 

   

 

   

 

   

 

   

 

General & administrative

 

(316,115

)

 

555

%

 

(43,398

)

 

900

%

 

(272,717

)

 

628

%

Impairment expense

 

(112,329

)

 

197

%

 

 

 

0

%

 

(112,329

)

 

 

Sales and marketing

 

(152,731

)

 

268

%

 

(2,924

)

 

61

%

 

(149,807

)

 

5,123

%

Related party management fee

 

(130,000

)

 

228

%

 

(56,108

)

 

1164

%

 

(73,892

)

 

132

%

Research & Development

 

(36,894

)

 

65

%

 

(4,083

)

 

85

%

 

(32,811

)

 

804

%

Total Operating Expenses

 

(748,069

)

 

1,312

%

 

(106,513

)

 

2,209

%

 

(641,556

)

 

602

%

     

 

   

 

   

 

   

 

   

 

   

 

Other income

 

2,120

 

 

4

%

 

 

   

 

 

2,120

 

 

 

Interest expense

 

(4,966

)

 

9

%

 

 

   

 

 

(4,966

)

 

 

Total Other Income/(Expense)

 

(2,846

)

 

5

%

 

 

   

 

 

(2,846

)

 

 

     

 

   

 

   

 

   

 

   

 

   

 

Net Loss

 

(768,184

)

 

1,348

%

 

(109,427

)

 

2,270

%

 

(658,757

)

 

602

%

52

Revenue

Our revenue increased to $56,997 for the year ended December 31, 2020 as compared to $4,821 for the period ended December 31, 2019. For the year ended December 31, 2020, the Company recorded $50,352 related to non-prescription frame sales, and $6,645 related to glasses with prescription lenses. In 2019, the entirety of the Company’s sales related to non-prescription glasses.

While we consider both years to be largely developmental in nature before launch of Lucyd Lyte in 2021, limited product releases were made in order to gather customer feedback.

Cost of goods sold

Our cost of sold increased to $74,266 for the year ended December 31, 2020, of which $23,917 related to cost of glasses with prescription frames and $50,349 for non-prescription frames, as compared to $7,735 for the period ended December 31, 2019, when all frames sold were non-prescription frames.

The increase was primarily due to an increase in related product costs for our increased product sales. Due to the beta testing nature of the sales and related costs, we do not consider the fluctuations to be indicative of the nature of ongoing costs of goods sold. We recommend you review “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Comparison of the nine months ended September 30, 2021 and September 30, 2020” for a better indication of our anticipated costs of goods sold in the future.

Gross profit (loss)

Our gross profit (loss) increased to $(17,269) for the year ended December 31, 2020 as compared to $(2,914) for the period ended December 31, 2019. The increase was primarily due to the beta testing nature of our limited product releases that were discontinued in December 2020, before Lucyd Lytes were launched in January 2021.

Operating expenses

Our operating expenses increased to $748,069 for the year ended December 31, 2020 as compared to $106,513 for the period ended December 31, 2019. This increase was primarily due to the expansion of our business in anticipation of our launch of Lucyd Lytes in the beginning of 2021 and included, but was not limited to, the following:

General and administrative expenses

Our general and administrative expenses increased to $316,115 for the year ended December 31, 2020 as compared to $43,398 for the period ended December 31, 2019. This increase was primarily due to an increase of consulting fees and cash fees paid to our employees of $76,589 and stock compensation expenses of $81,645.

Impairment expenses

We recorded an impairment expense of $112,329 for the year ended December 31, 2020 as compared to $0 for the period ended December 31, 2019.

The license agreement subject to the impairment had been originally entered into between the Company’s Parent (Lucyd Ltd) and University of Central Florida (“UCF”) and subsequently contributed from Lucyd to the Company as a contribution to capital via an exclusive, irrevocable license of these assets from Lucyd. The impairment charge represented the total net book value of any licenses to intellectual property previously held by the Company.

Lucyd Ltd licensed a group of patents from UCF covering augmented reality glasses, specifically enabling the display of information on the lenses of glasses. The UCF patents were subsequently, with UCF’s permission, exclusively licensed to Innovative Eyewear, Inc. by Lucyd Ltd. After conducting significant research on this licensed technology, Innovative Eyewear Inc. determined that the technology was not ready for commercialization, so it amicably terminated the license, consistent with its terms and conditions. Innovative Eyewear no longer has any obligation under the license to UCF nor does Innovative Eyewear have a current business relationship with UCF. UCF has no rights to any properties currently held by Innovative Eyewear Inc.

None of Innovative Eyewear’s current patents and applications are related to the previously licensed patents from UCF. The Company does not believe the charge is representative of material trends in the business as following the impairment charge, our patent portfolio includes only patents developed internally in the last few years.

Sales and marketing expenses

Our sales and marketing expenses increased to $152,731 for the year ended December 31, 2020 as compared to $2,924 for the period ended December 31, 2019. We had immaterial sales and marketing expenses in 2019 and the increase was related to our initial market tests of beta versions of our product.

53

Related party management fee

Our related party management fees increased to $130,000 for the year ended December 31, 2020 as compared to $56,108 for the period ended December 31, 2019. The increase was primarily due to ramp up of assistances provided by the affiliate of the Parent in hiring and overall scale up of Company’s operations post formation in 2019.

Research and development costs

Our research and development costs increased to $36,894 for the year ended December 31, 2020 as compared to $4,083 for the period ended December 31, 2019. The increase was primarily due to expenditures of $13,821 for smart eyewear product development, $13,742 for Vyrb app development and $9,331 for website development we incurred in primarily in 2020.

Seasonality

Historically, our business has not experienced material seasonal fluctuations in net revenue. However, we do observe moderately higher seasonal demand during the months of November and December due in part to holiday shopping.

Liquidity and capital resources

Since inception, we have financed our operations primarily from:

•        capital contribution from the Parent at the time of inception,

•        issuance of convertible note held by Parent and,

•        two equity crowdfunds.

We expect that operating losses could continue in the foreseeable future as we continue to invest in the expansion of our business, further research and development and sales and marketing activities. We believe our existing cash and cash equivalents, proceeds from this offering, funds available under our existing credit facility, and cash flows from operating activities will be sufficient to fund our operations for at least the next twelve months. We intend to use proceeds from this offering primarily on (i) sales and marketing, (ii) expanding our inventory, (iii) updating and developing our in-store displays, (iv) development of new smart eyewear styles and sizes, as well as further development and commercialization of the Vyrb app and (v) working capital and general corporate purposes.

However, our future capital requirements will depend on many factors, including, but not limited to, growth in the number of retail store customers, the needs of our ecommerce business and retail distribution network, expansion of our product and software offerings, and the timing of investments in technology and personnel to support the overall growth of our business. To the extent that current and anticipated future sources of liquidity are insufficient to fund our future business activities and requirements, we may be required to seek additional equity or debt financing. The sale of additional equity would result in additional dilution to our stockholders. The incurrence of debt financing would result in debt service obligations and the instruments governing such debt could provide for operating and financing covenants that would restrict our operations. There can be no assurances that we will be able to raise additional capital. In the event that additional financing is required from outside sources, we may not be able to negotiate terms acceptable to us or at all. In particular, the recent COVID-19 pandemic has caused disruption in the global financial markets, which could reduce our ability to access capital and negatively affect our liquidity in the future. If we are unable to raise additional capital when required, or if we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, results of operations, financial condition, and cash flows would be adversely affected.

Going Concern

The Company has a limited operating history. The Company’s business and operations are sensitive to general business and economic conditions in the United States. A host of factors beyond the Company’s control could cause fluctuations in these conditions. Adverse conditions may include: recession, downturn or otherwise, changes in regulations or restrictions in imports, competition or changes in consumer taste including the economic impacts from the COVID-19 pandemic. These adverse conditions could affect the Company’s financial condition and the results of its operations.

54

The Company meets its day to day working capital requirements through monies raised through sales of eyewear and issues of equity including crowdfunding. The Company also has issued a convertible note held by its parent company. Company’s forecasts and projections indicate that the Company expects to have sufficient cash reserves to operate within the level of its current facilities. Whilst it is the Company’s intention to rely on the available cash reserves, future income generated from its product sales, a negative variance in the forecasts and projections would make the Company’s ability to continue as a going concern dependent on an additional fund raise. Based on these factors, there is substantial doubt about the Company’s ability to continue as a going concern.

Off-Balance sheet arrangements

As of September 30, 2021, we did not have any off-balance sheet arrangements.

Critical Accounting Policies and Significant Developments and Estimates

Management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with GAAP. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, as well as the reported revenue generated and expenses incurred during the reporting periods, as well as related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities and the amount of revenue and expenses that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions, and any such differences may be material. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management’s judgments and estimates.

We believe that our application of accounting policies, and the estimates inherently required therein, are reasonable. We periodically reevaluate these accounting policies and estimates and make adjustments when facts and circumstances dictate a change. Historically, we have found our application of accounting policies to be appropriate, and actual results have not differed materially from those determined using necessary estimates.

Inventory

Our inventory includes purchased eyewear and is stated at the lower of cost or net realizable value, with cost determined on a weighted average first-in, first-out basis. Provisions for excess, obsolete or slow moving inventory are recorded after periodic evaluation of historical sales, current economic trends, forecasted sales, estimated product life cycles and estimated inventory levels. No provisions were determined as needed at September 30, 2021.

In accordance with our donation policy started in May 2021, we donate an optical frame for every Lucyd Lyte sold. During the nine month period ended September 30, 2021 we donated total of $7,556 of glasses to charity. The amount was recorded at historical cost under General and Administrative Expenses.

As of September 30, 2021, we recorded an inventory prepayment in the amount of $295,200 related to down payment on eyewear purchased from the manufacturer, prior to shipment of the product that occurred after September 30, 2021. As of December 31, 2020, we recorded an inventory prepayment in the amount $85,740 for inventory paid for during 2020 but shipped after December 31, 2020.

Intangible Assets

Intangible assets relate to:

•        internally developed and licensed utility and design patents. We amortize these assets over the estimated useful life of the patents, and

•        capitalized software costs incurred due to development of the Vyrb app. We amortize these assets over the estimated useful life of the software application.

We review our intangible assets for impairment whenever changes in circumstances indicate that the carrying amount of the assets may not be recoverable.

55

Income Taxes

We are taxed as a C corporation. We comply with Financial Accounting Standards Board (FASB) ASC 740 for accounting for uncertainty in income taxes recognized in a company’s financial statements, which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. FASB ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Based on our evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in our financial statements. We believe that its income tax positions would be sustained on audit and does not anticipate any adjustments that would result in a material change to its financial position.

We have incurred taxable losses since inception but are current in its tax filing obligations. We are not presently subject to any income tax audit in any taxing jurisdiction.

Stock-Based Compensation

We account for stock-based compensation to employees and directors in accordance with FASB ASC Topic 718, which require that compensation expense be recognized in the financial statements for stock-based awards based on the grant date fair value. For stock option awards, the Black-Scholes-Merton option pricing model was used to estimate the fair value of share-based awards. The Black-Scholes-Merton option pricing model incorporates various and highly subjective assumptions, including expected term and share price volatility. The expected term of the stock options was estimated based on the simplified method as allowed by Staff Accounting Bulletin 107 (SAB 107).

We note that the fair value of common stock used in the option pricing model in 2020 and for 9 months ended September 30, 2021 (no option grants in 2019) was determined using the most recent price paid by independent investors through Regulation Crowdfund (“REG CF”) securities offering undertaken by the Company. For a majority of the time during which stock option awards were granted by the Company in 2021 and 2020, the Company had been raising funds from investors under Regulation CF campaigns, with a significant number of transactions from both accredited and non-accredited investors. Specifically, (i) from June 2020 to April 2021, the Company was conducting a REG CF offering of its shares of common stock at a price of $1 per share and the Company utilized this $1 per share price to issue and value its stock-based awards during such period and (ii) from May 2021 to September 2021, the Company was conducting a second REG CF offering of it shares of common stock at a price of $3.56 per share and the Company utilized this $3.56 per share price to issue and value its stock-based awards during such period.

The pre-money valuation determining price per share was agreed upon each time with the crowdfund platform, who has great deal of experience in setting the proper pre-money valuations for companies that list on their platforms. The determination was made using Company’s business progress.

The share price volatility at the grant date is estimated using historical stock prices based upon the expected term of the options granted, using stock prices of comparably profiled public companies. The risk-free interest rate assumption is determined using the rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued.

Revenue Recognition

Our revenue is generated from the sales of prescription and non-prescription optical glasses, sunglasses and shipping charges, which are charged to the customer, associated with these purchases. We sell products through our retail store resellers, distributors and on our own website Lucyd.co and on Amazon.

To determine revenue recognition, we perform the following steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. At contract inception, we assess the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

All revenue, including sales processed online and through our retail store resellers and distributors, is reported net of sales taxes collected from customers on behalf of taxing authorities, returns and discounts.

56

For sales generated through our e-commerce channels, we identify the contract with a customer upon online purchase of our eyewear and transaction price at the manufacturer suggested retail price (“MSRP”) for non-prescription, polarized sunglass and blue light blocking glasses across all of our online channels. Our e-commerce revenue is recognized upon meeting of the performance obligation when the eyewear is shipped to end customers. Only U.S. consumers enjoy free USPS first class postage, with faster delivery options available for extra cost, for sales processed through our website and on Amazon. For Amazon sales, shipping is free for U.S consumers while international customers pay shipping charges on top of MSRP. Any costs associated with fees charged by the online platforms (Shopify for Lucyd.co website and Amazon) are not recharged to customers and are recorded as a component of cost of goods sold as incurred. The Company charges applicable state sales taxes in addition to the MSRP for both online channels and all other marketplaces on which the company sells products.

For sales to our retail store partners, we identify the contract with a customer upon receipt of an order of our eyewear through our Shopify wholesale portal or direct purchase order. Our revenue is recognized upon meeting the performance obligation which is delivery of our eyewear products to retail store, and also recorded net of returns and discounts. Our wholesale pricing for eyewear sold to retail store partners includes volume discounts, due to the nature of large quantity orders. The pricing includes shipping charges, while excluding any state sales tax charges applicable. Due to the nature of wholesale retail orders, no e-commerce fees are applicable.

For sales to distributors, we identify the contract with a customer upon receipt of an order of our eyewear through a direct purchase order. Our revenue is recognized upon meeting the performance obligation, which is delivery of our eyewear products to the distributor, and is also recorded net of returns and discounts. Our wholesale pricing for eyewear sold to distributors includes volume discounts, due to the nature of large quantity orders. The pricing includes shipping charges, while excluding any state sales tax charges applicable. Due to the nature of wholesale distributor orders, no e-commerce fees are applicable.

The Company’s sales to both retail store partners and through the e-commerce channels do not contain any variable consideration.

We allow our customers to return our products, subject to our refund policy, which allows any customer to return our products for any reason within the first:

•        7 days for sales made through our website (Lucyd.co)

•        30 days for sales made through Amazon

•        30 days for sales to wholesale retailers and distributors

For all of our sales, at the time of sale, we establish a reserve for returns, based on historical experience and expected future returns, which is recorded as a reduction of sales. Additionally, we reviewed all individual returns received in October 2021 pertaining to orders processed prior to September 30, 2021. We had no reserve because the identified amounts were nominal.

Shipping and Handling

Costs incurred for shipping and handling are included in cost of goods sold at the time the related revenue is recognized. Amounts billed to a customer for shipping and handling are reported as revenues.

Earnings/loss per share

We present earnings and loss per share data by calculating the quotient of earnings/(loss) and loss divided by the number of common shares outstanding (common shares as of December 31, 2020) as required by ASC 260-10-50. As of September 30, 2021 all shares underlying the related party convertible debt and common stock options were excluded from the earnings per share calculation due to their anti-dilutive effect.

Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed by, or under the supervision of, that company’s principal executive and principal financial officers, or persons performing similar functions, and influenced by that company’s board of directors, management and other personnel, to provide reasonable assurance regarding the

57

reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies or procedures may deteriorate.

As of September 30, 2021, we were a private company and historically had limited accounting and financial reporting personnel and other resources with which to address our internal control over financial reporting. In connection with the preparation and audit of our financial statements for the year ended December 31, 2020, we identified material weaknesses in our internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.

We did not have a sufficient number of personnel with an appropriate degree of accounting and internal controls knowledge, experience, and training to appropriately analyze, record and disclose accounting matters commensurate with Innovative Eyewear’s accounting and reporting requirements, which resulted in an inability to consistently establish appropriate authorities and responsibilities in pursuit of their financial reporting objectives. This material weakness contributed to the following additional material weaknesses:

•        We did not design and maintain effective controls over the review of journal entries and account reconciliations. Specifically, certain personnel had the ability to both (i) create and post journal entries within Innovative Eyewear’s general ledger system, and (ii) prepare and review account reconciliations.

•        We did not design and maintain effective controls over information technology general controls for information systems that are relevant to the preparation of our financial statements. Specifically, we did not design and maintain: (i) program change management controls for the financial systems to ensure that information technology program and data changes affecting financial IT applications and underlying accounting records are identified, tested, authorized and implemented appropriately; (ii) appropriate user access controls to ensure appropriate segregation of duties and that adequately restrict user and privileged access to financial applications, programs and data to appropriate our personnel; (iii) computer operations controls to ensure data backups are authorized and restorations monitored; and (iv) testing and approval controls for program development to ensure that new software development is aligned with business and IT requirements.

These material weaknesses could result in a misstatement of substantially all accounts or disclosures that would result in a material misstatement to the annual or interim financial statements that would not be prevented or detected.

With the oversight of senior management, we have instituted plans to remediate these material weaknesses and will continue to take remediation steps, including hiring additional key supporting accounting personnel with public company reporting and accounting operations experience. We are also implementing the required segregation of roles and duties both in manual and systems related processes including for journal entries and account reconciliation, and formalizing the documentation and performance of remaining information technology general controls for information systems utilized for financial reporting. We believe the measures described above will remediate the material weakness identified and strengthen our internal control over financial reporting. We are committed to continuing to improve our internal control processes and will continue to diligently and vigorously review our financial reporting controls and procedures.

Quantitative and Qualitative Disclosures about Market Risk

Market risk represents the risk of loss that may impact our financial position because of adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of exposure resulting from potential changes in currency rates, interest rates, or inflation.

58

BUSINESS

Our History

We develop and sell smart eyeglasses and sunglasses, which are designed to allow our customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Founded and headquartered in Miami, Florida, we were initially organized as a Florida limited liability company effective August 15, 2019. We were founded by Lucyd Ltd., the inventor and licensor of the technology that our products are based upon which is a portfolio company of Tekcapital Europe Ltd. (“Tekcapital”). Tekcapital is a U.K. based university intellectual property accelerator. Tekcapital builds portfolio companies around new technologies. On March 26, 2020, we converted from a Florida limited liability company into a Florida corporation.

Our Product

In January 2020, we introduced our first beta product and began market testing.

In January 2021, we officially launched our first commercial product, Lucyd Lyte® (“Lucyd Lyte”). This initial product offering embodies our goal of creating smart eyewear for all day wear that looks like and is priced similarly to designer eyewear, but is also light weight and comfortable, and enables the wearer to remain connected to their digital lives. The product was initially launched with six styles. In September 2021, an additional six styles were added. These twelve styles are each available with 56 different lens types, resulting in 668 variations of products currently available.

Additionally, Lucyd Lyte glasses enable the wearer to listen to music, take and make calls, and use voice assistants to perform many common smartphone tasks hands-free. Some of the many things that can be done with Lucyd Lyte glasses include:

1.      “Send a voice message to (contact)”: this command begins the recording of an audio message to be sent to named contact.

2.      “Send a text to (contact)”: begins recording of a speech-to-text message to be sent by SMS to named contact.

3.      “Call (contact)”: speed-dials the named contact.

4.      “Send $___ to (contact)”: this command allows our user to send money to a contact via Venmo or Apple Pay. Follow the digital assistant’s prompts to confirm.

5.      “Check my messages”: this command reads out our user’s latest incoming text messages and offers a prompt to reply to each. Close out the digital assistant to end the readout.

6.      “Check my mailbox”: this command announces the number of unread emails, and reads them out with a prompt to continue after each one. In the prompt after each one, our customers can tell their digital assistant “Reply” and dictate an email response to the previous email.

7.      “Find (cuisine type) food nearby”: this command reads through a list of nearby restaurants and their ratings, and prompts our user for directions or to call after each one.

8.      “Call me an Uber”: this command prompts our user on which type of Uber ride they want, then asks to confirm to send a car to our user’s location.

9.      “What time is it?”: announces the current time.

10.    “Play (song/album/artist)”: this command begins playing the requested song, album or artist via Apple Music.

11.    “Get me directions to (location)”: this command begins navigating on phone, with audible directions on glasses.

12.    “Take a memo”: this command begins recording a speech-to-text memo in Notes. Say “Read my Notes” to play back.

59

Since the launch of Lucyd Lyte, we witnessed interest and demand from customers throughout the United States and have sold thousands of our smart glasses. Within six months of the launch of Lucyd Lyte, several optical stores in the United States and Canada have on- boarded the product and we have had discussions with several other large eyewear chains (by number of locations) regarding onboarding our product. We believe smart eyewear is a product category whose time has come, and we believe we are well positioned to capitalize on and help develop this exciting new sector–where eyewear meets electronics in a user-friendly, mass market format, priced similarly to designer eyewear.

Additionally, we anticipate introducing our first line of Bluetooth safety glasses, and five new styles of Lucyd Lytes designed specifically for women and youths in the first quarter of 2022. We plan on expanding our safety glasses line by adding two additional sizes in the second quarter of 2022, along with five new styles of Lucyd Lytes in titanium and acetate. In the third quarter of 2022, we are hoping to introduce four sports frames, five new styles of Lucyd Lytes in titanium and acetate, as well as additional lens packs focused on gamers, boating and fishing, as well as running, cycling and fashion. We anticipate adding five more styles of Lucyd Lytes in the fourth quarter of 2022, along with a rollout of software upgrades to Vyrb.

Our Mission

Our mission is to Upgrade Your Eyewear®. Our smart eyewear is a fusion of headphones with glasses, bringing vision correction and protection together with digital connectivity and clear audio, while also offering a safer solution for listening to music outdoors (as compared to in-ear headphones). The convenience of having a Bluetooth headset and comfortable glasses in one, especially for those who are already accustomed to all-day eyewear use, offers a lifestyle upgrade at a price most consumers can afford.

In a sense, we view this integration of technology and vison correction/protection as the next evolutionary step in the development of eyewear. Over the entire course of eyewear development and history, many of the innovations have dealt with improving the lenses of the glasses. Notably, eyewear frames have not improved much in the past 400 years, with the exception, in our view, of the utilization of plastic to reduce weight and provide a wider range of designs and finishes, and the introduction of new hinge types. We view the integration of Bluetooth technology into the arms of the glasses as one of the key next steps to Upgrade Your Eyewear®.

60

Our focus is to enhance one of the world’s most important wearables: eyewear.

Additionally, as part of our commitment to a great customer experience, we listen to feedback from our customers, and continuously strive to improve customer satisfaction and experience with our products. Our customers’ extensive feedback pointed to a need and desire for better interaction with social media while on-the-go. We are addressing this need by developing an exciting software application called Vyrb™, which enables Lucyd Lyte users to hear and reply to social media posts, with their voice, hands-free, through their glasses (“Vyrb”). Other Vyrb users will be able hear these posts. Additionally, Vyrb offers Lucyd Lyte users external social media sharing features, which allow posts made on Vyrb to be exported to other platforms such as Facebook, Twitter and Instagram. We launched Vyrb in December 2021 for both iOS and Android, and we believe that Vyrb is one of the first social applications designed specifically with a focus on smart glasses and other voice enabled wearables. We anticipate expanding Vyrb’s capabilities through software upgrades that are currently slated for release in the fourth quarter of 2022.

As part of our mission to make smart eyewear accessible to the mass market, we are seeking to develop a complete line of Bluetooth eyewear for nearly every size and style preference, with twelve styles available at the end of 2021, and forty styles anticipated by the end of 2022. When paired with the Vyrb application, Lucyd Lyte glasses will provide a new and safer wearable user experience suitable for everyone.

Our goal is to become a meaningful player in the smart eyewear market. Innovative Eyewear’s early successes have shown our ability to not only compete, but to lead in this rapidly changing and expanding technological eyewear market, and our goal is to continue spearheading innovation in the field.

Giving Back

We donate an optical frame for every Lucyd Lyte sold.

We are also very active in supporting the various communities we serve through donations and support. From the beginning, Innovative Eyewear has supported those in need through its donation of glasses frames to New Eyes (https://new-eyes.org/about-us), a charity dedicated to helping children and adults in need of eyewear. We’ve partnered with New Eyes because they fit the Lucyd brand mission: enhancing the vision of people all over the world, and we believe that it simply is the right thing to do.

Additionally, university students, educators, healthcare workers, uniformed service members, and veterans are eligible for an ongoing 18% discount off all frames and lens upgrades on www.lucyd.co.

Our Competitive Strengths

A Unique Solution to a Common Problem.    While immensely useful, smartphones can present a safety hazard to motorists, pedestrians and cyclists because smartphones can distract people from the task or activity at hand. In 2018, pedestrian deaths were at a 28-year high and experts believe smartphones were partially to blame. Additionally, recent data from the Governors Highway Safety Association indicates that in 2020 there was the largest ever annual increase in the rate at which drivers struck and killed pedestrians. The report mentioned that during the past ten years, the number of drivers striking and killing a pedestrian after dark increased by 54%, compared to a 16% rise in pedestrian fatalities in daylight. We believe that the distraction created by smartphones originates in two forms: (1) via headphones or earbuds, where the user is deprived of full audible situational awareness; and, (2) via the visual interface of the phone, which distracts the user completely from their surroundings. Lucyd Lyte open ear audio helps address this problem by having the speakers mounted at the temples (in the arms) of the glasses. There is nothing in the ear canal and, as a result, individuals can better maintain situational awareness, such as hearing the traffic around them, as well as nearby sounds. Many of our competitors have relatively bulky speakers enclosed within the temples, while Lucyd Lyte’s speakers and temples are thin, which allows them to look similar to traditional designer glasses. Furthermore, through the quick and easy touch controls on the Lucyd Lyte, the wearer can perform many tasks that they would normally pull out their phone for, untethering the eyes of the user from their smartphones throughout the day and enabling them to remain more visually vigilant and aware of the traffic around them.

61

Affordable Price Point.    Comfortable and affordable Bluetooth audio glasses that seamlessly integrate vision correction and protection with our customer’s digital life. Our Lucyd Lyte line of smart eyewear enables prescription and sunglass wearers to interact with digital assistants and social media without having to take their eyes off the road and are nearly hands-free, thereby improving the safety and convenience of taking calls, listening to music and audibly accessing digital information on the go. Our Lucyd Lyte eyewear provides both optical-quality glasses and a Bluetooth headset together, at roughly the same price as a traditional pair of designer glasses. The Manufacturer’s Suggested Retail Price (“MSRP”) for Lucyd Lyte eyewear starts at $149, with advanced options and customizations available at higher price points, which are at the discretion of the customer, and $35 upcharge for single vision. By comparison, most of our U.S.-based competitors offer products that are significantly more expensive, starting at approximately $249 or higher.

Quality.    All of our frames can be outfitted in-house or by optical resellers with any combination of: prescription, sunglass, readers and blue light formats. Our frame fronts are made with what we believe are high quality optical materials to ensure easy lens fitting by any optician.

Customizable Product Offering.    There are 56 lens types available for Lucyd Lyte, making it the most customizable smart eyewear in the world. Innovative Eyewear has a partnership with a high-quality optical lab in Boston to produce prescription and custom lenses for our frames quickly and affordably. Our contract with a third-party optical lab also allows us to offer direct fulfillment to our customers.

Comfort.    At just 1.0-1.45 ounces, our eyewear has a feather-light fit, suitable for all day vision correction or sun protection (traditional glasses weigh about 1 ounce). This is especially important while on the go. Our 1.0 ounce titanium aviators are among the lightest smart eyewear ever made.

Long Battery Life.    At 6.5-8 hours of playback per charge, Lucyd Lyte glasses outpace most, if not all, of the competition on battery life.

Capital Light Business Model.    All of our products are sold through multiple ecommerce channels, including on our website (Lucyd.co), BestBuy.com, DickSportingGoods.com and Amazon.com, and are distributed through optical or other retailers (such as, but not limited to, Metro Optics Eyewear and Marca Eyewear Group, Inc.). We believe this capital light approach is highly scalable and efficient in the deployment of resources. We view “capital light” as being more efficient by obviating the need to build factories and retail stores, but rather contract with both.

Multiple-Channel Approach.    We sell our products both through multiple online channels and multiple categories of brick-and-mortar retail stores. We believe this multi-channel approach provides us with an advantage against our competitors who either solely sell their products online or in brick-and-mortar retail stores.

Experienced Management Team.    We have an experienced board of directors with more than 80 years of combined experience in the eyewear industry and a management team with substantial experience in operating eyewear and technology companies.

Our Business Strategy

When we organized Innovative Eyewear two years ago, there were, in our view, no attractive smart eyewear that addressed the basic consumer need for good looking designer glasses that were stylish, comfortable, lightweight and provided the functionality of hearables, and priced around the same as regular glasses.

All of our products are designed in Miami, manufactured in China, sold through ecommerce, channels, including on our website (Lucyd.co), BestBuy.com, DickSportingGoods.com and Amazon.com, or sold by over 100 optical and sporting goods retailers. Additionally, we are pursuing online and in-store big box retailers, and in-store and online specialty retailers. We believe this capital light approach is highly scalable and efficient in the deployment of resources. We view “capital light” as being more efficient, by obviating the need to build factories and retail distribution but rather contracting with both. Based on the existing demand for our products, current distribution and recently consummated supply agreements, we anticipate that our products will be available in a significant number of new third-party retail locations in 2022.

62

We believe that people care about what they wear on their faces, and because we understand that customers have diverse preferences about the shape, size and design of their eyewear, we aim to continuously introduce new models in an effort to offer a wide variety of designs. We continuously present new models of eyewear to our network of followers to vote on those styles they find most appealing. We view this as community approved design.

Sales

We have two major sales channels: (1) ecommerce via Lucyd.co and Amazon and, (2) our ongoing development of a network of eyewear, sporting goods and electronics resellers, including but not limited to, BestBuy.com, DickSportingGoods.com and Brookstone, to offer our frames in the future. Most of our resellers are experienced opticians who provide valuable feedback that informs the development of our product lines, which we would not receive if we were solely direct to consumer. Additionally, we have a robust presence on multiple ecommerce and social media platforms, with more than 160,000 followers and 20,000 email subscribers, which facilitates several customer on-ramps for the Lucyd brand, and numerous ad campaign strategies. Building on our early successes of driving traffic to Lucyd.co, the website run by a subsidiary of our majority stockholder, from Facebook and TikTok, we deploy high quality content on multiple platforms to continuously keep customers engaged and drive brand awareness.

63

We have two levels of margins, one for business to consumers (“B2C”), and one for business to business (“B2B”). The majority of our sales have been through ecommerce with gross margins at approximately 60% and retail sales, which have recently started, have gross margins of approximately 38%. We have an average additional gross profit margin of approximately 20% on custom and prescription lenses. We expect that our retail sales will account for the majority of our sales by 2023.

Ecommerce Channels

1.      Company website: Lucyd.co

Lucyd.co is our primary ecommerce point of sale. The site offers the most customization options of any of our sales channels and a full prescription lens lab, offering a total of 56 different lens combinations (16 key lens tints offered in plano, single prescription and progressive bifocal; seven types of reading lenses; and, a unique lens sold in the 3-lens pack items). Additionally, the Lucyd website ships worldwide and is used to provide a quick and smooth buying experience.

2.      Amazon

Amazon.com/lucyd is our brand shop on Amazon. It drives approximately half of our online sales, but limits the number of variations we can offer on our frames (e.g., prescription lenses are not permitted on Amazon). However, through Amazon, we are still able to offer color lens sunglass variants and blue light blocker pairs, in addition to our lens pack accessory item. We are constantly testing traffic flow to Lucyd.co vs. Amazon to ensure our online ad spend is fully optimized.

3.      Walmart.com, BestBuy.com, DickSportingGoods.com, Brookstone.com and eBay

In addition to our key online sales channels at Lucyd.co, BestBuy.com, DickSportingGoods.com and Amazon, we are on these four marketplaces to gain additional brand awareness and drive online sales.

64

4.      Social Selling

Not only do we use social media to drive traffic to our main sales channels, we take advantage of intra-social shops as well, and have deployed shopping experiences through Facebook, Instagram and TikTok to gain further brand awareness.

We also offer two affiliate platforms via shareasale.com and Shopify for peer-driven sales. The Shareasale program is for professional affiliate and deal promotion companies, and increases revenue on Lucyd.co by offering direct commissions in exchange for converting web traffic. The Shopify affiliate program enables Lucyd brand enthusiasts to get a financial reward for sharing the brand, and operates on similar terms as the Shareasale program where we provide a commission rate in exchange for converting web traffic.

Retail Channels

1.      Independent Eyewear Stores

The core of our B2B business is formed by our relationship with numerous eyewear store retailers across the United States and Canada, which provide Lucyd Lyte frames directly to their optical customers. Many of these retail stores have placed multiple stocking orders in the few short months since launching our wholesale business in June 2021. To support our resellers, we offer a strong co-op marketing program that includes free store display materials. As part of this strategy, we are launching a digital try-on kiosk for our resellers to help educate their in-store customers about Lucyd eyewear, and increase our brand’s physical presence in the optical industry. We anticipate introducing our in-store digital try-on kiosk to key retailers in the first quarter of 2022, and are planning on upgrading the kiosk’s capabilities in the second quarter of 2022 to allow for in-store re-ordering.

2.      National Eyewear Chains

Lucyd eyewear is currently being evaluated by multiple leading eyewear chains in the United States for potential inclusion in their brick-and-mortar stores. After the recent introduction of Ray Ban Stories smart eyewear, retailers are keen to include one or more smart eyewear products in their stores and on their ecommerce platforms. Based on our current discussion with several major optical chains (by store size), we believe at least one major optical chain will onboard our product line by the end of 2021.

3.      Big Box Retail Stores (Electronics, sporting goods, general merchandise)

In addition to mainstream optical channels, we have begun placing our products and are pursuing additional product placements with leading big box stores, either in their eyewear or electronics departments. Specifically, we have begun placing our products in Best Buy stores and other notable chains in electronics and sporting goods are testing our products, with positive feedback, and we anticipate having our product line onboarded on the ecommerce sites of a leading electronics and sporting goods specialty retailers in the next thirty days.

4.      Specialty Retail stores (Apparel, travel and more)

We are leaving no stone unturned in our mission to bring smart eyewear mainstream. We are in talks with several leading fashion brands to launch co-branded Lucyd products in their brick-and-mortar retail locations, with a “Powered by Lucyd” designation alongside their brand identity on the packaging. These would be meaningful collaborations, and if successful, could rapidly expand Lucyd brand recognition. Additionally, we are pursuing other potential sales outlets such as home shopping channels, airport electronics shops and boutique retailers.

Manufacturing and Supply Chain

Our products are designed and specified in the United States and subsequently manufactured in China. The products are designed in-house, 3-D CAD files are then produced with product renderings. We then subject these rendered images for focus group review, to determining which designs we should move to the prototype development stage. Pre-production prototypes are developed by our contractor in China to our specifications. Our contractor sources components for the smart eyewear in China including plastic and titanium for the frames, electronic components, speakers, microphones and batteries. All packaging is designed in Miami and fabricated in China. Once completed, our products are tested in the United States, to assess functionality, fit and finish. Orders received on our eshop, Amazon store and bulk retail orders are aggregated in Miami and then placed and fabricated in China, whereupon they

65

undergo a rigorous eleven-point third party product inspection process. The inspection is conducted on 100% of our manufactured products. Inspections include testing procedures to help ensure our customers receive only functional, high-quality products.

If products are ordered with non-prescription sunglass lenses, they are manufactured by our third party contractor and shipped to a warehouse in Miami for direct to consumer or retail store shipment. If products are ordered with prescription or specialty lenses, then the smart eyewear frames are sent to an optical contractor laboratory in Boston, Massachusetts, to have the lenses cut, ground and mounted in the frames, whereupon they are directly shipped to customers. If products are ordered from Canada, they are shipped to a Canadian distributor’s warehouse for subsequent delivery to stores within Canada.

For our in-store displays, we developed the proprietary software and video for the virtual try-on, in-house, the fixtures are manufactured for us in the United States and the tablets used for the displays are made in China. The displays and the fixtures are assembled in Miami and then provided to a third-party warehouse in Miami for retail store distribution.

Marketing

We employ a 360-degree marketing mix that encompasses both brand and user generated content syndication across earned, owned and paid platforms (channels where the company pays a fee to have its product advertised). Long form and video content generation are a key focus points for the brand, they allow us to better leverage both emerging and critical smart eyewear narratives through persistent search engine optimization (SEO); increasing our organic brand awareness across the board, in addition to strategic loyalty, influencer and affiliate marketing campaigns.

This strategy includes, but is not limited to, pay per click advertising, Email, Social and Content marketing, PR and traditional print Ads. Our robust Company-paid Ads span Broadcast TV, Audio, Google (search/video), CTV, Facebook, IG, TikTok, Pinterest, Twitter, Taboola, AI-driven ads and Amazon native ads.

We believe we are trendsetters in creating relevant, omni-channel touchpoints that derive meaningful experiences and products designed for our customers.

From a brand perspective, strategically offering value-added, tangible products and/or services coupled with a well-organized non-fungible token promotional initiative has become a relevant marketing tool that can potentially rapidly expand brand awareness and revenue. At Innovative Eyewear, we strive to lead and own critical narratives within the Bluetooth and smart eyewear space.

We seek to create memorable experiences and products that resonate with our customers, coupled with premium content and campaigns designed to expand our brand presence and market share.

Our influencers

To accelerate brand awareness and product sales, we are embarking on an influencer strategy to engage leading figures in sports and the arts, who like and enjoy wearing Lucyd Lytes. To date we have onboarded Chris Clark, a PGA golfer, Monique Billings, a WNBA basketball player, and Hadar Adora, an up-and-coming musical artist. We plan to add additional influencers to enhance awareness and sell-through for a number of key demographics.

Influencers are a key part of our marketing strategy, as they help our products relate to large, variable audiences. Lucyd Lyte is a perfect fit for the fitness tech and audio product spaces, so athletes and musicians are a natural fit for our brand and the active lifestyles that Lucyd products promote. We plan to add A-list musical talent to the brand in the near future, as well as a host of audio content creators to support the Vyrb experience.

Our Market Opportunity

According to Statista, the total addressable market for eyewear in the U.S. is projected to be $28.3 billion in 2021. The market for digital assistants like Siri, Google Voice, Bixby and Alexa has grown rapidly in North America, and had $2.5 billion in revenue in 2020. In the U.S., our primary market, the hearables market is projected to be $5.1 billion in 2021. We view the popularity of hearables as an important catalyst for the smart eyewear market.

66

The common denominator among markets for the hearables and digital assistant is that they facilitate real-time access to digital data, whether it is through music, calls, navigational directions, or information, among other uses. The combination of hearables and digital assistants provides a transparent, ergonomic interface between the users and their digital lives. At Innovative Eyewear, we are dedicated to a touch-free interface and untethering our customers eyes from their smartphone screens, through our smart eyewear product.

The synergistic fusion of these three markets enables, in our view, an opportunity to create a completely new experience of connected eyewear, which smoothly delivers the functionality of both optical glasses and headphones, eliminating the need for either on its own. Nevertheless, several orthodoxies of the eyewear industry still hold, namely: if you want to sell a lot of eyewear, we believe it should be attractive, stylish, comfortable (e.g., lightweight, which we believe to be approximately 1oz) and cost roughly the same as traditional eyewear. This is what we have sought to achieve, and in our view have accomplished with the introduction of Lucyd Lyte eyewear.

Intellectual Property

We license from Lucyd Ltd., a subsidiary of our majority stockholder, an intellectual property portfolio designed to protect our unique eyewear designs and certain technological features in current and anticipated future products.

We have licensed 41 patents to date, covering all of our current product designs and certain advanced features such as Vyrb, replaceable front frames, and multi-channel Bluetooth connectivity. The Company will seek to file new IP to protect new styles and features of its smart eyewear as they are introduced.

Our current patent portfolio is as listed below.

Application/Patent Number

 

Title

 

Country

 

Filing/Issue Date

 

Status

 

Grant Date

 

Anticipated
Expiration
Date

10,908,419

 

Smartglasses and Methods and Systems for Using Artificial Intelligence to Control Mobile Devices Used for Displaying and Presenting Tasks and Applications and Enhancing Presentation and Display of Augmented Reality Information

 

US

 

June 28, 2018

 

Issued

 

February 2, 2021

 

October 5, 2038
(Patent Term Adjustment – 99 days)

D899,493

 

Smart Glasses

 

US

 

March 22, 2019

 

Issued

 

October 20, 2020

 

October 20, 2035

D900,203

 

Smart Glasses

 

US

 

March 22, 2019

 

Issued

 

October 27, 2020

 

October 27, 2035

D899,494

 

Smart Glasses

 

US

 

March 22, 2019

 

Issued

 

October 20, 2020

 

October 20, 2035

D899,495

 

Smart Glasses

 

US

 

March 22, 2019

 

Issued

 

October 20, 2020

 

October 20, 2035

D899,496

 

Smart Glasses

 

US

 

March 22, 2019

 

Issued

 

October 20, 2020

 

October 20, 2035

D900,204

 

Smart Glasses

 

US

 

March 22, 2019

 

Issued

 

October 27, 2020

 

October 27, 2035

D900,205

 

Smart Glasses

 

US

 

March 22, 2019

 

Issued

 

October 27, 2020

 

October 27, 2035

D900,920

 

Smart Glasses

 

US

 

March 22, 2019

 

Issued

 

November 3, 2020

 

November 3, 2035

D900,206

 

Smart Glasses

 

US

 

March 22, 2019

 

Issued

 

October 27, 2020

 

October 27, 2035

D899,497

 

Smart Glasses

 

US

 

March 22, 2019

 

Issued

 

October 20, 2020

 

October 20, 2035

D899,498

 

Smart Glasses

 

US

 

March 22, 2019

 

Issued

 

October 20, 2020

 

October 20, 2035

D899,499

 

Smart Glasses

 

US

 

March 22, 2019

 

Issued

 

October 20, 2020

 

October 20, 2035

D899,500

 

Smart Glasses

 

US

 

March 22, 2019

 

Issued

 

October 20, 2020

 

October 20, 2035

67

Application/Patent Number

 

Title

 

Country

 

Filing/Issue Date

 

Status

 

Grant Date

 

Anticipated
Expiration
Date

29/716,878

 

Round Smartglasses Having Flat Connector Hinges

 

US

 

December 12, 2019

 

Pending

 

n/a

 

n/a

29/716,882

 

Round Smartglasses Having Pivot Connector Hinges

 

US

 

December 12, 2019

 

Pending

 

n/a

 

n/a

29/716,892

 

Sport Smartglasses Having Flat Connector Hinges

 

US

 

December 12, 2019

 

Pending

 

n/a

 

n/a

29/716,895

 

Wayfarer Smartglasses Having Pivot Connector Hinges

 

US

 

December 12, 2019

 

Pending

 

n/a

 

n/a

62/941,466

 

Wireless Smartglasses with Quick Connect Front Frames

 

US

 

November 27, 2019

 

Non-Provisional Application filed on November 25, 2020; U.S. App. No. 17/104,849

 

n/a

 

November 27, 2020

29/717,878

 

Flat Connector Hinges for Smartglasses Temples

 

US

 

December 19, 2019

 

Pending

 

n/a

 

n/a

29/717,884

 

Pivot Hinges for Smartglasses Temples

 

US

 

December 19, 2019

 

Pending

 

n/a

 

n/a

16/829,841

 

Voice Assistant Management

 

US

 

March 25, 2020

 

Notice of Allowance received 11/30/2021

 

TBD

 

TBD

29/743,256

 

Wayfarer Smartglasses

 

US

 

July 20, 2020

 

Pending

 

n/a

 

n/a

29/743,258

 

Round Smartglasses

 

US

 

July 20, 2020

 

Pending

 

n/a

 

n/a

17/104,849

 

Wireless Smartglasses with Quick Connect Front Frames

 

US

 

November 25, 2020

 

Pending

 

n/a

 

n/a

29/806,200

 

Smartglasses

 

US

 

September 1, 2021

 

Pending

 

n/a

 

n/a

29/806,204

 

Smartglasses

 

US

 

September 1, 2021

 

Pending

 

n/a

 

n/a

29/806,207

 

Smartglasses

 

US

 

September 1, 2021

 

Pending

 

n/a

 

n/a

29/806,209

 

Smartglasses

 

US

 

September 1, 2021

 

Pending

 

n/a

 

n/a

207516

 

Smartglasses

 

Canada

 

October 29, 2021

 

Pending

 

n/a

 

n/a

207517

 

Smartglasses

 

Canada

 

October 29, 2021

 

Pending

 

n/a

 

n/a

207518

 

Smartglasses

 

Canada

 

October 29, 2021

 

Pending

 

n/a

 

n/a

207519

 

Smartglasses

 

Canada

 

October 29, 2021

 

Pending

 

n/a

 

n/a

29/814,016

 

Safety Smartglasses

 

US

 

November 2, 2021

 

Pending

 

n/a

 

n/a

29/814,017

 

Safety Shields

 

US

 

November 2, 2021

 

Pending

 

n/a

 

n/a

63/274,920

 

Safety Glasses

 

US

 

November 2, 2021

 

Pending

 

n/a

 

n/a

29/815,040

 

Charging Cradle

 

US

 

November 10, 2021

 

Pending

 

n/a

 

n/a

207956

 

Safety Smartglasses

 

Canada

 

November 17, 2021

 

Pending

 

n/a

 

n/a

207957

 

Safety Shields

 

Canada

 

November 17, 2021

 

Pending

 

n/a

 

n/a

2021307950576

 

Safety Smartglasses

 

China

 

December 2, 2021

 

Pending

 

n/a

 

n/a

2021307955902

 

Safety Shields

 

China

 

December 2, 2021

 

Pending

 

n/a

 

n/a

68

Additionally, Innovative Eyewear has acquired the exclusive rights to 11 registered trademarks and applications as follows:

Trademark

 

Trademark Number

 

Status

 

Jurisdiction

LUCYD

 

UK00003258030

 

Registered

 

UK

Lucyd Lens

 

UK00003258093

 

Registered

 

UK

Lucyd Loud

 

UK00003400531

 

Registered

 

UK

Upgrade your eyewear

 

UK00003400579

 

Registered

 

UK

GaaS

 

UK00003451728

 

Registered

 

UK

Vyrb

 

UK00003477240

 

Registered

 

UK

Lyte

 

UK00003526151

 

Registered

 

UK

Upgrade your eyewear

 

Application No. 90/407,646

 

Application

 

US

LUCYD

 

Application No. 90/407,723

 

Application

 

US

Lyte

 

Application No. 90/381051

 

Application

 

US

Vyrb

 

Application No. 90/820713

 

Application

 

US

Material Agreements

License Agreement between Innovative Eyewear, Inc. and Lucyd Ltd.

On April 1, 2020, we entered into an exclusive, worldwide license agreement with Lucyd Ltd. for all fields of use of the Lucyd® brand, and the associated intellectual property and assets (the “License Agreement”). We were founded by Lucyd Ltd., the inventor and licensor of the technology that our products are based upon, which is a portfolio company of Tekcapital, our majority stockholder. The License Agreement is royalty-free, fully paid up, perpetual license, for the exclusive use of the following assets:

1.      All Lucyd intellectual property, including, all patents, patent applications and any continuations of such.

2.      All Lucyd trademarks.

3.      All Lucyd collateral material, artwork, subscriber lists, eyeglass model and frame shots and renders, as well as 3D models.

4.      All Lucyd logos such as, but not limited to: Lucyd® word mark, Lucyd Hexagon, Upgrade Your Eyewear® slogan and the Vyrb™ pending trademark application.

5.      All Lucyd company developed software and any new software developed by Innovative Eyewear, utilizing the Lucyd software, will be owned by Innovative Eyewear.

6.      Lucyd Store portals through Shopify, Amazon and Walmart.

7.      Relevant websites domain names including Lucyd.co, Lucyd.net, Lucyd.eu.

8.      All supply and endorsement agreements.

9.      All current inventory as of the execution date of license.

10.    All social media accounts under the Lucyd name, including, but not limited to: Twitter, Facebook and Instagram.

11.    All advertising material and trade show displays, brochures and related materials.

Under the terms of the License Agreement, we have the exclusive right to effectuate sublicenses, either exclusively or non-exclusively, to any or all of our licensed intellectual property, at its sole discretion. Upon execution of the License Agreement, we paid Lucyd Ltd. £1 for the life of the licensed assets, and the License Agreement shall continue in perpetuity, unless terminated according to the terms of the agreement. Additionally, we issued 3,750,000 shares of our common stock to Lucyd Ltd. as compensation for entering into the License Agreement and for the contribution of certain other assets. Lucyd Ltd. may terminate the license with immediate effect by providing written notice to us if, among other things: we commit a material breach, as such is defined by the terms of the agreement; or, if we suspend, or threaten to suspend, payment of our debts or are unable to pay our debts.

69

The License Agreement requires us to indemnify Lucyd against all liabilities, costs, expenses, damages, and losses(including but not limited to any direct, indirect or consequential losses, loss of profit, loss of reputation and all interest, penalties, and legal costs (calculated on a full indemnity basis) and all other reasonable professional costs and expenses) suffered or incurred by Lucyd Ltd. arising out of or in connection with actual or alleged infringement of third party intellectual property rights; our breach or non-performance of or the enforcement of License Agreement. We have the right to sublicense any of our rights under the License Agreement, provided that any sublicense also shall enter into a supplemental agreement satisfactory to Lucyd Ltd.

On October 5, 2021, the parties to the License Agreement executed an Addendum, to the exclusive license agreement, which clarified that Innovative Eyewear shall commercialize, continue with any on-going intellectual property prosecutions and pay all maintenance or other patent fees (the “Addendum”). For all new intellectual property, Innovative Eyewear will own control it and be responsible for all prosecution and maintenance costs. The Addendum also confirms that Innovative Eyewear issued Lucyd Ltd. 3,750,000 shares of its common stock as consideration for the license.

Sales Representation Agreement

On March 4, 2021, we entered into a commission-only, sale representation agreement with D. Landstrom Associates, Inc. to provide distribution into big box retailers in the United States (the “Representation Agreement”). The Representation Agreement provides for D. Landstrom to act as our commission based, manufacturer’s representative, with the exclusive right to solicit offers on behalf of us to purchase our products in the United States, for five big box stores. The term of the Representation Agreement is five years. Contract may be terminated for “good cause” with 90 days’ notice by either party. Upon termination, commissions of orders procured will extend 180 days beyond termination date.

Distribution Agreement

On June 30, 2021, we entered into a distribution agreement with 8 Points Inc., a subsidiary of Marca Eyewear Group Inc., for exclusive distribution of Lucyd Lyte products in Canada (the “Distribution Agreement”). The Distribution Agreement provides that 8 Points Inc. will have exclusive purchase and distribution rights and obligations in Canada. The term of the Distribution Agreement is 3.5 years and either party may terminate by providing 180 days’ notice to the other party. The distributor will perform services, which shall include, but shall not be limited to the following):

1.      Sales of our products into retail distribution by servicing potential purchasers and by generating new business within the Territory (as defined in the Distribution Agreement).

2.      Handling of all account inquiries on sales made pursuant to this Distribution Agreement.

3.      Innovative Eyewear will receive all Canadian returns on a timely basis. Currently, distributor will organize customer returns such that all returns will be shipped in bulk to Company’s distribution center in Miami, Florida.

4.      Company will provide marketing activities to support the sales of all the collections sold by the Distributor in the territory.

5.      Distributor will provide logistic service to distribute the product in the territory covering all provinces and provide internal customer service and warehousing and shipping, as well as after purchase care to customer.

6.      Distributor will provide a minimum purchase of $4.6 million worth of Lucyd Lyte products over 30 months to maintain exclusivity for sales in Canada.

7.      Monthly minimum committed purchases increase incrementally over the term of the Distribution Agreement. In the event that 8 Points Inc. does not meet the minimum monthly purchase requirements then we may convert 8 Points Inc. exclusive contract to a non-exclusive contract or terminate the Distribution Agreement.

70

The Next Step

Vyrb

We believe eyewear should enable customers to freely interact with social media. While digital assistants, once enabled, can provide the basis for this interaction, we believe that the ability to receive and send social media posts with an individual’s voice may greatly enhance ease of use of these platforms on the go. To facilitate this, we have been developing Vyrb, our full stack social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with an individual’s voice. The application launched out of beta in December 2021 and we are aiming to roll out software upgrades to Vyrb in the fourth quarter of 2022, which we anticipate will include new features like: monetization, ad-buying modules, an itemized upgrade system, and content selling capabilities for social media creators.

We believe that Vyrb will enhance the utility of current and future Lucyd Lyte glasses by enabling users to be untethered from their smartphones, yet still be able to hear and make social media posts. A goal of our products is to free our customers from other technologies. As such, we are designing Vyrb with a transparent, voice-centric interface in mind, so that as soon as our customers can say “Ok Google,” they are connected to a world of engaging audio content and have the ability to create audio posts and messages. We believe social interaction via smart eyewear will be instrumental in bringing new, youthful customers to our company.

A number of companies recently have started to launch voice mediated social media applications, such as Clubhouse, Discord, Audlist, Listen and Riffr. We are designing Vyrb to host audiobooks, podcasts and entire music albums on the platform. With Vyrb, Lucyd Lyte customers will be able to hear their social media feeds, post messages, hold gatherings and musical performances (by inviting other Vyrb users to connect with each other at a specific date and time), and enjoy social media with the authenticity of their own voice: all through their eyewear and without taking their phone out of their pocket.

The Product and Market for Vyrb

Vyrb is being designed as a full social media experience to enhance voice-based communications on wearables and mobile devices. The sophistication of Vyrb’s interface enables a large array of in-app purchases and subscriptions, as well as easy connectivity with the Lucyd Lyte line of smart eyewear. In addition to an ad-driven revenue model

71

that is typical of social media applications, the robust and highly variable selection of planned in-app purchases provide important improvements and fine-tuned customizations to help personalize the user experience. We plan to roll out these and other exciting features of Vyrb over the course of several software updates.

The Vyrb app is contemplated to feature an in-app item shop with a number of fun and useful upgrades, such as:

•        Loot Boxes — Random packs of multiple upgrade items, a best-selling in-app purchase format frequently deployed in online video games.

•        Skins — Items that alter the appearance of the app to help personalize it to the user’s preferences, such as Dark Mode.

•        Accents — Items that change the accent used by the app’s text-to-speech engine, which is employed frequently to vocalize textual content.

•        Metal Mics — Items that lengthen the maximum allowable verbal post length and image/video sizes per post for users.

•        Post Embellishments — Items that can be used to animate posts in the feed to make them more prominent.

•        Sound FX Packs — Items that increase the number of audio emojis (Sound FX) available to the user, livening up their posts.

•        Ad Tokens — Items that can be spent to expand the reach of a feed post to a larger audience.

•        Vyrb Gold — A premium, monthly subscription to the app that blocks all ads and brings additional benefits like a more prominent username.

•        Vyrb Gems — In-app currency that can be spent to tip a user’s favorite content creators, to buy premium paywalled content and to buy certain other in-app purchases. Gems can also be traded to other users for their items on the Vyrb Marketplace module. Users will also be rewarded Gems for their engagement with ads on the platform, creating a positive feedback loop that rewards app engagement with premium content and experiences.

•        Command Tokens — Items that can be spent to create new custom voice assistant commands (based on Vyrb’s Voice Command Creation Interface).

•        Mega-Tag Tokens — Items that can expand the number of mega-tags available to the user (mega-tags are a unique Vyrb feature, they are automatically applied hashtags that make a user’s posts more discoverable to others).

Users spend approximately 145 minutes per day on social media applications and regularly click on advertisements they view through their applications. We believe Vyrb is strategically positioned to become a prime advertisement space, allowing both visual and audible advertisements to be purchased. Vyrb ads will be shown in a user’s regular newsfeed, which we believe will create an opportunity and need for a subscription in-app purchase (Vyrb Gold) for a premium, ad-free browsing experience. For ease of use, Vyrb ads can be created by any user through the application in just moments: users will be able to purchase “Ad Token” items from the in-app store, and then use these tokens to turn standard posts into wide-reaching ads. A rapid-response reporting system will be developed and monitored to remove objectionable or illegal content from the platform. With its focus on high quality audio, we are designing Vyrb to lift up professional and creative audio content developers by helping them reach new audiences. To ensure a positive user experience, we are developing a system in Vyrb which will automatically promote positively reviewed content, and automatically remove content that has been reported in a high ratio compared to the number of viewers, providing the basis for user product discovery as well as a failsafe against any mistake in our manual and algorithmic moderation of the application’s hosted content.

Vyrb users will be able to purchase and support content from indie and professional creators via an in-app currency (referred to as “gems” in this document, a virtual point the user typically accumulates by viewing ad content or by purchasing them). Creators will receive gems from typical users as tips during live broadcasts, and in exchange for access to premium posts. The creators will then be able to cash out these gems at an exchange rate that provides profit to Vyrb. For example, users purchase the gems, its in-app loyalty token at a rate of $1 each, but creators only receive $0.75 for each gem they cash out. A 25% effective platform fee would put the content transaction fees of Vyrb at a lower rate than most digital content marketplaces. In the case of typical livestreaming applications, a functionality Vyrb supports, they are often exorbitant, taking as much as 50% in effective fees on in-app currency transactions.

72

To acquire the gems, users must buy them in the Vyrb Shop or gain them by engaging with sufficient ad content (e.g., using the application for an hour, or an amount of time that effectively pays for the gem).  While Vyrb allows users the flexibility of choice of either buying or earning these gems, we believe that there is a huge revenue stream potential for us through a strategic implementation of the Vyrb Shop and peer-to-peer content transactions.

Also, we plan for users to be able to charge a fixed price to be able to access particular audio posts. For example, this feature could be used by a podcaster to sell their premium episodes, or by a recording artist to sell their music albums. In tandem with this feature, audio posts will be divisible into tracks to support long form content such as albums and audiobooks. Vyrb will take a flat percentage fee on all sales of premium content within the application by allowing creators to cash out gems they receive for selling their content. We believe the major benefit of this system is that it will provide audio content creators a new platform for rapidly creating, listing and selling their content, and help create an environment full of rich, unique and interactive audio experiences such as live “radio shows,” indie content and virtual concerts for typical Vyrb users.

We believe that Vyrb will effectively leverage multiple successful gamification models from the world of social media to provide a flexible and highly interactive user experience that can potentially draw high-value content creators. A fundamental aspiration of Vyrb is to provide a new platform and source of revenue for high quality audio content creators in particular; to that end, we designed Vyrb with a goal of providing a rapid, user-friendly platform for creators and consumers to share, sell and enjoy the best audio the web has to offer. We believe that through Vyrb, we can make the interaction between our users and our product a fun and rewarding experience, which can also be monetized by the company and content creators alike. By putting audio front and center, we hope to provide a new meeting ground for audio content creators and those who enjoy lots of music, podcasts and talk shows. We hope to provide a mutually beneficial relationship, where Vyrb takes a reasonable fee on the transacting of these parties in exchange for bringing them together.

Competition

The smart eyewear industry in which we operate is competitive and subject to changes in practice. While we believe that our products are hybrid of eyeglasses and audio technology, which gives us a unique product that provides us with competitive advantages, we may face competition from many different entities now and in the future. As of now, we face competition from the following products:

•        Bose Corporation’s Bose Frames.    These are a Bluetooth eyewear product, but in a bulkier form factor and with what we believe to be comparable models at a higher price ($199 to $249 MSRP) than Lucyd Lyte.

•        Amazon’s Echo Glasses.    Another entry in the Bluetooth eyewear space. Not available directly from the manufacturer in prescription with a limited number of frame styles. The cost of the Amazon Echo Glasses is higher than Lucyd Lyte. While lightweight like Lucyd Lyte glasses, Amazon Echo Glasses have, in our view, a muted form factor, and the battery life is about half of that of Lucyd Lyte.

•        Snapchat Spectacles.    This is a camera-focused smart eyewear product and, in our view, not a direct competitor as to its style, weight, pricing and suitability for all-day wear, as compared with our products; however, Snapchat Spectacles may introduce further entries in the space that may directly compete with Lucyd Lyte. Snapchat Spectacles Version 3 have an MSRP of $380.

•        Ray-Ban Stories Glasses.    Developed in association with Facebook, are a camera-focused smart eyewear product, and despite the fact they are available in prescription, in our view not a direct competitor; Ray-Ban may, however, introduce further entries in the space that may directly compete with Lucyd Lyte. Ray-Ban Spectacles have a well-known and respected brand, and an MSRP starting $299, which makes them twice as expensive as Lucyd Lyte. They weigh considerably more (20-70% depending upon the Lyte model) than Lucyd Lyte glasses, have a shorter battery life, thicker temple profiles and are not water resistant.

All of the competitors discussed above have substantially greater manufacturing, financial, research and development, personnel and marketing resources than we do. As a result, although we believe our products are currently superior, our competitors may be able to develop superior products, and compete more aggressively and sustain their competitive advantage over a longer period of time than us. Our products may be rendered obsolete in the face of competition.

73

Government Regulation

We are subject to a wide variety of laws and regulations in the United States and other jurisdictions in which we operate. The laws and regulations govern many issues related to our business practices, including but not limited to those regarding contact lens prescriptions, worker classification, wage and hour, sick pay and leaves of absence, anti-discrimination and harassment, whistleblower protections, privacy, data security, intellectual property, product liability and taxation.

These laws and regulations are constantly evolving and may be interpreted, applied, created, superseded, or amended in a manner that could harm our business. These changes may occur immediately or develop over time through judicial decisions or as new guidance or interpretations are provided by regulatory and governing bodies, such as federal, state, and local administrative agencies. As we expand our business into new markets or introduce new products, features, or offerings into existing markets, regulatory bodies or courts may claim that we are subject to additional requirements, or that we are prohibited from conducting business in certain jurisdictions.

FDA Regulations

Our eyewear is considered a medical device by the FDA and regulated as such, and we are subject to the requirements set by the Consumer Product Safety Commission (the “CPSC”). Prescription eyeglasses are regulated as medical devices in the United States by the Food and Drug Administration (the “FDA”), and under the Food, Drug, and Cosmetic Act (the “FDCA”), such medical devices must meet a number of regulatory requirements. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs, or lower than anticipated sales. Failure to comply with applicable regulations could jeopardize our contract manufacturers’ ability to manufacture and result in FDA enforcement actions against the Company.

Data Privacy and Security

Additionally, because we receive, use, store, and transmit personal data, relating to our customers, we are subject to numerous laws and regulations in the United States, as well as industry standards, relating to privacy, data security and data protection. Such laws, regulations, and industry standards include, but are not limited to, Section 5(a) of the Federal Trade Commission Act, the California Consumer Privacy Act of 2018, the California Online Privacy Protection Act, and HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, that impose requirements on covered entities, including certain healthcare providers, health plans, and healthcare clearinghouses, and their respective business associates that create, receive, maintain, or transmit individually identifiable health information for or on behalf of a covered entity as well as their covered subcontractors relating to the privacy, security, and transmission of individually identifiable health information. Enforcement activity with respect to one or more breaches of data privacy and security can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources.

Employees and Human Capital Resources

As of the date of this prospectus, we have eight (8) full time employees with two in product development, two in sales, one in finance, one in customer service, one in marketing and one in graphic design. Employees are supported by a number of consultants and part time employees.

Our experienced employees and management team are our most valuable resources and we are committed to attracting, motivating, and retaining top professionals going forward. We have been able to locate and engage highly qualified employees as needed and do not expect our growth efforts to be constrained by a lack of qualified personnel. We consider our employee relations to be good.

Our success is directly related to the satisfaction, growth, and development of our employees. We strive to offer a work environment where employee opinions are valued and one that provides our employees the opportunities to use and augment their professional skills. To achieve our human capital goals, we intend to remain focused on providing our key personnel with raises as appropriate, a 401(k) program, and company stock options. We continue to search out well qualified highly skilled individuals to help us expand and grow our operations.

74

Legal Proceedings

We are not currently subject to any material legal proceedings. However, we may from time to time become a party to various legal proceedings arising in the ordinary course of our business.

Facilities

Our executive offices are located at 8101 Biscayne Blvd., Miami, Florida 33138. Our executive offices are provided to us by the parent of our majority stockholder, Tekcapital. Since, June 1, 2020, we have paid Tekcapital $25,000 per fiscal quarter for office space, utilities, advisory services and any other services. We consider our current office space adequate for our current operations. To accommodate our anticipated growth, Tekcapital signed a lease for an additional facility for the Company, located at 11900 Biscayne Blvd., Suite 630 Miami, Florida 33181, which lease will commence on February 1, 2022 and the Company anticipates relocating its executive offices and headquarters to this new facility on or around February 1, 2022.

75

Management

Directors and Officers

The following table sets forth certain information regarding our board of directors, our executive officers, and some of our key employees, as of the date of this prospectus.

Name

 

Age

 

Position

Harrison R. Gross

 

29

 

Chief Executive Officer and Director

Konrad Dabrowski

 

38

 

Chief Financial Officer

Frank Rescigna

 

61

 

Vice President of Global Sales and Director

David Cohen

 

49

 

Chief Technology Officer

Kristen Mclaughlin

 

49

 

Director

Louis Castro

 

63

 

Director

Olivia C. Bartlett

 

63

 

Director

Harrison Gross is one of the founders of Innovative Eyewear and has served as our Chief Executive Officer and as a director since August 2019, where he guides the company’s product and brand development. Prior to his employment at Innovative Eyewear, from August 2017 to August 2019, Mr. Gross served in various positions, including chief executive officer and media & UX lead, of Lucyd Ltd., our largest stockholder and the licensor of our technology which is also a smart eyewear development company where he developed the company’s brand identity and oversaw general operations and product development. Additionally, from November 2015 to August 2021, Mr. Gross served as the Digital Media Manager of Tekcapital PLC (“Tekcapital”) (LON: TEK), a university intellectual property investment firm that is the parent company of Tekcapital Europe Limited, and Lucyd Ltd, the holding company for Tekcapital’s shares in Innovative Eyewear, where he created, developed and marketed for the company’s licensed properties. Prior to that, from October 2013 to September 2014, Mr. Gross worked as a credit analyst for a Verizon, Inc. contractor, where he managed credit systems and provided support to Verizon agents. Mr. Gross is a graduate of Columbia University with a BA in Writing and received a BA in Jewish Studies from the Jewish Theological Seminary. Mr. Gross is well qualified to serve as a director due to his substantial knowledge of our product and his experience in marketing, product and app development.

Konrad Dabrowski has served as our Chief Financial Officer on a part-time basis since August 2019. Between June 2017 and July 2020, Mr. Dabrowski has served as the group controller, and starting on July 2020 the chief financial officer of Tekcapital PLC (“Tekcapital”), where he co-manages the group’s investment strategy and oversees financial reporting for all of its portfolio companies. Prior to his employment at Tekcapital, from  March 2016 to June 2017, Mr. Dabrowski was a Global Accounting Manager for Restaurant Brands International (NYSE:QSR), a multinational fast food holding company, where he oversaw accounting and tax projects for Burger King within the Europe Middle East and Africa (EMEA) market. Prior to his employment at Restaurant Brands International, Mr. Dabrowski was an Audit Manager at Deloitte, where he managed end-to-end accounting audits for a portfolio of public and private corporate clients. Mr. Dabrowski has a Master’s in Finance and Banking from the Warsaw School of Economics and is a Certified Public Accountant.

Frank Rescigna has served as our Vice President of Global Sales and a director since August 2021. Mr. Rescigna has more than 25 years of brand building and sales experience in the eyewear industry. Prior to his employment at Innovative Eyewear, from October 2019 to May 2021, Mr. Rescigna was the Director of Global Sales at House of Wu, a global wholesale luxury bridal and evening dress distributor, where he led the company’s sales strategy throughout the world. Prior to his employment at House of Wu, from September 2018 to September 2019, Mr. Rescigna was the President of Teka Eyewear, a boutique global wholesale luxury eyewear distributor specializing in exotic materials, where he managed all aspects of its sales organization and operations. Prior to his employment at Teka Eyewear, from March 2015 to August 2018, Mr. Rescigna was the Senior Vice President of Global Sales at Wiley X, a multi-brand global eyewear company that designs and distributes sunglasses, where he managed the company’s sales activities at the corporate and sales level. Prior to his employment at Wiley X, from February 2011 to February 2015, Mr. Rescigna was the President of Jewelry & Global Brand Licensing for Guess Inc. (NYSE: GES), a global fashion/lifestyle company with varying business models, distribution models and products, where he assisted the company with the expansion of its brand and new brands/products. Prior to his employment at Guess, from February 2004 to January 2011, Mr. Rescigna was the President of Viva International Group, a large eyewear company that designs, manufactures and distributes core

76

and luxury global brands, where he led the company’s expansion and integration with its parent company Highmark Vision Holding Company. He received a degree in Opticianry from Middlesex College. Mr. Rescigna is well qualified to serve as a director due his substantial brand and sales experience and his experience in the eyewear industry.

David Cohen is one of the founders of Innovative Eyewear and has served as our Chief Technology Officer since September 2019. Prior to his employment at Innovative Eyewear, from August 2017 to August 2019, Mr. Cohen served as the chief technology officer of Lucyd Ltd., a smart eyewear development company, where he led the company’s technological advancements and digital ad campaigns. Also, prior to his employment at Innovative Eyewear, from September 2009 to October 2019, Mr. Cohen served as President of Emaze Design Agency, a digital design agency, where he led the development of web and applications for e-commerce, web performance monitoring, website design and mobile applications. Prior to his employment at Emaze Design Agency, Mr. Cohen was lead Business Intelligence Specialist at Jewish General Hospital where he assisted with the data solutions and business processes and requirements. He received a BS in Computer Science from the Academy of Bordeaux and an MS in Advanced Technician & Information Systems Management from Hadassah University.

Kristen Mclaughlin has served as one of our directors since August 2021. Ms. Mclaughlin has 20 years’ experience launching, managing and developing products in the eyewear, accessories, cosmetics and skincare industries. From March 2019 to April 2020, Ms. Mclaughlin served as the Global Marketing Director at DePasquale Companies, a skincare, hair care and cosmetics manufacturer, where she led the global marketing strategy and new product development. Prior to her employment at DePasquale Companies, from March 2000 to January 2019, Ms. Mclaughlin was employed at Silhouette International, an eyewear manufacturer, where she served as the Director of Marketing: Eyewear Manufacturer, Regional Sales Manager, and Brand Manager: Daniel Swarovski Crystal Eyewear. While at Silhouette International, Ms. Mclaughlin led the company’s brand portfolio in the U.S. and its brand direction, product development and campaign content. She has a BS and MBA from Ramapo College of New Jersey. Ms. Mclaughlin is well qualified to serve as a director due to her substantial experience in the eyewear industry and her experience in brand and product development.

Louis Castro has served as one of our directors since August 2021. Mr. Castro is an experienced public company director and chartered accountant. Mr. Castro is currently on the board of directors of the following public companies (1) Tekcapital where he has been a director since December 2019, (2) Orosur Mining Inc. (TSE:OMI), a company exploring for minerals in South America, where he has been chairman of the board since April 2020, (3) Stanley Gibbons Group plc (LON:SGI), a company that specializes in the retailing of collectable stamps and similar products, where he has been a director since June 2016, (4) Tomco Energy plc (LON:TOM), an oil exploration and technology company, where he has been a director since April 2021, (5) Predator Oil & Gas Holdings plc (LON:PRD), an oil and gas exploration company, where he has been a director since July 2020, and (6) Veteran Capital Corp. (TSX-V:VCC), a capital pool company, where he has been a director since January 2021. From September 2012 to June 2016, Mr. Castro was a director and, from September 2014 to June 2016 served as the Chief Financial Officer, of Eland Oil & Gas plc, a Nigerian focused upstream oil and natural gas exploration and production company, where he was responsible for the company’s finance, legal and corporate finance activities. Prior to his employment at Eland, from May 2011 to May 2014, Mr. Castro served as Head of Capital Markets and then as Chief Executive Officer of Northland Capital Partners, an investment bank, where he was responsible for the investment banks day-to-day activities. He is a fellow of the Institute of Chartered Accountants of England & Wales, has a double degree in Engineering Production and Economics from Birmingham University and attended the Postgraduate Advanced Course in Production Management and Methods at Cambridge University. Mr. Castro is well qualified to serve as a director due to his substantial experience as a director of public companies and his distinction as chartered accountant.

Olivia C. Bartlett has served as one of our directors since August 2021. Ms. Bartlett has been in the eyewear industry for over 40 years holding various roles including optician, optical manager, marketing manager and operations management. Since September 2015, Ms. Bartlett has been the Chief Operating Officer of Todd Rogers Eyewear, a specialty eyewear company, where she manages the day-to-day operations of the company. Prior to her time at Todd Rogers Eyewear, from March 2010 to May 2015, Ms. Bartlett was the sales representative for eyewear sales in the northeast of Massachusetts for Safilo USA, a specialty eyewear company. Additionally, from September 2013 to May 2018, Ms. Bartlett was an Adjunct Professor at Benjamin Franklin Institute of Technology in Boston, Massachusetts. Since February 2020 Ms. Bartlett has been the President of the Opticians Association of America, a national organization representing the professional, business, educational, legislative and regulatory interests of opticianry. Prior to that, Ms. Bartlett was a director for ten years for the Opticians Association of Massachusetts.

77

Ms. Bartlett has received a number of awards through her time in the industry, including but not limited to, the 2020 Eyecare Business Game Changer Award and the 2020 and 2018 Vision Monday Most Influential Woman Executive. Ms. Bartlett received her Massachusetts Opticians license in 1987 and is ABO certified. Ms. Bartlett received her BA in Political Science from Clark University. Ms. Bartlett is well qualified to serve as a director due to her substantial experience in the optical industry.

Number and Terms of Office of Officers and Directors

Upon the effectiveness of the registration statement of which this prospectus forms a part, we expect that our board of directors will continue to consist of five members. Our directors are appointed for one year terms to hold office until the next annual general meeting of our stockholders or until removed from office in accordance with our second amended and restated bylaws, which will be in effect upon the consummation of this offering.

Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our second amended and restated bylaws, which will be in effect upon the consummation of this offering, as it deems appropriate.

Director Independence and Committees of the Board of Directors

Director Independence

Of our directors, we have determined that Mr. Louis Castro and Mss. Kristen Mclaughlin and Olivia Bartlett are “independent” directors under NASDAQ listing standards, while Messrs. Harrison Gross and Frank Rescigna are not independent under such standards. We have also determined that each of the three prospective members of the Audit Committee is “independent” for purposes of Section 10A(m)(3) of the Exchange Act and the rules promulgated thereunder and under the NASDAQ listing standards. Further, the Board has determined that each of the two members of both the Compensation Committee and the Nominating and Corporate Governance Committee is “independent” under NASDAQ listing standards.

Board Committees

Prior to the consummation of this offering, we will have three standing committees of the Board: the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee. Each of the board committees will act pursuant to a separate written charter adopted by our board of directors, each of which is available on our website at www.lucyd.co. Our board of directors may at any time or from time to time appoint certain other committees in its sole discretion as it deems necessary or appropriate to carry out its functions.

Audit Committee

The Audit Committee will consist of Mr. Louis Castro (Chairman) and Mss. Kristen Mclaughlin and Olivia Bartlett. The Board has determined that all of the prospective members of the Audit Committee are “independent,” as defined by NASDAQ listing standards and by applicable SEC rules. In addition, the Board has determined that Mr. Castro is an audit committee financial expert, as that term is defined by the SEC rules, by virtue of having the following attributes through relevant experience: (i) an understanding of generally accepted accounting principles and financial statements; (ii) the ability to assess the general application of such principles in connection with the accounting for estimates, accruals, and reserves; (iii) experience preparing, auditing, analyzing, or evaluating financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of issues that can reasonably be expected to be raised by the Company’s financial statements, or experience actively supervising one or more persons engaged in such activities; (iv) an understanding of internal controls and procedures for financial reporting; and (v) an understanding of audit committee functions.

The function of the Audit Committee relates to oversight of the auditors, the auditing, accounting, and financial reporting processes, and the review of the Company’s financial reports and information. In addition, the functions of the Audit Committee will include, among other things, recommending to the Board the engagement or discharge of independent auditors, discussing with the auditors their review of the Company’s quarterly results and the results of their audit, and reviewing the Company’s internal accounting controls.

78

Compensation Committee

The Compensation Committee will consist of Ms. Kristen Mclaughlin (Chairman) and Mr. Louis Castro. The Board has determined that all of the prospective members of the Compensation Committee are “independent,” as defined by NASDAQ listing standards. The responsibility of the Compensation Committee is to review and approve the compensation and other terms of employment of our President and Chief Executive Officer and our other executive officers, including all of the executive officers named in the Summary Compensation Table under the heading “Executive Compensation” below (the “named executive officers”). Among its other duties, the Compensation Committee oversees all significant aspects of the Company’s compensation plans and benefit programs. The Compensation Committee annually reviews and approves corporate goals and objectives for the President and Chief Executive Officer’s compensation and evaluates the Chief Executive Officer’s performance in light of those goals and objectives. The Compensation Committee also recommends to the Board the compensation and benefits for members of the Board. The Compensation Committee has also been appointed by the Board to administer our 2021 Equity Incentive Plan. The Compensation Committee does not delegate any of its authority to other persons.

Nominating and Corporate Governance Committee

The Nominating and Corporate Governance Committee will be comprised of Mss. Olivia Bartlett (Chairman) and Kristen Mclaughlin and Mr. Harrison Gross. The majority of committee members are independent under applicable NASDAQ rules and regulations. The Nominating and Corporate Governance Committee is responsible for, among other things, considering potential board members, making recommendations to the full board as to nominees for election to the board, assessing the effectiveness of the board and implementing our corporate governance guidelines.

Compensation Committee Interlocks and Insider Participation

None of our officers currently serves, and in the past year have not served, as a member of the compensation committee of any entity that has one or more officers serving on our board of directors.

Code of Business Conduct and Ethics and Insider Trading Policy

Effective upon consummation of this offering, our Board of Directors will adopt a Code of Ethical Conduct and an Insider Trading Policy. We will file a copy of our Code of Ethics as an exhibit to the registration statement filed in connection with our initial public offering. Once filed, you can review these documents by accessing our public filings at the SEC’s web site at www.sec.gov. The Code of Ethics will also be available on our website at www.lucyd.co. In addition, a copy of the Code of Ethics will be provided without charge upon request from us. We intend to disclose any amendments to or waivers of certain provisions of our Code of Ethics in a Current Report on Form 8-K.

Limitation of Directors Liability and Indemnification

The Florida Business Corporation Act authorizes corporations to limit or eliminate, subject to certain conditions, the personal liability of directors to corporations and their stockholders for monetary damages for breach of their fiduciary duties. Our second amended and restated articles of incorporation, which will become effective upon the completion of this offering, limits the liability of our directors to the fullest extent permitted by Florida law. In addition, upon the closing of this offering, we will enter into indemnification agreements with all of our directors and named executive officers whereby we will agree to indemnify those directors and officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director or officer is or was a director, officer, employee or agent of ours, provided that such director or officer acted in good faith and in a manner that the director or officer reasonably believed to be in, or not opposed to, our best interests.

Prior to the consummation of this offering, we will obtain director and officer liability insurance to cover liabilities our directors and officers may incur in connection with their services to us, including matters arising under the Securities Act. Our second amended and restated articles of incorporation and bylaws also provide that we will indemnify our directors and officers who, by reason of the fact that he or she is or was one of our officers or directors of our Company, is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative related to their board role with us.

There is no pending litigation or proceeding involving any of our directors, officers, employees or agents in which indemnification will be required or permitted. We are not aware of any threatened litigation or proceeding that may result in a claim for such indemnification.

79

Executive Compensation

The following table sets forth the aggregate compensation paid to our named executive officers for the fiscal years ended December 31, 2021 and 2020. Individuals we refer to as our “named executive officers” include our Chief Executive Officer, our Chief Financial Officer and our V.P. of Global Sales.

Summary Compensation Table

Name and Principal Position

 

Year

 

Salary
($)

 

Bonus
($)

 

Option
Awards ($)

 

Non-Equity
Incentive Plan
Compensation
($)

 

Nonqualified
Deferred
Compensation
Earnings
($)

 

All Other
Compensation
($)

 

Total
($)

Harrison Gross,

 

2021

 

69,532

 

 

1,783,200

(1)

 

 

 

 

1,852,732

Chief Executive Officer

 

2020

 

42,000

 

 

251,250

(2)

 

 

 

 

293,250

Konrad Dabrowski,

 

2021

 

21,885

 

 

158,400

 

 

 

 

 

180,285

Chief Financial Officer

 

2020

 

27,000

 

 

 

 

 

 

 

27,000

Frank Rescigna,

 

2021

 

56,500

 

 

253,200

 

 

 

 

 

309,700

V.P. of Global Sales(3)

 

2020

 

 

 

 

 

 

 

 

____________

(1)      Consists of 375,000 options to purchase common stock of the Company issued to Mr. Gross for services rendered to the Company for the fiscal year ended December 31, 2020.

(2)      Consists of 700,000 options to purchase common stock of the Company issued to Mr. Gross for services rendered to the Company for the fiscal year ended December 31, 2021.

(3)      Mr. Rescigna began his employment on May 1, 2021 and received no compensation for the fiscal years ended December 31, 2020.

Employment Arrangements with our Executive Officers

Harrison Gross

On August 11, 2021, we entered into an employment agreement with Harrison Gross to serve in the capacity of the Chief Executive Officer of the Company. We agreed to pay Mr. Gross an annual base salary of $85,800 for the remainder of 2021, and we also agreed that on January 1, 2022 we will increase the base salary to $150,000 per year. Pursuant to the terms of the employment agreement, our Board may exercise its sole discretion to grant Mr. Gross an annual bonus, the amount of which bonus shall be determined in the sole discretion of our Board. Additionally, we granted Mr. Gross an option to purchase 100,000 shares of our common stock.

The agreement has an initial term of three years, and will terminate on the third anniversary of the effective date unless Mr. Gross and the Company agree otherwise in writing. If we terminate the employment agreement for any reason other than for cause (as such is defined in the agreement) or Mr. Gross terminates his employment for good reason (as such is defined in the agreement): (1) Mr. Gross shall be entitled to payment of his base salary for the balance of the agreement’s term; (2) if Mr. Gross elects to continue group health insurance benefits, we shall reimburse Mr. Gross for any COBRA premiums he pays for the duration of COBRA’s coverage; and, (3) we shall provide Mr. Gross with payment of all accrued amounts (as defined in the agreement).

Konrad Dabrowski

On August 11, 2021, we entered into an employment agreement with Konrad Dabrowski to serve as the Chief Financial Officer of the Company on a part-time basis, which agreement became effective on September 1, 2021. Mr. Dabrowski devotes 50% of his business time to our Company. We agreed to pay Mr. Dabrowski an annual base salary of $100,000. Pursuant to the terms of the employment agreement, we may exercise our discretion to grant Mr. Dabrowski an annual bonus, the amount of which bonus shall be determined in the sole discretion of the Company. Additionally, we granted Mr. Dabrowski an option to purchase 60,000 shares of our common stock.

80

Following the effective date, the employment agreement shall continue, unless terminated by Mr. Dabrowski or the Company. Mr. Dabrowski’s employment is at-will, which may be terminated by the Company or by Mr. Dabrowski at any time and for any reason. Pursuant to the terms of the employment agreement, a sixty days’ written notice of termination or resignation is required. If Mr. Dabrowski notifies us of his resignation, or if we terminate Mr. Dabrowski’s employment agreement, the Company reserves the right to determine, in its sole discretion, whether Mr. Dabrowski will be required to actively work during the sixty day notice period; however, Mr. Dabrowski will be entitled to receive his base salary for the duration of the sixty day notice period. The Company has the right to terminate Mr. Dabrowski’s employment agreement for cause (as defined in the agreement), which termination shall be effective immediately.

Frank Rescigna

On May 1, 2021, we entered into a consulting services agreement with Frank Rescigna. The initial term of the agreement is effective through December 31, 2021, and may be extended for additional twelve month periods. Pursuant to the consulting agreement, we agreed to pay Mr. Rescigna a monthly consulting fee of $6,000 and a commission of 3.5% on any wholesale sales generated and received for the duration of his agreement. The consulting agreement may be terminated for any reason either by Mr. Rescigna or the Company, with fifteen days’ notice.

Under the terms of the consulting agreement, Mr. Rescigna will receive a $50,000 bonus upon successful completion of a sales quota of $8,000,000. Additionally, we granted Mr. Rescigna an option to purchase 100,000 shares of our common stock, which will vest upon reaching this sales quota.

Compensation of Directors

There was no cash or equity compensation paid to our directors for the year ended December 31, 2020.

Olivia C. Bartlett

On July 29, 2021, we entered into an agreement with Olivia C. Bartlett to serve as a member of the Company’s Board. We agreed to pay Ms. Bartlett compensation of $10,000 per calendar year, with the annual retainer becoming effective upon consummation of the IPO. The Company agreed to pay Ms. Bartlett $200 per meeting she attends pre-IPO. Additionally, for the first year of services to the Company, we granted Ms. Bartlett an option to purchase 25,000 shares of our common stock.

Louis Castro

On July 29, 2021, we entered into an agreement with Louis Castro to serve as a member of the Company’s Board. We agreed to pay Mr. Castro compensation of $30,000 per calendar year, with the annual retainer becoming effective upon consummation of the IPO. Additionally, for the first year of services to the Company, we granted Mr. Castro an option to purchase 25,000 shares of our common stock.

Kristen Mclaughlin

On August 20, 2021, we entered into an agreement with Kristen Mclaughlin to serve as a member of the Company’s Board. We agreed to pay Ms. Mclaughlin compensation of $20,000 per calendar year, with the annual retainer becoming effective upon consummation of the IPO. Additionally, for the first year of services to the Company, we granted Ms. Mclaughlin an option to purchase 25,000 shares of our common stock.

Frank Rescigna

On July 29, 2021, we entered into an agreement with Frank Rescigna to serve as a member of the Company’s Board. We agreed to pay Mr. Rescigna compensation of $5,000 per calendar year, with the annual retainer becoming effective upon consummation of the IPO. Additionally, for the first year of services to the Company, we granted Mr. Rescigna an option to purchase 25,000 shares of our common stock.

81

Outstanding Equity Awards

The following table sets forth outstanding equity awards to our named executive officers as of December 31, 2021.

 

Option awards

 

Stock awards

Name

 

Number of
securities
underlying
unexercised
options
(#)
exercisable

 

Number of
securities
underlying
unexercised
options
(#)
unexercisable

 

Equity
incentive
plan
awards:
Number of
securities
underlying
unexercised
unearned
options
(#)

 

Option
exercise
price
($)

 

Option
expiration
date

 

Number
of shares
or units
of stock
that
have not
vested
(#)

 

Market
value of
shares
of units
of stock
that
have not
vested
($)

 

Equity
incentive
plan
awards:
Number of
unearned
shares,
units or
other
rights that
have not
vested
(#
)

 

Equity
incentive
plan awards:
Market or
payout value
of unearned
shares, units
or other
rights that
have not
vested
($)

Harrison Gross

 

187,500

 

187,500

 

 

$

1.00

 

04/01/2024

 

 

 

 

Harrison Gross

 

0

 

600,000

 

 

$

3.56

 

05/05/2025

 

 

 

 

Harrison Gross

 

11,108

 

88,892

 

 

$

3.56

 

11/11/2024

 

 

 

 

Konrad Dabrowski

 

6,664

 

53,336

 

 

$

3.56

 

11/11/2024

 

 

 

 

Frank Rescigna

 

 

100,000

 

 

$

3.56

 

5/1/2023

 

 

 

 

Frank Rescigna

 

 

25,000

 

 

$

3.56

 

7/29/2024

 

 

 

 

Our 2021 Equity Incentive Plan was adopted by the Board and approved by our shareholders on July 1, 2021, under which: (i) Mr. Gross was issued stock options on May 5, 2021 to purchase an additional 600,000 shares of our common stock; (ii) Mr. Gross was also issued stock options on August 11, 2021, to purchase an additional 100,000 shares of our common stock; (iii) Konrad Dabrowski was issued stock options on August 11, 2021, to purchase 60,000 shares of our common stock; (iv) Frank Rescigna was issued stock options on May 1, 2021, to purchase 100,000 shares of our common stock; (v) Mr. Rescigna was also issued stock options on July 29, 2021, to purchase an additional 25,000 shares of our common stock; (vi) Olivia Bartlett was issued stock options on July 29, 2021, to purchase 25,000 shares of our common stock; (vii) Louis Castro was issued stock options on July 21, 2021, to purchase 20,000 shares of our common stock; (viii) Mr. Castro was also issued stock options on July 29, 2021, to purchase an additional 25,000 shares of our common stock; (ix) Kristen Mclaughlin was issued stock options on August 20, 2021, to purchase 25,000 shares of our common stock. All stock options were issued under our Equity Incentive Plan and are subject to time-based vesting, except for Mr. Rescigna’s May 5, 2021 option grant that vests upon successful completion of the $8 million sales quota and Mr. Castro’s July 21, 2021 option grant that vests upon an acquisition or flotation at a valuation greater than or equal to four time (400%) of the most recent published annual Company valuation (2020: $2.7 million). See “Note 9 Stock Based Compensation” to our financial statement for more information.

Employee benefits plans

We currently do not provide retirement, health or welfare benefits to any of our employees.

Limitation of Directors Liability and Indemnification

The Florida Business Corporation Act authorizes corporations to limit or eliminate, subject to certain conditions, the personal liability of directors to corporations and their stockholders for monetary damages for breach of their fiduciary duties. Our second amended and restated articles of incorporation, which will become effective upon the completion of this offering, limits the liability of our directors to the fullest extent permitted by Florida law. In addition, upon the closing of this offering, we will enter into indemnification agreements with all of our directors and named executive officers whereby we will agree to indemnify those directors and officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director or officer is or was a director, officer, employee or agent of ours, provided that such director or officer acted in good faith and in a manner that the director or officer reasonably believed to be in, or not opposed to, our best interests.

Prior to the consummation of this offering, we will obtain director and officer liability insurance to cover liabilities our directors and officers may incur in connection with their services to us, including matters arising under the Securities Act. Our second amended and restated articles of incorporation and bylaws also provide that we will indemnify our

82

directors and officers who, by reason of the fact that he or she is or was one of our officers or directors of our Company, is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative related to their board role with us.

There is no pending litigation or proceeding involving any of our directors, officers, employees or agents in which indemnification will be required or permitted. We are not aware of any threatened litigation or proceeding that may result in a claim for such indemnification.

2021 Equity Incentive Plan

General

Our 2021 Equity Incentive Plan was adopted by the Board and approved by our shareholders on July 1, 2021. The general purposes of the 2021 Equity Incentive Plan are to (i) enable the Company and its subsidiaries to attract and retain the types of employees, consultants, and directors who will contribute to the Company’s long range success; (ii) provide incentives that align the interests of employees, consultants, and directors with those of our shareholders; and (iii) promote the success of the Company’s business.

Description of the 2021 Equity Incentive Plan

The following description of the principal terms of the 2021 Equity Incentive Plan is a summary and is qualified in its entirety by the full text of the 2021 Equity Incentive Plan.

Administration.    The 2021 Equity Incentive Plan is administered by a committee appointed by our Board, or in the Board’s discretion, by the Board (as applicable, the “Incentive Plan Administrator”). Subject to the terms of the 2021 Equity Incentive Plan, the Incentive Plan Administrator has the authority to (a) determine the eligible individuals who are to receive awards, (b) determine the terms and conditions of each award, including exercise price, vesting or performance criteria, performance period, and terms of the award, (c) determine whether vesting and performance criteria have been achieved, (d) accelerate the vesting or exercisability of, payment for or lapse of restrictions on, or otherwise modify or amend awards, (e) construe and interpret the 2021 Equity Incentive Plan, including the ability to reconcile any inconsistency in, correct any defect in and/or supply any omission in the plan and award agreement; any instrument or agreement, (f) promulgate, amend, and rescind rules and regulations relating to the administration of the 2021 Equity Incentive Plan, and (g) exercise discretion to make any and all other determinations which it determines to be necessary or advisable for the administration of the 2021 Equity Incentive Plan and awards granted thereunder. The Incentive Plan Administrator may also delegate its authority to a subcommittee or to one or more officers of the Company, subject to terms and conditions determined by the Incentive Plan Administrator. All decisions made by the Incentive Plan Administrator are final and binding on the Company and the participants.

Types of Awards.    The 2021 Equity Incentive Plan provides for the grant of stock options, which may be incentive stock options (“ISOs”) or nonqualified stock options (“NSOs”), stock appreciation rights (“SARs”), restricted stock, restricted stock units (“RSUs”), performance share awards, and other cash-based or equity-based awards, or collectively, awards.

Share Reserve.    A total equal to 20% of our issued and outstanding common stock shall be available for the grant of awards under the 2021 Equity Incentive Plan.

If options, stock appreciation rights, restricted stock units or any other awards are forfeited, cancelled or expire before being exercised or settled in full, the shares subject to such awards will again be available for issuance under the 2021 Equity Incentive Plan. If restricted stock or shares issued upon exercise of an option are reacquired by the Company pursuant to a forfeiture provision, repurchase right or for any other reason, then such shares will again be available for issuance under the 2021 Equity Incentive Plan. Notwithstanding the foregoing, shares applied to pay the exercise price of an option or satisfy withholding taxes related to any award will not become available for issuance under the 2021 Equity Incentive Plan.

Shares issued under the 2021 Equity Incentive Plan may be authorized but unissued shares or treasury shares. As of the date hereof, awards covering 2,332,500 shares of Common Stock were issued, of which 1,685,000 option awards were granted by the Company prior to the approval of the Plan and 647,500 option awards were granted subject to the 2021 Equity Incentive Plan.

83

Incentive Stock Option Limit.    No more than 25,000,000 shares of Common Stock may be issued under the 2021 Equity Incentive Plan upon the exercise of ISOs.

Eligibility.    Employees (including officers), non-employee directors and consultants who render services to the Company or a parent or subsidiary thereof (whether now existing or subsequently established) are eligible to receive awards under the 2021 Equity Incentive Plan. ISOs may only be granted to employees of the Company or a parent or subsidiary thereof (whether now existing or subsequently established).

Stock Options.    A stock option is the right to purchase a certain number of shares of stock at a fixed exercise price which, pursuant to the 2021 Equity Incentive Plan, may not be less than 100% of the fair market value of Common Stock on the date of grant. Subject to limited exceptions, an option may have a term of up to 10 years and will generally expire sooner if the optionholder’s service terminates. Options will vest at the rate determined by the Incentive Plan Administrator. An optionholder may pay the exercise price of an option in cash, or, with the Incentive Plan Administrator’s consent, with shares of stock the optionholder already owns, with proceeds from an immediate sale of the option shares, through a net exercise procedure or by any other method permitted by applicable law.

Tax Limitations on Incentive Stock Options.    The aggregate fair market value, determined at the time of grant, of the Common Stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of the Company’s stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of the Company’s total combined voting power or that of any of the Company’s affiliates unless (a) the option exercise price is at least 110% of the fair market value of Common Stock on the date of grant and (b) the term of the ISO does not exceed five years from the date of grant.

Stock Appreciation Rights.    A stock appreciation right provides the recipient with the right to the appreciation in a specified number of shares of stock. The Incentive Plan Administrator determines the exercise price of stock appreciation rights granted under the 2021 Equity Incentive Plan, which may not be less than 100% of the fair market value of Common Stock on the date of grant. A stock appreciation right may have a term of up to 10 years and will generally expire sooner if the recipient’s service terminates. SARs will vest at the rate determined by the Incentive Plan Administrator. Upon exercise of a SAR, the recipient will receive an amount in cash, stock, or a combination of stock and cash determined by the Incentive Plan Administrator, equal to the excess of the fair market value of the shares being exercised over their exercise price.

Restricted Stock Awards.    Shares of restricted stock may be issued under the 2021 Equity Incentive Plan and may be subject to vesting, as determined by the Incentive Plan Administrator. Recipients of restricted stock generally have all of the rights of a shareholder with respect to those shares, including voting rights and dividends, except as provided in the award agreement.

Restricted Stock Units.    A restricted stock unit is a right to receive a share, at no cost to the recipient, upon satisfaction of certain conditions, including vesting conditions, established by the Incentive Plan Administrator. RSUs vest at the rate determined by the Incentive Plan Administrator and any unvested RSUs will generally be forfeited upon termination of the recipient’s service. Settlement of restricted stock units may be made in the form of cash, stock or a combination of cash and stock, as provided in the award agreement and as determined by the Incentive Plan Administrator. Recipients of restricted stock units generally will have no voting or dividend rights prior to the time the vesting conditions are satisfied and the award is settled.

Performance Share Award.    A performance share award is a right to receive a share or share units based upon the Company’s performance during a specified performance period, as determined by the Incentive Plan Administrator. The Incentive Plan Administrator has the discretion to determine: (i) the number of shares or stock-denominated units subject to a Performance Share Award granted to any recipient; (ii) the performance period applicable to any award; (iii) the conditions that must be satisfied for a recipient to earn an award; and, (iv) the other terms, conditions and restrictions of the award.

Cash Awards and Other Equity-Based Awards.    The Incentive Plan Administrator may grant cash awards and other awards based in whole or in part by reference to Common Stock, either alone or in tandem with other awards. The Incentive Plan Administrator will determine the terms and conditions of any such awards.

Changes to Capital Structure.    In the event of certain changes in capitalization, including a stock split, reverse stock split, stock dividend, or an extraordinary corporate transaction such as any recapitalization, reorganization, merger,

84

consolidation, combination, or exchange, proportionate adjustments will be made in the number and kind of shares available for issuance under the 2021 Equity Incentive Plan, the limit on the number of shares that may be issued under the 2021 Equity Incentive Plan as ISOs, the number and kind of shares subject to each outstanding award and/or the exercise price of each outstanding award.

Change in Control.    If the Company is party to certain change in control transactions, each outstanding award will be treated as the Incentive Plan Administrator determines, which may include the continuation, assumption or substitution of an outstanding award, the cancellation of an outstanding award after an opportunity to exercise or the cancellation of an outstanding award in exchange for a payment equal to the value of the shares subject to such award less any applicable exercise price.

Transferability of Awards.    Unless the Incentive Plan Administrator determines otherwise, an award generally will not be transferable other than by beneficiary designation, a will or the laws of descent and distribution. The Incentive Plan Administrator may permit transfer of an award in a manner consistent with applicable law.

Amendment and Termination.    The Board may amend or terminate the 2021 Equity Incentive Plan at any time. Any such amendment or termination will not affect outstanding awards. If not sooner terminated, the 2021 Equity Incentive Plan will terminate automatically 10 years after its adoption by the Board. Shareholder approval is not required for any amendment of the 2021 Equity Incentive Plan, unless required by applicable law, government regulation or exchange listing standards.

Certain Federal Income Tax Aspects of Awards Under the 2021 Equity Incentive Plan

This is a brief summary of the U.S. federal income tax aspects of awards that may be made under the 2021 Equity Incentive Plan based on existing U.S. federal income tax laws as of the date of this prospectus. This summary covers only the basic tax rules. It does not describe a number of special tax rules, including the alternative minimum tax and various elections that may be applicable under certain circumstances. It also does not reflect provisions of the income tax laws of any municipality, state or foreign country in which a holder may reside, nor does it reflect the tax consequences of a holder’s death. Therefore, no one should rely on this summary for individual tax compliance, planning or decisions. Participants in the 2021 Equity Incentive Plan should consult their own professional tax advisors concerning tax aspects of awards under the 2021 Equity Incentive Plan. The discussion below concerning tax deductions that may become available to the Company under U.S. federal tax law is not intended to imply that the Company will necessarily obtain a tax benefit or asset from those deductions. The tax consequences of awards under the 2021 Equity Incentive Plan depend upon the type of award. Changes to tax laws following the date of this prospectus could alter the tax consequences described below.

Incentive Stock Options.    No taxable income is recognized by an optionholder upon the grant or vesting of an ISO, and no taxable income is recognized at the time an ISO is exercised unless the optionholder is subject to the alternative minimum tax. The excess of the fair market value of the purchased shares on the exercise date over the exercise price paid for the shares is includable in alternative minimum taxable income.

If the optionholder holds the purchased shares for more than one year after the date the ISO was exercised and more than two years after the ISO was granted (the “required ISO holding periods”), then the optionholder will generally recognize long-term capital gain or loss upon disposition of such shares. The gain or loss will equal the difference between the amount realized upon the disposition of the shares and the exercise price paid for such shares. If the optionholder disposes of the purchased shares before satisfying either of the required ISO holding periods, then the optionholder will recognize ordinary income equal to the fair market value of the shares on the date the ISO was exercised over the exercise price paid for the shares (or, if less, the amount realized on a sale of such shares). Any additional gain will be a capital gain and will be treated as short-term or long-term capital gain depending on how long the shares were held by the optionholder.

Nonqualified Stock Options.    No taxable income is recognized by an optionholder upon the grant or vesting of an NSO, provided the NSO does not have a readily ascertainable fair market value. If the NSO does not have a readily ascertainable fair market value, the optionholder will generally recognize ordinary income in the year in which the option is exercised equal to the excess of the fair market value of the purchased shares on the exercise date over the exercise price paid for the shares. If the optionholder is an employee or former employee, the optionholder will be

85

required to satisfy the tax withholding requirements applicable to such income. Upon resale of the purchased shares, any subsequent appreciation or depreciation in the value of the shares will be treated as short-term or long-term capital gain or loss depending on how long the shares were held by the optionholder.

Stock Appreciation Rights.    In general, no taxable income results upon the grant of a SAR. A participant will generally recognize ordinary income in the year of exercise equal to the value of the shares or other consideration received. In the case of a current or former employee, this amount is subject to income tax withholding. Upon resale of the shares acquired pursuant to a SAR, any subsequent appreciation or depreciation in the value of the shares will be treated as a short-term or long-term capital gain or loss, depending on how long the shares were held by the recipient.

Restricted Stock.    A participant who receives an award of restricted stock generally does not recognize taxable income at the time of the award. Instead, the participant recognizes ordinary income when the shares vest, subject to withholding if the participant is an employee or former employee. The amount of taxable income is equal to the fair market value of the shares on the vesting date(s) less the amount, if any, paid for the shares. Alternatively, a participant may make a one-time election to recognize income at the time the participant receives restricted stock in an amount equal to the fair market value of the restricted stock (less any amount paid for the shares) on the date of the award by making an election under Section 83(b) of the Code. Upon resale of the shares acquired pursuant to a restricted stock award, any subsequent appreciation or depreciation in the value of the shares will be treated as short-term or long-term capital gain or loss, depending on how long the shares were held by the recipient.

Restricted Stock Units.    In general, no taxable income results upon the grant of an RSU. The recipient will generally recognize ordinary income, subject to withholding if the recipient is an employee or former employee, equal to the fair market value of the shares that are delivered to the recipient upon settlement of the RSU. Upon resale of the shares acquired pursuant to an RSU, any subsequent appreciation or depreciation in the value of the shares will be treated as short-term or long-term capital gain or loss depending on how long the shares were held by the recipient.

Performance Share Award, Cash Award, or Other Equity-Based Award.    A participant who receives a performance share award, cash award, or other equity-based award generally does not recognize taxable income at the time of the award. Instead, the participant recognizes ordinary income when the award vests or is otherwise no longer subject to a substantial risk of forfeiture, subject to withholding if the participant is an employee or former employee. The amount of taxable income is equal to the cash paid or fair market value of the shares on the vesting date(s) less the amount, if any, paid for the shares. Upon resale of the shares acquired pursuant to a performance share award or other equity-based award, any subsequent appreciation or depreciation in the value of the shares will be treated as short-term or long-term capital gain or loss, depending on how long the shares were held by the recipient.

Section 409A.    The foregoing description assumes that Section 409A of the Code does not apply to an award. In general, options and stock appreciation rights are exempt from Section 409A if the exercise price per share is at least equal to the fair market value per share of the underlying stock at the time the option or stock appreciation right was granted. RSUs are subject to Section 409A unless they are settled within two and one half months after the end of the later of (a) the end of the Company’s fiscal year in which vesting occurs or (b) the end of the calendar year in which vesting occurs. Restricted stock awards are not generally subject to Section 409A. If an award is subject to Section 409A and the provisions for the exercise or settlement of that award do not comply with Section 409A, then the participant would be required to recognize ordinary income whenever a portion of the award vested (regardless of whether it had been exercised or settled). This amount would also be subject to a 20% U.S. federal tax and premium interest, in addition to the U.S. federal income tax at the participant’s usual marginal rate for ordinary income.

Tax Treatment for the Company.    The Company will generally be entitled to an income tax deduction at the time and to the extent a participant recognizes ordinary income as a result of an award granted under the 2021 Equity Incentive Plan. However, Section 162(m) of the Code may limit the deductibility of certain awards granted under the 2021 Equity Incentive Plan. Although the Incentive Plan Administrator considers the deductibility of compensation as one factor in determining executive compensation, the Incentive Plan Administrator retains the discretion to award and pay compensation that is not deductible as it believes that it is in the shareholders’ best interests to maintain flexibility in the approach to executive compensation and to structure a program that the Company considers to be the most effective in attracting, motivating and retaining key employees.

86

Principal Stockholders

Based solely upon information made available to us, the following table sets forth information as of January 5, 2022 regarding the beneficial ownership of our common stock:

•        each person known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock;

•        each of our named executive officers and directors; and

•        all our executive officers and directors as a group.

The percentage ownership information shown in the table is based upon 6,113,220 shares of common stock outstanding as of the date hereof, which gives into effect the conversion of the Notes. In addition, the number of shares and percentage of shares beneficially owned after the offering gives effect to the issuance by us of 2,857,142 shares of common stock in this offering assuming an initial public offering price of $5.25 per Unit (the mid-point of the price range set forth on the cover page of this prospectus). The percentage ownership information assumes no exercise of the underwriters’ over-allotment option.

Beneficial ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the securities. Except as otherwise indicated, each person or entity named in the table has sole voting and investment power with respect to all shares of our capital shown as beneficially owned, subject to applicable community property laws.

In computing the number and percentage of shares beneficially owned by a person, shares that may be acquired by such person (for example, upon the exercise of options or warrants) within 60 days of the date of this prospectus are counted as outstanding, while these shares are not counted as outstanding for computing the percentage ownership of any other person.

The address of each holder listed below, except as otherwise indicated, is 8101 Biscayne Blvd., Suite 705, Miami, Florida, 33138.

Name of Beneficial Owner

 

Shares of
Common Stock
Beneficially
Owned
(1)

 

Percent of
Common Stock
Beneficially
Owned Before
Offering

 

Percent of
Common Stock
Beneficially
Owned After
Offering

Named Executive Officers and Directors

       

 

   

 

Harrison Gross(2)

 

204,162

 

3.37

%

 

2.22

%

Konrad Dabrowski(3)

 

9,996

 

1.65

%

 

*

%

Frank Rescigna

 

 

 

 

 

Kristen McLaughlin

 

 

 

 

             —

 

Louis Castro(4)

 

20,000

 

3.3

%

 

*

 

Olivia Bartlett

 

 

 

 

             —

 

All directors and executive officers as a group (7 persons)

 

234,158

 

3.86

%

 

2.54

%

5% Stockholders

       

 

   

 

Lucyd Ltd.(5)(6)

 

4,922,115

 

81.2

%

 

54.87

%

____________

*        Less than 1%.

Percentage ownership is based on 6,113,220 shares of our common stock outstanding and options exercisable into 2,332,500 shares of our common stock outstanding prior to this offering and 8,970,362 shares of our common stock outstanding after this offering.

(1)      We have determined beneficial ownership in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended, which is generally determined by voting power and/or dispositive power with respect to securities. Unless otherwise noted, the shares of common stock listed above are owned as of the date of this prospectus, and are owned of record by each individual named as beneficial owner and such individual has sole voting and dispositive power with respect to the shares of common stock owned by each of them.

87

(2)      Includes 204,162 shares of common stock issuable upon exercise of stock options held by Mr. Gross exercisable within 60 days of the date of this prospectus.

(3)      Includes 9,996 shares of common stock issuable upon exercise of stock options held by Mr. Dabrowski exercisable within 60 days of the date of this prospectus.

(4)      Includes 20,000 shares of common stock issuable upon exercise of stock options held by Mr. Castro exercisable within 60 days of the date of this prospectus.

(5)      Tekcapital plc, a public company listed on the London Stock Exchange, owns all issued and outstanding securities of Tekcapital Europe Ltd., which owns all issued and outstanding securities of Lucyd Ltd. As such, Tekcapital plc may be deemed to beneficially own the shares held by Lucyd Ltd. by virtue of their control over Lucyd Ltd. Tekcapital plc disclaims beneficial ownership of the shares held by Lucyd Ltd. Mr. Clifford Gross, the Chief Executive Officer of Tekcapital plc, is the father of Mr. Harrison Gross, our Chief Executive Officer.

(6)      Includes 1,172,115 shares of common stock issuable to Lucyd Ltd. upon conversion of the outstanding Notes.

88

Certain Relationships and Related Party Transactions

On occasion we may engage in certain related party transactions. All prior related party transactions were approved by our board of directors and a majority of our issued and outstanding shares of capital stock. Upon the consummation of offering, our policy is that all related party transactions will be reviewed and approved by the Audit Committee of our Board of Directors prior to our entering into any related party transactions.

License Agreement

On April 1, 2020, we entered into an exclusive, worldwide license agreement with Lucyd Ltd., the majority stockholder of the Company, for the use of the Lucyd brand, and the associated intellectual property and assets (the “License Agreement”). The License Agreement is royalty-free, fully paid up, and perpetual license for the exclusive use of certain assets of Lucyd Ltd. related to Innovative Eyewear current products and trademarks. As compensation for entrance into the License Agreement, we issued Lucyd Ltd. 3,750,000 shares of our common stock. On October 5, 2021, the parties to the License Agreement executed an Addendum, to the exclusive license agreement, which clarified that Innovative Eyewear shall commercialize, continue with any on-going intellectual property prosecutions and pay all maintenance or other patent fees (the “Addendum”). For all new intellectual property, Innovative Eyewear will own control it and be responsible for all prosecution and maintenance costs. The Addendum also confirms that Innovative Eyewear issued Lucyd Ltd. 3,750,000 shares of its common stock as consideration for the license. Please see “Business — Material Agreements” for a more complete description of the License Agreement and Addendum.

Management Agreement

On June 1, 2020, we entered into a management agreement with Tekcapital Europe Ltd., an affiliate of our majority stockholder, Lucyd Ltd., who’s Chief Executive Officer is the father of our Chief Executive Officer, pursuant to which we have agreed to pay Tekcapital Europe Ltd. $25,000 per fiscal quarter for office space, utilities, advisory services and any other services in accordance with Tekcapital Europe Ltd.’s areas of expertise. The management agreement shall be in force perpetually, with the right of either party to terminate for any reason with 30 days’ notice.

Additionally, the Tekcapital Europe Ltd. incurred $100,000 in 2019 and $80,000 in 2020 in management fee charges on behalf of the Company. These payables were assigned to the Company based on the related party convertible debt agreement, dated June 1, 2021 and included in the Notes balance discussed above. Tekcapital Europe Ltd. incurred $9,975 in management fee charges on behalf of the Company for the nine months ended September 30, 2021.

Convertible Note Financing

On December 1, 2020, we issued a convertible note for an aggregate principal amount of up to $2,000,000 to Lucyd Ltd., the majority stockholder of the Company (the “Note”). On June 1, 2021, we completed the partial conversion of an aggregate of $778,500 of the outstanding balance on the Note, at $1.00 per share, into an aggregate of 778,500 shares of common stock. On September 5, 2021, we completed the partial conversion of an aggregate of $500,002 of the outstanding balance on the Note, at $3.56 per share, into an aggregate of 140,449 shares of common stock. As of September 30, 2021, $420,104 remained outstanding on the Note. On November 16, 2021, we completed the partial conversion of an aggregate of $901,270.96 of the outstanding balance of the Note, at $3.56 per share, into an aggregate of 253,166 shares of common stock. As of January 5, 2022, approximately $283,134 remains outstanding on the Note.

The Note has an interest rate of 10.0% per annum, is unsecured, matures on December 1, 2023 and provides for conversion, at the election of Lucyd Ltd., into our common stock upon the earlier of (i) the Company consummating an equity financing pursuant to which it raises an aggregate amount of not less than $750,000, (ii) the Company entering into a transaction pursuant to which the Company sells not less than 10% of the Company’s shares, excluding any and all convertible notes which are convertible into shares, (iii) the Company lists its shares on a national securities exchange or (iv) the holder determines to convert the Note. The Note can be converted by the Holder using the price of either (i) the per share purchase price paid for by investors under the terms of recent equity financing, (ii) the closing price of the Company’s trading shares on the relevant public exchange for the day immediately preceding the date of conversion of the Note or (iii) the valuation of the last equity investment. If not converted earlier, upon the closing of this offering, the Notes will convert into 53,930 shares of our common stock at a conversion price equal to $5.25 per share, the assumed offering price. The principal amount and accrued but unpaid interest under each note will automatically convert into shares of our common stock at the stated conversion price per share.

89

Intercompany Loan and Debt Transfer Agreements

On June 1, 2021, we entered into an intercompany loan and debt transfer agreement, whereby Lucyd Ltd, Tekcapital plc, Tekcapital Europe Ltd or Tekcapital LLC incurred a debt on behalf of the Company in the amount of $387,328. Pursuant to the terms of the agreement, there is no interest payable on the amount of the debt outstanding, unless we agree otherwise with Lucyd Ltd. The debt, along with any accrued interest and other amounts that may be due in connection with the debt, is repayable by the Company upon demand from Lucyd Ltd, at any time, unless we agree otherwise with Lucyd Ltd. The Company may prepay the whole or any part of the debt at any time, unless we agree otherwise.

On September 5, 2021, we entered into an intercompany loan and debt transfer agreement, whereby Lucyd Ltd, Tekcapital plc, Tekcapital Europe Ltd or Tekcapital LLC incurred a debt on behalf of the Company in the amount of $500,002. Pursuant to the terms of the agreement, there is no interest payable on the amount of the debt outstanding, unless we agree otherwise with Lucyd Ltd. The debt, along with any accrued interest and other amounts that may be due in connection with the debt, is repayable by the Company upon demand from Lucyd Ltd, at any time, unless we agree otherwise with Lucyd Ltd. The Company may prepay the whole or any part of the debt at any time, unless we agree otherwise.

Statement of Policy

All future transactions between us and our officers, directors or five percent stockholders, and respective affiliates will be on terms no less favorable than could be obtained from unaffiliated third parties and will be approved by a majority of our independent directors who do not have an interest in the transactions and who had access, at our expense, to our legal counsel or independent legal counsel.

To the best of our knowledge, during the past three fiscal years, other than as set forth above, there were no material transactions, or series of similar transactions, or any currently proposed transactions, or series of similar transactions, to which we were or are to be a party, in which the amount involved exceeds the lesser of $120,000 or one percent of the average of our total assets at year-end for the last two completed financial years, and in which any director or executive officer, or any security holder who is known by us to own of record or beneficially more than 5% of any class of our common stock, or any member of the immediate family of any of the foregoing persons, has an interest (other than compensation to our officers and directors in the ordinary course of business).

90

Description of Capital Stock

General

Pursuant to our second amended and restated articles of incorporation, our authorized capital stock will consist of fifty million (50,000,000) shares of Common Stock, $0.00001 par value and fifteen million (15,000,000) shares of preferred stock, $0.00001 par value. As of the date of this prospectus, after giving effect to the conversion of our outstanding Notes into an aggregate of 53,930 shares of common stock upon the closing of this offering, there are 6,113,220 shares of common stock outstanding. In addition, as of the date of this prospectus, we had outstanding options to purchase an aggregate of 2,332,500 shares of our common stock under the 2021 Equity Incentive Plan, at a weighted average exercise price equal to $2.59 per share. Our authorized but unissued shares of common stock and preferred stock are available for issuance without further action by our stockholders, unless such action is required by applicable law or the rules of any stock exchange or automated quotation system on which our securities may be listed or traded in the future. The following description summarizes the material terms of our capital stock. Because it is only a summary, it may not contain all the information that is important to you.

Common Stock

As of January 5, 2022, 6.059,290 shares of common stock were issued and outstanding held by ___ stockholders of record. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and are not entitled to cumulative voting rights.

Holders of our common stock are entitled to receive ratably such dividends, if any, as may be declared by our Board of Directors out of funds legally available therefor, subject to any preferential distribution rights of third parties. Upon our liquidation, dissolution or winding up, the holders of our common stock are entitled to receive ratably our net assets available after the payment of all debts and other liabilities.

Holders of our common stock have no preemptive, subscription, redemption or conversion rights. There are no redemption or sinking fund provisions applicable to the common stock. All of the outstanding shares of our common stock are fully-paid and nonassessable. The rights, preferences and privileges of holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of any indebtedness of our company.

Stock Options

As of the date of this prospectus, we had reserved the following shares of common stock for issuance pursuant to stock options under the 2021 Equity Incentive Plan described below:

•        2,332,500 shares of our common stock reserved for issuance under stock option agreements issued pursuant to the 2021 Equity Incentive Plan with a weighted average exercise price of $2.59 per share; and

•                       shares of our common stock reserved for future issuance under the 2021 Equity Incentive Plan (which is equal to 20% of our issued and outstanding common stock immediately after the consummation of this offering, less the number of outstanding option grants).

Convertible Promissory Notes

As of the date of this prospectus, we had outstanding Notes in an aggregate principal amount of approximately $283,134 with an interest rate of 10% per annum.

If not converted earlier, at the closing of this offering the aggregate principal amount and any accrued but unpaid interest on all notes will automatically convert into an aggregate of 53,930 shares of our common stock at an assumed conversion price of $5.25 per share. Please see “Certain Relationships and Related Party Transactions” for a more complete description of the Notes.

91

Warrants Offered in this Offering

The following summary of certain terms and provisions of the Warrants offered hereby is not complete and is subject to, and qualified in its entirety by the provisions of the form of Warrant, which is filed as an exhibit to the registration statement of which this prospectus is a part. Prospective investors should carefully review the terms and provisions set forth in the form of Warrant.

The Warrants issued in this offering entitle the registered holders to purchase common stock at a price equal to $[__] per share (which shall not be less than 100% of the public offering price per Unit), subject to adjustment as discussed below, immediately following the issuance of such Warrants and terminating at 5:00 p.m., New York City time, five years after the closing of this offering.

The exercise price and number of shares of common stock issuable upon exercise of the Warrants may be adjusted in certain circumstances, including in the event of a stock dividend or recapitalization, reorganization, merger or consolidation. However, the Warrants will not be adjusted for issuances of shares of common stock at prices below its exercise price.

Exercisability.    The Warrants are exercisable immediately upon issuance and at any time up to the date that is five years from the date of issuance. The Warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of common stock purchased upon such exercise. Each Warrant entitles the holder thereof to purchase one share of common stock. Warrants are not exercisable for a fraction of a share and may only be exercised into whole numbers of shares. In lieu of fractional shares, we will, pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price and round down to the nearest whole share. Unless otherwise specified in the Warrant, the holder will not have the right to exercise the Warrants, in whole or in part, if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or 9.99% at the holder’s election) of the number of our shares of common stock outstanding immediately after giving effect to the exercise, as such percentage is determined in accordance with the terms of the Warrant. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon at least 61 days’ prior notice from the holder to us.

Exercise Price.    The exercise price per share of common stock purchasable upon exercise of the Warrants is $             per share, or 100% of the public offering price per Unit, and is subject to adjustments for stock splits, reclassifications, subdivisions, and other similar transactions. In addition to the exercise price per share of common stock, and other applicable charges and taxes are due and payable upon exercise.

Warrant Agent; Global Certificate.    The Warrants will be issued in registered form under a warrant agency agreement between the warrant agent and us. The Warrants will initially be represented only by one or more global warrants deposited with the warrant agent, as custodian on behalf of The Depository Trust Company, or DTC, and registered in the name of Cede & Co., a nominee of DTC, or as otherwise directed by DTC.

The name, address and telephone number of the warrant agent is VStock Transfer, LLC, 18 Lafayette Pl, Woodmere, New York 11598, (212) 828-8436.

Listing; Transferability.    There is no established trading market for any of the Warrants, and we do not expect a market to develop. We do not intend to apply for a listing for any of the Warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the Warrants will be limited. We intend to have the Warrants issued in registered form under the warrant agency agreement between us and the warrant agent. Subject to applicable laws, the Warrants may be transferred at the option of the holders upon surrender of the Warrants to the warrant agent, together with the appropriate instruments of transfer.

Adjustments; Fundamental Transaction.    The exercise price and the number of shares underlying the Warrants are subject to appropriate adjustment in the event of stock splits, stock dividends on our shares of common stock, stock combinations or similar events affecting our shares of common stock. In addition, in the event we consummate a merger or consolidation with or into another person or other reorganization event in which our shares of common stock are converted or exchanged for securities, cash or other property, or we sell, lease, license, assign, transfer, convey or otherwise dispose of all or substantially all of our assets or we or another person acquire 50% or more of our outstanding shares of common stock (each, a Fundamental Transaction), then following such Fundamental Transaction the holders of the Warrants will be entitled to receive upon exercise of the Warrants the same kind and amount of securities, cash or property which the holders would have received had they exercised the Warrants immediately prior to such Fundamental Transaction. Any successor to us or surviving entity will assume the obligations under the Warrants.

92

Rights as a Shareholder.    Except by virtue of such holder’s ownership of our common stock, the holder of a Warrant does not have rights or privileges of a shareholder, including any voting rights, until the holder exercises such Warrant.

Representative’s Warrants

We have agreed to sell to the representative of the underwriters of this offering, or its permitted designees, for nominal consideration, warrants to purchase              shares of our common stock as additional consideration to the underwriters in this offering. The representative’s warrants will have an exercise price equal to 110.0% of the public offering price in this offering and shall be exercisable during the five (5) year period commencing 180 days following the commencement of sales of the securities in this offering, which is also the effective date of the registration statement of which this prospectus is a part, and will contain customary “cashless” exercise and registration rights provisions. The warrants shall not be exercisable for a period of 180 days following the commencement of sale of the securities in this offering, which is also the date of effectiveness of the registration statement of which this prospectus forms a part. See “Underwriting — Representative’s Warrants.”

Florida Law and Certain Charter and Bylaw Provisions

Florida Anti-Takeover Law.    As a Florida corporation, we are subject to certain anti-takeover provisions that apply to public corporations under Florida law.

Pursuant to Section 607.0901 of the Florida Business Corporation Act, or the FBCA, a publicly held Florida corporation may not engage in a broad range of business combinations or other extraordinary corporate transactions with an interested shareholder without the approval of the holders of two-thirds of the voting shares of the corporation (excluding shares held by the interested shareholder), unless:

•        The transaction is approved by a majority of disinterested directors before the shareholder becomes an interested shareholder;

•        The interested shareholder has owned at least 80% of the corporation’s outstanding voting shares for at least five years preceding the announcement date of any such business combination;

•        The interested shareholder is the beneficial owner of at least 90% of the outstanding voting shares of the corporation, exclusive of shares acquired directly from the corporation in a transaction not approved by a majority of the disinterested directors; or

•        The consideration paid to the holders of the corporation’s voting stock is at least equal to certain fair price criteria.

An interested shareholder is defined as a person who, together with affiliates and associates, beneficially owns more than 10% of a corporation’s outstanding voting shares. We have not made an election in our second amended and restated articles of incorporation to opt out of Section 607.0901.

In addition, we are subject to Section 607.0902 of the FBCA which prohibits the voting of shares in a publicly held Florida corporation that are acquired in a control share acquisition unless (i) the board of directors approved such acquisition prior to its consummation or (ii) after such acquisition, in lieu of prior approval by the board of directors, the holders of a majority of the corporation’s voting shares, exclusive of shares owned by officers of the corporation, employee directors or the acquiring party, approve the granting of voting rights as to the shares acquired in the control share acquisition. A control share acquisition is defined as an acquisition that immediately thereafter entitles the acquiring party to 20% or more of the total voting power in an election of directors.

Second Amended and Restated Articles of Incorporation and Bylaws.

Our second amended and restated articles of incorporation and second amended and restated bylaws contain provisions that could have the effect of discouraging potential acquisition proposals or tender offers or delaying or preventing a change of control of our company. These provisions are as follows:

•        they provide that special meetings of shareholders may be called by the board of directors, on the call of its board of directors or the person or persons authorized to do so by the second amended and restated bylaws, or at the request in writing by shareholders of record owning at least 25% of the issued and outstanding voting shares of common stock; and

93

•        they do not include a provision for cumulative voting in the election of directors. Under cumulative voting, a minority shareholder holding a sufficient number of shares may be able to ensure the election of one or more directors. The absence of cumulative voting may have the effect of limiting the ability of minority shareholders to effect changes in the board of directors.

Elimination of Monetary Liability for Officers and Directors

Pursuant to the FBCA, our second amended and restated articles of incorporation exclude personal liability for our directors for monetary damages based upon any violation of their fiduciary duties as directors, except as to liability for any breach of the duty of loyalty, acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, or any transaction from which a director receives an improper personal benefit. This exclusion of liability does not limit any right which a director may have to be indemnified and does not affect any director’s liability under federal or applicable state securities laws. We have agreed to indemnify our directors against expenses, judgments, and amounts paid in settlement in connection with any claim against a director if he acted in good faith and in a manner he believed to be in our best interests.

Indemnification of Officers and Directors

Our second amended and restated articles of incorporation also contain provisions to indemnify the directors, officers, employees or other agents to the fullest extent permitted by the FBCA. These provisions may have the practical effect in certain cases of eliminating the ability of shareholders to collect monetary damages from directors. We are also a party to indemnification agreements with each of our directors. We believe that these provisions will assist us in attracting or retaining qualified individuals to serve as our directors.

Disclosure of Commission Position on Indemnification for Securities Act Liabilities

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

Transfer Agent and Registrar

The name, address and telephone number of our stock transfer agent is VStock Transfer, LLC, 18 Lafayette Pl, Woodmere, New York 11598, (212) 828-8436.

Listing

We have applied to have our common stock listed on NASDAQ under the symbol “LUCY”. There is no established trading market for any of the Warrants, and we do not expect a market to develop. We do not intend to apply for a listing for any of the Warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the Warrants will be limited.

94

Shares Eligible For Future Sale

Immediately prior to this offering, there was no public market for our common stock or Warrants. Future sales of substantial amounts of our common stock in the public market could adversely affect prevailing market prices. Furthermore, since only a limited number of shares will be available for sale shortly after this offering because of contractual and legal restrictions on resale described below, sales of substantial amounts of common stock in the public market after the restrictions lapse could adversely affect the prevailing market price for our common stock as well as our ability to raise equity capital in the future.

Based on the number of shares outstanding as of the date of this prospectus, upon the closing of this offering, approximately 8,970,362 shares of common stock will be outstanding, assuming an initial public offering price of $5.25 per Unit (the mid-point of the price range set forth on the cover page of this prospectus), no exercise of the Warrants included in the Units offered hereby and further assuming no exercise of the underwriters’ over-allotment option. Of the shares to be outstanding immediately after completion of the offering, all 2,857,142 shares sold in this offering will be freely tradable unless held by an affiliate of ours. Of the remaining 6,113,220 shares of common stock outstanding after this offering, 381,469 shares are, or will be, freely tradable without restriction immediately after the consummation of this offering, approximately 755,706 of these shares, representing shares not held by our “affiliates,” generally may be resold under SEC Rule 144 beginning 90 days from the effectiveness of the registration statement of which this prospectus forms a part, subject to any lock-up agreements entered into between such stockholders and Maxim Group LLC, and 4,976,045 of these shares may be resold under SEC Rule 144 beginning 180 days from the effectiveness of the registration statement of which this prospectus forms a part, subject to any lock-up agreements entered into between such stockholders and Maxim Group LLC and subject in certain circumstances to the volume, manner of sale and other limitations under Rule 144.

Rule 144

In general, under Rule 144 as currently in effect, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, any person who is not an affiliate of ours and has held their shares for at least six months, as measured by SEC rule, including the holding period of any prior owner other than one of our affiliates, may sell shares without restriction, provided current public information about us is available. In addition, under Rule 144, any person who is not an affiliate of ours and has held their shares for at least one year, as measured by SEC rule, including the holding period of any prior owner other than one of our affiliates, would be entitled to sell an unlimited number of shares immediately upon the closing of this offering without regard to whether current public information about us is available. Beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is an affiliate of ours and who has beneficially owned restricted securities for at least six months, as measured by SEC rule, including the holding period of any prior owner other than one of our affiliates, is entitled to sell a number of restricted shares within any three-month period that does not exceed the greater of:

•        1% of the number of shares of our common stock then outstanding, which will equal approximately 89,703 shares immediately after this offering; and

•        the average weekly trading volume of our common stock on NASDAQ during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.

Sales of restricted shares under Rule 144 held by our affiliates are also subject to requirements regarding the manner of sale, notice and the availability of current public information about us. Rule 144 also provides that affiliates relying on Rule 144 to sell shares of our common stock that are not restricted shares must nonetheless comply with the same restrictions applicable to restricted shares, other than the holding period requirement. Notwithstanding the availability of Rule 144, the holders of 4,976,045 of our restricted shares have entered into lock-up agreements as described below and their restricted shares will become eligible for sale at the expiration of the restrictions set forth in those agreements.

Rule 701

Under Rule 701, shares of our common stock acquired upon the exercise of currently outstanding options or pursuant to other rights granted under our stock plans may be resold, by:

•        persons other than affiliates, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, subject only to the manner-of-sale provisions of Rule 144; and

95

•        our affiliates, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, subject to the manner-of-sale and volume limitations, current public information and filing requirements of Rule 144, in each case, without compliance with the six-month holding period requirement of Rule 144.

Lock-up Agreements

We, all of our directors, officers, employees and the holders of 1.0% or more of the outstanding shares of our Common Stock as of the effective date of the registration statement of which this prospectus is a part have entered into lock-up agreements with respect to the disposition of their shares. See “Underwriting — Lock-Up Agreements” for additional information.

Equity Incentive Plans

We intend to file registration statements on Form S-8 under the Securities Act after the closing of this offering to register the shares of our common stock that are issuable pursuant to our 2021 Equity Incentive Plan. The registration statement is expected to be filed and become effective as soon as practicable after the completion of this offering, but in no event prior to the six months after the date of this prospectus. Accordingly, shares registered under the registration statements will be available for sale in the open market following their effective dates, subject to Rule 144 volume limitations and the lock-up arrangement described above, if applicable.

96

CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS

The following discussion summarizes certain U.S. federal income tax considerations generally applicable to the acquisition, ownership and disposition of our units (each consisting of one share of our common stock one warrant) that are purchased in this offering by U.S. Holders (as defined below) and Non-U.S. Holders (as defined below). Because the components of a unit are separable, the holder of a unit generally should be treated, for U.S. federal income tax purposes, as the owner of the underlying share of our common stock and one warrant components of the unit. As a result, the discussion below with respect to holders of shares of our common stock and warrants should also apply to holders of units (as the deemed owners of the underlying share of our common stock and warrants that constitute the units).

This discussion is limited to certain U.S. federal income tax considerations to beneficial owners of our securities who are initial purchasers of a unit pursuant to this offering and hold the unit and each component of the unit as capital assets within the meaning of Section 1221(a) of the U.S. Internal Revenue Code of 1986, as amended (the “Code”) (generally, property held for investment). This discussion assumes that the shares of our common stock and warrants will trade separately and that any distributions made (or deemed made) by us on the shares of our common stock and any consideration received (or deemed received) by a holder in consideration for the sale or other disposition of our securities will be in U.S. dollars. This discussion is a summary only and does not consider all aspects of U.S. federal income taxation that may be relevant to the acquisition, ownership and disposition of a unit by a prospective investor in light of its particular circumstances or that is subject to special rules under the U.S. federal income tax laws, including, but not limited to:

•        our officers, directors or other holders of our common stock or private placement warrants;

•        banks and other financial institutions or financial services entities;

•        broker-dealers;

•        mutual funds;

•        retirement plans, individual retirement accounts or other tax-deferred accounts;

•        taxpayers that are subject to the mark-to-market tax accounting rules;

•        tax-exempt entities;

•        S-corporations, partnerships or other flow-through entities and investors therein;

•        governments or agencies or instrumentalities thereof;

•        insurance companies;

•        regulated investment companies;

•        real estate investment trusts;

•        passive foreign investment companies;

•        controlled foreign corporations;

•        qualified foreign pension funds;

•        expatriates or former long-term residents of the United States;

•        persons that actually or constructively own five percent or more of our voting shares;

•        persons that acquired our securities pursuant to an exercise of employee share options, in connection with employee share incentive plans or otherwise as compensation or in connection with services;

•        persons required for U.S. federal income tax purposes to conform the timing of income accruals to their financial statements under Section 451 of the Code;

•        persons subject to the alternative minimum tax;

97

•        persons that hold our securities as part of a straddle, constructive sale, hedging, conversion or other integrated or similar transaction; or

•        U.S. Holders (as defined below) whose functional currency is not the U.S. dollar.

The discussion below is based upon current provisions of the Code, applicable U.S. Treasury regulations promulgated under the Code (“Treasury Regulations”), judicial decisions and administrative rulings of the IRS, all as in effect on the date hereof, and all of which are subject to differing interpretations or change, possibly on a retroactive basis. Any such differing interpretations or change could alter the U.S. federal income tax consequences discussed below. Furthermore, this discussion does not address any aspect of U.S. federal non-income tax laws, such as gift, estate or Medicare contribution tax laws, or state, local or non-U.S. tax laws.

We have not sought, and will not seek, a ruling from the IRS as to any U.S. federal income tax consequence described herein. The IRS may disagree with the discussion herein, and its determination may be upheld by a court. Moreover, there can be no assurance that future legislation, regulations, administrative rulings or court decisions will not adversely affect the accuracy of the statements in this discussion.

As used herein, the term “U.S. Holder” means a beneficial owner of units, shares of our common stock or warrants that is for U.S. federal income tax purposes:

(i)     an individual who is a citizen or resident of the United States,

(ii)    a corporation (or other entity treated as a corporation for U.S. federal income tax purposes) that is created or organized (or treated as created or organized) in or under the laws of the United States, any state thereof or the District of Columbia,

(iii)   an estate the income of which is subject to U.S. federal income taxation regardless of its source or

(iv)   a trust if (A) a court within the United States is able to exercise primary supervision over the administration of the trust and one or more United States persons have the authority to control all substantial decisions of the trust, or (B) it has in effect a valid election under Treasury Regulations to be treated as a United States person.

This discussion does not consider the tax treatment of partnerships or other pass-through entities (including branches) or persons who hold our securities through such entities. If a partnership (or other entity or arrangement classified as a partnership for U.S. federal income tax purposes) is the beneficial owner of our securities, the U.S. federal income tax treatment of a partner in the partnership generally will depend on the status of the partner and the activities of the partner and the partnership. If you are a partner or a partnership holding our securities, we urge you to consult your own tax advisor.

THIS DISCUSSION IS ONLY A SUMMARY OF CERTAIN U.S. FEDERAL INCOME TAX CONSIDERATIONS ASSOCIATED WITH THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR UNITS. EACH PROSPECTIVE INVESTOR IN OUR UNITS IS URGED TO CONSULT ITS OWN TAX ADVISOR WITH RESPECT TO THE PARTICULAR TAX CONSEQUENCES TO SUCH INVESTOR OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR UNITS, INCLUDING THE APPLICABILITY AND EFFECT OF ANY STATE, LOCAL, AND NON-UNITED STATES TAX LAWS

Personal Holding Company Status

We could be subject to a second level of U.S. federal income tax on a portion of our income if we are determined to be a personal holding company (a “PHC”) for U.S. federal income tax purposes. A U.S. corporation generally would be classified as a PHC for U.S. federal income tax purposes in a given taxable year if (i) at any time during the last half of such taxable year, five or fewer individuals (without regard to their citizenship or residency and including as individuals for this purpose certain entities such as certain tax-exempt organizations, pension funds and charitable trusts) own or are deemed to own (pursuant to certain constructive ownership rules) more than 50% of the stock of the corporation by value and (ii) at least 60% of the corporation’s adjusted ordinary gross income, as determined for U.S. federal income tax purposes, for such taxable year consists of PHC income (which includes, among other things, dividends, interest, certain royalties, annuities and, under certain circumstances, rents). If we are or were to become a PHC in a given taxable year, we would be subject to an additional PHC tax, currently 20%, on our undistributed PHC income, which generally includes our taxable income, subject to certain adjustments.

98

Allocation of Purchase Price and Characterization of a Unit

No statutory, administrative or judicial authority directly addresses the treatment of a unit or instruments similar to a unit for U.S. federal income tax purposes, and therefore, that treatment is not entirely clear. The acquisition of a unit should be treated for U.S. federal income tax purposes as the acquisition of one share of our common stock and one warrant, with each warrant exercisable to acquire one share of our common stock, and we intend to treat the acquisition of a unit in this manner. For U.S. federal income tax purposes, each holder of a unit must allocate the purchase price paid by such holder for such unit between the one share of our common stock and the one warrant based on the relative fair market value of each at the time of issuance. Under U.S. federal income tax law, each investor must make its own determination of such value based on all the relevant facts and circumstances. Therefore, we strongly urge each investor to consult its tax advisor regarding the determination of value for these purposes. The price allocated to each share of our common stock and each warrant should constitute the holder’s initial tax basis in such share and such warrant, respectively. Any disposition of a unit should be treated for U.S. federal income tax purposes as a disposition of the share of our common stock and warrant comprising the unit, and the amount realized on the disposition should be allocated between the share of our common stock and warrant based on their respective relative fair market values at the time of disposition. The separation of the share of our common stock and the warrant constituting a unit should not be a taxable event for U.S. federal income tax purposes.

The foregoing treatment of the shares of our common stock and warrants and a holder’s purchase price allocation are not binding on the IRS or the courts. Because there are no authorities that directly address instruments that are similar to the units, no assurance can be given that the IRS or the courts will agree with the characterization described above or the discussion below. Accordingly, each prospective investor is urged to consult its tax advisor regarding the tax consequences of an investment in a unit (including alternative characterizations of a unit). The balance of this discussion assumes that the characterization of the units described above is respected for U.S. federal income tax purposes.

U.S. Holders

Taxation of Distributions

If we pay distributions in cash or other property (other than certain distributions of our stock or rights to acquire our stock) to U.S. Holders of our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below zero) the U.S. Holder’s adjusted tax basis in our shares of our common stock. Any remaining excess will be treated as gain realized on the sale or other disposition of the shares of our common stock and will be treated as described under “U.S. Holders — Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Our Common Stock and Warrants” below.

Dividends we pay to a corporate U.S. Holder generally will qualify for the dividends received deduction if certain holding period requirements are met. With certain exceptions (including, but not limited to, dividends treated as investment income for purposes of investment interest deduction limitations), and provided certain holding period requirements are met, dividends we pay to a non-corporate U.S. Holder will generally be taxed as qualified dividend income at the preferential tax rate for long-term capital gains. If the holding period requirements are not met, then a corporation may not be able to qualify for the dividends received deduction and would have taxable income equal to the entire dividend amount, and non-corporate holders may be subject to tax on such dividend at regular ordinary income tax rates instead of the preferential rate that applies to qualified dividend income.

Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Our Common Stock and Warrants

A U.S. Holder generally will recognize capital gain or loss on a sale or other taxable disposition of our shares of common stock or warrants. Any such capital gain or loss generally will be long-term capital gain or loss if the U.S. Holder’s holding period for such shares of our common stock or warrants exceeds one year. Long-term capital gains recognized by a non-corporate U.S. Holder are currently eligible to be taxed preferential rates. The deductibility of capital losses is subject to limitations.

The amount of gain or loss recognized on a sale or other taxable disposition generally will be equal to the difference between (i) the sum of the amount of cash and the fair market value of any property received in such disposition (or,

99

if the shares of our common stock or warrants are held as part of units at the time of the disposition, the portion of the amount realized on such disposition that is allocated to the shares of our common stock or warrants based upon the then relative fair market values of the shares of our common stock and the warrants included in the units) and (ii) the U.S. Holder’s adjusted tax basis in its shares of our common stock or warrants so disposed of. A U.S. Holder’s adjusted tax basis in its shares of our common stock and warrants generally will equal the U.S. Holder’s acquisition cost (that is, the portion of the purchase price of a unit allocated to a share of our common stock or warrant, as described above under “— Allocation of Purchase Price and Characterization of a Unit”) reduced, in the case of a share of our common stock, by any prior distributions treated as a return of capital. See “U.S. Holders — Exercise, Lapse or Redemption of a Warrant” below for a discussion regarding a U.S. Holder’s tax basis in a share of our common stock acquired pursuant to the exercise of a warrant.

Redemption of Our Common Stock

In the event that a U.S. Holder’s shares of our common stock are redeemed or if we purchase a U.S. Holder’s shares of our common stock in an open market transaction (each referred to herein as a “redemption”), the treatment of the redemption for U.S. federal income tax purposes will depend on whether it qualifies as a sale or exchange of the shares of our common stock under Section 302 of the Code. If the redemption qualifies as a sale or exchange of the shares of our common stock under the tests described below, the U.S. Holder will be treated as described under “U.S. Holders — Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Our Common Stock and Warrants” above. If the redemption does not qualify as a sale or exchange of the shares of our common stock, the U.S. Holder will be treated as receiving a corporate distribution with the tax consequences described above under “U.S. Holders — Taxation of Distributions.” Whether a redemption qualifies for sale or exchange treatment will depend largely on the total number of our shares treated as held by the U.S. Holder (including any shares constructively owned by the U.S. Holder as described in the following paragraph) relative to all of our shares outstanding both before and after such redemption. The redemption of our common stock generally will be treated as a sale or exchange of the shares of our common stock (rather than as a corporate distribution) if, within the meaning of Section 302 of the Code, such redemption (i) is “substantially disproportionate” with respect to the U.S. Holder, (ii) results in a “complete termination” of the U.S. Holder’s interest in us or (iii) is “not essentially equivalent to a dividend” with respect to the U.S. Holder.

In determining whether any of the foregoing tests are satisfied, a U.S. Holder must take into account not only shares of our stock actually owned by the U.S. Holder, but also shares of our stock that are constructively owned by it. A U.S. Holder may constructively own, in addition to stock owned directly, stock owned by certain related individuals and entities in which the U.S. Holder has an interest or that have an interest in such U.S. Holder, as well as any stock the U.S. Holder has a right to acquire by exercise of an option, which would generally include shares of our common stock which could be acquired pursuant to the exercise of the warrants. In order to meet the “substantially disproportionate” test, the percentage of our outstanding voting shares actually and constructively owned by the U.S. Holder immediately following the redemption of shares of our common stock must, among other requirements, be less than 80% of the percentage of our outstanding voting stock actually and constructively owned by the U.S. Holder immediately before the redemption. The shares of our common stock may not be treated as voting shares for this purpose and, consequently, this substantially disproportionate test may not be applicable. There will be a complete termination of a U.S. Holder’s interest if either (i) all of our shares actually and constructively owned by the U.S. Holder are redeemed or (ii) all of our shares actually owned by the U.S. Holder are redeemed and the U.S. Holder is eligible to waive, and effectively waives in accordance with specific rules, the attribution of shares owned by certain family members and the U.S. Holder does not constructively own any other shares of our stock. The redemption of the shares of our common stock will not be essentially equivalent to a dividend with respect to a U.S. Holder if it results in a “meaningful reduction” of the U.S. Holder’s proportionate interest in us. Whether the redemption will result in a meaningful reduction in a U.S. Holder’s proportionate interest in us will depend on the particular facts and circumstances. However, the IRS has indicated in a published ruling that even a small reduction in the proportionate interest of a small minority stockholder in a publicly-held corporation who exercises no control over corporate affairs may constitute such a “meaningful reduction.” A U.S. Holder should consult with its own tax advisors as to the tax consequences of a redemption.

If none of the foregoing tests are satisfied, then the redemption will be treated as a corporate distribution and the tax effects will be as described under “U.S. Holders — Taxation of Distributions” above. After the application of those rules, any remaining tax basis of the U.S. Holder in the redeemed shares of our common stock will be added to the U.S. Holder’s adjusted tax basis in its remaining shares, or, if it has none, to the U.S. Holder’s adjusted tax basis in its warrants or possibly in other stock constructively owned by it.

100

Exercise, Lapse or Redemption of a Warrant

Except as discussed below with respect to the cashless exercise of a warrant, a U.S. Holder generally will not recognize gain or loss upon the acquisition of a share of our common stock on the exercise of a warrant for cash. A U.S. Holder’s initial tax basis in a share of our common stock received upon exercise of the warrant generally will equal the sum of the U.S. Holder’s initial investment in the warrant (that is, the portion of the U.S. Holder’s purchase price for the units that is allocated to the warrant, as described above under “— Allocation of Purchase Price and Characterization of a Unit”) and the exercise price of such warrant. It is unclear whether a U.S. Holder’s holding period for the share of our common stock received upon exercise of the warrants will commence on the date of exercise of the warrant or the day following the date of exercise of the warrant; in either case, the holding period will not include the period during which the U.S. Holder held the warrant. If a warrant is allowed to lapse unexercised, a U.S. Holder generally will recognize a capital loss equal to such holder’s tax basis in the warrant.

The tax consequences of a cashless exercise of a warrant are not clear under current law. A cashless exercise may not be taxable, either because the exercise is not a realization event or because the exercise is treated as a “recapitalization” for U.S. federal income tax purposes. In either situation, a U.S. Holder’s tax basis in the shares of our common stock received generally would equal the U.S. Holder’s tax basis in the warrants exercised therefor. If the cashless exercise were not a realization event, it is unclear whether a U.S. Holder’s holding period for the shares of our common stock will commence on the date of exercise of the warrant or the day following the date of exercise of the warrant. If the cashless exercise were treated as a recapitalization, the holding period of the shares of our common stock would include the holding period of the warrants exercised therefor.

It is also possible that a cashless exercise could be treated in whole or in part as a taxable exchange in which gain or loss would be recognized. In such event, a U.S. Holder could be deemed to have surrendered a number of warrants having an aggregate value (as measured by the excess of the fair market value of our common stock over the exercise price of the warrants) equal to the exercise price for the total number of warrants to be exercised (i.e., the warrants underlying the number of shares of our common stock actually received by the U.S. Holder pursuant to the cashless exercise). The U.S. Holder would recognize capital gain or loss in an amount equal to the difference between the value of the warrants deemed surrendered and the U.S. Holder’s tax basis in such warrants. Such gain or loss would be long-term or short-term, depending on the U.S. Holder’s holding period in the warrants deemed surrendered. In this case, a U.S. Holder’s tax basis in the common stock received would equal the sum of the U.S. Holder’s tax basis in the warrants exercised and the exercise price of such warrants. It is unclear whether a U.S. Holder’s holding period for the common stock would commence on the date following the date of exercise or on the date of exercise of the warrant; in either case, the holding period would not include the period during which the U.S. Holder held the warrant.

Alternative characterizations are also possible (including as a taxable exchange of all of the warrants surrendered by the U.S. Holder for shares of our common stock received upon exercise). Due to the absence of authority on the U.S. federal income tax treatment of a cashless exercise, including when a U.S. Holder’s holding period would commence with respect to the common stock received, there can be no assurance which, if any, of the alternative tax consequences and holding periods described above would be adopted by the IRS or a court of law. Accordingly, U.S. Holders should consult their tax advisors regarding the tax consequences of a cashless exercise.

If we redeem warrants for cash or if we purchase warrants in an open market transaction, such redemption or purchase generally will be treated as a taxable disposition to the U.S. Holder, taxed as described above under “U.S. Holders — Gain or Loss on Sale, Taxable Exchange or Other Taxable Disposition of Our Common Stock and Warrants.”

Possible Constructive Distributions

The terms of each warrant provide for an adjustment to the number of shares of our common stock for which the warrant may be exercised or to the exercise price of the warrant in certain events. Depending on the circumstances, such adjustments may be treated as constructive distributions. An adjustment which has the effect of preventing dilution pursuant to a bona fide reasonable adjustment formula generally is not taxable. The U.S. Holders of the warrants would, however, be treated as receiving a constructive distribution from us if, for example, the adjustment increases the warrant holders’ proportionate interest in our assets or earnings and profits (e.g., through an increase in the number of shares of our common stock that would be obtained upon exercise or through a decrease to the exercise price) as a result of a taxable distribution of cash or other property to the holders of shares of our common stock.

101

Any such constructive distribution would generally be subject to tax as described under “U.S. Holders — Taxation of Distributions” above in the same manner as if the U.S. Holders of the warrants received a cash distribution from us equal to the fair market value of such increased interest resulting from the adjustment.

Non-U.S. Holders

This section applies to “Non-U.S. Holders.” As used herein, the term “Non-U.S. Holder” means a beneficial owner of our units, common stock or warrants that is not a U.S. Holder and is not a partnership or other entity classified as a partnership for U.S. federal income tax purposes, but such term generally does not include an individual who is present in the United States for 183 days or more in the taxable year of disposition. If you are such an individual, you should consult your tax advisor regarding the U.S. federal income tax consequences of the acquisition, ownership or sale or other disposition of our securities.

Taxation of Distributions

In general, any distributions (including constructive distributions) we make to a Non-U.S. Holder of shares of our common stock, to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles), will constitute dividends for U.S. federal income tax purposes. Provided such dividends are not effectively connected with the Non-U.S. Holder’s conduct of a trade or business within the United States (or, if required pursuant to an applicable income tax treaty, are not attributable to a permanent establishment of fixed base maintained by the Non-U.S. Holder in the United States), we will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless such Non-U.S. Holder is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification of its eligibility for such reduced rate (usually on an IRS Form W-8BEN or W-8BEN-E, as applicable). In the case of any constructive dividend, it is possible that this tax would be withheld from any amount owed to a Non-U.S. Holder by the applicable withholding agent, including cash distributions on other property or sale proceeds from warrants or other property subsequently paid or credited to such holder. Any distribution not constituting a dividend will be treated first as reducing (but not below zero) the Non-U.S. Holder’s adjusted tax basis in its shares of our common stock and, to the extent such distribution exceeds the Non-U.S. Holder’s adjusted tax basis, as gain realized from the sale or other disposition of the shares of our common stock, which will be treated as described under “Non-U.S. Holders — Gain on Sale, Taxable Exchange or Other Taxable Disposition of Our Common Stock and Warrants” below. In addition, if we determine that we are or are likely to be classified as a “United States real property holding corporation” (see “Non-U.S. Holders — Gain on Sale, Taxable Exchange or Other Taxable Disposition of Our Common Stock and Warrants” below), we will withhold 15% of any distribution that exceeds our current and accumulated earnings and profits, including a distribution in redemption of shares of our common stock. See also “Non-U.S. Holders — Possible Constructive Distributions” for potential U.S. federal tax consequences with respect to constructive distributions.

Dividends that we pay to a Non-U.S. Holder that are effectively connected with such Non-U.S. Holder’s conduct of a trade or business within the United States (and, if a tax treaty applies, are attributable to a permanent establishment or fixed base maintained by the Non-U.S. Holder in the United States) will not be subject to U.S. withholding tax, provided such Non-U.S. Holder complies with certain certification and disclosure requirements (usually by providing an IRS Form W-8ECI). Instead, the effectively connected dividends will be subject to regular U.S. federal income tax as if the Non-U.S. Holder were a U.S. resident, unless an applicable income tax treaty provides otherwise. A Non-U.S. Holder that is a foreign corporation receiving effectively connected dividends may also be subject to an additional “branch profits tax” imposed at a rate of 30% (or a lower treaty rate).

Exercise, Lapse or Redemption of a Warrant

The U.S. federal income tax treatment of a Non-U.S. Holder’s exercise of a warrant, or the lapse of a warrant held by a Non-U.S. Holder, generally will correspond to the U.S. federal income tax treatment of the exercise or lapse of a warrant by a U.S. Holder, as described under “U.S. Holders — Exercise, Lapse or Redemption of a Warrant” above, although to the extent a cashless exercise results in a taxable exchange, the consequences would be similar to those described below under “Non-U.S. Holders — Gain on Sale, Taxable Exchange or Other Taxable Disposition of Our Common Stock and Warrants.” The U.S. federal income tax treatment for a Non-U.S. Holder of a redemption of warrants for cash (or if we purchase warrants in an open market transaction) would be similar to that described below in “Non-U.S. Holders — Gain on Sale, Taxable Exchange or Other Taxable Disposition of Our Common Stock and Warrants.”

102

Gain on Sale, Taxable Exchange or Other Taxable Disposition of Our Common Stock and Warrants

Subject to the discussion of FATCA and backup withholding below, a Non-U.S. Holder generally will not be subject to U.S. federal income or withholding tax in respect of gain recognized on a sale, taxable exchange or other taxable disposition of shares of our common stock or warrants (including an expiration or redemption of our warrants), in each case without regard to whether such securities were held as part of a unit, unless:

•        the gain is effectively connected with the conduct of a trade or business by the Non-U.S. Holder within the United States (and, under certain income tax treaties, is attributable to a permanent establishment or fixed base maintained by the Non-U.S. Holder in the United States); or

•        we are or have been a “United States real property holding corporation” for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the Non-U.S. Holder held our common stock, and, in the case where shares of our common stock are regularly traded on an established securities market, the Non-U.S. Holder has owned, directly or constructively, more than 5% of our common stock at any time within the shorter of the five-year period preceding the disposition or such Non-U.S. Holder’s holding period for the shares of our common stock. There can be no assurance that our common stock will be treated as regularly traded on an established securities market for this purpose. These rules may be modified for Non-U.S. Holders of warrants. If we are or have been a “United States real property holding corporation” and you own warrants, you are urged to consult your own tax advisor regarding the application of these rules.

Unless an applicable treaty provides otherwise, gain described in the first bullet point above will generally be subject to tax at the applicable U.S. federal income tax rates as if the Non-U.S. Holder were a U.S. resident. Any gains described in the first bullet point above of a Non-U.S. Holder that is a foreign corporation may also be subject to an additional “branch profits tax” at a 30% rate (or lower treaty rate).

If the second bullet point above applies to a Non-U.S. Holder, gain recognized by such holder on the sale, exchange or other disposition of our common stock or warrants will generally be subject to tax at applicable U.S. federal income tax rates as if the Non-U.S. Holder were a U.S. resident. In addition, a buyer of our common stock or warrants from such holder may be required to withhold U.S. federal income tax at a rate of 15% of the amount realized upon such disposition. In general, we would be classified as a United States real property holding corporation if the fair market value of our “United States real property interests” equals or exceeds 50% of the sum of the fair market value of our worldwide real property interests plus our other assets used or held for use in a trade or business, as determined for U.S. federal income tax purposes.

Redemption of Our Common Stock

The characterization for U.S. federal income tax purposes of any redemption of a Non-U.S. Holder’s shares of our common stock will generally correspond to the U.S. federal income tax characterization of such a redemption of a U.S. Holder’s shares of our common stock, as described under “U.S. Holders — Redemption of Our Common Stock” above, and the consequences of the redemption to the Non-U.S. Holder will be as described above under “Non-U.S. Holders — Taxation of Distributions” and “Non-U.S. Holders — Gain on Sale, Taxable Exchange or Other Taxable Disposition of Our Common Stock and Warrants,” as applicable.

Possible Constructive Distributions

The terms of each warrant provide for an adjustment to the number of shares of our common stock for which the warrant may be exercised or to the exercise price of the warrant in certain events. Depending on the circumstances, such adjustments may be treated as constructive distributions. An adjustment which has the effect of preventing dilution pursuant to a bona fide reasonable adjustment formula generally is not taxable. The Non-U.S. Holders of the warrants would, however, be treated as receiving a constructive distribution from us if, for example, the adjustment increases the warrant holders’ proportionate interest in our assets or earnings and profits (e.g., through an increase in the number of shares of our common stock that would be obtained upon exercise or through a decrease to the exercise price) as a result of a taxable distribution of cash or other property to the holders of shares of our common stock. Any such constructive distribution would generally be taxed as described under “Non-U.S. Holders — Taxation of Distributions” above, in the same manner as if the Non-U.S. Holders of the warrants received a cash distribution from us equal to the fair market value of such increased interest resulting from the adjustment.

103

Information Reporting and Backup Withholding

Dividend payments (including constructive dividends) with respect to our common stock and proceeds from the sale, exchange or redemption of shares of our common stock or warrants may be subject to information reporting to the IRS and possible United States backup withholding. Backup withholding will not apply, however, to payments made to a U.S. Holder who furnishes a correct taxpayer identification number and makes other required certifications, or who is otherwise exempt from backup withholding and establishes such exempt status. Payments made to a Non-U.S. Holder generally will not be subject to backup withholding if the Non-U.S. Holder provides certification of its foreign status, under penalties of perjury, on a duly executed applicable IRS Form W-8 or by otherwise establishing an exemption.

Backup withholding is not an additional tax. Amounts withheld under the backup withholding rules may be credited against a holder’s U.S. federal income tax liability, and a holder generally may obtain a refund of any excess amounts withheld by timely filing the appropriate claim for refund with the IRS and furnishing any required information. All holders should consult their tax advisors regarding the application of information reporting and backup withholding to them.

FATCA Withholding Taxes

Sections 1471 through 1474 of the Code and the Treasury Regulations and administrative guidance promulgated thereunder (commonly referred to as the “Foreign Account Tax Compliance Act” or “FATCA”) generally impose withholding of 30% in certain circumstances on payments of dividends (including constructive dividends) and, subject to the proposed Treasury Regulations discussed below, on proceeds from sales or other disposition of our securities paid to “foreign financial institutions” (which is broadly defined for this purpose and includes investment vehicles) and certain other non-U.S. entities unless various U.S. information reporting and due diligence requirements (relating to ownership by U.S. persons of interests in or accounts with those entities) have been satisfied or an exemption applies (typically certified as to by the delivery of a properly completed IRS Form W-8BEN-E). If FATCA withholding is imposed, a beneficial owner that is not a foreign financial institution will be entitled to a refund of any amounts withheld by filing a U.S. federal income tax return (which may entail significant administrative burden). Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. Similarly, dividends and, subject to the proposed Treasury Regulations discussed below, proceeds from sales or other disposition in respect of our units held by an investor that is a non-financial non-U.S. entity that does not qualify under certain exceptions generally will be subject to withholding at a rate of 30%, unless such entity either (i) certifies to us or the applicable withholding agent that such entity does not have any “substantial United States owners” or (ii) provides certain information regarding the entity’s “substantial United States owners,” which will in turn be provided to the U.S. Department of the Treasury. The U.S. Department of the Treasury has proposed regulations which eliminate the federal withholding tax of 30% applicable to the gross proceeds of a sale or other disposition of our securities. Withholding agents may rely on the proposed Treasury Regulations until final regulations are issued. Prospective investors should consult their tax advisors regarding the possible effects of FATCA on their investment in our securities.

THE U.S. FEDERAL INCOME TAX DISCUSSION SET FORTH ABOVE IS INCLUDED FOR GENERAL INFORMATION ONLY AND MAY NOT BE APPLICABLE DEPENDING UPON A HOLDER’S PARTICULAR SITUATION. HOLDERS ARE URGED TO CONSULT THEIR OWN TAX ADVISORS WITH RESPECT TO THE TAX CONSEQUENCES TO THEM OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK AND WARRANTS, INCLUDING THE TAX CONSEQUENCES UNDER STATE, LOCAL, ESTATE, NON-U.S. AND OTHER TAX LAWS AND TAX TREATIES AND THE POSSIBLE EFFECTS OF CHANGES IN U.S. OR OTHER TAX LAWS.

104

Underwriting

Maxim Group LLC is acting as the representative of the underwriters of the offering (the “Representative”). We have entered into an underwriting agreement dated             , 2022 with the Representative, with respect to the Units being offered. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to each underwriter named below and each underwriter named below has severally and not jointly agreed to purchase from us, at the public offering price per Unit, less the underwriting discounts set forth on the cover page of this prospectus, the number of Units listed next to its name in the following table:

Underwriter

 

Number of
Units

Maxim Group LLC

 

Total

 

The underwriters are committed to purchase all the Units offered by us other than those covered by the over-allotment option described below, if any, are purchased. The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of non-defaulting underwriters may be increased, or the offering may be terminated. The underwriters are not obligated to purchase the securities covered by the underwriters’ over-allotment option described below. The underwriters are offering the Units, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer’s certificates and legal opinions. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part.

Over-Allotment Option

We have granted to the Representative an option, exercisable one or more times in whole or in part, not later than 45 days after the date of this prospectus, to purchase from us up to an additional 428,571 shares of our Common Stock at a price of $           per (which is the public offering price of $            per Unit minus $0.01) and/or up to an additional 428,571 Warrants to purchase up to 428,571 shares of Common Stock at a price of $0.01 per Warrant, in each case, less the underwriting discounts and commissions set forth on the cover of this prospectus, in any combination thereof, to cover over-allotments, if any. To the extent that the Representative exercises this option, each of the underwriters will become obligated, subject to conditions, to purchase approximately the same percentage of these additional shares of Common Stock and/or Warrants as the number of Units to be purchased by it in the above table bears to the total number of Units offered by this prospectus. We will be obligated, pursuant to the option, to sell these additional shares of Common Stock and/or Warrants to the underwriters to the extent the option is exercised. If any additional shares of Common Stock and/or Warrants are purchased, the underwriters will offer the additional shares of Common Stock and/or Warrants on the same terms as those on which the other shares of Common Stock and/or Warrants are being offered hereunder. If this option is exercised in full, the total offering price to the public will be $           and the total net proceeds, before expenses and after the credit to the underwriting commissions described below, to us will be $          .

Discounts and Commissions; Expenses

The following table shows the public offering price, underwriting discount and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the Representative of the over-allotment option.

 

Per Unit

 

Total Without
Over-allotment
Option

 

Total With Full
Over-allotment
Option

Public offering price

 

$

   

$

   

$

 

Underwriting discounts and commissions (7.0%)

 

$

   

$

   

$

 

Proceeds, before expenses, to us

 

$

   

$

   

$

 

Non-accountable expense allowance (1.0%)(1)

 

$

   

$

   

$

 

____________

(1)      The non-accountable expense allowance will not be payable with respect to the representative’s exercise of the over-allotment option, if any.

105

We have agreed to pay a non-accountable expense allowance to the representative of the underwriters equal to 1.0% of the gross proceeds received at the completion of the offering. The non-accountable expense allowance of 1.0% is not payable with respect to any shares sold upon exercise of the representative’s over-allotment option.

We have also paid an expense deposit of $25,000 to the Representative and will pay an additional $25,000 expense deposit to the Representative concurrently with the filing with the Commission of the registration statement of which this prospectus forms a part, which will be applied against the accountable expenses that will be paid by us to the Representative in connection with this offering. The combined $50,000 expense deposit will be returned to us to the extent not actually incurred. The underwriting agreement also provides that in the event the offering is terminated, the combined $50,000 expense deposit paid to the Representative will be returned to us to the extent that offering expenses are not actually incurred by the Representative in accordance with Financial Industry Regulation Authority (“FINRA”) Rule 5110(g)(4)(A).

The underwriters propose to offer the Units offered by us to the public at the public offering price per Unit set forth on the cover of this prospectus. In addition, the underwriters may offer some of the Units to other securities dealers at such price less a concession of $               per Unit. After the initial offering, the public offering price and concession to dealers may be changed.

We have also agreed to reimburse the Representative for reasonable out-of-pocket expenses not to exceed $150,000 in the aggregate. We estimate that total expenses payable by us in connection with this offering, other than the underwriting discount, will be approximately $792,898.

Discretionary Accounts

The underwriters do not intend to confirm sales of the shares of Common Stock and/or Warrants offered hereby to any accounts over which they have discretionary authority.

Indemnification

We have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act, and to contribute to payments the underwriters may be required to make in respect thereof.

Lock-Up Agreements

We and our officers and directors, and the holders of 1.0% or more of the outstanding shares of our Common Stock as of the effective date of the registration statement of which this prospectus is a part, have agreed, subject to limited exceptions, for a period of six (6) months after the closing of this offering, not to offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of, directly or indirectly any shares of our Common Stock or any securities convertible into or exchangeable for our Common Stock either owned as of the date of the underwriting agreement or thereafter acquired without the prior written consent of the Representative. The Representative may, in its sole discretion and at any time or from time to time before the termination of the lock-up period, without notice, release all or any portion of the securities subject to lock-up agreements.

Pricing of this Offering; Market Information

Prior to this offering, there has been no public market for our Common Stock. The initial public offering price was determined through negotiations between us and the Representative. In addition to prevailing market conditions, the factors considered in determining the initial public offering price included the following:

•        the information included in this prospectus and otherwise available to the Representative;

•        the valuation multiples of publicly traded companies that the Representative believes to be comparable to us;

•        our financial information;

•        our prospects and the history and the prospects of the industry in which we compete;

106

•        an assessment of our management, its past and present operations, and the prospects for, and timing of, our future revenues;

•        the present state of our development; and

•        the above factors in relation to market values and various valuation measures of other companies engaged in activities similar to ours.

An active trading market for our Common Stock may not develop. It is also possible that after the offering our Common Stock will not trade in the public market at or above the public offering price. There is no established trading market for any of the Warrants, and we do not expect a market to develop. We do not intend to apply for a listing for any of the Warrants on any securities exchange or other nationally recognized trading system. Without an active trading system, the liquidity of the Warrants will be limited.

Representative’s Warrants

We have agreed to issue to the Representative (or its permitted designees) warrants to purchase up to a total of                shares of Common Stock (6.0% of the shares of Common Stock issued in this offering, including the over-allotment, if any). The representative’s warrants will be exercisable at any time, and from time to time, in whole or in part, during the five (5) year period commencing 180 days from the commencement of sales of the Common Stock and the Warrants in this offering, which is also the effective date of the registration statement of which this prospectus is a part, which period is in compliance with applicable FINRA rules. The representative’s warrants are exercisable at a per share price equal to $               per share, or 110% of the public offering price per share of Common Stock issued in this offering (based on the assumed public offering price of $               per share). The representative’s warrants have been deemed compensation by FINRA and are therefore subject to a 180-day lock-up pursuant to Rule 5110(e)(1)(A) of FINRA. The Representative (or permitted assignees under Rule 5110(e)(2)) will not sell, transfer, assign, pledge, or hypothecate these representative’s warrants or the securities underlying these representative’s warrants, nor will they engage in any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the representative’s warrants or the underlying securities for a period commencing 180 days from the commencement of sales of the Common Stock in this offering. In addition, the representative’s warrants provide for cashless exercise and registration rights upon request, in certain cases. The unlimited piggyback registration rights provided will not be greater than three (3) years from the closing date of the offering in compliance with applicable FINRA rules (provided such registration rights will not apply to any universal shelf registration statement). We will bear all fees and expenses attendant to registering the securities issuable on exercise of the representative’s warrants. The exercise price and number of shares issuable upon exercise of the representative’s warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary cash dividend or our recapitalization, reorganization, merger, or consolidation. However, the exercise price of the representative’s warrants or underlying shares of Common Stock will not be adjusted for issuances of shares of Common Stock at a price below the warrant exercise price.

Right of First Refusal

Subject to the closing of this offering, for a period of eighteen (18) months after the closing of the offering, Maxim Group LLC (“Maxim”) shall have a right of first refusal to act as underwriter and book-running manager and/or placement agent for any and all future public or private equity and debt (excluding commercial bank debt and other customary exceptions) offerings undertaken during such period by us, or any of our successors or subsidiaries. We and Maxim agree that the provisions of the preceding sentence shall not be applicable to financing provided by or solicited from any person or entity who is a holder of our debt or equity as of July 29, 2021.

Nasdaq Capital Market Listing

We have applied to have our Common Stock listed on Nasdaq under the symbol “LUCY”. No assurance can be given that our listing application will be approved by the Nasdaq Capital Market. There is no established trading market for any of the Warrants, and we do not expect a market to develop. We do not intend to apply for a listing for any of the Warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the Warrants will be limited.

107

Transfer Agent and Registrar

The name, address and telephone number of our stock transfer agent is VStock Transfer, LLC, 18 Lafayette Pl, Woodmere, New York 11598, (212) 828-8436.

Price Stabilization, Short Positions and Penalty Bids

In connection with this offering the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate covering transactions and penalty bids in accordance with Regulation M under the Exchange Act:

•        Stabilizing transactions permit bids to purchase securities so long as the stabilizing bids do not exceed a specified maximum.

•        Over-allotment involves sales by the underwriters of securities in excess of the number of securities the underwriters are obligated to purchase, which creates a syndicate short position. The short position may be either a covered short position or a naked short position. In a covered short position, the number of securities over-allotted by the underwriters is not greater than the number of securities that they may purchase in the over-allotment option. In a naked short position, the number of securities involved is greater than the number of securities in the over-allotment option. The underwriters may close out any covered short position by either exercising their over-allotment option and/or purchasing securities in the open market.

•        Syndicate covering transactions involve purchases of the securities in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of securities to close out the short position, the underwriters will consider, among other things, the price of securities available for purchase in the open market as compared to the price at which they may purchase securities through the over-allotment option. A naked short position occurs if the underwriters sell more securities than could be covered by the over-allotment option. This position can only be closed out by buying securities in the open market. A naked short position is more likely to be created if the underwriters are concerned that there could be downward pressure on the price of the securities in the open market after pricing that could adversely affect investors who purchase in this offering.

•        Penalty bids permit the underwriters to reclaim a selling concession from a syndicate member when securities originally sold by the syndicate member is purchased in a stabilizing or syndicate covering transaction to cover syndicate short positions.

These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our securities or preventing or retarding a decline in the market price of the securities. As a result, the price of our shares of Common Stock and Warrants may be higher than the price that might otherwise exist in the open market. These transactions may be discontinued at any time.

Neither we nor the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our shares of Common Stock and Warrants. In addition, neither we nor the underwriters make any representation that the underwriters will engage in these transactions or that any transaction, if commenced, will not be discontinued without notice.

Passive Market Making

In connection with this offering, the underwriters and selling group members may also engage in passive market making transactions in our Common Stock. Passive market making consists of displaying bids limited by the prices of independent market makers and effecting purchases limited by those prices in response to order flow. Rule 103 of Regulation M promulgated by the SEC limits the amount of net purchases that each passive market maker may make and the displayed size of each bid. Passive market making may stabilize the market price of the Common Stock at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time.

Electronic Distribution

This prospectus in electronic format may be made available on websites or through other online services maintained by the underwriters, or by their affiliates. Other than this prospectus in electronic format, the information on the

108

underwriters’ websites and any information contained in any other websites maintained by the underwriters is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or the underwriters in their capacity as underwriters, and should not be relied upon by investors.

Other

From time to time, the underwriters and/or their affiliates have provided, and may in the future provide, various investment banking and other financial services for us for which services it has received and, may in the future receive, customary fees. Except for the services provided in connection with this offering and other than as described below, the underwriters have not provided any investment banking or other financial services during the 180-day period preceding the date of this prospectus.

Notice to Prospective Investors in Canada

This prospectus constitutes an “exempt offering document” as defined in and for the purposes of applicable Canadian securities laws. No prospectus has been filed with any securities commission or similar regulatory authority in Canada in connection with the offer and sale of the securities. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon this prospectus or on the merits of the securities and any representation to the contrary is an offence.

Canadian investors are advised that this prospectus has been prepared in reliance on section 3A.3 of National Instrument 33-105 Underwriting Conflicts (“NI 33-105”). Pursuant to section 3A.3 of NI 33-105, this prospectus is exempt from the requirement that the Company and the underwriter(s) provide Canadian investors with certain conflicts of interest disclosure pertaining to “connected issuer” and/or “related issuer” relationships that may exist between the Company and the underwriter(s) as would otherwise be required pursuant to subsection 2.1(1) of NI 33-105.

Resale Restrictions

The offer and sale of the securities in Canada is being made on a private placement basis only and is exempt from the requirement that the Company prepares and files a prospectus under applicable Canadian securities laws. Any resale of securities acquired by a Canadian investor in this offering must be made in accordance with applicable Canadian securities laws, which may vary depending on the relevant jurisdiction, and which may require resales to be made in accordance with Canadian prospectus requirements, pursuant to a statutory exemption from the prospectus requirements, in a transaction exempt from the prospectus requirements or otherwise under a discretionary exemption from the prospectus requirements granted by the applicable local Canadian securities regulatory authority. These resale restrictions may under certain circumstances apply to resales of the securities outside of Canada.

Representations of Purchasers

Each Canadian investor who purchases securities will be deemed to have represented to the Company, the underwriters and to each dealer from whom a purchase confirmation is received, as applicable, that the investor is (i) purchasing as principal, or is deemed to be purchasing as principal in accordance with applicable Canadian securities laws, for investment only and not with a view to resale or redistribution; (ii) an “accredited investor” as such term is defined in section 1.1 of National Instrument 45-106 Prospectus Exemptions or, in Ontario, as such term is defined in section 73.3(1) of the Securities Act (Ontario); and (iii) is a “permitted client” as such term is defined in section 1.1 of National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations.

Taxation and Eligibility for Investment

Any discussion of taxation and related matters contained in this prospectus does not purport to be a comprehensive description of all of the tax considerations that may be relevant to a Canadian investor when deciding to purchase the securities and, in particular, does not address any Canadian tax considerations. No representation or warranty is hereby made as to the tax consequences to a resident, or deemed resident, of Canada of an investment in the securities or with respect to the eligibility of the securities for investment by such investor under relevant Canadian federal and provincial legislation and regulations.

109

Rights of Action for Damages or Rescission

Securities legislation in certain of the Canadian jurisdictions provides certain purchasers of securities pursuant to an offering memorandum (such as this prospectus), including where the distribution involves an “eligible foreign security” as such term is defined in Ontario Securities Commission Rule 45-501 Ontario Prospectus and Registration Exemptions and in Multilateral Instrument 45-107 Listing Representation and Statutory Rights of Action Disclosure Exemptions, as applicable, with a remedy for damages or rescission, or both, in addition to any other rights they may have at law, where the offering memorandum, or other offering document that constitutes an offering memorandum, and any amendment thereto, contains a “misrepresentation” as defined under applicable Canadian securities laws. These remedies, or notice with respect to these remedies, must be exercised or delivered, as the case may be, by the purchaser within the time limits prescribed under, and are subject to limitations and defenses under, applicable Canadian securities legislation. In addition, these remedies are in addition to and without derogation from any other right or remedy available at law to the investor.

Language of Documents

Upon receipt of this document, each Canadian investor hereby confirms that it has expressly requested that all documents evidencing or relating in any way to the sale of the securities described herein (including for greater certainty any purchase confirmation or any notice) be drawn up in the English language only. Par la réception de ce document, chaque investisseur canadien confirme par les présentes qu’il a expressément exigé que tous les documents faisant foi ou se rapportant de quelque manière que ce soit à la vente des valeurs mobilières décrites aux présentes (incluant, pour plus de certitude, toute confirmation d’achat ou tout avis) soient rédigés en anglais seulement.

European Economic Area and United Kingdom

In relation to each Member State of the European Economic Area and the United Kingdom (each a “Relevant State”), no Common Stock has been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the Common Stock which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of shares may be made to the public in that Relevant State at any time under the following exemptions under the Prospectus Regulation:

•        to legal entities which are qualified investors as defined under the Prospectus Regulation;

•        by the underwriters to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Regulation), subject to obtaining the prior consent of the representatives of the underwriters for any such offer; or

•        in any other circumstances falling within Article 1(4) of the Prospectus Regulation, provided that no such offer of Common Stock shall result in a requirement for us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.

For the purposes of this provision, the expression an “offer of Common Stock to the public” in relation to any Common Stock in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any Common Stock to be offered so as to enable an investor to decide to purchase or subscribe for our Common Stock, and the expression “Prospectus Regulation” means Regulation (EU) 2017/1129.

United Kingdom

This prospectus has only been communicated or caused to have been communicated and will only be communicated or caused to be communicated as an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act of 2000, or the FSMA) as received in connection with the issue or sale of our Common Stock in circumstances in which Section 21(1) of the FSMA does not apply to us. All applicable provisions of the FSMA will be complied with in respect to anything done in relation to our Common Stock in, from or otherwise involving the United Kingdom.

110

Offers Outside the United States

Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.

111

Experts

The financial statements of Innovative Eyewear, Inc. as of December 31, 2020 and 2019 and for each of the periods then ended included in this Registration Statement, of which this Prospectus forms a part, have been so included in reliance on the report of Cherry Bekaert LLP, an independent registered public accounting firm (the report on the financial statements contains an explanatory paragraph regarding the Company’s ability to continue as a going concern) appearing elsewhere herein, given on the authority of said firm as experts in auditing and accounting.

Legal Matters

Ellenoff Grossman & Schole LLP, New York, New York, is acting as counsel in connection with the registration of our common stock and warrants under the Securities Act, and as such, will pass upon the validity of the securities offered hereby. Certain matters are being passed on for the underwriters by Gracin & Marlow, LLP, New York, New York.

Where You Can Find More Information

We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed with the registration statement. For further information about us and the common stock offered hereby, we refer you to the registration statement and the exhibits filed with the registration statement. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement. The SEC also maintains an internet website that contains reports, proxy statements and other information about registrants, like us, that file electronically with the SEC. The address of that website is www.sec.gov.

Upon the closing of this offering, we will be required to file periodic reports, proxy statements, and other information with the SEC pursuant to the Exchange Act. These reports, proxy statements, and other information will be available on the website of the SEC referred to above.

We also maintain a website at www.lucyd.co, through which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on or accessed through our website is not a part of this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only.

112

INDEX TO FINANCIAL STATEMENTS

 

Page

Audited Financial Statements

   

Report of Independent Registered Public Accounting Firm

 

F-2

Balance Sheets as of December 31, 2020 and 2019

 

F-3

Statements of Operations for the year ended December 31, 2020 and the period from August 15, 2019 (inception) through December 31, 2019

 

F-4

Statements of Stockholders’ (Deficit) for the year ended December 31, 2020 and the period from August 15, 2019 (inception) through December 31, 2019

 

F-5

Statements of Cash Flows for the year ended December 31, 2020 and the period from August 15, 2019 (inception) through December 31, 2019

 

F-6

Notes to Financial Statements

 

F-7

Interim Unaudited Financial Statements

   

Condensed Balance Sheets as of September 30, 2021 and December 31, 2020 (Unaudited)

 

F-16

Condensed Statements of Operations for the nine months ended September 30, 2021 and September 30, 2020 (Unaudited)

 

F-17

Condensed Statements of Changes in Stockholders’ Equity (Deficit) for the nine months ended September 30, 2021 and 2020 (Unaudited)

 

F-18

Condensed Statements of Cash Flows for the nine months ended September 30, 2021 and 2020 (Unaudited)

 

F-19

Notes to Condensed Financial Statements (Unaudited)

 

F-20

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders
Innovative Eyewear, Inc.
Miami, Florida

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Innovative Eyewear, Inc. (the “Company”) as of December 31, 2020 and 2019, and the related statements of operations, changes in stockholders’ deficit, and cash flows for the year ended December 31, 2020 and for the period from August 15, 2019 (inception) through December 31, 2019, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the periods then ended, in conformity with accounting principles generally accepted in the United States of America.

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has recurring losses and negative cash flows from operations that raise substantial doubt about its ability to continue as a going concern. Management’s evaluations of the events and conditions and management’s plans regarding those matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

We have served as the Company’s auditor since 2021.

/s/ CHERRY BEKAERT LLP

Tampa, Florida
October 12, 2021

F-2

INNOVATIVE EYEWEAR, INC.
BALANCE SHEETS
December 31, 2020 and 2019

 

2020

 

2019

TOTAL ASSETS

 

 

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

27,023

 

 

$

 

Prepaid expenses

 

 

25,000

 

 

 

 

 

Inventory prepayment

 

 

85,740

 

 

 

 

Inventory

 

 

4,040

 

 

 

 

Total Current Assets

 

 

141,803

 

 

 

 

   

 

 

 

 

 

 

 

Non-Current Assets

 

 

 

 

 

 

 

 

Patent costs, net

 

 

69,213

 

 

 

 

TOTAL ASSETS

 

$

211,016

 

 

$

 

   

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ (DEFICIT)

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

 

 

   

 

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

51,410

 

 

$

 

Due to parent and affiliates

 

 

114,901

 

 

 

483,825

 

Related party convertible debt

 

 

599,542

 

 

 

 

   

 

 

 

 

 

 

 

Total Current Liabilities

 

 

765,853

 

 

 

483,825

 

   

 

 

 

 

 

 

 

TOTAL LIABILITIES

 

 

765,853

 

 

 

483,825

 

   

 

 

 

 

 

 

 

Stockholders’ (Deficit)

 

 

 

 

 

 

 

 

Common stock (10,000,000 shares authorized, 4,131,469 and 0 shares issued and outstanding as of December 31, 2020 and 2019, respectively at par value $0.00001)

 

 

41

 

 

 

 

Additional paid-in capital

 

 

845,417

 

 

 

127,639

 

Stock Subscription Receivable

 

 

(20,647

)

 

 

 

Accumulated deficit

 

 

(1,379,648

)

 

 

(611,464

)

TOTAL STOCKHOLDERS’ (DEFICIT)

 

 

(554,837

)

 

 

(483,825

)

   

 

 

 

 

 

 

 

TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT)

 

$

211,016

 

 

$

 

F-3

INNOVATIVE EYEWEAR, INC.
STATEMENTS OF OPERATIONS
For the year ended December 31, 2020 and
period from August 15, 2019 (inception) through December 31, 2019

 

2020

 

2019

Revenues, net

 

$

56,997

 

 

$

4,821

 

Less: Cost of Goods Sold

 

 

(74,266

)

 

 

(7,735

)

Gross (loss)

 

 

(17,269

)

 

 

(2,914

)

   

 

 

 

 

 

 

 

Operating Expenses:

 

 

 

 

 

 

 

 

General and administrative

 

 

(316,115

)

 

 

(43,398

)

Sales and marketing

 

 

(152,731

)

 

 

(2,924

)

Research & development

 

 

(36,894

)

 

 

(4,083

)

Related party management fee

 

 

(130,000

)

 

 

(56,108

)

Impairment expense

 

 

(112,329

)

 

 

 

Total Operating Expenses

 

 

(748,069

)

 

 

(106,513

)

   

 

 

 

 

 

 

 

Other Income

 

 

2,120

 

 

 

 

Interest Expense

 

 

(4,966

)

 

 

 

Total Other Income/(Expense)

 

 

(2,846

)

 

 

 

   

 

 

 

 

 

 

 

   

 

 

 

 

 

 

 

Net Loss

 

$

(768,184

)

 

$

(109,427

)

   

 

 

 

 

 

 

 

Weighted average number of shares outstanding

 

 

2,960,289

 

 

 

 

Earnings per share, basic and diluted

 

$

(0.26

)

 

$

0.00

 

F-4

INNOVATIVE EYEWEAR, INC.
STATEMENTS OF CHANGES IN STOCKHOLDERS’ (DEFICIT)
For the year ended December 31, 2020 and
period from August 15, 2019 (inception) through December 31, 2019

 

Common Stock (LLC
Units until
March 26, 2020)

 

Additional
Paid-in
Capital

 

Stock
Subscription
Receivable

 

Accumulated
Deficit

 

Total
Stockholders’
(Deficit)

   

Shares

 

Amount

 

Balance, August 15, 2019

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net expenses incurred by parent and affiliates pre-formation

 

 

 

 

 

 

 

 

 

 

(502,037

)

 

 

(502,037

)

Forgiveness of amounts due to related party

 

 

 

 

 

127,639

 

 

 

 

 

 

 

 

127,639

 

Net loss

 

 

 

 

 

 

 

 

 

 

(109,427

)

 

 

(109,427

)

Balances, December 31, 2019

 

 

$

 

$

127,639

 

$

 

 

$

(611,464

)

 

$

(483,825

)

Shares issued for contribution of assets from Parent and Affiliates

 

3,750,000

 

 

38

 

 

395,143

 

 

 

 

 

 

 

 

395,181

 

Issuance of shares, net of offering expenses of $222,962

 

381,469

 

 

3

 

 

146,969

 

 

(20,647

)

 

 

 

 

 

126,325

 

Forgiveness of amounts due to related party

 

 

 

 

 

94,021

 

 

 

 

 

 

 

 

94,021

 

Stock based compensation

 

 

 

 

 

81,645

 

 

 

 

 

 

 

 

81,645

 

Net loss

 

 

 

 

 

 

 

 

 

 

(768,184

)

 

 

(768,184

)

Balances, December 31, 2020

 

4,131,469

 

$

41

 

$

845,417

 

$

(20,647

)

 

$

(1,379,648

)

 

$

(554,837

)

F-5

INNOVATIVE EYEWEAR, INC.
STATEMENTS OF CASH FLOWS
For the year ended December 31, 2020 and
period from August 15, 2019 (inception) through December 31, 2019

 

2020

 

2019

Operating Activities

 

 

 

 

 

 

 

 

Net loss

 

$

(768,184

)

 

$

(109,427

)

Adjustments to reconcile net loss to operating activities:

 

 

 

 

 

 

 

 

Impairment

 

 

112,329

 

 

 

 

Amortization

 

 

994

 

 

 

 

Non-Cash interest expense

 

 

4,966

 

 

 

 

 

Stock based compensation

 

 

81,645

 

 

 

 

Expenses paid by Parent and Affiliates

 

 

536,211

 

 

 

109,427

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Accounts payable and accrued expenses

 

 

46,444

 

 

 

 

Prepaid expenses

 

 

(25,000

)

 

 

 

Inventory

 

 

(29,668

)

 

 

 

Net cash flows from operating activities

 

 

(40,263

)

 

 

 

   

 

 

 

 

 

 

 

Investing Activities

 

 

 

 

 

 

 

 

Patent costs

 

 

(59,039

)

 

 

 

Net cash flows from investing activities

 

 

(59,039

)

 

 

 

   

 

 

 

 

 

 

 

Financing Activities

 

 

 

 

 

 

 

 

Proceeds from issuance of shares, net of offering expenses

 

 

126,325

 

 

 

 

Net cash flows from financing activities

 

 

126,325

 

 

 

 

   

 

 

 

 

 

 

 

Net Change In Cash

 

$

27,023

 

 

 

 

   

 

 

 

 

 

 

 

Cash at Beginning of Period

 

 

 

 

 

 

Cash at End of Period

 

$

27,023

 

 

 

 

   

 

 

 

 

 

 

 

Non-Cash Transactions

 

 

 

 

 

 

 

 

   

 

 

 

 

 

 

 

Expenses paid for by Parent and Affiliates, pre-formation, recorded as a decrease in accumulated deficit

 

$

 

 

$

502,037

 

Forgiveness of amounts due to related party recorded as an increase in Additional Paid in Capital

 

 

94,021

 

 

 

127,639

 

Expenses paid for by Parent and Affiliates recorded as an increase in Due to Parent and Affiliates and Related Party Convertible Debt

 

 

536,211

 

 

 

109,427

 

Shares issued for contribution of assets from Parent and Affiliates (intangible assets)

 

 

123,497

 

 

 

 

 

Shares issued for contribution of assets from Parent and Affiliates
(inventory)

 

 

60,112

 

 

 

 

Shares issued for settlement of Due to Parent and Affiliates

 

 

211,572

 

 

 

 

F-6

INNOVATIVE EYEWEAR, INC.
NOTES TO THE FINANCIAL STATEMENTS
As of December 31, 2020 and 2019

NOTE 1 — GENERAL INFORMATION AND INITIAL CAPITALIZATION

General Information — INNOVATIVE EYEWEAR, INC. (f/k/a Innovative Eyewear LLC) (“the Company”) is a corporation organized under the laws of the State of Florida. The principal activity of the Company is designing, manufacturing and selling smart eyewear through its e-commerce channels and retail distribution.

The Company was formed as a limited liability company in Florida on August 15, 2019, but converted from a Florida limited liability company to a Florida Corporation on March 26, 2020. The Company is a subsidiary of Lucyd, Ltd. (the “Parent” or “Lucyd”), who is a wholly-owned subsidiary of Tekcapital Plc, through Tekcapital Europe, Ltd (collectively the “Parent and Affiliates”).

Initial capitalization — Upon conversion to Innovative Eyewear Inc. and in consideration of contributed assets (as discussed below) and reimbursement of pre-formation costs, the Company issued 3,750,000 shares of common stock to its sole stockholder and Parent, Lucyd.

During the year ended December 31, 2020, the Company received intangible assets from Lucyd as its sole shareholder as a contribution to capital. The Company received $123,497 net book value of trademark and license costs via an exclusive, irrevocable license of these assets from Lucyd. Additionally, the Company received $60,112 of inventory. These amounts have been recorded on the balance sheet at the historical book value of Lucyd as an addition to additional paid-in capital based on the related party nature of the transaction. Upon contribution, these amounts were originally recorded as capitalized license costs and trademark under intangible assets and inventory on the balance sheet of the Company. Subsequently, during the year ended December 31, 2020, we recorded an impairment expense of $112,329 related to capitalized license costs and reclassified trademark amounts to Statement of Operations. For more detailed discussions, please refer to Intangible Assets section of Note 2.

Additionally, the Parent and Affiliates incurred a number of costs on behalf of the Company both prior to its legal formation and for both of the years ended December 31, 2020 and 2019, as summarized below:

Company

 

2020*

 

2019*

Expenses paid for by Parent and Affiliates, pre-formation, recorded as an increase in accumulated deficit

 

$

 

 

$

502,037

 

Expenses paid for by Parent and Affiliates recorded as increase in due to Parent and Affiliates and Related Party Convertible debt

 

 

442,190

 

 

 

109,427

 

   

 

442,190

*

 

 

611,464

*

____________

*        offset by $94,021 and $127,639 in amounts forgiven by the Parent and Affiliates for the year and period ended December 31, 2020 and December 31, 2019 respectively, recorded as increase in Additional Paid in Capital.

Key expenses paid by Parent and Affiliates in the period prior to the Company’s formation, from 2017 to August 2019, included:

 

Amount

General & Administrative expenses

 

$

607,479

 

Advertising & Marketing

 

 

401,046

 

Management fees

 

 

54,354

 

Cost of Sales

 

 

10,819

 

R&D expenses

 

 

27,076

 

Sales

 

 

(21,684

)

Forgiveness of amounts due from Parent and Affiliates

 

 

(577,053

)

   

$

502,037

 

These expenses paid for by Parent and Affiliates provided support crucial to the Company’s ability to significantly advance product development, assemble a team of capable individuals, build a portfolio of intellectual property, as well as provide other operational support.

F-7

INNOVATIVE EYEWEAR, INC.
NOTES TO THE FINANCIAL STATEMENTS
As of December 31, 2020 and 2019

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, all adjustments considered necessary for the fair presentation of the financial statements for the years presented have been included. The Company has adopted December 31 as its year end for accounting purposes. These financials statements present the available period since inception (August 15, 2019).

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties associated with the ongoing coronavirus pandemic (“COVID-19”) and COVID-19 control responses.

Cash and Cash Equivalents

The Company considers short-term, highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. Cash consists of funds held in the Company’s checking account. The Company maintains its cash with a major financial institution located in the United States of America, which it believes to be credit worthy. The Federal Deposit Insurance Corporation insures balances up to $250,000. At times, the Company may maintain balances in excess of the federally insured limits.

Receivables and Credit Policy

Trade receivables from customers are uncollateralized customer obligations due under normal trade terms, primarily requiring payment before product is shipped. Trade receivables are stated at the amount billed to the customer. Payments of trade receivables are allocated to the specific invoices identified on the customer’s remittance advice or, if unspecified, are applied to the earliest unpaid invoice. The Company, by policy, routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited and it has not experienced any significant write-downs in its accounts receivable balances. As of December 31, 2020, the Company had no accounts receivable nor allowance for bad debt.

Sales Taxes

Various states impose a sales tax on the Company’s sales to non-exempt customers. The Company collects the sales tax from customers and remits the entire amount to each respective state. The Company’s accounting policy is to exclude the tax collected and remitted to the states from revenue and cost of sales.

Inventory

Company’s inventory includes purchased eyewear and is stated at the lower of cost or net realizable value, with cost determined on a weighted average first-in, first-out basis. Provisions for excess, obsolete or slow moving inventory are recorded after periodic evaluation of historical sales, current economic trends, forecasted sales, estimated product life cycles and estimated inventory levels. No provisions were determined as needed at December 31, 2020.

The Company recorded an inventory prepayment in the amount of $85,740 related to down payment on eyewear purchase from the manufacturer, prior to shipment of the product that occurred in January 2021.

F-8

INNOVATIVE EYEWEAR, INC.
NOTES TO THE FINANCIAL STATEMENTS
As of December 31, 2020 and 2019

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Intangible Assets

Intangible assets relate to a license agreement and patent costs received in conjunction with the initial capitalization of the Company, as described in Note 1. The Company amortizes the license agreement over the estimated useful life of the license agreement.

Intangible assets also related to internally developed utility and design patents. The Company amortizes these assets over the estimated useful life of the patents.

The Company reviews its intangibles assets for impairment whenever changes in circumstances indicate that the carrying amount of the assets may not be recoverable. We recorded an impairment expense of $112,329 for the year ended December 31, 2020 as compared to $0 for the period ended December 31, 2019.

The license agreement subject to the impairment had been originally entered into between Company’s Parent (Lucyd Ltd) and University of Central Florida (“UCF”) and subsequently contributed from Lucyd to Company as a contribution to capital via an exclusive, irrevocable license of these assets from Lucyd. The impairment charge represented the total net book value of any licenses to intellectual property previously held by the Company.

Lucyd Ltd licensed a group of patents from UCF covering augmented reality glasses, specifically enabling the display of information on the lenses of glasses. The UCF patents were subsequently, with UCF’s permission, exclusively licensed to Innovative Eyewear, Inc. by Lucyd Ltd. After conducting significant research on this licensed technology, Innovative Eyewear Inc. determined that the technology was not ready for commercialization, so it amicably terminated the license, consistent with its terms and conditions. Innovative Eyewear no longer has any obligation under the license to UCF nor does Innovative Eyewear have a current business relationship with UCF. UCF has no rights to any properties currently held by Innovative Eyewear Inc.

All of Innovative Eyewear’s current patents and applications are not related to the previously licensed patents from UCF. The Company does not believe the charge is representative of material trends in the business as following the impairment charge, our patent portfolio includes only patents developed internally in the last few years.

Income Taxes

The Company is taxed as a C corporation. The Company complies with Financial Accounting Standards Board (FASB) ASC 740 for accounting for uncertainty in income taxes recognized in a company’s financial statements, which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. FASB ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s financial statements. The Company believes that its income tax positions would be sustained on audit and does not anticipate any adjustments that would result in a material change to its financial position.

The Company has incurred taxable losses since inception but is current in its tax filing obligations. The Company is not presently subject to any income tax audit in any taxing jurisdiction.

Stock-Based Compensation

The Company accounts for stock-based compensation to employees and directors in accordance with FASB ASC Topic 718, which requires that compensation expense be recognized in the financial statements for stock-based awards based on the grant date fair value. For stock option awards, the Black-Scholes-Merton option pricing model was used to estimate the fair value of share-based awards. The Black-Scholes-Merton option pricing model incorporates various and highly subjective assumptions, including expected term and share price volatility. The expected term of the stock options was estimated based on the simplified method as allowed by Staff Accounting Bulletin 107 (SAB 107). The share price volatility at the

F-9

INNOVATIVE EYEWEAR, INC.
NOTES TO THE FINANCIAL STATEMENTS
As of December 31, 2020 and 2019

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

grant date is estimated using historical stock prices based upon the expected term of the options granted, using stock prices of comparably profiled public companies. The risk-free interest rate assumption is determined using the rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued.

Revenue Recognition

Our revenue is generated from the sales of prescription and non-prescription optical glasses, sunglasses and shipping charges, which are charged to the customer, associated with these purchases. We sell products through our retail store resellers, distributors and on our own website Lucyd.co and on Amazon.

To determine revenue recognition, we perform the following steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation.

At contract inception, we assess the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

All revenue, including sales processed online and through our retail store resellers and distributors, is reported net of sales taxes collected from customers on behalf of taxing authorities, returns and discounts.

For sales generated through our e-commerce channels, we identify the contract with a customer upon online purchase of our eyewear and transaction price at the manufacturer suggested retail price (“MSRP”) for non-prescription, polarized sunglass and blue light blocking glasses across all of our online channels. Our e-commerce revenue is recognized upon meeting of the performance obligation when the eyewear is shipped to end customers. Only U.S. consumers enjoy free USPS first class postage, with faster delivery options available for extra cost, for sales processed through our website and on Amazon. For Amazon sales, shipping is free for U.S. consumers while international customers pay shipping charges on top of MSRP. Any costs associated with fees charged by the online platforms (Shopify for Lucyd.co website and Amazon) are not recharged to customers and are recorded as a component of cost of goods sold as incurred. The Company charges applicable state sales taxes in addition to the MSRP for both online channels and all other marketplaces on which the company sells products.

For sales to our retail store partners, we identify the contract with a customer upon receipt of an order of our eyewear through our Shopify wholesale portal or direct purchase order. Our revenue is recognized upon meeting the performance obligation which is delivery of the company’s eyewear products to retail store or the distributor, and also recorded net of returns and discounts. Our wholesale pricing for eyewear sold to retail store partners and distributors includes volume discounts, due to the nature of large quantity orders. The pricing includes shipping charges, while excluding any state sales tax charges applicable. Due to the nature of wholesale retail orders, no e-commerce fees are applicable.

The Company’s sales to both retail store partners and through the e-commerce channels do not contain any variable consideration.

We allow our customers to return our products, subject to our refund policy, which allows any customer to return our products for any reason within the first:

•        7 days for sales made through our website (Lucyd.co)

•        30 days for sales made through Amazon

•        30 days for sales to wholesale retailers and distributors

For all of our sales, at the time of sale, we establish a reserve for returns, based on historical experience and expected future returns, which is recorded as a reduction of sales.

F-10

INNOVATIVE EYEWEAR, INC.
NOTES TO THE FINANCIAL STATEMENTS
As of December 31, 2020 and 2019

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Shipping and Handling

Costs incurred for shipping and handling are included in cost of revenue at the time the related revenue is recognized. Amounts billed to a customer for shipping and handling are reported as revenues.

Earnings/loss per share

The Company presents earnings and loss per share data by calculating the quotient of earnings/(loss) and loss divided by the number of common shares outstanding (common shares as of December 31, 2020) as required by ASC 260-10-50. As of December 31, 2020, all shares underlying the related party convertible debt and common stock options were excluded from the earnings per share calculation due to their anti-dilutive effect.

Sales and Marketing Expenses

The Company expenses advertising costs as they are incurred.

Recent Accounting Pronouncements

In February 2017, FASB issued ASU No. 2017-02, “Leases (Topic 842),” that requires organizations that lease assets, referred to as “lessees,” to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2017-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The Company plans to adopt ASU 2017-02 as of January 1, 2022 and does not believe it will have a material impact on the Company’s financial statements.

In May 2018, FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20), and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contract’s in Entity’s Own Equity. The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. The amendments in ASU 2020-06 further revise the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. The Company plans to adopt ASU 2020-06 as of January 1, 2021 and does not believe it will have a material impact on the Company’s financial statements.

NOTE 3 — GOING CONCERN

The Company has a limited operating history. The Company’s business and operations are sensitive to general business and economic conditions in the United States. A host of factors beyond the Company’s control could cause fluctuations in these conditions. Adverse conditions may include: recession, downturn or otherwise, changes in regulations or restrictions in imports, competition or changes in consumer taste including the economic impacts from the COVID-19 pandemic. These adverse conditions could affect the Company’s financial condition and the results of its operations.

The Company meets its day to day working capital requirements through monies raised through sales of eyewear and issues of equity including crowdfunding. The Company also has issued a convertible note held by its parent company. Company’s forecasts and projections indicate that the Company expects to have sufficient cash reserves to operate within the level of its current facilities. Whilst it is the Company’s intention to rely on the available cash reserves, future income generated from its product sales, a negative variance in the forecasts and projections would make the Company’s ability to continue as a going concern dependent on an additional fund raise. Based on these factors, there is substantial doubt about the Company’s ability to continue as a going concern.

F-11

INNOVATIVE EYEWEAR, INC.
NOTES TO THE FINANCIAL STATEMENTS
As of December 31, 2020 and 2019

NOTE 4 — INCOME TAX PROVISION

As discussed above, the Company is a C corporation for federal income tax purposes. The Company has incurred tax losses since inception, however valuation allowances has been established against the deferred tax assets associated with the carryforwards of those losses as there does not yet exist evidence the deferred tax assets created by those losses will ever by utilized.

 

2020

 

2019

Current tax expense

 

$

 

 

$

Deferred tax benefit

 

 

181,891

 

 

 

Increase in valuation allowance

 

 

(181,891

)

 

 

Total provision for income taxes

 

$

 

 

$

At December 31, 2020 and 2019, the Company had temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and their respective income tax bases, measured by enacted state and federal tax rates, as follows:

 

2020

 

2019

Deferred tax assets (liabilities)

 

$

 

 

 

 

Net Operating Loss carryforward

 

 

181,891

 

 

$

Less: valuation allowance

 

 

(181,891

)

 

 

Total net deferred tax assets

 

$

 

 

$

The following is a reconciliation of tax computed at the statutory federal rate to the income tax benefit in the statements of operations:

 

2020

 

2019

Income tax benefit at the statutory federal rate

 

$

149,208

 

 

$

State income tax benefits, net of federal benefit

 

 

32,683

 

 

 

Change in valuation allowance

 

 

(181,891

)

 

 

Total

 

$

 

 

$

Tax returns once filed which will remain subject to examination by the Internal Revenue Service under the statute of limitations for a period of three years from the date it is filed.

NOTE 5 — INTANGIBLE ASSETS

Cost

 

Patents
$

 

Total
$

At December 31, 2019

 

 

At December 31, 2020

 

70,207

 

70,207

         

Accumulated amortization

       

At December 31, 2019

 

 

At December 31, 2020

 

994

 

994

         

Net book value

       

At December 31, 2019

 

 

At December 31, 2020

 

69,213

 

69,213

F-12

INNOVATIVE EYEWEAR, INC.
NOTES TO THE FINANCIAL STATEMENTS
As of December 31, 2020 and 2019

NOTE 6 — RELATED PARTY ADVANCES AND OTHER INTERCOMPANY AGREEMENTS

Convertible Note and Due to Parent and Affiliates

During the year, the Company had availability, but not the contractual right, to additional intercompany financing from the Parent and Affiliates in the form of cash advances. As of December 31, 2020, the Company had an outstanding balance of $714,443 due to related parties, as shown on the accompany balance sheet of $114,901 in due to Parent and Affiliates and $599,542 of related party convertible debt.

On December 1, 2020, the Company issued a convertible note to its Parent and Affiliates for up to $2,000,000 that bear interest at 10% per annum, which includes the option to convert the debt into shares at market price. The note can be converted into shares of common stock of the Company upon occurrence of certain conversion events, as defined. Subsequently to issuing the note, the Company reclassified its existing payable due to Parent and Affiliates of $599,542 to related party convertible note on its balance sheet and incurred $4,966 in interest expense which is included in Trade and other payables in the accompanying December 31, 2020 balance sheet.

Management Service Agreement

In 2020, The Company entered into a Management services agreement with a related party (related through common ownership). The Company is billed $25,000 quarterly. While the agreement does not stipulate a specific maturity date, it can be terminated with 30 calendar days written notice by any party. The related party provides the following services:

•        Provision of support and advise to the Company in accordance with their area of expertise

•        Undertake research, technical review, legal review, recruitment, software development, marketing, public relations and advertisement

•        Provide advice, assistance and consultation services to support the Company or in relation to any other related matter

•        Rent-free office space.

As of December 31, 2020 the balance related to this agreement is $50,000 and is included in the related party convertible note balance on the accompanying December 31, 2020 balance sheet.

Additionally, the Company’s Parent and Affiliates incurred $100,000 in 2019 and $80,000 in 2020 in management fee charges on behalf of the Company. These payables were assigned to the Company based on the related party convertible debt agreement with the Company’s Parent and Affiliates, dated June 1, 2021 and included in the Convertible Note balances discussed above.

NOTE 7 — COMMITMENTS AND CONTINGENCIES

Legal Matters

The Company is not currently involved in or aware of threats of any litigation.

Commitments

See related party management services agreement discussed in Note 6.

F-13

INNOVATIVE EYEWEAR, INC.
NOTES TO THE FINANCIAL STATEMENTS
As of December 31, 2020 and 2019

NOTE 8 — SHAREHOLDERS’ EQUITY

Conversion to Corporation

On March 26, 2020, the Company converted from a limited liability company into a corporation. The Company had not issued LLC units nor had any commercial activity prior to the conversion.

Crowdfunded Offering

In 2020, the Company offered securities in a Regulation CF campaign and raised $369,930 through the issuance of 381,469 shares. The Company incurred $222,962 in offering costs associated with the Crowdfunded Offering and has reduced the additional paid-in capital by the amount of the offering costs. Terms of the crowdfund investment round included pricing discounts on the Company’s products and access to an exclusive investors club.

NOTE 9 — STOCK BASED COMPENSATION

The Director and CEO, Harrison Gross, received a grant of 375,000 stock options on April 1, 2020. These share options vest over 36 months, with 1/6 vesting every six months from the date of the agreement, April 1, 2020. The exercise price for the options is $1 for each share, based upon fair market value of shares at the time of the grant. Calvin Peters, Company’s Marketing Director, received a grant of 270,000 stock options on October 5, 2020. These share options are vesting over 36 months, with 1/6 vesting every six months from the date of the agreement, October 5, 2020. The exercise price for the options is $1 for each share, based upon fair market value of shares at the time of the grant.

Both option grants terminate three years from date of issuance.

The fair value options granted is expensed over the vesting period and is calculated using the Black-Scholes model. The assumptions inherent in the use of this model for the above grants are as follows:

Attribute

 

Input

Share price at date of grant

 

$

1.00

 

Options life in years

 

 

3

 

Risk free rate

 

 

0.36

%

Expected volatility

 

 

112

%

Expected dividend yield

 

 

0

 

Grant date fair value of options

 

$

0.71

 

The weighted average fair value of each option outstanding was $0.71. Volatility was calculated using historical share price performance of peer companies in the 3 year period prior to December 31, 2020.

Details of the number of share options and the weighted average exercise price outstanding during the year as follows (the Company did not grant any share options until year ended December 31, 2020):

Company

 

Av. Exercise
price per share
$

 

Options
(Number)

As at January 1, 2020

 

 

Granted

 

1.00

 

645,000

Exercised

 

 

Forfeited

 

 

As at December 31, 2020

 

1.00

 

645,000

Exercisable as at December 31, 2020

 

1.00

 

62,500

The weighted average remaining contractual life is 2.5 years. The weighted average exercise price of options granted during the year was $1.00. The range of exercise prices for options outstanding at the end of the year was $1.00. Unrecognized stock compensation expense at December 31, 2020 was $375,134 to be taken over 2.5 years.

F-14

INNOVATIVE EYEWEAR, INC.
NOTES TO THE FINANCIAL STATEMENTS
As of December 31, 2020 and 2019

NOTE 10 — SUBSEQUENT EVENTS

Crowdfunded Offering

During 2021, the Company continued its first Crowdfunded Offering and raised $683,662 in gross proceeds in a securities offering considered exempt from registration under Regulation CF. The Crowdfunded Offering was facilitated by StartEngine, a FINRA-approved Regulation CF funding portal (the “Intermediary”), resulting in issuance of 710,248 shares.

In July 2021, the Company launched its second Crowdfunded offering of common stock in a securities in which it raised $163,886, corresponding to 47,986 shares to be issued in a securities offering to be considered exempt from registration under Regulation CF (40,011 issued as of September 30, 2021). The Crowdfunded Offering was facilitated by StartEngine, a FINRA-approved Regulation CF funding portal. The crowdfund was completed on September 24, 2021.

Convertible Note

On June 1, 2021, the Company converted borrowings totaling $778,500 into 778,500 shares of common stock at $1.00 each.

On September 5, 2021, the Company converted borrowings totaling $500,002 into 140,449 shares at $3.56 each.

Stock Option Issuances

During 2021, the Company issued total of 1,657,500 stock options to its employees and directors, with grant price ranging from $1 to $3.56.

On July 1, 2021, an Equity Incentive Plan was approved, allowing for total of 20%, or 1,124,043, of total issued shares to be available for the grant of awards under the Plan.

Second Amended and Restated Articles of Incorporation

Pursuant to a resolution on July 1, 2021, the Company authorized 15,000,000 preferred stock shares and 50,000,000 common stock shares.

F-15

INNOVATIVE EYEWEAR, INC.
CONDENSED BALANCE SHEETS
September 30, 2021 and December 31, 2020

 

Unaudited
2021

 

Audited
2020

TOTAL ASSETS

 

 

 

 

 

 

 

 

Current Assets

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

65,056

 

 

$

27,023

 

Accounts receivable

 

 

27,069

 

 

 

 

Prepaid expenses

 

 

51,000

 

 

 

25,000

 

Deferred offering costs

 

 

50,000

 

 

 

 

Inventory prepayment

 

 

295,200

 

 

 

85,740

 

Inventory

 

 

37,833

 

 

 

4,040

 

Other current assets

 

 

20,065

 

 

 

 

Total Current Assets

 

 

546,223

 

 

 

141,803

 

   

 

 

 

 

 

 

 

Non-Current Assets

 

 

 

 

 

 

 

 

Patent costs, net

 

 

76,579

 

 

 

69,213

 

Capitalized software costs

 

 

63,000

 

 

 

 

Property and equipment, net

 

 

10,662

 

 

 

 

TOTAL ASSETS

 

$

696,464

 

 

$

211,016

 

   

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

 

Current Liabilities

 

 

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

115,738

 

 

$

51,410

 

Deferred revenue

 

 

17,950

 

 

 

 

Due to Parent and Affiliates

 

 

111,801

 

 

 

114,901

 

Related party convertible debt

 

 

420,104

 

 

 

599,542

 

Total Current Liabilities

 

 

665,593

 

 

 

765,853

 

   

 

665,593

 

 

 

765,853

 

   

 

 

 

 

 

 

 

TOTAL LIABILITIES

 

 

 

 

 

 

 

 

Stockholders’ Equity (Deficit)

 

 

 

 

 

 

 

 

Common stock (50,000,000 shares authorized, 5,801,677 and 4,131,469 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively at par value $0.00001)

 

 

58

 

 

 

41

 

Preferred stock, $0.00001 par value per share; 15,000,000 shares authorized, is 0 issued or outstanding as of September 30, 2021 and December 31, 2020

 

 

 

 

 

 

Additional paid-in capital

 

 

3,294,841

 

 

 

845,417

 

Stock subscription receivable

 

 

(25,286

)

 

 

(20,647

)

Accumulated deficit

 

 

(3,238,742

)

 

 

(1,379,648

)

TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)

 

 

30,871

 

 

 

(554,837

)

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)

 

$

696,464

 

 

$

211,016

 

F-16

INNOVATIVE EYEWEAR, INC.
CONDENSED STATEMENTS OF OPERATIONS
For the nine months ended September 30, 2021 and September 30, 2020
(Unaudited)

 

9 months ended
September 30,

   

2021

 

2020

Revenues, net

 

$

415,185

 

 

$

33,592

 

Less: Cost of Goods Sold

 

 

(332,378

)

 

 

(34,783

)

Gross Profit (Loss)

 

 

82,807

 

 

 

(1,191

)

   

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

General & administrative

 

 

(883,356

)

 

 

(210,509

)

Impairment expense

 

 

 

 

 

(112,329

)

Sales and marketing

 

 

(903,795

)

 

 

(98,789

)

Related party management fee

 

 

(84,975

)

 

 

(102,475

)

Research and development

 

 

(36,121

)

 

 

(30,822

)

Total Operating Expenses

 

 

(1,908,247

)

 

 

(554,924

)

   

 

 

 

 

 

 

 

Other (Expense):

 

 

 

 

 

 

 

 

Interest Expense

 

 

(33,654

)

 

 

 

Total Other (Expense)

 

 

(33,654

)

 

 

 

   

 

 

 

 

 

 

 

Net Loss

 

$

(1,859,094

)

 

$

(556,115

)

   

 

 

 

 

 

 

 

Weighted average number of shares outstanding

 

 

5,033,823

 

 

 

2,602,987

 

Earnings per share, basic and diluted

 

 

(0.37

)

 

 

(0.21

)

F-17

INNOVATIVE EYEWEAR, INC.
CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)
For the nine months ended September 30, 2021 and 2020
(Unaudited)

 

Common Stock

 

Additional
Paid-in
Capital

 

Stock
Subscription
Receivable

 

Accumulated
Deficit

 

Total
Stockholders’
Equity
(Deficit)

Shares

 

Amount

 

Balance – January 1, 2021

 

4,131,469

 

$

41

 

$

845,417

 

$

(20,647

)

 

$

(1,379,648

)

 

$

(554,837

)

Shares issued for conversion of related party convertible note

 

918,949

 

 

9

 

 

1,278,493

 

 

 

 

 

 

 

 

1,278,502

 

Issuance of shares,
net of offering
expenses of $339,529

 

751,259

 

 

8

 

 

476,157

 

 

(45,404

)

 

 

 

 

 

430,761

 

Collection of stock subscription receivable

 

 

 

 

 

 

 

40,765

 

 

 

 

 

 

40,765

 

Stock based compensation

 

 

 

 

 

694,774

 

 

 

 

 

 

 

 

694,774

 

Net loss

 

 

 

 

 

 

 

 

 

 

(1,859,094

)

 

 

(1,859,094

)

Balance – September 30, 2021

 

5,801,677

 

$

58

 

$

3,294,841

 

$

(25,286

)

 

$

(3,238,742

)

 

$

30,871

 

 

Common Stock

 

Additional Paid-in Capital

 

Stock Subscription Receivable

 

Accumulated Deficit

 

Total Stockholders’ Equity (Deficit)

Shares

 

Amount

 

Balance – January 1, 2020

 

 

 

 

$

127,639

 

 

 

$

(611,464

)

 

$

(483,825

)

Shares issued for contribution of assets from Parent and Affiliates

 

3,750,000

 

 

38

 

 

395,143

 

 

 

 

 

 

 

395,181

 

Issuance of shares,
net of offering
expenses of $72,900

 

180,727

 

 

2

 

 

72,426

 

(9,659

)

 

 

 

 

 

 

62,769

 

Forgiveness of amounts due to related party

 

 

 

 

 

94,021

 

 

 

 

 

 

 

94,021

 

Stock based compensation

 

 

 

 

 

41,875

 

 

 

 

 

 

 

41,875

 

Net loss

 

 

 

 

 

 

 

 

 

(556,115

)

 

 

(556,115

)

Balance – September 30, 2020

 

3,930,727

 

$

40

 

$

731,104

 

(9,659

)

 

$

(1,167,579

)

 

$

(446,094

)

F-18

INNOVATIVE EYEWEAR, INC.
CONDENSED STATEMENTS OF CASH FLOWS
For the nine months ended September 30, 2021 and 2020
(Unaudited)

 

2021

 

2020

Operating Activities

 

 

 

 

 

 

 

 

Net (Loss)

 

$

(1,859,094

)

 

 

(556,115

)

Adjustments to reconcile net loss to net cash flows from operating activities:

 

 

 

 

 

 

 

 

Amortization

 

 

6,218

 

 

 

 

Impairment

 

 

 

 

 

112,329

 

Non-cash interest expense

 

 

38,621

 

 

 

 

Stock based compensation

 

 

694,774

 

 

 

41,875

 

Expenses paid by Parent and Affiliates

 

 

631,765

 

 

 

364,391

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(27,069

)

 

 

 

Accounts payable and Accrued Expenses

 

 

25,707

 

 

 

108,047

 

Prepaid expenses

 

 

(26,000

)

 

 

 

Inventory

 

 

(243,253

)

 

 

(74,199

)

Other current assets

 

 

(20,065

)

 

 

 

Deferred revenue

 

 

17,950

 

 

 

 

Deferred offering costs

 

 

(50,000

)

 

 

 

Net cash flows from operating activities

 

 

(810,446

)

 

 

(3,672

)

   

 

 

 

 

 

 

 

Investing Activities

 

 

 

 

 

 

 

 

Patent costs

 

 

(13,584

)

 

 

(29,634

)

Purchases of equipment and fixtures

 

 

(10,662

)

 

 

 

Capitalized software costs

 

 

(63,000

)

 

 

 

Net cash flows from investing activities

 

 

(87,246

)

 

 

(29,634

)

   

 

 

 

 

 

 

 

Financing Activities

 

 

 

 

 

 

 

 

Proceeds from issuance of shares net of offering expenses

 

 

430,761

 

 

 

62,769

 

Collection of stock subscription receivable

 

 

40,765

 

 

 

 

Proceeds from related party convertible debt

 

 

521,000

 

 

 

 

Repayments of related party convertible debt

 

 

(52,801

)

 

 

 

Repayments of Amounts Due to Parent and Affiliates

 

 

(4,000

)

 

 

 

Net cash flows from financing activities

 

 

935,725

 

 

 

62,769

 

   

 

 

 

 

 

 

 

Net Change In Cash

 

 

38,033

 

 

 

29,463

 

   

 

 

 

 

 

 

 

Cash at Beginning of Period

 

$

27,023

 

 

 

 

Cash at End of Period

 

$

65,056

 

 

$

29,463

 

   

 

 

 

 

 

 

 

Significant Non-Cash Transaction

 

 

 

 

 

 

 

 

Expenses paid for by Parent reported as increase in Due to
Parent and Affiliates and related party convertible debt

 

 

631,765

 

 

 

364,391

 

Increase in amounts Due to Parent and Affiliates reported as decrease in Additional Paid in Capital

 

 

 

 

 

94,021

 

Shares issued for contribution of assets from Parent and
Affiliates (intangible assets)

 

 

 

 

 

123,497

 

Shares issued for contribution of assets from Parent and Affiliates (inventory)

 

 

 

 

 

60,112

 

Shares issued for settlement of Due to Parent and Affiliates

 

 

 

 

 

211,572

 

Shares issued from conversion of related party convertible debt

 

 

1,278,502

 

 

 

 

F-19

INNOVATIVE EYEWEAR, INC.
NOTES TO THE FINANCIAL STATEMENTS
September 30, 2021 and December 31, 2020

NOTE 1 — GENERAL INFORMATION

General Information — INNOVATIVE EYEWEAR, INC. (f/k/a Innovative Eyewear LLC) (“the Company”) is a corporation organized under the laws of the State of Florida. The principal activity of the Company is designing, manufacturing and selling smart eyewear through its e-commerce channels and retail distribution.

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, all adjustments considered necessary for the fair presentation of the financial statements for the years presented have been included. The results of operations for the nine months ended September 30, 2021 are not necessarily indicative of the results to be expected for future periods or the full year.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, particularly given the significant social and economic disruptions and uncertainties associated with the ongoing coronavirus pandemic (“COVID-19”) and COVID-19 control responses.

Receivables and Credit Policy

Trade receivables from customers are uncollateralized customer obligations due under normal trade terms, primarily requiring payment before product is shipped. Trade receivables are stated at the amount billed to the customer. Payments of trade receivables are allocated to the specific invoices identified on the customer’s remittance advice or, if unspecified, are applied to the earliest unpaid invoice. The Company, by policy, routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited and it has not experienced any significant write-downs in its accounts receivable balances. As of September 30, 2021 and December 31, 2020, the Company had no allowance for bad debt.

Sales Taxes

Various states impose a sales tax on the Company’s sales to non-exempt customers. The Company collects the sales tax from customers and remits the entire amount to each respective state. The Company’s accounting policy is to exclude the tax collected and remitted to the states from revenue and cost of sales.

Capitalized Software

The Company incurred software development costs related to development of the Vyrb app. The Company capitalized these costs in accordance with ASC 985-20, Software — Costs of Software to be Sold, Leased, or Marketed, considering it is Company’s intention to market and sell the software externally. Planning, designing, coding and testing occurred necessary to meet Vyrb’s design specifications. As such, all coding, development and testing costs incurred subsequent to establishing technical feasibility were capitalized.

F-20

INNOVATIVE EYEWEAR, INC.
NOTES TO THE FINANCIAL STATEMENTS
September 30, 2021 and December 31, 2020

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

Inventory

Our inventory includes purchased eyewear and is stated at the lower of cost or net realizable value, with cost determined on a weighted average first-in, first-out basis. Provisions for excess, obsolete or slow moving inventory are recorded after periodic evaluation of historical sales, current economic trends, forecasted sales, estimated product life cycles and estimated inventory levels. No provisions were determined as needed at September 30, 2021.

In accordance with the donation policy started in May 2021, we donate an optical frame for every Lucyd Lyte sold. During the nine month period ended September 30, 2021 we donated total of $7,656 of glasses to charity. The amount was recorded at historical cost under General and Administrative Expenses.

As of September 30, 2021, the Company recorded an inventory prepayment in the amount of $295,200 related to down payment on eyewear purchase from the manufacturer, prior to shipment of the product that occurred after September 30, 2021. As of December 31, 2020, the Company recorded an inventory prepayment in the amount $85,740 for inventory paid for during 2020 but shipped after December 31, 2020.

Income Taxes

The Company is taxed as a C corporation. The Company complies with FASB ASC 740 for accounting for uncertainty in income taxes recognized in a company’s financial statements, which prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. FASB ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s financial statements. The Company believes that its income tax positions would be sustained on audit and does not anticipate any adjustments that would result in a material change to its financial position.

The Company has incurred taxable losses since inception but is current in its tax filing obligations. The Company is not presently subject to any income tax audit in any taxing jurisdiction.

Stock-Based Compensation

The Company accounts for stock-based compensation to employees and directors in accordance with FASB ASC Topic 718, which requires that compensation expense be recognized in the financial statements for stock-based awards based on the grant date fair value. For stock option awards, the Black-Scholes-Merton option pricing model was used to estimate the fair value of share-based awards. The Black-Scholes-Merton option pricing model incorporates various and highly subjective assumptions, including expected term and share price volatility. The expected term of the stock options was estimated based on the simplified method as allowed by Staff Accounting Bulletin 107 (SAB 107).

The share price volatility at the grant date is estimated using historical stock prices based upon the expected term of the options granted, using stock prices of comparably profiled public companies. The risk-free interest rate assumption is determined using the rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award being valued. The expected term is calculate using the vesting term of 3 years and contractual term of 3 years, resulting in a holding period of 3 years.

We note that the fair value of common stock used in the option pricing model in 2020 and for 9 months ended September 30, 2021 (no option grants in 2019) was determined using the most recent price paid by independent investors through Regulation Crowdfund (“REG CF”) securities offering undertaken by the Company. For majority of time during which stock option awards were granted by the Company in 2021 and 2020, the Company has been raising funds from investors under Regulation CF campaigns, with significant number of transactions from both accredited and non-accredited investors.

F-21

INNOVATIVE EYEWEAR, INC.
NOTES TO THE FINANCIAL STATEMENTS
September 30, 2021 and December 31, 2020

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

The pre-money valuation determining price per share was agreed upon each time with the crowdfund platform, who has great deal of experience in setting the proper pre-money valuations for companies that list on their platforms. The determination was made using Company’s business progress.

Revenue Recognition

Our revenue is generated from the sales of prescription and non-prescription optical glasses, sunglasses and shipping charges, which are charged to the customer, associated with these purchases. We sell products through our retail store resellers, distributors and on our own website Lucyd.co and on Amazon.

To determine revenue recognition, we perform the following steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract and (v) recognize revenue when (or as) the entity satisfies a performance obligation. At contract inception, we assess the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. We then recognize as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.

All revenue, including sales processed online and through our retail store resellers and distributors, is reported net of sales taxes collected from customers on behalf of taxing authorities, returns and discounts.

For sales generated through our e-commerce channels, we identify the contract with a customer upon online purchase of our eyewear and transaction price at the manufacturer suggested retail price (“MSRP”) for non-prescription, polarized sunglass and blue light blocking glasses across all of our online channels. Our e-commerce revenue is recognized upon meeting of the performance obligation when the eyewear is shipped to end customers. Only U.S. consumers enjoy free USPS first class postage, with faster delivery options available for extra cost, for sales processed through our website and on Amazon. For Amazon sales, shipping is free for U.S consumers while international customers pay shipping charges on top of MSRP. Any costs associated with fees charged by the online platforms (Shopify for Lucyd.co website and Amazon) are not recharged to customers and are recorded as a component of cost of goods sold as incurred. The Company charges applicable state sales taxes in addition to the MSRP for both online channels and all other marketplaces on which the company sells products.

For sales to our retail store partners, we identify the contract with a customer upon receipt of an order of our eyewear through our Shopify wholesale portal or direct purchase order. Our revenue is recognized upon meeting the performance obligation which is delivery of the company’s eyewear products to retail store or the distributor, and also recorded net of returns and discounts. Our wholesale pricing for eyewear sold to retail store partners and distributors includes volume discounts, due to the nature of large quantity orders. The pricing includes shipping charges, while excluding any state sales tax charges applicable. Due to the nature of wholesale retail orders, no e-commerce fees are applicable.

For sales to distributors, we identify the contract with a customer upon receipt of an order of our eyewear through a direct purchase order. Our revenue is recognized upon meeting the performance obligation, which is delivery of our eyewear products to the distributor, and is also recorded net of returns and discounts. Our wholesale pricing for eyewear sold to distributors includes volume discounts, due to the nature of large quantity orders. The pricing includes shipping charges, while excluding any state sales tax charges applicable. Due to the nature of wholesale distributor orders, no e-commerce fees are applicable.

The Company’s sales to both retail store partners and through the e-commerce channels do not contain any variable consideration.

We allow our customers to return our products, subject to our refund policy, which allows any customer to return our products for any reason within the first:

•        7 days for sales made through our website (Lucyd.co)

F-22

INNOVATIVE EYEWEAR, INC.
NOTES TO THE FINANCIAL STATEMENTS
September 30, 2021 and December 31, 2020

NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (cont.)

•        30 days for sales made through Amazon

•        30 days for sales to wholesale retailers and distributors

For all of our sales, at the time of sale, we establish a reserve for returns, based on historical experience and expected future returns, which is recorded as a reduction of sales. Additionally, we reviewed all individual returns received in October 2021 pertaining to orders processed prior to September 30, 2021. The identified amounts were nominal.

Shipping and Handling

Costs incurred for shipping and handling are included in cost of revenue at the time the related revenue is recognized. Amounts billed to a customer for shipping and handling are reported as revenues.

Earnings/loss per share

The Company presents earnings and loss per share data by calculating the quotient of earnings/(loss) and loss divided by the number of common shares outstanding (common shares as of September 30, 2021) as required by ASC 260-10-50. As of September 30, 2021, all shares underlying the related party convertible debt and common stock options were excluded from the earnings per share calculation due to their anti-dilutive effect.

Recent Accounting Pronouncements

In February 2017, FASB issued ASU No. 2017-02, “Leases (Topic 842),” that requires organizations that lease assets, referred to as “lessees,” to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2017-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The Company adopted ASU 2017-02 as of January 1, 2021. Company’s management determined it had no material impact on financial statements due to the lack of long-term leasing arrangements.

In May 2018, FASB issued ASU 2020-06, “Debt — Debt with Conversion and Other Options (Subtopic 470-20), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contract’s in Entity’s Own Equity. The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. The amendments in ASU 2020-06 further revise the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. The Company adopted ASU 2020-06 as of January 1, 2021. Company’s management determined it had no material impact on financial statements due to the lack of beneficial conversion features.

NOTE 3 — GOING CONCERN

The Company has a limited operating history. The Company’s business and operations are sensitive to general business and economic conditions in the United States. A host of factors beyond the Company’s control could cause fluctuations in these conditions. Adverse conditions may include: recession, downturn or otherwise, changes in regulations or restrictions in imports, competition or changes in consumer taste including the economic impacts from the COVID-19 pandemic. These adverse conditions could affect the Company’s financial condition and the results of its operations.

F-23

INNOVATIVE EYEWEAR, INC.
NOTES TO THE FINANCIAL STATEMENTS
September 30, 2021 and December 31, 2020

NOTE 3 — GOING CONCERN (cont.)

The Company meets its day to day working capital requirements through monies raised through sales of eyewear and issues of equity including crowdfunding. The Company also has issued a convertible note held by its parent company. Company’s forecasts and projections indicate that the Company expects to have sufficient cash reserves to operate within the level of its current facilities. Whilst it is the Company’s intention to rely on the available cash reserves, future income generated from its product sales, a negative variance in the forecasts and projections would make the Company’s ability to continue as a going concern dependent on an additional fund raise. Based on these factors, there is substantial doubt about the Company’s ability to continue as a going concern.

NOTE 4 — RELATED PARTY ADVANCES AND OTHER INTERCOMPANY AGREEMENTS

Convertible Note

On December 1, 2020, the Company issued a convertible note to its Parent and Affiliates for up to $2,000,000 that bear interest at 10% per annum, which includes the option to convert the debt into shares at market price.

On June 1, 2021, the Company converted related party borrowings totaling $778,500 into 778,500 shares of common stock at $1 each. On September 5, 2021, the Company converted related party borrowings totaling $500,002 into 140,449 shares of common stock at $3.56 each. The Company had an outstanding balance of $420,104 as of September 30, 2021.

Management Service Agreement

During nine months ended September 30, 2021, the Company incurred $75,000 under its agreement with Tekcapital Europe Ltd. Additionally, the Company’s Parent and Affiliates incurred $9,975 in management charges on behalf of the Company.

The outstanding unpaid balance of $74,943 as of September 30, 2021 was included in the Convertible Note balances discussed above.

NOTE 5 — COMMITMENTS AND CONTINGENCIES

Legal Matters

The Company is not currently involved in or aware of threats of any litigation.

Commitments

See related party management services agreement discussed in Note 4.

NOTE 6 — SHAREHOLDERS’ EQUITY

Crowdfunded Offering

In April 2021, the Company concluded its crowdfund launched in 2020, with the Company raising additional $770,290 in the nine months period ended September 30, 2021, offset by $339,529 in offering costs.

In July 2021, the Company launched its second Crowdfunded offering of common stock in which it raised $154,712, amounting to 44,458 shares (40,011 issued as of September 30, 2021), offset by $93,341 in offering costs.

NOTE 7 — STOCK BASED COMPENSATION

On July 1, 2021, an Equity Incentive Plan was approved, allowing for total of 20%, or 1,124,043, of total issued shares to be available for the grant of awards under the Plan. 1,685,000 option awards were granted by the Company prior to the approval of the Plan, while 647,500 option awards were granted subject to the Plan.

F-24

INNOVATIVE EYEWEAR, INC.
NOTES TO THE FINANCIAL STATEMENTS
September 30, 2021 and December 31, 2020

NOTE 7 — STOCK BASED COMPENSATION (cont.)

During the nine-month period ended September 30, 2021, the Company, granted 1,687,500 option awards, of which 1,347,500 vest ratably over time and 340,000 vest based on certain performance conditions, which the Company believes are probable of occurring.

The fair value of options granted is expensed over the vesting period and is calculated using the Black-Scholes model. The assumptions inherent in the use of this model for the current period option grants are as follows:

Attribute

 

Input

Share price at date of grant

 

$1.00 – $3.56

Options life in years

 

3

Risk free rate

 

0.46% – 0.53%

Expected volatility

 

122% – 130%

Expected dividend yield

 

0

Grant date fair value of options

 

$0.71 – $2.64

The weighted average grant date fair value of options outstanding was $1.87. Volatility was calculated using historical share price performance of peer companies in the 3 year period prior to option grant.

Details of the number of share options and the weighted average exercise price outstanding during the nine months ended September 30, 2021 are as follows:

Company

 

Av. Exercise
price per share
$

 

Options
(Number)

As at January 1, 2021

 

1.00

 

645,00

Granted

 

3.19

 

1,687,500

Exercised

 

 

Forfeited

 

 

As at September 30, 2021

 

2.59

 

2,332,500

Exercisable as at September 30, 2021

 

1.40

 

170,000

The weighted average remaining contractual life is 2 years. The weighted average exercise price of options granted during the year was $3.19. The range of exercise prices for options outstanding at the end of the year was $1.00-$3.56. Unrecognized stock compensation expense of $3,318,597 remains to be recognized over next 2 years related to options granted during nine months ended September 30, 2021 and $242,265 remains to be recognized over next 2 years related to options granted prior to January 1, 2021.

NOTE 8 — SUBSEQUENT EVENTS

Convertible Note

On November 1, 2021, the Company executed an addendum for its December 1, 2020 convertible note agreement with Parent and Affiliates, increasing the amount of available financing from $2,000,000 to $3,000,000.

On November 16, 2021, the Company converted related party borrowings totaling $901,270.96 into 253,166 shares of common stock at $3.56 per share.

F-25

 

2,857,142 Units consisting of
2,857,142 Shares of Common Stock
and

2,857,142 Warrants to Purchase 2,857,142 Shares of Common Stock

_______________________________

PROSPECTUS

_______________________________

Sole Book-Running Manager

Maxim Group LLC

            , 2022

Through and including         , 2022 (the 25th day after the date of this offering), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer’s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.

 

 

PART II — INFORMATION NOT REQUIRED IN PROSPECTUS

Item 13. Other Expenses of Issuance and Distribution

The following table sets forth the expenses in connection with this registration statement. All of such expenses are estimates, other than the filing fees payable to the Securities and Exchange Commission and to FINRA.

 

Amount
to be paid

SEC registration fee

 

$

3,303

FINRA filing fee

 

$

1,896

NASDAQ initial listing fee

 

$

45,000

Transfer agent and registrar fees

 

$

199

Accounting fees and expenses

 

$

17,500

Legal fees and expenses

 

$

500,000

Printing expenses

 

$

25,000

Miscellaneous expenses

 

$

50,000

Total

 

$

642,898

Item 14. Indemnification of Directors and Officers

The Florida Business Corporation Act (the “FBCA”) provides that a corporation may indemnify a director or officer against liability if the director or officer acted in good faith, the director or officer acted in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the corporation, and in the case of any criminal proceeding, the director or officer had no reasonable cause to believe his or her conduct was unlawful. A corporation may not indemnify a director or an officer except for expenses and amounts paid in settlement not exceeding, in the judgment of the board of directors, the estimated expense of litigating the proceeding to conclusion, actually and reasonably incurred in connection with the defense or settlement of such proceeding, including any appeal thereof, where such person acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the best interests of the corporation.

The FBCA provides that a corporation must indemnify a director or officer who was wholly successful, on the merits or otherwise, in the defense of any proceeding to which the individual was a party because he or she is or was a director or officer of the corporation against expenses incurred by the individual in connection with the proceeding.

A corporation may, before final disposition of a proceeding, advance funds to pay for or reimburse expenses incurred in connection with the proceeding by a director or an officer if the director or officer delivers to the corporation a signed written undertaking of the director or officer to repay any funds advanced if such director or officer is not entitled to indemnification.

Our amended and restated articles of incorporation and bylaws provide that we shall indemnify our directors, officers, employees and agents to the full extent permitted by FBCA, including in circumstances in which indemnification is otherwise discretionary under such law.

These indemnification provisions may be sufficiently broad to permit indemnification of our officers, directors and other corporate agents for liabilities (including reimbursement of expenses incurred) arising under the Securities Act.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of our company pursuant to the foregoing provisions, or otherwise, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

We have the power to purchase and maintain insurance on behalf of any person who is or was one of our directors or officers, or is or was serving at our request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other business against any liability asserted against the person or incurred by the person in any

II-1

of these capacities, or arising out of the person’s fulfilling one of these capacities, and related expenses, whether or not we would have the power to indemnify the person against the claim under the provisions of the FBCA. We do not currently maintain director and officer liability insurance on behalf of our director and officers; however, we intend to so purchase and maintain such insurance when economically feasible.

Additionally, our second amended and restated articles of incorporation provides that we shall, to the maximum extent permitted from time to time under the law of the State of Florida, indemnify and upon request shall advance expenses to any person who is or was a party or is threatened to be made a party to any threatened, pending or completed action, suit, proceeding or claim, whether civil, criminal, administrative or investigative, by reason of the fact that such person is or was or has agreed to be a director or officer of ours or while a director or officer is or was serving at our request as a director, officer, partner, trustee, employee or agent of any corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, against expenses (including attorneys’ fees and expenses), judgments, fines, penalties and amounts paid in settlement incurred in connection with the investigation, preparation to defend or defense of such action, suit, proceeding or claim; provided, however, that the foregoing shall not require us to indemnify or advance expenses to any person in connection with any action, suit, proceeding or claim initiated by or on behalf of such person or any counterclaim against us initiated by or on behalf of such person. Such indemnification shall not be exclusive of other indemnification rights arising under any by-law, agreement, vote of directors or stockholders or otherwise and shall inure to the benefit of the heirs and legal representatives of such person. Any person seeking indemnification shall be deemed to have met the standard of conduct required for such indemnification unless the contrary shall be established. Any repeal or modification of our second amended and restated articles of incorporation shall not adversely affect any right or protection of a director or officer of ours with respect to any acts or omissions of such director or officer occurring prior to such repeal or modification.

Expenses incurred by such a person in defending a civil or criminal action, suit or proceeding by reason of the fact that such person is or was, or has agreed to become, a director or officer of ours, or is or was serving, or has agreed to serve, at our request, as a director, officer or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, including any employee benefit plan, or by reason of any action alleged to have been taken or omitted in such capacity shall be paid by us in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such person to repay such amount if it shall ultimately be determined that he is not entitled to be indemnified by us as authorized by relevant sections of the FBCA. Notwithstanding the foregoing, we shall not be required to advance such expenses to a person who is a party to an action, suit or proceeding brought by us and approved by a majority of our Board of Directors that alleges willful misappropriation of corporate assets by such person, disclosure of confidential information in violation of such person’s fiduciary or contractual obligations to us or any other willful and deliberate breach in bad faith of such person’s duty to us or our stockholders.

We shall not indemnify any such person seeking indemnification in connection with a proceeding (or part thereof) initiated by such person unless the initiation thereof was approved by our Board of Directors.

The indemnification rights provided in our bylaws, which will be in effect upon the consummation of this offering, shall not be deemed exclusive of any other rights to which those indemnified may be entitled under any by-law, agreement or vote of stockholders or disinterested directors or otherwise, both as to action in their official capacities and as to action in another capacity while holding such office, continue as to such person who has ceased to be a director or officer, and inure to the benefit of the heirs, executors and administrators of such a person.

If the FBCA Law is amended to expand further the indemnification permitted to indemnitees, then we shall indemnify such persons to the fullest extent permitted by the FBCA, as so amended.

We may, to the extent authorized from time to time by our Board of Directors, grant indemnification rights to other employees or agents of ours or other persons serving us and such rights may be equivalent to, or greater or less than, those set forth in our bylaws, which will be in effect upon the consummation of this offering.

Our obligation to provide indemnification under our bylaws, which will be in effect upon the consummation of this offering, shall be offset to the extent of any other source of indemnification or any otherwise applicable insurance coverage under a policy maintained by us or any other person.

To assure indemnification under our bylaws, which will be in effect upon the consummation of this offering, of all directors, officers, employees or agents who are determined by us or otherwise to be or to have been “fiduciaries” of

II-2

any employee benefit plan of ours that may exist from time to time, the FBCA shall, for the purposes of our bylaws, which will be in effect upon the consummation of this offering, be interpreted as follows: an “other enterprise” shall be deemed to include such an employee benefit plan, including without limitation, any plan of ours that is governed by the Act of Congress entitled “Employee Retirement Income Security Act of 1974,” as amended from time to time; we shall be deemed to have requested a person to serve an employee benefit plan where the performance by such person of his duties to us also imposes duties on, or otherwise involves services by, such person to the plan or participants or beneficiaries of the plan; and excise taxes assessed on a person with respect to an employee benefit plan pursuant to such Act of Congress shall be deemed “fines.”

Our bylaws, which will be in effect upon the consummation of this offering, shall be deemed to be a contract between us and each person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, by reason of the fact that person is or was, or has agreed to become, a director or officer of ours, or is or was serving, or has agreed to serve, at our request, as a director, officer or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, including any employee benefit plan, or by reason of any action alleged to have been taken or omitted in such capacity, at any time while this by-law is in effect, and any repeal or modification thereof shall not affect any rights or obligations then existing with respect to any state of facts then or theretofore existing or any action, suit or proceeding theretofore or thereafter brought based in whole or in part upon any such state of facts.

The indemnification provision of our bylaws, which will be in effect upon the consummation of this offering, does not affect directors’ responsibilities under any other laws, such as the federal securities laws or state or federal environmental laws.

We may purchase and maintain insurance on behalf of any person who is or was a director, officer or employee of ours, or is or was serving at our request as a director, officer, employee or agent of another company, partnership, joint venture, trust or other enterprise against liability asserted against him and incurred by him in any such capacity, or arising out of his status as such, whether or not we would have the power to indemnify him against liability under the provisions of this section. We currently maintain such insurance.

The right of any person to be indemnified is subject to our right, in lieu of such indemnity, to settle any such claim, action, suit or proceeding at our expense of by the payment of the amount of such settlement and the costs and expenses incurred in connection therewith.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling our company pursuant to the foregoing provisions, or otherwise, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

In the event that a claim for indemnification against such liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered herewith, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to the court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

The Registrant plans to enter into an underwriting agreement, which provides that the underwriters are obligated, under some circumstances, to indemnify the Registrant’s directors, officers and controlling persons against specified liabilities, including liabilities under the Securities Act.

Item 15. Recent Sales of Unregistered Securities

During the last three years, the Company has not issued unregistered securities to any person, except as described below. None of these transactions involved any underwriters, underwriting discounts or commissions, except as specified below, or any public offering, and, unless otherwise indicated below, the Company believes that each transaction was exempt from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof and/or Rule 506 of Regulation D promulgated thereunder, and/or Regulation S promulgated thereunder regarding offshore offers and sales. All recipients had adequate access, though their relationships with the Company, to information about the Company.

II-3

Original Issuance of Stock

On March 26, 2020, the Company issued an aggregate of 3,750,000 shares of common stock to Lucyd Ltd. as part of the consideration for the Company entering into an exclusive licensing agreement with Lucyd Ltd.

Convertible Promissory Notes

On December 1, 2020, we issued a convertible note for an aggregate principal amount of up to $2,000,000 to Lucyd Ltd., the majority stockholder of the Company (the “Note”). On June 1, 2021, we completed the partial conversion of $778,500 of the outstanding balance on the Note into an aggregate of 778,500 shares of common stock. On September 5, 2021, we completed the partial conversion of an aggregate of $500,002 of the outstanding balance on the Note, at $3.56 per share, into an aggregate of 140,449 shares of common stock. On November 16, 2021, we completed the partial conversion of an aggregate of $901,270.96 of the outstanding balance on the Note, at $3.56 per share, into an aggregate of 253,166 shares of common stock. As of January 5, 2022, $283,134 remains outstanding on the Note.

The Note has an interest rate of 10.0 % per annum, is unsecured, matures on December 1, 2023 and provide for conversion, at the election of Lucyd Ltd., into our common stock upon the earlier of (i) the Company consummating an equity financing pursuant to which it raises an aggregate amount of not less than $750,000, (ii) the Company entering into a transaction pursuant to which the Company sells not less than 10% of the Company’s shares, excluding any and all convertible notes which are convertible into shares, (iii) the Company lists its shares on a national securities exchange or (iv) the holder determines to convert the Note. If not converted earlier, upon the closing of this offering, the Notes will convert into 53,930 shares of our common stock at a conversion price equal to $5.25 per share. The principal amount and accrued but unpaid interest under each note will automatically convert into shares of our common stock at the stated conversion price per share.

Regulation CF Offerings

In June 2020, the Company commenced an offering pursuant to Regulation CF of the Securities Act, through the intermediary portal, StartEngine.com, pursuant to which we offered shares of our common stock for $1.00 per share. The offering was terminated in April 2021 and we issued 1,091,717 shares of common stock for aggregate gross proceeds of $1,091,717.

On July 12, 2021, the Company issued an aggregate of 1,000 shares of common stock for $1.00 per share to an individual investor, pursuant to a subscription agreement with the Company, for aggregate gross proceeds of $1,000.

In July 2021, the Company launched its second Crowdfunded offering of common stock in which it raised $154,712, amounting to 44,458 shares (40,011 issued as of September 30, 2021), offset by $93,341 in offering costs.

Stock Options

Since our inception, we have issued options exercisable for an aggregate of 2,332,500 shares of common stock. These options have a weighted average exercise price of $2.59 per share.

II-4

Item 16. Exhibits

The following is a list of exhibits filed as a part of this registration statement:

Exhibit Number

 

Description of Document

1.1

 

Form of Underwriting Agreement*

3.1

 

Amended and Restated Articles of Incorporation of Innovative Eyewear, Inc.

3.2

 

Form of Second Amended and Restated Articles of Incorporation of Innovative Eyewear, Inc.

3.3

 

Amended and Restated Bylaws of Innovative Eyewear, Inc.

3.4

 

Form of Second Amended and Restated Bylaws of Innovative Eyewear, Inc.

4.1

 

Form of Representative’s Warrant*

4.2

 

Form of Warrant*

4.3

 

Form of Warrant Agency Agreement between Innovative Eyewear, Inc. and VStock Transfer, LLC*

5.1

 

Opinion of Ellenoff Grossman & Schole LLP*

10.1

 

License Agreement between Innovative Eyewear, Inc. and Lucyd Ltd.

10.2

 

Addendum to the License Agreement between Innovative Eyewear, Inc. and Lucyd Ltd.

10.3

 

Management Agreement between Innovative Eyewear, Inc. and Tekcapital Europe Ltd.#

10.4

 

Convertible Note, dated December 1, 2020, issued to Lucyd Ltd.

10.5

 

Intercompany Loan and Debt Transfer Agreement, dated June 1, 2021, by and among Innovative Eyewear, Inc., Lucyd Ltd., Tekcapital pk, Tekcapital Europe Ltd. and Tekcapital LLC

10.6

 

Employment Agreement by and between Innovative Eyewear, Inc. and Harrison Gross#

10.7

 

Employment Agreement by and between Innovative Eyewear, Inc. and Konrad Dabrowksi#

10.8

 

Consulting Agreement by and between Innovative Eyewear, Inc. and Frank Rescigna#

10.9

 

Amendment to the Consulting Agreement by and between Innovative Eyewear, Inc. and Frank Rescigna#

10.10

 

Innovative Eyewear, Inc. 2021 Equity Incentive Plan

10.11

 

Sale Representation Agreement by and between Innovative Eyewear, Inc. and D. Landstrom Associates, Inc.

10.12

 

Distribution Agreement by and between Innovative Eyewear, Inc. and 8 Points Inc.

14.1

 

Form of Code of Ethics of Innovative Eyewear, Inc.

23.1

 

Consent of Cherry Bekaert LLP, Independent Registered Public Accounting Firm

23.2

 

Consent of Ellenoff Grossman & Schole LLP (contained in Exhibit 5.1)*

24.1

 

Powers of Attorney (included on signature page to Registration Statement filed on December 13,
2021)**

99.1

 

Form of Audit Committee Charter

99.2

 

Form of Compensation Committee Charter

99.3

 

Form of Nominating and Corporate Governance Committee Charter

____________

*        To be filed by amendment.

**      Previously filed.

#        Indicates management contract or compensatory plan.

II-5

Item 17. Undertakings

The undersigned registrant hereby undertakes:

(1)    To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

(i)     To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii)    To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

(iii)   To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

(2)    That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3)    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(4)    That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A (§230.430A of this chapter), shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

(5)    That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities:

The undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

(i)     Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

(ii)    Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

(iii)   The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

(iv)   Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

II-6

(6)    Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by the final adjudication of such issue.

(7)    The undersigned registrant hereby undertakes to provide to the underwriter at the closing specified in the underwriting agreements certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser.

(8)    The undersigned Registrant hereby undertakes that:

(i)     For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

(ii)    For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

II-7

Signatures

Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Miami, State of Florida, on January 10, 2022.

 

Innovative Eyewear, Inc.

   

By:

 

/s/ Harrison Gross

       

Name: Harrison Gross

       

Title: Chief Executive Officer

Pursuant to the requirements of the Securities Act, this registration statement has been signed below by the following persons in the capacities and on the dates indicated.

Person

 

Capacity

 

Date

/s/ Harrison Gross

 

Chief Executive Officer and Director

 

January 10, 2022

Harrison Gross

 

(Principal Executive Officer)

   

/s/ Konrad Dabrowski

 

Chief Financial Officer

 

January 10, 2022

Konrad Dabrowski

 

(Principal Financial and Accounting Officer)

   

*

 

Vice President of Global Sales and Director

 

January 10, 2022

Frank Rescigna

       

*

 

Director

 

January 10, 2022

Kristen Mclaughlin

       

*

 

Director

 

January 10, 2022

Louis Castro

       

*

 

Director

 

January 10, 2022

Olivia C. Bartlett

       

*By: /s/ Harrison Gross

       

Harrison Gross, Attorney-in-Fact

       

II-8

 

Exhibit 3.1

 

AMENDED AND RESTATED
ARTICLES OF INCORPORATION
OF

INNOVATIVE EYEWEAR, INC.
A Florida Corporation

 

Pursuant to section 607.1007 of the Business Corporation Act of the State of Florida (the “FBCA”), the undersigned, being the Chief Executive Officer of Innovative Eyewear, Inc. (hereinafter the “Corporation”), a Florida corporation, and desiring to amend and restate its Articles of Incorporation, does hereby certify:

 

FIRST: the Articles of Conversion and Articles of Incorporation of the Corporation were filed with the Secretary of State of Florida on March 25, 2020, Document No. P20000028782, with an organizational date deemed effective August 15, 2019;

 

SECOND: these Amended and Restated Articles of Incorporation (these “Articles of Incorporation”) were adopted by all of the directors on the board of directors of the Corporation and by the holders of a majority of the voting stock of the Corporation in accordance with and in the manner required by sections 607.1003 and 607.1007 of the FBCA on July 1, 2021. The number of votes cast for the approval of this amendment and restatement to the Corporation’s Articles of Incorporation was sufficient for approval pursuant to sections 607.1003 and 607.1006 of the FBCA;

 

THIRD: these duly adopted restated Articles of Incorporation consolidate all amendments to the Articles of Incorporation into a single document pursuant to section 607.1007 of the FBCA including all new amendments to the Articles of Incorporation; and

 

FOURTH: these duly adopted restated Articles of Incorporation supersede the original Articles of Incorporation and all previous amendments to the Articles of Incorporation pursuant to section 607.1007 of the FBCA.

 

ARTICLE I
CORPORATE NAME

 

The name of this corporation is Innovative Eyewear, Inc. (the “Corporation”).

 

ARTICLE II
PRINCIPAL OFFICE

 

The principal office and mailing address of the Corporation is 8101 Biscayne Bl #705, Miami, FL 33138 United States.

 

ARTICLE III
REGISTERED OFFICE AND AGENT

 

The street address of the Corporation’s registered office is 8101 Biscayne Bl #705, Miami, FL 33138 United States. The name of the Corporation’s registered agent at that office is Harrison Gross.

 

ARTICLE IV
DURATION

 

The duration of the Corporation is perpetual.

 

 

 

 

ARTICLE V
PURPOSE

 

The Corporation is formed to engage in any lawful act or activity for which corporations may be organized under the FBCA, including any amendments thereto.

 

ARTICLE VI
SHARES

 

The maximum number of shares that the Corporation shall be authorized to issue and have outstanding at any one time shall be sixty-five million (65,000,000) shares, having a par value of $0.00001, of which:

 

(i) fifty million (50,000,000) shares shall be designated as common stock, having a par value of $0.00001 per share (“Common Stock”). All shares of Common Stock shall be identical with each other in every respect, and the holders thereof shall be entitled to one vote for each share of Common Stock upon all matters upon which the holders of the Common Stock have the right to vote; and

 

(ii) fifteen million (15,000,000) shares shall be designated as blank check preferred stock, having a par value of $0.00001 per share (“Preferred Stock”), with such preferences, limitations and relative rights as may be determined from time to time pursuant to a resolution adopted by a majority of the Directors participating in a duly convened meeting of the board of directors of the Corporation at which a quorum is present or by written consent of the Directors adopted in accordance with the bylaws of the Corporation (the “Bylaws”).

 

ARTICLE VII
AFFILIATED TRANSACTIONS

 

The Corporation expressly elects not to be governed by Section 607.0901 of the Florida Business Corporation Act, as amended from time to time, relating to affiliated transactions.

 

ARTICLE VIII
CONTROL SHARE ACQUISITIONS

 

The Corporation expressly elects not to be governed by Section 607.0902 of the Florida Business Corporation Act, as amended from time to time, relating to control share acquisitions.

 

ARTICLE IX
BOARD OF DIRECTORS

 

The name of the current director of the Corporation is Harrison Gross and the address of the current directo is 8101 Biscayne Bl #705, Miami, FL 33138 United States.

 

The business and affairs of the Corporation shall be managed by or under the direction of a board of directors (the “Board” or “Board of Directors”) consisting of not less than one director with no maximum number of directors. The exact number of directors of the Corporation within the minimum specified in the preceding sentence shall be as from time to time determined in the manner provided in the Bylaws. The election of directors need not be by written ballot unless the Bylaws so provide. The term of the directors and the renewal, replacement or removal of the directors shall be determined in the manner provided in the Bylaws. The directors shall be permitted to serve an unlimited number of terms as directors.

 

2

 

 

To the fullest extent permitted by the FBCA as in effect on the date hereof, and as hereafter amended from time to time, a director of the Corporation shall not be liable to the Corporation or its shareholders for monetary damages for breach of fiduciary duty as a director. If the FBCA or any successor statute is amended after adoption of this provision to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the FBCA, as so amended from time to time, or such successor statute.

 

In addition to the powers and authority hereinbefore or by statute expressly conferred upon them, the directors are hereby empowered to exercise all such powers and do all such acts and things as may be exercised or done by the Corporation, subject, nevertheless, to the provisions of the FBCA, these Articles of Incorporation and the Bylaws.

 

ARTICLE X
INDEMNIFICATION

 

This Corporation shall indemnify and hold harmless each and every one of present and former directors, officers, employees, attorneys and agents to the fullest extent now or hereafter permitted by the laws of the State of Florida.

 

ARTICLE XI
AMENDMENT

 

The Corporation reserves the right to amend, after, change or repeal any provisions contained in these Articles of Incorporation in the manner now or hereafter prescribed by statue, all rights conferred on the shareholders of the Corporation hereunder are granted subject to this reservation. These Articles of Incorporation may be amended in the manner provided by law.

 

ARTICLE XII
INCORPORATOR

 

The name and street address of the incorporator to the original Articles of Incorporation is Harrison Gross, 66 West Flagler Street, Suite 900, Miami, FL, 33130 United States.

 

The undersigned has executed these Amended and Restated Articles of Incorporation on July 1 2021.

 

  /s/ Harrison Gross
  Name: Harrison Gross
  Title: Chief Executive Officer and Director

 

3

 

 

CERTIFICATE OF ACCEPTANCE BY REGISTERED AGENT

 

Pursuant to the provisions of section 607.0501 of the Florida Business Corporation Act (the “FBCA”), the undersigned submits the following statement in accepting the designation as registered agent and registered office of Innovative Eyewear, Inc., a Florida corporation (the Corporation”), in the Corporation’s Amended and Restated Articles of Incorporation dated July 1, 2021:

 

Having been named as registered agent and to accept services of process for the Corporation at the registered office designated in the Corporation’s Amended and Restated Articles of Incorporation, the undersigned accepts the appointment as registered agent and agrees to act in this capacity. The undersigned further agrees to comply with the provisions of all statutes relating to the proper and complete performance of its duties, and the undersigned is familiar with and accepts the obligations of its position as registered agent pursuant to Section 607.0501(3) of the FCBA.

 

IN WITNESS WHEREOF, the undersigned has executed this certificate this 1st day of July 2021.

 

  /s/ Harrison Gross
  Harrison Gross
  Registered Agent

 

4

 

Exhibit 3.2

 

SECOND AMENDED AND RESTATED

ARTICLES OF INCORPORATION OF
INNOVATIVE EYEWEAR, INC.

 

As Amended and Restated on January [__], 2022

 

Pursuant to Section 607.0821, 607.1001, 607.1003, 607.1004, and 607.1007 of the Florida Business Corporation Act (the “FBCA”), Innovative Eyewear, Inc., a Florida corporation (the “Corporation”), certifies as follows:

 

FIRST: The Corporation is named “Innovative Eyewear, Inc.” and was originally organized as a limited liability company under the laws of the State of Florida on August 15, 2019, and thereafter was converted from a Florida limited liability company into a Florida corporation on March 25, 2020.

 

SECOND: These Second Amended and Restated Articles of Incorporation (the “Amended and Restated Articles of Incorporation”) amend, restate, and supersede in their entirety any and all prior Articles of Incorporation of the Corporation filed with the Secretary of State for the State of Florida from the date of the Corporation’s original organization through the date hereof.

 

THIRD: These Amended and Restated Articles of Incorporation increase the number of authorized shares of capital stock of the Corporation.

 

FOURTH: These Amended and Restated Articles of Incorporation have been approved by the Board of Directors and shareholders of the Corporation. The number of votes cast for the amendment and restatement of the Articles of Incorporation was sufficient for approval by the holders of Common Stock of the Corporation.

 

The text of the Corporation’s Articles of Incorporation is hereby amended and restated in its entirety, effective as of the date of filing of these Amended and Restated Articles of Incorporation with the Secretary of State for the State of Florida, to read as follows:

  

ARTICLE I

COMPANY NAME

 

The name of this Corporation is Innovative Eyewear, Inc.

 

ARTICLE II

COMPANY ADDRESS

 

The address of the Corporation’s registered office in the State of Florida is 8101 Biscayne Blvd., Suite 705, Miami, Florida, 33138; and the name of the registered agent of the Corporation in the State of Florida at such address is Harrison Gross.

 

ARTICLE III

BUSINESS AND ACTIVITIES OF THE COMPANY

 

The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the FBCA, as the same exists or may hereafter be amended.

 

 

 

 

ARTICLE IV

CAPITAL STOCK

 

(1) Authorized Shares. The total number of shares that the Corporation shall have the authority to issue is sixty-five million (65,000,000), of which fifty million (50,000,000) shall be shares of Common Stock, $0.00001 par value per share (“Common Stock”), and fifteen million (15,000,000) shall be shares of Preferred Stock, $0.00001 par value per share (“Preferred Stock”).

 

(a) Common Stock may be issued by the Corporation from time to time for such consideration as may be determined from time to time by the Board of Directors subject to, and in accordance with the full discretion conferred upon the Board of Directors by, the FBCA. Any and all shares for which the consideration so determined shall have been paid or delivered shall be deemed fully paid shares and shall not be liable for any further call or assessment thereon, and the holders of such shares shall not be liable for any further payments in respect of such shares.

 

(b) Each share of Common Stock shall have one vote, and the exclusive voting power for all purposes shall be vested in the holders of Common Stock, unless Preferred Stock with voting rights is created pursuant to Article IV, Section 1(f) below.

 

(c) No holder of Common Stock as such shall have any preemptive right to subscribe for or acquire: (i) unissued or treasury shares of the Corporation of any class or series, (ii) securities of the Corporation convertible into or carrying a right to acquire or subscribe to shares of any class or series, or (iii) any other obligations, warrants, rights to subscribe to shares, or other securities of the Corporation of any class or series, in each case whether now or hereafter authorized.

 

(d) Subject to the provisions of law, dividends may be paid on the Common Stock (and any Preferred Stock authorized pursuant to Article IV, Section 1(f) below which has the right to receive dividends) at such times and in such amounts as the Board of Directors may deem advisable.

 

(e) In the event of any liquidation, dissolution, or winding up of the Corporation, whether voluntary or involuntary, the holders of Common Stock shall be entitled, after payment or provision for payment of the debts and other liabilities of the Corporation, to the remaining net assets of the Corporation, subject to any rights of the Preferred Stock to receive a portion of such net assets if Preferred Stock is subsequently authorized under Article IV, Section 1(f) below.

 

(f) The Board of Directors is hereby expressly authorized, without the additional vote of the shareholders holding any class or series of capital stock, to provide, out of the authorized, but unissued, shares of Preferred Stock, for one or more series of Preferred Stock and, with respect to each such series, to fix the number of shares constituting such series and the designation of such series, the voting powers, if any, of the shares of such series, and the preferences and relative, participating, optional, or other special rights, if any, and any qualifications, limitations, or restrictions thereof, of the shares of such series, all of which may be set forth in resolutions adopted by the Board of Directors and a Certificate of Amendment to these Amended and Restated Articles of Incorporation filed with the Florida Department of State, Division of Corporations. The powers, preferences, and relative, participating, optional, and other special rights of each series of Preferred Stock, and the qualifications, limitations, or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding.

 

ARTICLE V

AFFAIRS OF THE COMPANY

 

The following provisions are inserted for the regulation and conduct of the affairs of the Corporation, but it is expressly provided that the same are intended to be and shall be construed to be in furtherance and not in limitation or exclusion of the powers conferred by law:

 

(1) In furtherance and not in limitation of the powers conferred upon it by law, the Board of Directors is expressly authorized to adopt, alter, amend or repeal the Bylaws of the Corporation. The affirmative vote of at least a majority of the Board of Directors then in office shall be required in order to adopt, amend, alter or repeal the Corporation’s Bylaws. The Bylaws also may be adopted, amended, altered or repealed by the shareholders; provided, however, that in addition to any vote of the holders of any class or series of capital stock of the Corporation required by law or by this Amended and Restated Articles of Incorporation, the affirmative vote of the holders of at least a majority of the voting power of all then outstanding shares of capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required for the shareholders to adopt, amend, alter or repeal the Bylaws. No Bylaws hereafter adopted, amended, altered or repealed shall invalidate any prior act of the directors or officers of the Corporation, which would otherwise have been valid if such Bylaws had not been adopted, amended, altered or repealed. The Bylaws or any particular Bylaw provision may fix a greater quorum or voting requirement for shareholders (or voting groups of shareholders) than is required by the FBCA.

 

 

 

 

(2) All corporate powers of the Corporation shall be managed by or under the authority of, and its business and affairs shall be managed under the direction of, the Board of Directors. The Directors need not be shareholders. The Bylaws may: (i) prescribe the number of directors, which number shall not be less than three; (ii) provide for the increase or reduction of the number of directors; and (iii) prescribe the number of directors necessary to constitute a quorum, which number may be less than a majority of the whole Board of Directors, but not less than the number required by the FBCA. Whenever a vacancy occurs on the Board of Directors, including a vacancy resulting from an increase in the number of directors, it may be filled only by the affirmative vote of a majority of the remaining directors, which may be less than a quorum of the Board of Directors.

 

ARTICLE VI

INDEMNIFICATION AND EXPENSE ADVANCEMENT

 

(1) To the fullest extent permissible under the FBCA and other applicable laws, as is in effect on the date hereof and as hereafter may be amended from time to time, a director of the Corporation shall not be liable to the Corporation or its shareholders for monetary damages for breach of fiduciary duty as a director. No amendment to or repeal of this Article VI, Section (1) shall apply to or have any effect on the liability or alleged liability of any director for or with respect to any acts or omission of such director occurring prior to such amendment or repeal. If the FBCA is hereafter amended to authorize corporate action further eliminating or limiting the personal liability of a director, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent then permissible. Any repeal or modification of this Article VI, Section (1) shall adversely affect any right of or protection afforded to a director of the Corporation existing immediately prior to such repeal or modification, or with respect to events occurring prior to such time.

 

(2) (a) Each person (and the heirs, executors or administrators of such person) who was or is a party or is threatened to be made a party to, or is involved in, any threatened, pending, or completed action, suit, or proceeding, whether civil, criminal, administrative, or investigative, whether formal or informal and whether or not such action, suit, or proceeding is brought by or in the right of the Corporation, by reason of the fact that such person is or was a director, officer, employee, or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise, shall be indemnified and held harmless by the Corporation to the fullest extent permitted by the FBCA. The right to indemnification conferred in this Article VI shall also include the right to be paid by the Corporation the expenses incurred in connection with any such proceeding in advance of its final disposition to the fullest extent permitted by the FBCA. The right to indemnification conferred in this Article VI shall be a contract right.

 

(b) The Corporation may, by action of its Board of Directors, provide indemnification and advancement of expenses to such of the directors, officers, employees, and agents of the Corporation to such extent and to such effect as the Board of Directors shall determine to be appropriate and permitted by the FBCA.

 

(3) The Corporation shall have the power to purchase and maintain insurance on behalf of any person who is or was a director, officer, employee, or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise, against any liability asserted against such person and incurred by such person in any such capacity or arising out of such person’s status as such, whether or not the Corporation would have the power to indemnify such person against such liability under the FBCA.

 

(4) The rights and authority conferred in this Article VI shall not be exclusive of any other right which any person may otherwise have or hereafter acquire.

 

 

 

 

ARTICLE VII

REMOVAL OF DIRECTORS

 

A director of the Corporation may be removed from office by the shareholders with or without cause by the affirmative vote, at a special meeting of shareholders held for that purpose, of not less than a majority of the shareholders entitled to vote for the election of directors (or, if a director is elected by a voting group of shareholders, a majority of the shareholders entitled to vote for the election of such director). Upon any such removal, the term of the director who shall have been so removed shall forthwith terminate and there shall be a vacancy on the Board of Directors to be filled in such manner as shall be provided herein and by the Bylaws of the Corporation.

 

ARTICLE VIII

SPECIAL MEETING

 

A special meeting of shareholders of the Corporation shall be held (a) on the call of its Board of Directors or the person or persons authorized to do so by the Bylaws, or (b) if the holders of not less than 50% of all the votes entitled to be cast on any issue proposed to be considered at the proposed special meeting sign, date, and deliver to the Corporation’s Secretary one or more written demands for the meeting describing the purpose or purposes for which it is to be held. 

ARTICLE IX

AMENDMENTS

 

Subject to the provisions of Article IV and Article X hereof, the Corporation reserves the right to amend, alter, change, or repeal any provision contained in these Amended and Restated Articles of Incorporation in the manner now or hereafter prescribed by statute and, with the sole exception of those rights and powers conferred under Article V hereof, all rights and powers conferred herein upon the shareholders, directors, and officers, if any, are granted subject to this reservation.

 

ARTICLE X

ACTION BY SHAREHOLDERS

 

Any action to be taken at any annual or special meeting of the shareholders may be taken without a meeting, without prior notice, and without a vote if a consent (or consents) in writing setting forth the action to be so taken, shall be signed by the holders of outstanding capital stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered (by hand or by certified or registered mail, return receipt requested) to the Corporation by delivery to its registered office in the State of Florida, its principal place of business, or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of shareholders are recorded. Every written consent shall bear the date of signature of each shareholder who signs the consent, and no written consent shall be effective to take the corporate action referred to therein unless, within sixty (60) days after the earliest dated consent delivered in the manner required by this Article X, written consents signed by a sufficient number of holders to take action are delivered to the Corporation as aforesaid. Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall, to the extent required by applicable law, be given to those shareholders who have not consented in writing, and who, if the action had been taken at a meeting, would have been entitled to notice of the meeting if the record date for notice of such meeting had been the date that written consents signed by a sufficient number of shareholders to take the action were delivered to the Corporation.

 

The Corporation does hereby certify that pursuant to Sections 607.0821, 607.1001, 607.1003, 607.1004, and 607.1007 of the FBCA, the foregoing amendment and restatement was approved by the Board of Directors of the Corporation pursuant to that certain Written Consent of the Board of Directors of the Corporation, effective as of January [__], 2022, and was adopted by the shareholders at a Special Meeting of Shareholders on January [__], 2022.

 

[Remainder of Page Left Blank – Signature Page Follows]

 

 

 

 

IN WITNESS HEREOF, these Amended and Restated Articles of Incorporation have been executed by a duly authorized officer of the Corporation on January [__], 2022.

 

  /s/ Harrison Gross
  Harrison Gross, Chief Executive Officer

 

[Signature Page to Amended and Restated Articles of Incorporation]

 

 

 

  

Registered agent’s acceptance:

 

Having been named as registered agent and to accept service of process for the above stated corporation at the place designated in this application, I hereby accept the appointment as registered agent and agree to act in this capacity. I further agree to comply with the provisions of all statutes relative to the proper and complete performance of my duties, and I am familiar with and accept the obligations of my position as registered agent.

 

Corporation Service Company

 

By:____________________________________________________

Harrison Gross

 

 

 

[Signature Page to Amended and Restated Articles of Incorporation]

 

 

 

Exhibit 3.3

 

BYLAWS
OF

INNOVATIVE EYEWEAR INC

 

ARTICLE I
SHAREHOLDERS

 

Section 1. Annual Meeting. An annual meeting shall be held once each calendar year for the purpose of electing directors and for the transaction of such other business as may properly come before the meeting. The annual meeting shall be held at the time and place designated by the Board of Directors from time to time.

 

Section 2. Special Meetings. Special meetings of the shareholders may be requested by the President, the Board of Directors, or the holders of a majority of the outstanding voting shares.

 

Section 3. Notice. Written notice of all shareholder meetings, whether regular or special meetings, shall be provided under this section or as otherwise required by law. The Notice shall state the place, date, and hour of meeting, and if for a special meeting, the purpose of the meeting. Such notice shall be mailed to all shareholders of record at the address shown on the corporate books, at least 10 days prior to the meeting. Such notice shall be deemed effective when deposited in ordinary U.S. mail, properly addressed, with postage prepaid.

 

Section 4. Place of Meeting. Shareholders’ meetings shall be held at the corporation’s principal place of business unless otherwise stated in the notice. Shareholders of any class or series may participate in any meeting of shareholders by means of remote communication to the extent the Board of Directors authorizes such participation for such class or series. Participation by means of remote communication shall be subject to such guidelines and procedures as the Board of Directors adopts. Shareholders participating in a shareholders’ meeting by means of remote communication shall be deemed present and may vote at such a meeting if the corporation has implemented reasonable measures: (1) to verify that each person participating remotely is a shareholder, and (2) to provide such shareholders a reasonable opportunity to participate in the meeting and to vote on matters submitted to the shareholders, including an opportunity to communicate, and to read or hear the proceedings of the meeting, substantially concurrent with such proceedings.

 

Section 5. Quorum. A majority of the outstanding voting shares, whether represented in person or by proxy, shall constitute a quorum at a shareholders’ meeting. In the absence of a quorum, a majority of the represented shares may adjourn the meeting to another time without further notice. If a quorum is represented at an adjourned meeting, any business may be transacted that might have been transacted at the meeting as originally scheduled. The shareholders present at a meeting represented by a quorum may continue to transact business until adjournment, even if the withdrawal of some shareholders results in representation of less than a quorum.

 

Section 6. Informal Action. Any action required to be taken, or which may be taken, at a shareholders meeting, may be taken without a meeting and without prior notice if a consent in writing, setting forth the action so taken, is signed by the shareholders who own all of the shares entitled to vote with respect to the subject matter of the vote.

 

 

 

 

ARTICLE II
DIRECTORS

 

Section 1. Number of Directors. The corporation shall be managed by a Board of Directors consisting of 1 or more director(s).

 

Section 2. Election and Term of Office. The directors shall be elected at the annual shareholders’ meeting. Each director shall serve a term of 5 years year(s), or until a successor has been elected and qualified.

 

Section 3. Quorum. A majority of directors shall constitute a quorum.

 

Section 4. Adverse Interest. In the determination of a quorum of the directors, or in voting, the disclosed adverse interest of a director shall not disqualify the director or invalidate his or her vote.

 

Section 5. Regular Meeting. An annual meeting shall be held, without notice, immediately following and at the same place as the annual meeting of the shareholders. The Board of Directors may provide, by resolution, for additional regular meetings without notice other than the notice provided by the resolution.

 

Section 6. Special Meeting. Special meetings may be requested by the President, Vice- President, Secretary, or any two directors by providing five days’ written notice by ordinary United States mail or email, effective when mailed. Minutes of the meeting shall be sent to the Board of Directors within two weeks after the meeting.

 

Section 7. Procedures. The vote of a majority of the directors present at a properly called meeting at which a quorum is present shall be the act of the Board of Directors, unless the vote of a greater number is required by law or by these by-laws for a particular resolution. A director of the corporation who is present at a meeting of the Board of Directors at which action on any corporate matter is taken shall be presumed to have assented to the action taken unless their dissent shall be entered in the minutes of the meeting. The Board shall keep written minutes of its proceedings in its permanent records.

 

If authorized by the governing body, any requirement of a written ballot shall be satisfied by a ballot submitted by electronic transmission, provided that any such electronic transmission must either set forth or be submitted with information from which it can be determined that the electronic transmission was authorized by the member or proxy holder.

 

Section 8. Informal Action. Any action required to be taken at a meeting of directors, or any action which may be taken at a meeting of directors or of a committee of directors, may be taken without a meeting if a consent in writing setting forth the action so taken, is signed by all of the directors or all of the members of the committee of directors, as the case may be.

 

2

 

 

Section 9. Removal / Vacancies. A director shall be subject to removal, with or without cause, at a meeting of the shareholders called for that purpose. Any vacancy that occurs on the Board of Directors, whether by death, resignation, removal or any other cause, may be filled by the remaining directors. A director elected to fill a vacancy shall serve the remaining term of his or her predecessor, or until a successor has been elected and qualified.

 

Section 10. Resignation. Any director may resign effective upon giving written notice to the chairperson of the board, the president, the secretary or the Board of Directors of the corporation, unless the notice specifies a later time for the effectiveness of such resignation. If the resignation is effective at a future time, a successor may be elected to take office when the resignation becomes effective.

 

Section 11. Committees. To the extent permitted by law, the Board of Directors may appoint from its members a committee or committees, temporary or permanent, and designate the duties, powers and authorities of such committees.

 

ARTICLE III
OFFICERS

 

Section 1. Number of Officers. The officers of the corporation shall be a President, and a Secretary.

 

President/Chairman. The President shall be the chief executive officer and shall preside at all meetings of the Board of Directors and its Executive Committee, if such a committee is created by the Board.

 

Secretary. The Secretary shall give notice of all meetings of the Board of Directors and Executive Committee, if any, shall keep an accurate list of the directors, and shall have the authority to certify any records, or copies of records, as the official records of the corporation. The Secretary shall maintain the minutes of the Board of Directors’ meetings and all committee meetings.

 

Section 2. Election and Term of Office. The officers shall be elected annually by the Board of Directors at the first meeting of the Board of Directors, immediately following the annual meeting of the shareholders. Each officer shall serve a one year term or until a successor has been elected and qualified.

 

Section 3. Removal or Vacancy. The Board of Directors shall have the power to remove an officer or agent of the corporation. Any vacancy that occurs for any reason may be filled by the Board of Directors.

 

3

 

 

ARTICLE IV

CORPORATE SEAL, EXECUTION OF INSTRUMENTS

 

The corporation shall not have a corporate seal. All instruments that are executed on behalf of the corporation which are acknowledged and which affect an interest in real estate shall be executed by the President or any Vice-President and the Secretary or Treasurer. All other instruments executed by the corporation, including a release of mortgage or lien, may be executed by the President or any Vice-President. Notwithstanding the preceding provisions of this section, any written instrument may be executed by any officer(s) or agent(s) that are specifically designated by resolution of the Board of Directors.

 

ARTICLE V
AMENDMENT TO BYLAWS

 

The bylaws may be amended, altered, or repealed by the Board of Directors or the shareholders by a majority of a quorum vote at any regular or special meeting; provided however, that the shareholders may from time to time specify particular provisions of the bylaws which shall not be amended or repealed by the Board of Directors.

 

ARTICLE VI
INDEMNIFICATION

 

Any director or officer who is involved in litigation by reason of his or her position as a director or officer of this corporation shall be indemnified and held harmless by the corporation to the fullest extent authorized by law as it now exists or may subsequently be amended (but, in the case of any such amendment, only to the extent that such amendment permits the corporation to provide broader indemnification rights).

 

ARTICLE VII
STOCK CERTIFICATES

 

The corporation may issue shares of the corporation’s stock without certificates. Within a reasonable time after the issue or transfer of shares without certificates, the corporation shall send the shareholder a written statement of the information that is required by law to be on the certificates. Upon written request to the corporate secretary by a holder of such shares, the secretary shall provide a certificate in the form prescribed by the directors.

 

ARTICLE VIII
DISSOLUTION

 

The corporation may be dissolved only with authorization of its Board of Directors given at a special meeting called for that purpose, and with the subsequent approval by no less than two- thirds (2/3) vote of the members.

 

4

 

 

Certification

 

Konrad Dabrowski, Secretary of Innovative Eyewear Inc hereby certifies that the foregoing is a true and correct copy of the bylaws of the above-named corporation, duly adopted by the initial Board of Directors on April 15, 2020.

 

This Corporate Bylaws is executed and agreed to by:
Harrison Gross

 

Harrison Gross
cgross@tekcapital.com
April 14, 2020 at 01:41 pm

Recorded at IP 70.143.116.1

 

5

 

Exhibit 3.4

 

Second AMENDED AND RESTATED BYLAWS
OF
INNOVATIVE EYEWEAR, INC.

 

January [__], 2021

 

ARTICLE I
SHAREHOLDERS

 

SECTION 1. Place of Holding Meeting. The Board of Directors may designate any place, within or without the State of Florida, as the place of meeting for any annual or special meeting of the shareholders. If no designation is made, the place of meeting shall be the principal office of the Corporation.

 

SECTION 2. Quorum.

 

(a) Any number of shareholders, together holding a majority of the votes entitled to be cast by a voting group on a particular matter, represented in person or by proxy at any meeting of shareholders, constitutes a quorum of that voting group for action on that matter, except as may be otherwise provided by law, by the Amended and Restated Articles of Incorporation (as amended from time to time, the “Articles of Incorporation”) or by these Amended and Restated Bylaws. Except as otherwise provided in the Florida Business Corporation Act (the “FBCA”), a majority of the votes entitled to be cast on a matter shall constitute a quorum of the voting group for action on that matter. At any meeting of shareholders for the election of directors at which any voting group shall have a separate vote, the absence of a quorum of any other voting group shall not prevent the election of the directors to be elected by such voting group.

 

(b) Once a share is represented for any purpose at a meeting, other than for the purpose of objecting to holding the meeting or transacting business at the meeting, it is considered present for purposes of determining whether a quorum exists for the remainder of the meeting and for any adjournment of that meeting, unless a new record date is or must be set for the adjourned meeting.

 

SECTION 3. Adjournment of Meetings. If less than a quorum shall be in attendance at the time for which the meeting shall have been called, the meeting may be adjourned from time to time by a majority vote of the shares represented, and who would be entitled to vote at the meeting if a quorum were present, without any notice other than by announcement at the meeting. Any meeting at which a quorum is present may also be adjourned, in like manner, for such time, or upon such call, as may be determined by vote. At any such adjourned meeting at which a quorum may be present, any business may be transacted which might have been transacted at the meeting as originally called.

 

SECTION 4. Annual Election of Directors. The annual meeting of shareholders for the election of directors and the transaction of other business shall be held on the date and at the time fixed by resolution of the Board of Directors. If the election of directors does not occur on the day designated herein for the annual meeting or at an adjournment thereof, the Board of Directors shall cause a meeting of the shareholders for the election of a Board of Directors to be held as soon thereafter as may be convenient. At such meeting, the shareholders may elect the directors and transact other business with the same force and effect as at an annual meeting duly called and held. The directors shall hold office until the next annual election and until their successors are respectively elected and qualified, or until any such director’s earlier death, resignation, or removal; providedhowever, in the event that any voting group has the right to elect directors separately as a voting group and such right shall have vested, such right may be exercised as provided in the Articles of Incorporation and any voting or similar agreement entered into by and among a group of shareholders. The Secretary shall prepare, or cause to be prepared, at least ten (10) days before every election, a complete list of shareholders entitled to vote, arranged in alphabetical order, and such list shall be kept in a file at the principal office of the corporation for such ten (10) days, for the examination of any shareholder at any time during the usual business hours, and shall be produced and kept at the time and place of election during the whole time thereof, subject to the inspection of any shareholder who may be present.

 

SECTION 5. Voting at Shareholders’ Meeting. Unless otherwise provided in the Articles of Incorporation or these Amended and Restated Bylaws, and subject to the provisions of the FBCA, each shareholder entitled to vote shall have one (1) vote to each share of voting stock registered in its name on the books of the corporation.

 

 

 

 

SECTION 6. Notice of Shareholders’ Meetings.

 

(a) Content and Delivery. Written notice, stating the date, time and place of the meeting and, in the case of a special meeting, stating also a description of the purpose or purposes for which the meeting is called, shall be delivered by or at the direction of the President or the Secretary, or the officer or persons duly calling the meeting, to each shareholder of record entitled to vote at such meeting and to such other persons as required by the FBCA. Such notice may be delivered in person, by mail, or other method of delivery, or by e-mail or other electronic transmission if authorized by a shareholder, at least ten (10) but not more than sixty (60) days before the date of the meeting.

 

(b) Written Waiver of Notice. A written waiver of such notice signed by the person entitled thereto, whether before or after the date and time stated therein, shall be deemed equivalent to notice. The waiver, in writing and signed by the shareholder entitled to the notice, shall be delivered to the Corporation for inclusion in the minutes or filing with the corporate records.

 

(c) Waiver by Attendance. Attendance of a shareholder, whether in person or by proxy, at a meeting shall constitute a waiver of notice of such meeting, except when the person attends the meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any business because the meeting is not lawfully called or convened. Any notice or waiver of notice shall also satisfy the requirements of Article VISection 2 below.

 

SECTION 7. Nomination of Directors.

 

(a) Only persons who are nominated in accordance with the procedures set forth in these Amended and Restated Bylaws shall be eligible to serve as directors. Nominations of persons for election to the Board of Directors of the Corporation may be made at a meeting of shareholders (1) by or at the direction of the Board of Directors or (2) by any shareholder (or group of shareholders as provided in this Section 7(b) below) of the Corporation who is a shareholder of record at the time of giving of notice provided for in this Section 7, who shall be entitled to vote for the election of directors at the meeting, and who complies with the notice procedures set forth in this Section 7. Such nominations, other than those made by or at the direction of the Board of Directors, shall be made pursuant to timely notice in writing to the Secretary of the Corporation. To be timely, a shareholder’s notice (other than a notice submitted in order to include a Shareholder Nominee (as defined below) in the Corporation’s proxy materials, as defined and described in Section 7(b) below) shall be delivered to or mailed and received at the principal executive office of the Corporation not less than one hundred twenty (120) days prior to the first anniversary of the preceding year’s annual meeting; providedhowever, that in the event no annual meeting was held in the previous year or the date of the annual meeting has been changed by more than thirty (30) days, notice by the shareholder to be timely must be so received not later than the close of business on the later of one hundred twenty (120) days in advance of such annual meeting or ten (10) days following the day on which notice or public disclosure of the date of the meeting is first made by the Corporation.

 

Such shareholder’s notice shall set forth: (a) as to each person whom the shareholder proposes to nominate for election or reelection as a director, (i) all information relating to such person that is required to be disclosed in solicitations of proxies for election of directors, or is otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (including such person’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected); and (ii) a description of all direct and indirect compensation and other material monetary agreements, arrangements and understandings during the past three years, and any other material relationships, between or among such shareholder and the beneficial owner, if any, on whose behalf the nomination is made, and their respective affiliates and associates, or others acting in concert therewith, on the one hand, and each proposed nominee, and his or her respective affiliates and associates, or others acting in concert therewith, on the other hand, including all information that would be required to be disclosed pursuant to Rule 404 of Regulation S-K if the shareholder making the nomination and any beneficial owner on whose behalf the nomination is made, if any, or any affiliate or associate thereof or person acting in concert therewith, were the “registrant” for purposes of such rule and the nominee were a director or executive officer of such registrant; and (b) as to the shareholder giving the notice (1) the name and address, as they appear on the Corporation’s books, of such shareholder and such beneficial owner, and (2) the class and number of shares of the Corporation’s stock which are, directly or indirectly, owned by such shareholder and such beneficial owner.

 

At the request of the Board of Directors, any person nominated by the Board of Directors for election as a director shall furnish to the Secretary of the Corporation that information required to be set forth in a shareholder’s notice of nomination which pertains to the nominee. No person shall be eligible to serve as a director of the Corporation unless nominated in accordance with the procedures set forth in this Section 7.

 

2

 

 

(b) The corporation shall include in its proxy statement for an annual meeting of shareholders the name of any person nominated for election to the Board of Directors (the “Shareholder Nominee”) by a shareholder or group of not more than ten (10) shareholders that satisfies the requirements of this Section 7(b) (the “Eligible Shareholder”), together with the Required Information (defined below), who expressly elects at the time of providing the notice required by this Section 7(b) to have the Shareholder Nominee included in the Corporation’s proxy materials pursuant to this Section 7. Such notice shall consist of a copy of Schedule 14N filed with the Securities and Exchange Commission in accordance with Rule 14a-18 of the Exchange Act, along with any additional information as required to be delivered to the Corporation by this Section 7(b) (all such information collectively referred to as the “Notice”), and such Notice shall be delivered to the Corporation in accordance with the procedures and at the times set forth in this Section 7(b).

 

(i) Notwithstanding the procedures set forth in Section 7(a), the Notice, to be timely, must be received at the principal executive office of the Corporation not later than the close of business on the one hundred fiftieth (150th) day prior to the first anniversary of the preceding year’s annual meeting; providedhowever, that in the event that the date of the annual meeting is more than thirty (30) days before or more than sixty (60) days after such anniversary date, the Notice by the shareholder to be timely must be so delivered not later than the close of business on the later of the one hundred fiftieth (150th) day prior to the date of such annual meeting or, if the first public announcement of the date of such annual meeting is less than one hundred twenty (120) days prior to the date of such annual meeting, the tenth (10th) day following the day on which public announcement of the date of such meeting is first made by the Corporation. In no event shall any adjournment or postponement of a shareholders’ meeting, or the public announcement thereof, commence a new time period for the giving of a shareholder’s Notice as described above, except as required by law.

 

(ii) For purposes of this Section 7(b), the “Required Information” that the corporation will include in its proxy statement consists of: (A) the information concerning the Shareholder Nominee and the Eligible Shareholder that is required to be disclosed in a proxy statement of the Corporation by the rules and regulations of the Exchange Act; and (B) if the Eligible Shareholder so elects, a Statement (as defined below).

 

(iii) The Corporation shall not be required to include, pursuant to this Section 7(b), any Shareholder Nominee in its proxy materials for any meeting of shareholders for which the Secretary of the Corporation receives a notice that the nominating shareholder has nominated a person for election to the Board of Directors pursuant to the advance notice requirements for shareholder nominees for director set forth in Section 7(a) of these Bylaws.

 

(iv) The maximum number of Shareholder Nominees appearing in the Corporation’s proxy materials with respect to an annual meeting of shareholders shall not exceed 20% of the number of directors in office as of the last day on which the Notice may be delivered, or if such amount is not a whole number, the closest whole number below 20%. Shareholder Nominees that were submitted by an Eligible Shareholder for inclusion in proxy materials of the Corporation pursuant to this Section 7(b), but either are subsequently withdrawn, or that the Board of Directors itself determines to nominate for election, shall be included in this maximum number. In the event that the number of Shareholder Nominees submitted by Eligible Shareholders pursuant to this Section 7(b) exceeds this maximum number, each Eligible Shareholder will select one Shareholder Nominee for inclusion in the Corporation’s proxy materials until the maximum number is reached, going in order of the amount of shares of common stock of the Corporation (largest to smallest) disclosed as owned by each Eligible Shareholder in the Notice. If the maximum number is not reached after each Eligible Shareholder has selected one Shareholder Nominee, this selection process will continue as many times as necessary, following the same order each time, until the maximum number is reached.

 

3

 

 

(v) For purposes of this Section 7(b), an Eligible Shareholder shall be deemed to “own” only those outstanding shares of common stock of the Corporation as to which the shareholder possesses both: (1) the full voting and investment rights pertaining to the shares and (2) the full economic interest in (including the opportunity for profit and risk of loss on) such shares; providedhowever, that the number of shares calculated in accordance with clauses (1) and (2) shall not include any shares (A) sold by such shareholder or any of its affiliates in any transaction that has not been settled or closed, including short sales, (B) borrowed, for purposes other than a short sale, by such shareholder or any of its affiliates for any purposes or purchased by such shareholder or any of its affiliates pursuant to an agreement to resell, or (C) subject to any option, warrant, forward contract, swap, contract of sale, other derivative or similar agreement entered into by such shareholder or any of its affiliates, whether any such instrument or agreement is to be settled with shares or with cash based on the notional amount or value of shares of outstanding common stock of the corporation, in any such case which instrument or agreement has, or is intended to have, the purpose or effect of (x) reducing in any manner, to any extent or at any time in the future, such shareholder’s or its affiliates’ full right to vote or direct the voting of any such shares, and/or (y) hedging, offsetting or altering to any degree gain or loss arising from the full economic ownership of such shares by such shareholder or affiliate. A shareholder shall “own” shares held in the name of a nominee or other intermediary so long as the shareholder retains the right to instruct how the shares are voted with respect to the election of directors and possesses the full economic interest in the shares. A shareholder’s ownership of shares shall be deemed to continue during any period in which the shareholder has delegated any voting power by means of a proxy, power of attorney or other instrument or arrangement which is revocable at any time by the shareholder. The terms “owned,” “owning” and other variations of the word “own” shall have correlative meanings. Whether outstanding shares of the common stock of the Corporation are “owned” for these purposes shall be determined by the Board of Directors.

 

(vi) An Eligible Shareholder must have owned (as defined in Section 7(b)(v) above) 3% or more of the Corporation’s issued and outstanding common stock continuously for at least three (3) years (the “Required Shares”) as of both the date the Notice is required to be received by the Corporation in accordance with this Section 7(b) and the record date for determining shareholders entitled to vote at the annual meeting, and must continue to hold the Required Shares through the meeting date; providedhowever, that up to, but not more than, ten (10) individual shareholders who otherwise meet all of the requirements to be an Eligible Shareholder may aggregate their shareholdings in order to meet the 3% minimum ownership percentage prong, but not the holding period prong, of the Required Shares definition. Within the time period specified in this Section 7(b) for delivery of the Notice, an Eligible Shareholder (including each of the individual members of a group of Eligible Shareholders) must provide the following information in writing to the Secretary of the Corporation: (1) one or more written statements from the record holder of the shares (and from each intermediary through which the shares are or have been held during the requisite three-year holding period) verifying that, as of a date within three (3) days prior to the date the Notice is received by the Corporation, the Eligible Shareholder owns, and has owned continuously for the preceding three (3) years, the Required Shares, and the Eligible Shareholder’s agreement to provide, within five (5) business days after the record date for the annual meeting, written statements from the record holder and intermediaries verifying the Eligible Shareholder’s continuous ownership of the Required Shares through the record date, along with a written statement that the Eligible Shareholder will continue to hold the Required Shares through the meeting date; (2) the information required to be set forth in the Notice, together with the written consent of each Shareholder Nominee to being named in the proxy statement as a nominee and to serving as a director if elected; (3) a representation that the Eligible Shareholder (A) acquired the Required Shares in the ordinary course of business and not with the intent to change or influence control of the Corporation, and does not presently have such intent, (B) has not nominated and will not nominate for election to the Board of Directors at the annual meeting any person other than the Shareholder Nominee(s) being nominated pursuant to this Section 7(b), (C) has not engaged and will not engage in, and has not and will not be a “participant” in another person’s, “solicitation” within the meaning of Rule 14a-1(l) under the Exchange Act in support of the election of any individual as a director at the annual meeting other than its Shareholder Nominee or a nominee of the Board of Directors, and (D) will not distribute to any shareholder any proxy card for the annual meeting other than the form distributed by the Corporation; and (4) an undertaking that the Eligible Shareholder agrees to (A) assume all liability stemming from any legal or regulatory violation arising out of the Eligible Shareholder’s communications with the shareholders of the Corporation or out of the information that the Eligible Shareholder provided to the Corporation, (B) comply with all other laws and regulations applicable to any solicitation in connection with the annual meeting, and (C) provide to the corporation prior to the election of directors such additional information as requested with respect thereto. The inspector of election shall not give effect to the Eligible Shareholder’s votes with respect to the election of directors if the Eligible Shareholder does not comply with each of the representations set forth in clause (3) above.

 

(vii) The Eligible Shareholder may provide to the Secretary of the Corporation, at the time the information required by this Section 7(b) is provided, a written statement for inclusion in the proxy statement for the Corporation’s annual meeting, not to exceed 500 words, in support of the Shareholder Nominee’s candidacy (the “Statement”). Notwithstanding anything to the contrary contained in this Section 7(b), the Corporation may omit from its proxy materials any information or Statement that it, in good faith, believes is materially false or misleading, omits to state any material fact, or would violate any applicable law or regulation.

 

4

 

 

(c) The Corporation may request such additional information as necessary to permit the Board of Directors to determine if each Shareholder Nominee is independent under the listing standards of the principal U.S. exchange upon which the Corporation’s Common Stock is listed, any applicable rules of the Securities and Exchange Commission and any publicly disclosed standards used by the Board of Directors in determining and disclosing the independence of its directors. If the Board of Directors determines in good faith that the Shareholder Nominee is not independent under any of these standards, the Shareholder Nominee will not be eligible for inclusion in the Corporation’s proxy materials.

 

(d) Any Shareholder Nominee who is included in the Corporation’s proxy materials for a particular annual meeting of shareholders but either (1) withdraws from or becomes ineligible or unavailable for election at the annual meeting, or (2) does not receive at least 25% of the votes cast in favor of the election of such Shareholder Nominee, will be ineligible to be a Shareholder Nominee pursuant to this Section 7(b) for the next two (2) annual meetings of the Corporation.

 

(e) Notwithstanding anything in Section 7(a) or Section 7(b) to the contrary, in the event that the number of directors to be elected to the Board of Directors is increased by the Board of Directors, and there is no public announcement by the Corporation naming all of the nominees for director or specifying the size of the increased Board of Directors at least one hundred thirty (130) days prior to the first (1st) anniversary of the preceding year’s annual meeting, a shareholder’s notice required by Section 7(a) or Section 7(b) shall also be considered timely, but only with respect to nominees for any new positions created by such increase (and with respect to Section 7(b), only to the extent the increase in the size of the board increases the number of nominees permitted under Section 7(b)(iv)), if it shall be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the tenth (10th) business day following the day on which such public announcement is first made by the Corporation.

 

(f) The Chairman of the meeting shall have the power to determine and declare to the meeting whether a nomination was made in accordance with the procedures prescribed by these Amended and Restated Bylaws, and if the Chairman should so determine that such nomination was not made in compliance with these Amended and Restated Bylaws, declare to the meeting that no action shall be taken on such nomination and such defective nomination shall be disregarded. Notwithstanding the foregoing provisions of this Section, a shareholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth in this Section.

 

SECTION 8. Notice of Business. At any meeting of the shareholders, only such business shall be conducted as shall have been brought before the meeting: (a) by or at the direction of the Board of Directors; or (b) by any shareholder of the Corporation who is a shareholder of record at the time of giving of the notice provided for in this Section 8 and at the time of the meeting, who shall be entitled to vote at such meeting and who complies with the notice procedures set forth in this Section 8. The immediately preceding sentence shall be the exclusive means for a shareholder to make business proposals (other than matters properly brought under Rule 14a-8 under the Exchange Act and included in the Corporation’s notice of meeting) before a meeting of shareholders. For business to be properly brought before a shareholder meeting by a shareholder, the shareholder must have given timely notice thereof in writing to the Secretary of the Corporation in accordance with the timeliness provisions of Section 7 above. A shareholder’s notice to the Secretary shall set forth as to each matter the shareholder proposes to bring before the meeting: (a) brief description of the business desired to be brought before the meeting and the reasons for conducting such business at the meeting, (b) the name and address, as they appear on the Corporation’s books, of the shareholder proposing such business, (c) the class and number of shares of the Corporation which are beneficially owned by the shareholder and (d) any material interest of the shareholder in such business. The Chairman of the meeting shall have the power to determine and declare to the meeting whether a proposal of business was made in accordance with the procedures prescribed by these Amended and Restated Bylaws, and if the Chairman should so determine that such proposal of business was not made in compliance with these Amended and Restated Bylaws, declare to the meeting that no action shall be taken on such proposal and such defective proposal shall be disregarded. Notwithstanding the foregoing provisions of this Section, a shareholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth in this Section 8.

 

SECTION 9. Organization. At each meeting of shareholders, the Chairman of the board or, in the absence of the Chairman or if a Chairman shall not have been elected, a person appointed by the directors shall act as Chairman of the meeting. The Secretary of the Corporation (or, in the absence or inability to act of the Secretary of the Corporation, the person whom the Chairman of the meeting shall appoint secretary of the meeting) shall act as secretary of the meeting and keep the minutes thereof.

 

5

 

 

SECTION 10. Order of Business. The order of business at all meetings of shareholders, as well as the rules governing such meetings, shall be solely determined by the Chairman of the meeting.

 

ARTICLE II
DIRECTORS

 

SECTION 1. Organization. The Board of Directors may hold a meeting for the purpose of organization and the transaction of other business if a quorum be present, immediately before and/or after the annual meeting of the shareholders and immediately before and/or after any special meeting at which directors are elected. Notice of such meeting need not be given. Such organizational meeting(s) may be held at any other time or place, which shall be specified in a notice given as provided for special meetings of the Board of Directors, or in a consent and waiver of notice thereof signed by all the directors.

 

SECTION 2. Chairman of the Board. At the organizational meeting described in Article IISection 1 or at such other time as the Board of Directors deems appropriate, the Board of Directors shall elect from among its number a Chairman (or person having a similar title) of the Board of Directors, who shall hold office until the next organizational meeting described in Article IISection 1 and until his or her successor is elected and qualified, or until his or her earlier death, resignation, or removal by the Board of Directors with or without cause. The Chairman of the board shall preside at all meetings of the Board of Directors and all meetings of the shareholders. The Chairman of the board shall also exercise such other powers as the Board of Directors may from time to time direct or which may be required by law.

 

SECTION 3. Regular Meetings. Regular meetings of the Board of Directors shall be held on such dates as are designated, from time to time, by the Chairman of the board, and shall be held at the principal office of the Corporation or at such other location, within or without the State of Florida, as the Chairman of the Board of Directors selects. Each regular meeting shall commence at the time designated by the Chairman of the Board of Directors on at least five (5) days’ prior written notice to each director when sent by mail and on at least twenty-four (24) hours’ notice when sent by private express carrier or transmitted by fax, e-mail, or other electronic means.

 

SECTION 4. Special Meetings. Special meetings of the Board of Directors may be called by any director. Written notice of the date, time, place and purposes of each special meeting shall be sent by private express carrier or transmitted by fax, e-mail, or other electronic means to each director at least twenty-four (24) hours prior to such meeting. Notwithstanding the preceding, any meeting of the Board of Directors shall be a legal meeting without any notice thereof if all the members of the Board of Directors shall be present or if all absent members waive notice thereof.

 

SECTION 5. Number; Qualifications; Quorum; Term.

 

(a) The Board of Directors shall consist of not less than three (3) nor more than fifteen (15) members as determined from time to time by resolution of the Board of Directors. As of the date of these Amended and Restated Bylaws, the Board of Directors shall consist of seven (7) directors.

 

(b) Subject to the provisions of the Articles of Incorporation, one-third (1/3) of the total number of directors (but in no event less than two (2) directors) shall constitute a quorum for the transaction of business, but if at any meeting of the Board of Directors there shall be less than a quorum present, a majority of the directors present may adjourn the meeting from time to time without further notice other than by announcement at the meeting, until a quorum shall be present. Any meeting at which a quorum is present may also be adjourned in like manner, for such time or upon such call, as may be determined by vote. At any such adjourned meeting at which a quorum is present, any business may be transacted which might have been transacted at the meeting originally held if a quorum had been present thereat. The directors present at a duly organized meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough directors to leave less than a quorum. The affirmative vote of a majority of the directors present at a meeting at which a quorum is constituted shall be the act of the Board of Directors, unless the Articles of Incorporation or any voting agreement, side letter, or other written agreement entered into by and among the Corporation and any shareholders of the Corporation shall require a vote of a greater number of votes or the affirmative vote of particular directors.

 

6

 

 

(c) Except as otherwise provided in these Amended and Restated Bylaws, directors shall hold office until the next succeeding annual shareholders’ meeting and thereafter until their successors are respectively elected and qualified or until any such director’s earlier death, resignation or removal.

 

SECTION 6. Place of Meetings. The Board of Directors may hold its meetings and keep the books of the Corporation inside or outside of the State of Florida, at any office of the Corporation, or at any other place, as it may determine from time to time by resolution.

 

SECTION 7. Vacancies. Except as otherwise provided in the Articles of Incorporation, any vacancy in the Board of Directors because of death, resignation, retirement, disqualification, removal from office, increase in the number of directors, or any other cause may be filled by a majority of the remaining directors, though less than a quorum, or by a sole remaining director, at any regular or special meeting of the Board of Directors, subject to the terms and conditions of the Articles of Incorporation and any voting agreement, side letter, or other written agreement entered into by and among the Corporation and any shareholders of the Corporation.

 

SECTION 8. Election of Directors; Resignation of Directors.

 

(a) At all meetings of shareholders for the election of directors, each director shall be elected by a plurality of the votes cast by the shares entitled to vote in the election of directors at a meeting at which a quorum is present. Each shareholder who is entitled to vote at an election of directors has the right to vote the number of shares owned by him or her for each director. Shareholders do not have a right to cumulate their votes for directors.

 

(b) Any director of the Corporation may resign at any time by giving written notice to the Chairman of the Board of Directors or to the Secretary of the Corporation. Such resignation shall take effect at the time specified therein. Unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective.

 

(c) To be eligible to be a nominee for election or reelection as a director of the Corporation, a person must deliver (in accordance with the time periods prescribed for delivery of notice under Article ISection 7) to the Secretary at the principal executive office of the Corporation a written agreement (in the form provided by the secretary upon written request) that such person will abide by the requirements of Section 8(c).

 

SECTION 9. Compensation of Directors. The Board of Directors shall have the authority to fix the compensation of directors. In addition, each director shall be entitled to be reimbursed by the Corporation for all reasonable expenses incurred in attending meetings of the Board of Directors or of any committee of which such person is a member. Nothing herein contained shall be construed to preclude any director from serving the Corporation in any other capacity and receiving compensation for such services from the Corporation; providedhowever, that any person who is receiving a stated compensation as an officer of the Corporation for services as such officer shall not receive any additional compensation for services as a director during such period. A director entitled to receive stated compensation for services as director, who shall serve for only a portion of a year, shall be entitled to receive only that portion of the director’s annual stated compensation on which the period of such service during the year bears to the entire year. The annual compensation of directors shall be paid at such times and in such installments as the Board of Directors may determine.

 

SECTION 10. Committees.

 

(a) The Board of Directors shall designate an Audit Committee, a Compensation Committee, and a Nominating and Corporate Governance Committee, and may designate one or more other committees as it may deem advisable, each of which shall have and may exercise the powers and authority of the Board of Directors to the extent provided in the charter of each committee adopted by the Board of Directors in one or more resolutions. The members of the committees, who shall be at least two (2) in number, shall act only as a committee and, except to the extent otherwise set forth in the charter of each committee, the individual members shall have no power as such. Unless the Board of Directors elects a committee chairman, each committee shall elect its own chairman. Subject to the provisions of its charter, each committee shall have full power and authority to make rules for the conduct of its business. The Board of Directors shall have the power at any time to change the membership of committees, fill vacancies, and to abolish any committee other than the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee.

 

7

 

 

(b) The members of each committee shall be elected by the Board of Directors and shall serve until the first meeting of the Board of Directors after the annual meeting of shareholders and until their successors are elected and qualified or until the members’ earlier death, resignation or removal. Vacancies may be filled by the Board of Directors at any meeting. Subject to compliance with the respective committee charters for the Audit, Compensation, and Nominating and Corporate Governance Committees, the Chairman of the Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee to serve for that committee meeting only.

 

(c) The Chairman of the Board of Directors or Chief Executive Officer, the committee chairman, or a majority of any committee may call a meeting of that committee. A quorum of any committee shall consist of a majority of its members, unless otherwise provided by resolution of the Board of Directors. Except to the extent otherwise set forth in the charter of each committee, the majority vote of a quorum shall be required for the transaction of business. The committee may also take action by unanimous written consent of all committee members without a meeting. The chairman of the committee shall give, or cause the Secretary of the Corporation to give, notice of all meetings of the committee by mailing the notice to the members of the committee at least three (3) days before each meeting or by telephoning the members not later than one (1) day before the meeting. The notice shall state the time, date, and place of the meeting. Any notice or waiver of notice shall also satisfy the requirements of Article VISection 2 below. Each committee shall fix its other rules of procedure.

 

(d) No committee of the Board of Directors shall have the power or authority to: (i) approve or recommend to shareholders actions or proposals required by the FBCA to be approved by shareholders; (ii) fill vacancies on the Board of Directors or any committee thereof; (iii) adopt, amend, or repeal these Amended and Restated Bylaws; (iv) authorize or approve the reacquisition of shares unless pursuant to a general formula or method specified by the Board of Directors; or (v) authorize or approve the issuance or sale or contract for the sale of shares, or determine the designation and relative rights, preferences, and limitations of a voting group, except that the Board of Directors may authorize a committee (or a senior executive officer of the corporation) to do so within limits specifically prescribed by the Board of Directors.

 

ARTICLE III
OFFICERS

 

SECTION 1. Titles and Election. At the organizational meeting described in Article IISection 1 or at such other time as the Board of Directors deems appropriate, the Board of Directors may elect one or more persons to serve as a Chairman, Chief Executive Officer, a Vice Chairman, a President, and one or more Vice Presidents, a Secretary, and one or more Assistant Secretaries, and such other officers as the Board of Directors from time to time may deem proper, each of whom need not be directors. Such officers shall hold office until the next annual election of officers and until their successors are respectively elected and qualified, or until their respective earlier death, resignation or removal by the Board of Directors as provided in Article IIISection 8.

 

SECTION 2. Chairman. The Board of Directors shall annually elect one of its own members to be the Chairman of the Board of Directors. The Chairman of the Board (who may also be the Chief Executive Officer and President of the Corporation) may also be an executive officer of the Corporation. The Chairman of the Board shall preside at all meetings of the Board of Directors and of the shareholders, except as otherwise provided under these Bylaws.

 

SECTION 3. Chief Executive Officer. Subject to the direction and control of the Board of Directors, the Chief Executive Officer shall have supervisory authority over the policies of the Corporation as well as the management and control of the business and affairs of the Corporation.

 

SECTION 4. Vice Chairman. The Vice Chairman shall have such duties and responsibilities relating to the management of the Corporation as may be defined and designated by the Board of Directors. If the Chairman is not present, the Vice Chairman shall preside at the meeting of the Board of Directors and of the shareholders, except as otherwise provided under these Bylaws.

 

SECTION 5. President. The President shall have responsibility for the management of the operating businesses of the Corporation and shall do and perform all acts incident to the office of President or which are authorized by the Board of Directors, or as may be required by law. The Chief Executive Officer may also serve in the capacity of the President.

 

8

 

 

SECTION 6. Vice President(s). In the absence of the President or in the event of the President’s death, inability or refusal to act, or in the event for any reason it shall be impracticable for the President to act personally, the Vice President, if any (or in the event there be more than one Vice President, the Vice Presidents in the order designated by the Board of Directors, or in the absence of any designation, then in the order of their election), shall perform the duties of the President, and when so acting, shall have all the powers of and be subject to all the restrictions upon the President. Any Vice President may sign certificates for shares of the Corporation, the issuance of which shall have been authorized by a resolution of the Board of Directors; and shall perform such other duties and have such authority as from time to time may be delegated or assigned to him or her by the Board of Directors. The execution of any instrument of the Corporation by any Vice President shall be conclusive evidence, as to third parties, of his or her authority to act in the stead of the President. The Corporation may have one or more Executive Vice Presidents and one or more Senior Vice Presidents, who shall be Vice Presidents for purposes hereof.

 

SECTION 7. Secretary. The Secretary shall:

 

(a) keep the minutes of meetings of shareholders and of the Board of Directors in books provided for the purpose;

 

(b) see that all notices are duly given in accordance with the provisions of these Amended and Restated Bylaws and as required by law;

 

(c) be custodian of the records and have charge of the seal of the Corporation and see that it is affixed to all stock certificates prior to their issuance and to all documents, the execution of which on behalf of the Corporation under its seal is duly authorized in accordance with the provisions of these Amended and Restated Bylaws;

 

(d) have charge of the stock books of the Corporation and keep or cause to be kept the stock and transfer books in such manner as to show at any time the amount of the stock of the Corporation issued and outstanding, the manner in which and the time when such stock was paid for, the names, alphabetically arranged, and the addresses of the holders of record thereof, the number of shares held by each, and the time when each became such holder of record; exhibit or cause to be exhibited at all reasonable times to any director, upon application, the original or duplicate stock ledger;

 

(e) see that the books, reports, statements, certificates, and all other documents and records required by law are properly kept, executed, and filed; and

 

(f) in general, perform all duties incident to the office of the Secretary, and such other duties as from time to time may be assigned by the Board of Directors.

 

SECTION 8. Treasurer. The Treasurer shall: (a) have charge and custody of and be responsible for all funds and securities of the Corporation; (b) maintain appropriate accounting records; (c) receive and give receipts for moneys due and payable to the Corporation from any source whatsoever, and deposit all such moneys in the name of the Corporation in such banks, trust companies, or other depositories as shall be selected in accordance with the provisions of these Bylaws; and (d) in general perform all of the duties incident to the office of the Treasurer and have such other duties and exercise such other authority as from time to time may be delegated or assigned by the President or by the Board of Directors. If required by the Board of Directors, the Treasurer shall give a bond for the faithful discharge of his or her duties in such sum and with such surety or sureties as the Board of Directors shall determine.

 

SECTION 9. Assistant Secretaries and Assistant Treasurers. There shall be such number of Assistant Secretaries and Assistant Treasurers as the Board of Directors may from time to time authorize. The Assistant Secretaries and Assistant Treasurers, in general, shall perform such duties and have such authority as shall from time to time be delegated or assigned to them by the Secretary or the Treasurer, respectively, or by the President or the Board of Directors.

 

SECTION 10. Resignation and Removal of Officers. Any officer of the Corporation may resign at any time by giving written notice to the Chairman of the Board of Directors or to the Secretary. Such resignation shall take effect when the notice is so delivered unless the notice specifies a later effective date, and unless otherwise specified therein the acceptance of such resignation shall not be necessary to make it effective. Any officer may be removed summarily at any time, with or without cause, by vote of a majority of the Board of Directors, subject to the terms and conditions of the Articles of Incorporation and any voting agreement, side letter, or other written agreement entered into by and among the corporation and any of its shareholders.

 

9

 

 

SECTION 11. Salaries. The salaries of officers shall be fixed from time to time by the Board of Directors or a board committee authorized by the Board of Directors. The Board of Directors or authorized committee may authorize and empower the Chief Executive Officer, President or any Vice President of the Corporation designated by the Board of Directors or by the authorized committee to fix the salaries of all officers of the Corporation who are not directors of the Corporation. No officer shall be prevented from receiving a salary by reason of the fact that such officer is also a director of the Corporation.

 

ARTICLE IV
CAPITAL STOCK

 

SECTION 1. Issue of Stock With or Without Certificates. The Board of Directors may authorize the issuance of some or all of the shares of any or all of the Corporation’s classes or series of stock without certificates. Certificates for those shares of the capital stock of the Corporation that are represented by certificates shall be in such forms as shall be approved by the Board of Directors. Each holder of shares represented by certificates shall be entitled to have the certificate for such shares issued under the seal of the Corporation, signed by the Chairman, President or a Vice President and also by the Secretary or an Assistant Secretary; providedhowever, that where a certificate is countersigned by a transfer agent, other than the Corporation or its employee, or by a registrar, other than the Corporation or its employee, the Corporate seal and any other signature on such certificate may be a facsimile, engraved, stamped, or printed. In case any officer, transfer agent, or registrar of the Corporation who shall have signed, or whose facsimile signature shall have been used on any such certificate, shall cease to be such officer, transfer agent or registrar, whether because of death, resignation, or otherwise, before such certificate shall have been delivered by the Corporation, such certificate shall nevertheless be deemed to have been adopted by the Corporation and may be issued and delivered as though the person who signed such certificate or whose facsimile signature shall have been used thereon had not ceased to be such officer, transfer agent or registrar.

 

SECTION 2. Transfer of Shares. Subject to the terms and conditions of the Articles of Incorporation and any voting agreement, side letter, or other written agreement entered into by and among the Corporation and any of its shareholders, the shares of the Corporation shall be transferable upon its books by the holders thereof in person or by their duly authorized attorneys or legal representatives, and upon such transfer of any shares represented by certificates, the old certificates for such shares shall be surrendered to the Corporation by the delivery thereof to the person in charge of the shares and transfer books and ledgers, or to such other person as the Board of Directors may designate, by whom they shall be canceled, and new certificates (or an appropriate entry in respect of shares without certificates) shall thereupon be issued for the shares so transferred to the person entitled thereto. A record shall be made of each transfer and whenever a transfer shall be made for collateral security, and not absolutely, it shall be so expressed in the entry of the transfer.

 

SECTION 3. Lost Certificates. Any person claiming a certificate representing shares to be lost or destroyed shall make an affidavit or affirmation of that fact, and if requested to do so by the Board of Directors or the Secretary of the Corporation, shall advertise such fact in such manner as the Board of Directors or the Secretary may require, and shall give to the corporation, its transfer agent and registrar, if any, a bond or indemnity in such sum as the Board of Directors or Secretary may direct, but not less than double the value of the shares represented by such certificate, in form satisfactory to the Board of Directors and to the transfer agent and registrar of the Corporation, if any, and with or without sureties as the Board of Directors or Secretary with the approval of the transfer agent and registrar, if any, may prescribe; whereupon the Chairman, President or a Vice President and the Secretary or an Assistant Secretary may cause to be issued a new certificate of the same tenor (or cause an appropriate entry to be made in respect of shares without certificates) and for the same number of shares as the one alleged to have been lost or destroyed.

 

SECTION 4. Rules as to Issue of Shares. The Board of Directors shall make such rules and regulations as it may deem expedient concerning the issue, transfer, and registration of shares of the Corporation. It may appoint one or more transfer agents and/or registrars of transfer, and may require all certificates to bear the signature of either or both. Each and every person accepting shares from the corporation therein shall furnish the Corporation with a written statement of the residence or post office address of that person, and in the event of changing such residence shall advise the corporation of such new address.

 

SECTION 5. Holder of Record Deemed Holder in Fact. The Board of Directors shall be entitled to treat the holder of record of any share or shares as the holder in fact thereof, and accordingly shall not be bound to recognize any equitable or other claim to, or interest in, such share or shares on the part of any other person, whether or not it shall have express or other notice thereof, except as expressly provided by law.

 

10

 

 

SECTION 6. Closing of Transfer Books or Fixing Record Date. The Board of Directors shall have the power to close the share transfer books of the Corporation for a period not exceeding sixty (60) days preceding the date of any meeting of shareholders or the date for payment of any dividend or the date for the allotment of rights or the date when any change or conversion or exchange of capital stock shall go into effect; providedhowever, that in lieu of closing the share transfer books as aforesaid, the Board of Directors may fix in advance a date, not exceeding sixty (60) days preceding the date of any meeting of shareholders or the date for the payment of any dividend or the date for the allotment of rights or the date when any change or conversion or exchange of capital stock shall go into effect, as a record date for the determination of the shareholders entitled to notice of, and to vote at, any such meeting, or entitled to receive payment of any such dividend, or to any such allotment of rights, or to exercise the rights in respect of any such change, conversion, or exchange of capital stock, and in such case only such shareholders as shall be shareholders of record on the date so fixed shall be entitled to such notice of, and to vote at, such meeting, or to receive payment of such dividend, or to receive such allotment of rights, or to exercise such rights, as the case may be, notwithstanding any transfer of any shares on the books of the corporation after any such record date fixed as aforesaid.

 

ARTICLE V
CONTRACTS, CHECKS, DRAFTS, BANK ACCOUNTS, ETC.

 

SECTION 1. Contracts, Etc.; How Executed. The Board of Directors or such officer or person to whom such power shall be delegated by the Board of Directors by resolution, except as in these Amended and Restated Bylaws otherwise provided, may authorize any officer or officers, agent or agents, either by name or by designation of their respective offices, positions, or class, to enter into any contract or execute and deliver any instrument in the name of and on behalf of the Corporation, and such authority may be general or confined to specific instances.

 

SECTION 2. Loans. No loans shall be contracted on behalf of the Corporation and no negotiable paper shall be issued in its name, unless and except as authorized by the vote of the Board of Directors or by such officer or person to whom such power shall be delegated by the Board of Directors by resolution or by these Amended and Restated Bylaws. When so authorized by the Board of Directors or by such officer or person to whom such power shall be delegated by the Board of Directors by resolution or by these Amended and Restated Bylaws, any officer or agent of the Corporation may obtain loans and advances at any time for the Corporation from any bank, banking firm, trust company, or other institution, or from any firm, corporation, or individual, and for such loans and advances may make, execute and deliver promissory notes, bonds or other evidences of indebtedness of the Corporation, and, when authorized as aforesaid to give security for the payment of any loan, advance, indebtedness or liability of the Corporation, may pledge, hypothecate, or transfer any and all stocks, securities, and other personal property at any time held by the Corporation, and to that end endorse, assign and deliver the same, but only to the extent and in the manner authorized by the Board of Directors or by these Amended and Restated Bylaws. Such authority may be general or confined to specific instances.

 

SECTION 3. Deposits. All funds of the Corporation shall be deposited from time to time to the credit of the Corporation with such banks, banking firms, trust companies, or other depositaries as the Board of Directors may select or as may be selected by any officer or officers, agent or agents of the Corporation to whom such power may be delegated from time to time by the Board of Directors or by these Amended and Restated Bylaws.

 

SECTION 4. Checks, Drafts, Etc. All checks, drafts, or other orders for the payment of money, notes, acceptances, or other evidences of indebtedness issued in the name of the Corporation shall be signed by such officer or officers, agent, or agents of the Corporation and in such manner as shall be determined from time to time by resolution of the Board of Directors or by such officer or person to whom such power of determination shall be delegated by the Board of Directors by resolution or by these Amended and Restated Bylaws. Endorsements for deposit to the credit of the Corporation in any of its authorized depositaries may be made, without any countersignature, by the Chairman of the Board of Directors, President, or any Vice President or by any other officer or agent of the Corporation appointed by any officer of the Corporation to whom the Board of Directors, by resolution, shall have delegated such power of appointment, or by hand-stamped impression in the name of the corporation.

 

SECTION 5. Transaction of Business. The Corporation, or any division or department into which any of the business or operations of the Corporation may have been divided, may transact business and execute contracts under its own Corporate name, its division, or department name, a trademark, or a trade name.

 

11

 

 

ARTICLE VI
MISCELLANEOUS PROVISIONS

 

SECTION 1. Fiscal Year; Staff and Divisional Titles.

 

(a) Fiscal Year. The fiscal year of the Corporation shall end on December 31 each year or such other time as the Board of Directors shall determine.

 

(b) Staff and Divisional Titles. The Chief Executive Officer may appoint, at such officer’s discretion, such persons as he or she deems appropriate to hold the title of staff vice president, divisional president, or divisional vice president or other similar designation. Such persons shall not be officers of the Corporation and shall retain such title at the sole discretion of the Chief Executive Officer who may from time to time make or revoke such designation.

 

SECTION 2. Notice and Waiver of Notice. Whenever any notice is required by these Amended and Restated Bylaws to be given, personal notice to the person is not meant unless expressly so stated; and any notice so required shall be deemed to be sufficient if given by depositing the same in a post office or post box in a sealed postpaid wrapper, addressed to the person entitled thereto at the post office address as shown on the transfer books of the corporation, in case of a shareholder, and at the last known post office address in case of an officer or director who is not a shareholder; and such notice shall be deemed to have been given on the day of such deposit. In the case of notice by private express carrier or similar means, notice shall be deemed to be sufficient if transmitted or sent to the person entitled to notice or to any person at the residence or usual place of business of the person entitled to notice who it is reasonably believed will convey such notice to the person entitled thereto; and notice shall be deemed to have been given at the time of receipt at such residence or place of business. In the case of notice by fax, e-mail, or electronic means, notice shall be deemed to be sufficient if transmitted in a manner authorized by the recipient. Any notice required by these Amended and Restated Bylaws may be given to the person entitled thereto personally and attendance of a person at a meeting shall constitute a waiver of notice of such meeting. Whenever notice is required to be given under these Amended and Restated Bylaws, a written waiver thereof, signed by the person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent to notice.

 

SECTION 3. Inspection of Books. The Board of Directors shall determine from time to time whether and, if allowed, when and under what conditions and regulations the accounts, records, and books of the Corporation (except such as may, by statute, be specifically open to inspection), or any of them, shall be open to the inspection of the shareholders, and the shareholders are entitled to inspect and copy records of the Corporation, to the extent permitted under the FBCA.

 

SECTION 4. Construction. All references herein in the plural shall be construed to include the singular and in the singular shall be construed to include the plural, if the context so requires.

 

12

 

 

SECTION 5. Indemnification.

 

(a) Each person (and the heirs, executors or administrators of such person) who was or is a party or is threatened to be made a party to, or is involved in, any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (a “Proceeding”), whether formal or informal and whether or not such action, suit or proceeding is brought by or in the right of the Corporation, by reason of the fact that such person is or was a director, officer, trustee, employee, or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, trustee, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans maintained or sponsored by the Corporation (a “Covered Person”), whether the basis of such Proceeding is alleged action in an official capacity as a director, officer, trustee, employee or agent or in any other capacity while serving as a director, officer, trustee, employee or agent, shall be indemnified and held harmless by the Corporation (and any successor of the Corporation by merger or otherwise) to the fullest extent permitted by the FBCA as the same exists or may hereafter be amended or modified from time to time, against all expense, liability and loss (including attorneys’ fees, judgments, fines, ERISA excise taxes or penalties and amounts paid or to be paid in settlement) actually and reasonably incurred or suffered by such person in connection with such Proceeding if the person if the person acted in good faith and in a manner reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. The termination of any Proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which the person reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that the person’s conduct was unlawful. Such indemnification shall continue as to a person who has ceased to be a director, officer, trustee, employee or agent and shall inure to the benefit of his or her heirs, executors and administrators; providedhowever, that except as provided in Section 5(c)(i) below, the Corporation shall indemnify any such person seeking indemnification in connection with a Proceeding (or part thereof) initiated by such person only if such Proceeding (or part thereof) was authorized by the Board of Directors. The right to indemnification conferred in this Section 5(a) shall also include the right to be paid by the Corporation the expenses incurred in connection with any such proceeding in advance of its final disposition to the fullest extent permitted by the FBCA as the same exists or may hereafter be amended or modified from time to time. Each Covered Person shall have the right, without the need for any action by the Board of Directors, to be paid by the Corporation (and any successor of the Corporation by merger or otherwise) the expenses incurred in connection with any Proceeding in advance of its final disposition, such advances to be paid by the Corporation within twenty (20) days after the receipt by the Corporation of a statement or statements from the claimant requesting such advance or advances from time to time; providedhowever, the payment of such expenses incurred by a director or officer in his or her capacity as a director or officer (and not in any other capacity in which service was or is rendered by such person while a director or officer, including, without limitation, service to an employee benefit plan) shall be made only upon delivery to the corporation of an undertaking (an “Undertaking”) by or on behalf of such director or officer, to repay all amounts so advanced if it shall ultimately be determined by final judicial decision from which there is no further right of appeal (a “final disposition”) that such director or officer is not entitled to be indemnified for such expenses under these Amended and Restated Bylaws or otherwise. The right to indemnification and advancement of expenses conferred in this Section 5(a) shall be a contract right.

 

(b) To obtain indemnification under these Amended and Restated Bylaws, a claimant shall submit to the Corporation a written request, including therein or therewith such documentation and information as is reasonably available to the claimant and is reasonably necessary to determine whether and to what extent the claimant is entitled to indemnification. Upon written request by a claimant for indemnification, a determination, if required by applicable law, with respect to the claimant’s entitlement thereto shall be made as follows: (i) by a majority of Disinterested Directors (as defined below), even though less than a quorum, or (ii) by a committee of Disinterested Directors designated by majority vote of the Disinterested Directors, even though less than a quorum, or (iii) if there are no Disinterested Directors, or if the Disinterested Directors so direct, by Independent Counsel (as defined below), in a written opinion to the Board of Directors, a copy of which shall be delivered to the claimant, or (iv) if a majority of the Disinterested Directors so directs, by a majority vote of the shareholders of the Corporation. In the event the determination of entitlement to indemnification is to be made by Independent Counsel, the Independent Counsel shall be selected by the Disinterested Directors. If it is so determined that the claimant is entitled to indemnification, payment to the claimant shall be made within ten (10) days after such determination.

 

(c) (i) If a claim for indemnification under this Section 5 is not paid in full by the Corporation within thirty (30) days after a written claim pursuant to Section 5(b) above has been received by the Corporation, or (ii) if a request for advancement of expenses under this Section 5 is not paid in full by the Corporation within twenty (20) days after a statement pursuant to Section 5(a) above and the required Undertaking, if any, have been received by the Corporation, the claimant may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim for indemnification or request for advancement of expenses and, if successful in whole or in part, the claimant shall be entitled to be paid also the expense of prosecuting such claim. It shall be a defense to any such action that, under the FBCA, the claimant has not met the standard of conduct which makes it permissible for the Corporation to indemnify the claimant for the amount claimed or that the claimant is not entitled to the requested advancement of expenses, but (except where the required Undertaking, if any, has not been tendered to the Corporation) the burden of proving such defense shall be on the Corporation. Neither the failure of the Corporation (including its Disinterested Directors, Independent Counsel, or shareholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he or she has met the applicable standard of conduct set forth under the FBCA, nor an actual determination by the Corporation (including its Disinterested Directors, Independent Counsel, or shareholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that the claimant has not met the applicable standard of conduct.

 

(d) If a determination shall have been made pursuant to Section 5(b) above that the claimant is entitled to indemnification, the Corporation shall be bound by such determination in any judicial proceeding commenced pursuant to Section 5(c)(i) above.

 

13

 

 

(e) The Corporation shall be precluded from asserting in any judicial proceeding commenced pursuant to Section 5(c)(i) above that the procedures and presumptions of these Amended and Restated Bylaws are not valid, binding, and enforceable and shall stipulate in such proceeding that the corporation is bound by all the provisions of these Amended and Restated Bylaws.

 

(f) All of the rights conferred in this Section 5 as to indemnification, advancement of expenses, and otherwise shall be contract rights between the Corporation and each Covered Person to whom such rights are extended that vest at the commencement of such Covered Person’s service to or at the request of the Corporation and (i) any amendment or modification of this Section 5 that in any way diminishes or adversely affects any such rights shall be prospective only and shall not in any way diminish or adversely affect any such rights with respect to such Covered Person, and (ii) all of such rights shall continue as to any such Covered Person who has ceased to be a director, officer, trustee, employee or agent of the Corporation or ceased to serve at the Corporation’s request as a director, officer, trustee, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, as described herein, and shall inure to the benefit of such Covered Person’s heirs, executors and administrators.

 

(g) All of the rights conferred in this Section 5 as to indemnification, advancement of expenses, and otherwise (i) shall not be exclusive of any other rights to which any person seeking indemnification or advancement of expenses may be entitled or hereafter acquire under any statute, provision of the Articles of Incorporation, these Amended and Restated Bylaws, agreement, vote of shareholders or Disinterested Directors or otherwise, both as to action in such person’s official capacity and as to action in another capacity while holding such office and (ii) cannot be terminated or impaired by the Corporation, the Board of Directors or the shareholders of the Corporation with respect to a person’s service prior to the date of such termination.

 

(h) The Corporation shall have power to purchase and maintain, at its expense, insurance to protect itself and any person who is or was a director, officer, trustee, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, trustee, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss asserted against such person and incurred by such person in any such capacity or arising out of such person’s status as such, whether or not the Corporation would have the power to indemnify him against such liability under the FBCA. To the extent that the Corporation maintains any policy or policies providing such insurance, each such current or former director, officer, trustee, employee or agent shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage thereunder for any such current or former director, officer, trustee, employee or agent.

 

(i) Neither the amendment nor repeal of this Section 5, nor the adoption of any provision of the Articles of Incorporation or these Amended and Restated Bylaws, nor, to the fullest extent permitted by the FBCA, any modification of law, shall eliminate or reduce the effect of this Section 5 in respect of any acts or omissions occurring prior to such amendment, repeal, adoption, or modification.

 

(j) Any notice, request or other communication required or permitted to be given to the Corporation under these Bylaws shall be in writing and either delivered in person or sent by mail or other method of delivery, or by e-mail or other electronic transmission, to the Secretary of the Corporation and shall be effective only upon receipt by the Secretary.

 

(k) If any provision or provisions of this Section 5 shall be held to be invalid, illegal, or unenforceable for any reason whatsoever: (i) the validity, legality and enforceability of the remaining provisions of this Section 5 (including, without limitation, each portion of any paragraph of this Section 5 containing any such provision held to be invalid, illegal or unenforceable, that is not itself held to be invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby; and (ii) to the fullest extent possible, the provisions of this Section 5 (including, without limitation, each such portion of any paragraph of this Section 5 containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested by the provision held invalid, illegal or unenforceable.

 

(l) For purposes of this Section 5: (i) “Disinterested Director” means a director of the corporation who is not and was not a party to the matter in respect of which indemnification is sought by the claimant; and (ii) “Independent Counsel” means a large national law firm, a member of a large national law firm, or an independent practitioner, that is experienced in matters of corporation law and shall include any person who, under the applicable standards of professional conduct then prevailing, would not have a conflict of interest in representing either the Corporation or the claimant in an action to determine the claimant’s rights under these Bylaws.

 

14

 

 

ARTICLE VII
AMENDMENTS

 

SECTION 1. Amendment of Bylaws. All Bylaws of the Corporation (including these Amended and Restated Bylaws) shall be subject to adoption, alteration, amendment, or repeal as provided in, and subject to the provisions of, the Articles of Incorporation and the FBCA.

 

* * * * *

 

15

 

 

Exhibit 10.1

 

LICENCE AGREEMENT

 

between

 

INNOVATIVE EYEWEAR, INC

 

and

 

LUCYD LTD.

 

 

 

 

CONTENTS

 

CLAUSE

 

1. Interpretation 3
2. Grant 3
3. Title, goodwill and registrations 3
4. Confidentiality 4
5. Recordal of licence 4
6. Payment 4
7. Protection of the Intellectual Property 4
8. Liability, indemnity and insurance 5
9. Additional Licensee obligations 6
10. Sub-licensing 6
11. Assignment and other dealings 6
12. Duration and termination 7
13. Consequences of termination 7
14. Further assurance 8
15. Waiver 8
16. Entire agreement 8
17. Variation 8
18. Severance 8
19. Counterparts 9
20. Third party rights 9
21. No partnership or agency 9
22. Force majeure 9
23. Notices 9
24. Inadequacy of damages
25. Multi-tiered dispute resolution procedure
26. Governing law 10
27. Jurisdiction 10

 

2

 

 

This agreement is dated 1st April 2020

 

PARTIES

(1) INNOVATIVE EYEWEAR, INC a company whose registered office is at 12000 Biscayne Blvd, Suite 216, North Miami, FL 33181 (Licensee)

 

(2) LUCYD LTD. a company incorporated and registered in England with company number 09522087 whose registered office is at Acre House, 11-15 William Road, London, England, NW1 3ER (Licensor)

 

BACKGROUND

(A) The Licensor is the owner of the Intellectual Property and Assets (each as defined below).
(B) The Licensee wishes to have an exclusive worldwide licence to use the Intellectual Property and to receive the Assets, and the Licensor is willing to grant to the Licensee an exclusive licence to use the Intellectual Property and Assets on the terms and conditions set out in this agreement.

 

Agreed terms

1. Interpretation

The following definitions and rules of interpretation apply in this agreement.

1.1 Definitions:

Assets: means the assets set out in the Appendix.

Business Day: a day other than a Saturday, Sunday or public holiday in England or the United States, when banks are open for business.

Effective Date: 1st April 2020.

Group: in relation to a company, that company, any subsidiary or holding company from time to time of that company, and any subsidiary from time to time of a holding company of that company. Intellectual Property: all patents, rights to inventions, utility models, copyright and related rights,

trade marks, service marks, trade, business and domain names (including URLs), rights in trade

dress or get-up, unfair competition rights, rights in designs and logos, rights in computer software, database rights, semi-conductor topography rights, moral rights, rights in confidential information (including know-how and trade secrets) and any other intellectual property rights, in each case whether registered or unregistered and including all applications for and renewals or extensions of such rights, and all similar or equivalent rights or forms of protection in any part of the world which is to include the assets in the Appendix.

VAT: value added tax or any equivalent tax chargeable in the UK or elsewhere.

 

2. Grant
2.1 The Licensor hereby grants to the Licensee an exclusive worldwide licence to use the Intellectual Property and to receive the Assets.
2.2 The Licensor undertakes not to utilise the Intellectual Property and the Assets nor to grant others the right to do so.

 

3. Title, goodwill and registrations
3.1 The Licensee acknowledges that the Licensor is the proprietor of the Intellectual Property and the Assets.

 

3

 

3.2 Any goodwill derived from the use by the Licensee of the Intellectual Property or Assets shall accrue to the Licensor. The Licensor may, at any time, call for a document confirming the assignment of that goodwill and the Licensee shall immediately execute it.
3.3 The Licensee shall not do, or omit to do, or permit to be done, any act that will or may intentionally weaken, damage or be detrimental to the Intellectual Property, the Assets or the reputation or goodwill associated with the Intellectual Property, the Assets or the Licensor.
3.4 The Licensor shall at the Licensee’s expense take all commercially reasonable steps to maintain and protect the Intellectual Property and the Assets.

 

4. Confidentiality
4.1 Each party undertakes that it shall not at any time during this agreement, and for a period of five years after expiry or termination of this agreement, disclose to any person any confidential information concerning the business, affairs, customers, clients or suppliers of the other party or of any member of the group of companies to which the other party belongs, nor any of the terms of this agreement.
4.2 Each party may disclose the other party’s confidential information:
(a) to its employees, officers, representatives or advisers who need to know such information for the purposes of exercising the party’s rights or carrying out its obligations under or in connection with this agreement. Each party shall ensure that its employees, officers, representatives or advisers to whom it discloses the other party’s confidential information comply with this clause; and
(b) as may be required by law, a court of competent jurisdiction or any governmental or regulatory authority.
4.3 No party shall use any other party’s confidential information for any purpose other than to exercise its rights or perform its obligations under or in connection with this agreement.

 

5. Recordal of licence
5.1 To the extent appropriate the Licensee shall, at its own cost and as soon as reasonably practicable, record the licence granted to it in clause 2 in the relevant registries.
5.2 The Licensor shall provide reasonable assistance, at the Licensee’s cost, to enable the Licensee to comply with clause 5.1.

 

6. Payment

On the date of execution of this Agreement the Licensee shall pay to the Licensor the sum of £1 which is the fully paid up license fee for the life of the licensed properties.

 

7. Protection of the Intellectual Property
7.1 The Licensee shall immediately notify the Licensor in writing giving full particulars, if any of the following matters come to its attention:
(a) any actual, suspected or threatened infringement of the Intellectual Property;
(b) any actual or threatened claim that any part of the Intellectual Property is invalid;
(c) any actual or threatened opposition to any part of the Intellectual Property;
(d) any claim made or threatened that use of the Intellectual Property infringes the rights of any third party;

4

 

(e) any person applies for, or is granted, a registered trade mark by reason of which that person may be, or has been, granted rights which conflict with any of the rights granted to the Licensee under this agreement; or
(f) any other form of attack, charge or claim to which any part of the Intellectual Property may be subject;

and shall not make any admissions relating to these matters, other than to the Licensor, and shall provide the Licensor with all assistance that it may reasonably require in the conduct of any claims or proceedings.

7.2 In respect of any of the matters listed in clause 7.1, the Licensor shall (subject to the Licensee’s right under section 30(3) of the Trade Marks Act 1994):
(a) decide what action if any to take;
(b) have exclusive control over, and conduct of, all claims and proceedings.
7.3 the Licensor shall bear the cost of any proceedings relating to any of the matters listed in clause 7.1 and shall be entitled to retain all sums that it recovers in any action for its own account.
7.4 If any third party infringement of the Intellectual Property interferes materially in the Licensee’s business in any part of the Intellectual Property, subject to receiving advice from experienced intellectual property counsel that infringement proceedings stand a reasonable chance of success, the Licensee may commence proceedings and may require the Licensor to lend its name to such proceedings and provide reasonable assistance, subject to the Licensee giving the Licensor an indemnity in respect of all costs, damages and expenses that it may incur, including an award of costs against it, directly resulting from the Licensor’s involvement in such proceedings.
7.5 Nothing in this agreement shall constitute any representation or warranty that:
(a) any registration comprised in the Intellectual Property is valid;
(b) any application comprised in any part of the Intellectual Property shall proceed to grant or, if granted, shall be valid; or
(c) the exercise by the Licensee of rights granted under this agreement will not infringe the rights of any person.

 

8. Liability, indemnity and insurance
8.1 To the fullest extent permitted by law, the Licensor shall not be liable to the Licensee for any costs, expenses, loss or damage (whether direct, indirect or consequential, and whether economic or other) arising from the Licensee’s exercise of the rights granted to it under this agreement.
8.2 The Licensee shall indemnify the Licensor against all liabilities, costs, expenses, damages and losses (including but not limited to any direct, indirect or consequential losses, loss of profit, loss of reputation and all interest, penalties and legal costs (calculated on a full indemnity basis) and all other reasonable professional costs and expenses) suffered or incurred by the Licensor arising out of or in connection with:
(a) the Licensee’s exercise of its rights granted under this agreement, including any claim made against the Licensor for actual or alleged infringement of a third party’s intellectual property rights arising out of or in connection therewith;
(b) the Licensee’s breach or negligent performance or non-performance of this agreement; or
(c) the enforcement of this agreement.
8.3 This indemnity shall apply whether or not the Licensor has been negligent or at fault.
8.4 Nothing in this clause shall restrict or limit the Licensor’s general obligation at law to mitigate a loss it may suffer or incur as a result of an event that may give rise to a claim under this indemnity.
8.5 Nothing in this agreement shall have the effect of excluding or limiting any liability for death or personal injury caused by negligence.

5

 

 

9. Additional Licensee obligations
9.1 The Licensee shall:
(a) ensure that all products using the Intellectual Property are safe for the use for which they were intended;
(b) obtain at its own expense all licences, permits and consents necessary for utilising the Intellectual Property;
(c) perform its obligations in connection with the Intellectual Property with all due skill, care and diligence including good industry practice;
(d) only make use of the Intellectual Property for the purposes authorised in this agreement; and
(e) comply with all regulations and practices in force or use to safeguard the Licensor’s rights in the Intellectual Property and Assets.
9.2 The Licensee shall not, nor directly or indirectly assist any other person to:
(a) use the Intellectual Property or Assets except as permitted under this agreement; or
(b) do or omit to do anything to diminish the rights of the Licensor in the Intellectual Property and Assets.
9.3 The Licensee acknowledges and agrees that the exercise of the licence granted to the Licensee under this agreement is subject to all applicable laws, enactments, regulations and other similar instruments and the Licensee understands and agrees that it shall at all times be solely liable and responsible for such due observance and performance.

 

10. Sub-licensing

The Licensee shall have the right to grant to any person a sub-licence of any of its rights under this agreement provided that:

(a) the Licensee shall ensure that the terms of any sub-licence are in writing and are substantially the same as the terms of this agreement but may contain a subset of the licensed property rights e.g., just the logo, or just a specific patent (except that the sub- licensee shall not have the right to sub-license its rights) and the Licensee shall provide the Licensor with a copy of the sub-licence on request;
(b) all sub-licences granted shall terminate automatically on termination or expiry of this agreement;
(c) the Licensee shall be liable for all acts and omissions of any sub-licensee and shall indemnify the Licensor against all costs, expenses, claims, loss or damage incurred or suffered by the Licensor, or for which the Licensor may become liable, (whether direct, indirect or consequential and including any economic loss or other loss of profits, business or goodwill) arising out of any act or omission of any sub-licensee; and
(d) any sub-licensee shall first enter into a supplemental agreement direct with the Licensor in a form satisfactory to the Licensor.

 

11. Assignment and other dealings
11.1 Without prejudice to other terms set out in this agreement, the Licensee shall not assign, transfer, mortgage, charge, subcontract, sub-license, declare a trust over, or deal in any other manner with any or all of its rights under this agreement without the prior written consent of the Licensor (such consent not to be unreasonably withheld or delayed).

6

 

11.2 The Licensor may at any time assign, mortgage, charge, declare a trust over or deal in any other manner with any or all of its rights under this agreement, provided that it gives prior written notice of such dealing to the Licensee.
11.3 The Licensor may subcontract or delegate in any manner any or all of its obligations under this agreement to any third party, provided that it gives prior written notice of such subcontract or delegation to the Licensee.

 

12. Duration and termination
12.1 This agreement shall commence on the Effective Date and shall continue in perpetuity, unless terminated earlier in accordance with clause 16
12.2 Without affecting any other right or remedy available to it, the Licensor may terminate this agreement with immediate effect by giving written notice to the Licensee if:
(a) the Licensee fails to pay any amount due under this agreement on the due date for payment and remains in default not less than 10 days after being notified in writing to make such payment;
(b) the Licensee commits a material breach of any term of this agreement which breach is irremediable or (if such breach is remediable) fails to remedy that breach within a period of 90 days after being notified in writing to do so;
(c) the Licensee suspends, or threatens to suspend, payment of its debts or is unable to pay its debts as they fall due or admits inability to pay its debts or (being a company or limited liability partnership) is deemed unable to pay its debts within the meaning of section 123 of the Insolvency Act 1986 (IA 1986) as if the words “it is proved to the satisfaction of the court” did not appear in sections 123(1)(e) or 123(2) of the IA 1986;
(d) a petition is filed, a notice is given, a resolution is passed, or an order is made, for or in connection with the winding up of the Licensee (being a company);
(e) an application is made to court, or an order is made, for the appointment of an administrator, or if a notice of intention to appoint an administrator is given, or if an administrator is appointed over the Licensee (being a company);
(f) the holder of a qualifying floating charge over the assets of the Licensee (being a company) has become entitled to appoint or has appointed an administrative receiver;
(g) a person becomes entitled to appoint a receiver over all or any of the assets of the Licensee or a receiver is appointed over all or any of the assets of the Licensee;
(h) a creditor or encumbrancer of the Licensee attaches or takes possession of, or a distress, execution, sequestration or other such process is levied or enforced on or sued against, the whole or any part of its assets and such attachment or process is not discharged within 14 days; or
(i) the Licensee suspends or ceases, or threatens to suspend or cease, carrying on its business.

 

13. Consequences of termination
13.1 On expiry or termination of this agreement for any reason and subject to any express provisions set out elsewhere in this agreement:
(a) all outstanding sums payable by the Licensee to the Licensor shall immediately become due and payable;
(b) all rights and licences granted pursuant to this agreement shall cease;
(c) the Licensee shall cease all use of the Intellectual Property save as set out in this clause;

7

 

(d) the Licensee shall cooperate with the Licensor in the cancellation of any licences registered pursuant to this agreement and shall execute such documents and do all acts and things as may be necessary to effect such cancellation; and
(e) the Licensee shall return promptly to the Licensor at the Licensee’s expense all records and copies of promotional material in its possession relating to the Intellectual Property, and of any information of a confidential nature communicated to it by the Licensor, either preparatory to, or as a result of, this agreement to the extent such material remains confidential.
13.2 Any provision of this agreement that expressly or by implication is intended to come into or continue in force on or after termination or expiry of this agreement shall remain in full force and effect.
13.3 Termination or expiry of this agreement shall not affect any rights, remedies, obligations or liabilities of the parties that have accrued up to the date of termination or expiry, including the right to claim damages in respect of any breach of the agreement which existed at or before the date of termination or expiry.

 

14. Further assurance

At its own expense each party shall, and shall use all reasonable endeavours to procure that any necessary third party shall, promptly execute such documents and perform such acts as may reasonably be required for the purpose of giving full effect to this agreement.

 

15. Waiver

No failure or delay by a party to exercise any right or remedy provided under this agreement or by law shall constitute a waiver of that or any other right or remedy, nor shall it prevent or restrict the further exercise of that or any other right or remedy. No single or partial exercise of such right or remedy shall prevent or restrict the further exercise of that or any other right or remedy.

 

16. Entire agreement
16.1 This agreement constitutes the entire agreement between the parties and supersedes and extinguishes all previous agreements, promises, assurances, warranties, representations and understandings between them, whether written or oral, relating to its subject matter.
16.2 Each party agrees that it shall have no remedies in respect of any statement, representation, assurance or warranty (whether made innocently or negligently) that is not set out in this agreement. Each party agrees that it shall have no claim for innocent or negligent misrepresentation or negligent misstatement based on any statement in this agreement.

 

17. Variation

No variation of this agreement shall be effective unless it is in writing and signed by the parties (or their authorised representatives).

 

18. Severance
18.1 If any provision or part-provision of this agreement is or becomes invalid, illegal or unenforceable, it shall be deemed deleted, but that shall not affect the validity and enforceability of the rest of this agreement.
18.2 If any provision or part-provision of this agreement is deemed deleted under Clause 28.1 the parties shall negotiate in good faith to agree a replacement provision that, to the greatest extent possible, achieves the intended commercial result of the original provision.

8

 

19. Counterparts

This agreement may be executed in any number of counterparts, each of which when executed and delivered shall constitute a duplicate original, but all the counterparts shall together constitute the one agreement.

 

20. Third party rights

Unless it expressly states otherwise, this agreement does not give rise to any rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this agreement.

 

21. No partnership or agency
21.1 Nothing in this agreement is intended to, or shall be deemed to, establish any partnership or joint venture between any of the parties, constitute any party the agent of another party, or authorise any party to make or enter into any commitments for or on behalf of any other party.
21.2 Each party confirms it is acting on its own behalf and not for the benefit of any other person.

 

22. Force majeure

Neither party shall be in breach of this agreement nor liable for delay in performing, or failure to perform, any of its obligations under this agreement if such delay or failure result from events, circumstances or causes beyond its reasonable control. In such circumstances the time for performance shall be extended by a period equivalent to the period during which performance of the obligation has been delayed or failed to be performed. If the period of delay or non-performance continues for 3 weeks, the party not affected may terminate this agreement by giving 10 days’ written notice to the affected party.

 

23. Notices
23.1 Any notice or other communication given to a party under or in connection with this agreement shall be in writing and shall be:
(a) delivered by hand or by pre-paid first-class post or other next working day delivery service at its registered office (if a company) or its principal place of business (in any other case); or
(b) sent by email to the main contacts email address.
23.2 Any notice or communication shall be deemed to have been received:
(a) if delivered by hand, on signature of a delivery receipt or at the time the notice is left at the proper address; and
(b) if sent by pre-paid first-class post or other next working day delivery service, at 9.00 am on the second Business Day after posting or at the time recorded by the delivery service; and
(c) if sent by email, at the time of transmission, or, if this time falls outside business hours in the place of receipt, when business hours resume. In this clause (23.2(c)), business hours means 9.00am to 5.00pm Monday to Friday on a day that is not a public holiday in the place of receipt.
23.3 This clause does not apply to the service of any proceedings or other documents in any legal action or, where applicable, any arbitration or other method of dispute resolution.

9

 

24. Governing law

This agreement and any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with it or its subject matter or formation shall be governed by and construed in accordance with the law of England and Wales.

 

25. Jurisdiction

Each party irrevocably agrees that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with this agreement or its subject matter or formation.

 

This agreement has been entered into on the date stated at the beginning of it.

10

 

 

SIGNATURES

  

Signed by Harrison Gross for and on behalf of  
INNOVATIVE EYEWEAR INC.  
  /s/ Harrison Gross
  Director

 

Signed by Max Inglis  
for and on behalf of LUCYD LTD. /s/ Max Inglis
  Director

 

11

 

 

APPENDIX

 

The specific Intellectual Property and Assets to be transferred include:

 

1. IP to include all patents, patent applications and any continuations of such.
2. Trademarks
3. Collateral material, artwork, subscriber lists, eyeglass model shots and frame shots and renders and 3d models, etc.
4. Logos e.g., Lucyd word mar, Lucyd Hexagon, Upgrade your eyewear slogan and the Vyrb pending application
5. Software
6. Shopify, Walmart and Amazon sites
7. Relevant website urls e.g., Lucyd.co, Lucyd.net, Lucyd.eu
8. Supply and endorsement agreements e.g., Boston Ocular Group LLC, Richard Sherman endorsement deal, etc.
9. eShop, third party reseller channels such as Amazon, Walmart and EBay and all associated revenues from such channels beginning 1s April 2020 onward
10. All current inventory. The total approximate value of the inventory (at cost) is $40,000.
11. All social media accounts e.g, twitter, facebook & instagram under the Lucyd name
12. Contracts with Eye Health Advisers e.g., Dr’s Trattler and Clement
13. Advertising material and trade show displays, brochures and related materials

 

12

 

 

 

Exhibit 10.2

 

This ADDENDUM is dated effective 7th December 2021

 

PARTIES

(1) INNOVATIVE EYEWEAR, INC (Licensee)
(2) LUCYD LTD. a company incorporated and registered in England with company number 09522087 whose registered office is at Acre House, 11-15 William Road, London, England, NW1 3ER (Licensor)

 

BACKGROUND

The Licensor and Licensee executed Licence Agreements on 1st April 2020 and 15th September 2021 and as amended on 5th October 2021 (Licenses).

 

Agreed terms

1. Addendum

The Intellectual Property granted by the Licensor to the Licensee will include all patents and trademarks set out in the attached Appendix.

 

2. Further assurance

Each party shall use all reasonable endeavours to procure that any necessary third party shall, promptly execute such documents and perform such acts as may reasonably be required for the purpose of giving full effect to this agreement.

 

3. Waiver

No failure or delay by a party to exercise any right or remedy provided under this agreement or by law shall constitute a waiver of that or any other right or remedy, nor shall it prevent or restrict the further exercise of that or any other right or remedy. No single or partial exercise of such right or remedy shall prevent or restrict the further exercise of that or any other right or remedy.

 

4. Variation

No variation of this agreement shall be effective unless it is in writing and signed by the parties (or their authorised representatives).

 

5. Severance
5.1 If any provision or part-provision of this agreement is or becomes invalid, illegal or unenforceable, it shall be deemed deleted, but that shall not affect the validity and enforceability of the rest of this agreement.
5.2 If any provision or part-provision of this agreement is deemed deleted under Clause 28.1 the parties shall negotiate in good faith to agree a replacement provision that, to the greatest extent possible, achieves the intended commercial result of the original provision.

 

6. Counterparts

This agreement may be executed in any number of counterparts, each of which when executed and delivered shall constitute a duplicate original, but all the counterparts shall together constitute the one agreement.

1

 

7. Notices
7.1 Any notice or other communication given to a party under or in connection with this agreement shall be in writing and shall be:
(a) delivered by hand or by pre-paid first-class post or other next working day delivery service at its registered office (if a company) or its principal place of business (in any other case); or
(b) sent by email to the main contacts email address.
7.2 Any notice or communication shall be deemed to have been received:
(a) if delivered by hand, on signature of a delivery receipt or at the time the notice is left at the proper address; and
(b) if sent by pre-paid first-class post or other next working day delivery service, at 9.00 am on the second Business Day after posting or at the time recorded by the delivery service; and
(c) if sent by email, at the time of transmission, or, if this time falls outside business hours in the place of receipt, when business hours resume. In this clause (23.2(c)), business hours means 9.00am to 5.00pm Monday to Friday on a day that is not a public holiday in the place of receipt.
7.3 This clause does not apply to the service of any proceedings or other documents in any legal action or, where applicable, any arbitration or other method of dispute resolution.

 

8. Governing law

This agreement and any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with it or its subject matter or formation shall be governed by and construed in accordance with the law of England and Wales.

 

9. Jurisdiction

Each party irrevocably agrees that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with this agreement or its subject matter or formation.

 

This agreement has been entered into on the date stated at the beginning of it.

 

2

 

 

SIGNATURES

 

Signed by Harrison Gross for and on behalf of  
INNOVATIVE EYEWEAR INC.  
  /s/ Harrison Gross
  Director

 

Signed by Max Inglis  
for and on behalf of LUCYD LTD. /s/ Max Inglis
  Director

 

3

 

 

APPENDIX

 

Application/Patent

Number

Title Country Filing/Issue Date Status Grant Date

Anticipated

Expiration Date

10,908,419

Smartglasses and Methods and Systems for Using Artificial Intelligence to Control Mobile Devices Used for Displaying and Presenting Tasks and Applications and Enhancing Presentation and Display of Augmented

Reality Information

US June 28, 2018 Issued February 2, 2021

October 5, 2038

 

(Patent Term Adjustment – 99 days)

D899,493 Smart Glasses US March 22, 2019 Issued October 20, 2020 October 20, 2035
D900,203 Smart Glasses US March 22, 2019 Issued October 27, 2020 October 27, 2035
D899,494 Smart Glasses US March 22, 2019 Issued October 20, 2020 October 20, 2035
D899,495 Smart Glasses US March 22, 2019 Issued October 20, 2020 October 20, 2035
D899,496 Smart Glasses US March 22, 2019 Issued October 20, 2020 October 20, 2035
D900,204 Smart Glasses US March 22, 2019 Issued October 27, 2020 October 27, 2035
D900,205 Smart Glasses US March 22, 2019 Issued October 27, 2020 October 27, 2035
D900,920 Smart Glasses US March 22, 2019 Issued November 3, 2020 November 3, 2035
D900,206 Smart Glasses US March 22, 2019 Issued October 27, 2020 October 27, 2035
D899,497 Smart Glasses US March 22, 2019 Issued October 20, 2020 October 20, 2035
D899,498 Smart Glasses US March 22, 2019 Issued October 20, 2020 October 20, 2035
D899,499 Smart Glasses US March 22, 2019 Issued October 20, 2020 October 20, 2035
D899,500 Smart Glasses US March 22, 2019 Issued October 20, 2020 October 20, 2035
29/716,878

Round Smartglasses Having Flat Connector

Hinges

US December 12, 2019 Pending n/a n/a
29/716,882

Round Smartglasses Having Pivot Connector

Hinges

US December 12, 2019 Pending n/a n/a

4

 

 

Application/Patent Number Title Country Filing/Issue Date Status Grant Date Anticipated Expiration Date
29/716,892

Sport Smartglasses Having

Flat Connector Hinges

US December 12, 2019 Pending n/a n/a
29/716,895

Wayfarer Smartglasses

Having Pivot Connector Hinges

US December 12, 2019 Pending n/a n/a
62/941,466 Wireless Smartglasses with Quick Connect Front Frames US November 27, 2019

Non-Provisional Application filed on November 25, 2020;

U.S. App. No.

17/104,849

n/a November 27, 2020
29/717,878 Flat Connector Hinges for Smartglasses Temples US December 19, 2019 Pending n/a n/a
29/717,884 Pivot Hinges for Smartglasses Temples US December 19, 2019 Pending n/a n/a
16/829,841 Voice Assistant Management US March 25, 2020 Notice of Allowance received 11/30/2021 TBD TBD
29/743,256 Wayfarer Smartglasses US July 20, 2020 Pending n/a n/a
29/743,258 Round Smartglasses US July 20, 2020 Pending n/a n/a
17/104,849

Wireless Smartglasses with Quick Connect Front Frames

US November 25, 2020 Pending n/a n/a
29/806,200 Smartglasses US September 1, 2021 Pending n/a n/a
29/806,204 Smartglasses US September 1, 2021 Pending n/a n/a
29/806,207 Smartglasses US September 1, 2021 Pending n/a n/a
29/806,209 Smartglasses US September 1, 2021 Pending n/a n/a
207516 Smartglasses Canada October 29, 2021 Pending n/a n/a
207517 Smartglasses Canada October 29, 2021 Pending n/a n/a
207518 Smartglasses Canada October 29, 2021 Pending n/a n/a
207519 Smartglasses Canada October 29, 2021 Pending n/a n/a
29/814,016 Safety Smartglasses US November 2, 2021 Pending n/a n/a

5

 

 

Application/Patent Number Title Country Filing/Issue Date Status Grant Date Anticipated Expiration Date
29/814,017 Safety Shields US November 2, 2021 Pending n/a n/a
63/274,920 Safety Glasses US November 2, 2021 Pending n/a n/a
29/815,040 Charging Cradle US November 10, 2021 Pending n/a n/a
207956 Safety Smartglasses Canada November 17, 2021 Pending n/a n/a
207957 Safety Shields Canada November 17, 2021 Pending n/a n/a
2021307950576 Safety Smartglasses China December 2, 2021 Pending n/a n/a
2021307955902 Safety Shields China December 2, 2021

Awaiting confirmation of filing from Chinese associate

n/a n/a

  

TradeMark TradeMark Number Status Jurisdiction TradeMark
LUCYD UK00003258030 Registered UK LUCYD
Lucyd Lens UK00003258093 Registered UK Lucyd Lens
Lucyd Loud UK00003400531 Registered UK Lucyd Loud
Upgrade your eyewear UK00003400579 Registered UK Upgrade your eyewear
GaaS UK00003451728 Registered UK GaaS
Vyrb UK00003477240 Registered UK Vyrb
Lyte UK00003526151 Registered UK Lyte
Upgrade your eyewear Application No. 90/407,646 Application US Upgrade your eyewear
LUCYD Application No. 90/407,723 Application US LUCYD
Lyte Application No. 90/381051 Application US Lyte
Vyrb Application No. 90/820713 Application US Vyrb

 

6

 

 

Exhibit 10.3

 

THIS MANAGEMENT AGREEMENT is dated 1st June 2020

 

BETWEEN

 

(1) INNOVATIVE EYEWEAR INC a Florida corporation whose office is at 12000 Biscayne Bl, Suite 216, North Miami, FL 33181 (“Company”); and

 

(2) TEKCAPITAL EUROPE LTD whose registered office is at 12 New Fetter Lane, London, United Kingdom, EC4A 1JP (“Tek”).

 

OPERATIVE PROVISIONS

 

1. DEFINITIONS AND INTERPRETATION

 

1.1 In this Agreement:

 

Commencement Date” means 1st June 2020.

 

Party” means a party to this Agreement.

 

Representatives” means the employees, officers, agents, advisers, consultants, subcontractors and other representatives of the Recipient.

 

Services” means the services to be provided by Tek set out in Schedule 1 (Services).

 

1.2 Third party rights

A person who is not a Party has no right under the Contracts (Rights of Third Parties) Act 1999 to enforce or enjoy the benefit of any term of this Agreement.

 

2. SERVICES

 

2.1 The Company engages and retains Tek on the terms and conditions set out in this Agreement to provide Services to the Company.

 

2.2 Tek shall devote time, team members, resources and effort to the Company, shall use reasonable care and skill in carrying out the Services, shall provide the Services in accordance with the applicable law and will not do anything to bring the Company and/or its partners into disrepute.

 

3. TERM

 

This Agreement shall commence on the Commencement Date and shall (except as expressly provided otherwise in this Agreement) continue in force until terminated in accordance with the terms of this Agreement.

 

4. COMPENSATION AND EXPENSES

 

4.1 The Company will compensate Tek for a Quarterly Retainer Fee of USD $25,000 (exclusive of any appropriate taxes) which is effective from the Commencement Date and such other compensation as shall be determined by the Parties. The Quarterly Retainer fee shall be payable in equal quarterly instalments on the first applicable business day commencing on the 1st June 2020. Payment date maybe extended as parties may agree.

 

4.2 Tek shall be reimbursed all related expenses by the Company.

 

1 -

 

5. LIABILITY

 

Tek shall have no liability and its team members shall have no personal liability for any loss, liability, costs or expenses arising from their involvement with the Company.

 

6. STATUS

 

Tek will be an independent contractor and nothing in this Agreement shall render Tek or its Representatives an employee, worker or agent of the Company.

 

7. TERMINATION

 

7.1 This Agreement can be terminated with 30 calendar days written notice to the other Party with such notice deemed to be effective as at the date of receipt.

 

7.2 On termination of this Agreement:

 

7.2.1 The Company shall immediately pay to Tek all outstanding unpaid amounts and, in respect of Services supplied or due over the notice period, Tek will submit an invoice, which shall be payable upon receipt.

 

7.2.2 The accrued rights, remedies, obligations and liabilities of the Parties as at termination shall not be affected, including the right to claim damages in respect of any breach of the Agreement which existed at or before the date of termination.

 

7.2.3 Clauses which expressly or by implication have effect after termination shall continue in full force and effect, include the following Clauses: Clause 2 (Services), Clause 3 (Term), Clause 4 (Compensation and Expenses), Clause 5 (Liability), Clause 11 (Severance) and Clause 14 (Governing Law).

 

7.3 No failure to exercise, nor any delay in exercising, any right or remedy under this Agreement shall operate as a waiver, nor shall any single or partial exercise of any right or remedy prevent any further or other exercise or the exercise of any other right or remedy. The rights and remedies provided in this Agreement are cumulative and not exclusive of any rights or remedies provided by law.

 

8. ENTIRE AGREEMENT

 

This Agreement constitutes the entire agreement between the Parties and supersedes and extinguishes all previous drafts, arrangements, understandings or agreements between them, whether written or oral, relating to the subject matter of this Agreement.

 

9. COSTS AND EXPENSES

 

Except as provided otherwise in this Agreement, each Party shall pay the costs and expenses incurred by it in connection with this Agreement.

 

10. VARIATION

 

This Agreement may only be varied by a document signed by both Tek and the Company.

2 -

 

11. SEVERANCE

 

If any term or provision of this Agreement is declared invalid, void or unenforceable, such provision shall, to the extent required, be considered severed or deemed to be deleted from this Agreement and all other terms and provisions of this Agreement shall otherwise remain in full force and effect.

 

12. ASSIGNMENT

 

Either Party may assign or transfer its rights and/or obligations under this Agreement without written consent from the other Party.

 

13. COUNTERPARTS

 

This Agreement may be executed in any number of counterparts, and this has the same effect as if the signatures on the counterparts were on a single copy of the document.

 

14. GOVERNING LAW AND JURISDICTION

 

14.1 This Agreement and any non-contractual obligations arising out of or in connection with it shall be governed by and construed in accordance with English Law.

 

14.2 The courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim arising out of this Agreement.

3 -

 

 

SCHEDULE 1

 

THE SERVICES

 

Tek shall provide the services indicated below:

 

1. Provide support and advice to the Company in accordance with their area of expertise.

 

2. Undertake research, technical review, legal review, recruitment, software development, marketing, public relations and advertisement.

 

3. If available, to attend conference calls with identified individuals as shall be agreed between Tek and the Company.

 

4. Provide advice, assistance and consultation services to support the Company or in relation to any other related matter.

 

5. Carry out such other functions as agreed between Tek and the Company.

 

4 -

 

 

SIGNATURES

 

INNOVATIVE EYEWEAR INC.

 

Director  

 

 

TEKCAPITAL EUROPE LIMITED

 

Director  

 

 

5 -

 

 

Exhibit 10.4

 

 

 

 

 

 

INNOVATIVE EYEWEAR INC

 

 

 

 

 

 

 

 

 

 

CONVERTIBLE NOTE

 

 

 

 

 

 

 

 

CONTENTS

 

Clause   Page
       
1. DEFINITIONS AND INTERPRETATION   1
2. LOAN NOTES   2
3. TERMS   2
4. NOTE CONVERSION   2
5. REPAYMENT AND PREPAYMENT   3
6. INTEREST   3
7. CERTIFICATES   4
8. WARRANTIES AND REPRESENTATIONS   4
9. INDEMNITY AND TAX GROSS UP   4
10. U.S. SECURITIES ACT OF 1933   5
11. HOLDER LIABILITIES   5
12. HOLDER OPTION   5
13. COSTS AND EXPENSES   5
14. COMMUNICATIONS   5
15. ENTIRE AGREEMENT   5
16. VARIATION   6
17. ASSIGNMENT   6
18. NO WAIVER   6
19. RIGHTS AND REMEDIES   6
20. SEVERANCE   6
21. ARBITRATION   6
22. GOVERNING LAW   6
SCHEDULE 1 Certificate   8

  

 

 

 

THIS CONVERTIBLE NOTE is executed as a deed effective 1st December 2020.

 

PARTY

 

Innovative Eyewear Inc, a Forida based company (“Company”).

 

BACKGROUND

 

By exercising the powers conferred on them by the constitutional documents of the Company, the Company resolved to create unsecured convertible loan notes up to the principal amount of $2,000,000 USD and to constitute these loan notes in the manner set out in this Instrument.

 

OPERATIVE PROVISIONS

 

1. DEFINITIONS AND INTERPRETATION

 

1.1 In this Instrument:

 

Commencement Date” means the effective date of this Instrument.

 

Group” means in relation to a company, that company, each and any subsidiary or holding company from time to time of that company, and each and any subsidiary from time to time of a holding company of that company or an affiliate.

 

Holder” means Lucyd Ltd (09522087) or its assignees which can include group companies such as Tekcapital Europe Limited.

 

Instrument” means this unsecured convertible loan note, issued on the Commencement Date which is for the principal amount of $2,000,000 USD, the terms of which are established herein.

 

Loan Note” means the unsecured loan notes of the Company constituted by this Instrument, or the principal amount from time to time issued or drawn down for a facility as the case may require.

 

Maturity Date” means unless converted earlier in accordance with Clause 4 or delayed on mutual written agreement, the principal and accrued interest on this Instrument shall be due and payable on the third anniversary of this Instrument.

 

Party” means the Company or the Holder.

 

1.2 Construction

 

1.2.1 Unless a contrary indication appears a reference in this Instrument to:

 

(a) a “person” includes any individual, firm, company, corporation, government, state or agency of a state or any association, trust, joint venture, consortium or partnership (whether or not having separate legal personality);

 

(b) a “regulation” includes any regulation, rule, official directive, request or guideline (whether or not having the force of law) of any governmental, intergovernmental or supranational body, agency, department or of any regulatory, self-regulatory or other authority or organisation;

1 -

 

(c) references in this Instrument to the singular include references to the plural and vice versa; and

 

(d) a provision of law is a reference to that provision as amended or re-enacted.

 

1.2.2 Section, Clause and Schedule headings are for ease of reference only.

 

2. LOAN NOTES

 

2.1 The aggregate principal amount of the Loan Notes shall total USD $2,000,000.

 

2.2 Subject to this Instrument, the Loan Notes shall rank pari passu equally and rateably without discrimination or preference between them and as unsecured obligations of the Company under this Instrument.

 

2.3 Interest shall be payable on the Loan Notes in accordance with Clause 6.

 

2.4 This Instrument may be one of a series which have the exact same financial terms except as to the date of issuance and tenor.

 

3. TERMS

 

Pursuant to (i) any services agreement which compensates a Group company of Tekcapital plc, (ii) a direction of the Board and/or (iii) receipt of any funds then the Loan Notes shall be issued prior to the Maturity Date in denominations and integral multiples of USD $0.01 (or such other multiples or currency as the Company shall permit) and shall be held subject to the terms set out in this Instrument.

 

4. NOTE CONVERSION

 

4.1 At the election of the Holder, the Loan Notes and all interest accrued on them may be converted anytime after the occurrence of any of the following events (the “Conversion Events”):

 

4.1.1 in the event that the Company consummates an equity financing pursuant to which it raises an aggregate amount of not less than $750,000 USD;

 

4.1.2 in the event that the Company enters into a transaction pursuant to which the Company sells not less than 10% of the Company’s shares, excluding any and all convertible notes which are convertible into shares;

 

4.1.3 in the event that the Company lists shares on a public exchange; or

 

4.1.4 the Holder determines that it wants to convert the Note.

 

Upon the occurrence of any Conversion Event described in Clause 4.1, the Holder may, by written notice to the Company (the “Conversion Notice”), convert all, or a portion of, outstanding principal and accrued interest under the Note into that number of Company shares equal to the quotient obtained by dividing the amount of all outstanding principal and interest of the Note being converted by the Holder by (i) in the case of Clause 4.1.1 and Clause 4.1.2 above, the per share purchase price paid for by investors under the terms of such equity financing, (ii) in the case of 4.1.3 above, the closing price of the Company’s trading shares on the relevant public exchange for the day immediately preceding the date of conversion of the Note or (iii) in the case of 3.1.4 the valuation of the last equity investment or a figure determined by the CFO of the Holder.

 

2 -

 

 

4.2 In the event that the Holder does not effect to convert the entire Note and accrued interest thereunder before the Maturity Date, the Company shall repay in cash the full principal amount and all accrued interest on the Note.

 

4.3 Upon conversion of the Loan Notes:

 

4.3.1 the Company shall issue certificates evidencing the shares; and

 

4.3.2 the Holder shall (i) have the same rights provided to a purchaser of the shares in the equity financing, including without limitation, to the extent granted therein, information and registration rights and subject to any minimum share ownership thresholds and (ii) join into any such agreement entered into between the Company and a purchaser of the shares in such equity financing evidencing the rights described in Clause 4.3.2(i).

 

4.4 The Company shall not be required to issue fractional shares upon exercise of the Note. As to any fractional share that the Holder would otherwise be entitled to upon conversion then the Company shall pay to the Holder the difference in cash by wire transfer of immediately available funds.

 

5. REPAYMENT AND PREPAYMENT

 

5.1 Repayment

The Company shall repay in full the principal amount and all accrued interest on the Note on or before the Maturity Date.

 

5.2 Prepayment

The Company may with the prior written consent of the Holder, not to be unreasonably withheld, prepay the whole of the Note at any time prior to receipt of a Conversion Notice. There is no prepayment fee.

 

5.3 Late Payment

In the event that the Company fails to pay any amount due under this Instrument on the Maturity Date then it shall be liable to pay $150 USD for each day that the overdue amount remains due and payable.

 

6. INTEREST

 

6.1 The Company will pay to the Noteholders interest (less any withholding tax) on the principal amount of the Loan Notes for the time being held by them at an annual rate equal to 10 per cent with effect from the date of issue of the Loan Notes until the Maturity Date in accordance with this Instrument.

 

6.2 Interest shall accrue from day-to-day and shall be calculated on the basis of a year of 365 days and the actual number of days in the period for which it is paid.

 

6.3 Interest shall be paid or waived (or, at the election of the Holder in its sole discretion, converted) simultaneously with the conversion or repayment of the Loan Notes.

3 -

 

7. CERTIFICATES

 

Each Noteholder shall be entitled without charge to a certificate for the Loan Notes held by them.

 

8. WARRANTIES AND REPRESENTATIONS

 

The Company makes the representations and warranties set out in this Clause 8 to the Holder.

 

8.1 Binding obligations

That the obligations expressed to be assumed by it in this Instrument are legal, valid, binding and enforceable obligations.

 

8.2 Non-conflict with other obligations

The entry into and performance by it of, and the transactions contemplated by this Instrument do not and will not conflict with:

 

8.2.1 any law or regulation applicable to the Company;

 

8.2.2 any of the Company’s organisational and constitutional documents; or

 

8.2.3 any agreement or instrument binding upon the Company or any of its assets to the extent such conflict might reasonably be expected to have a material adverse effect.

 

8.3 Power and authority
8.3.1 It has the power to enter into, perform and deliver, and has taken all necessary action to authorise its entry into, performance and delivery of, this Instrument.

 

8.3.2 It has duly authorised and approved the terms of this Instrument and the issuance of this Instrument, in each case in accordance with the provisions of the law and its constitutional documents.

 

8.4 Validity and admissibility in evidence

All Authorisations required or desirable:

 

8.4.1 to enable it lawfully to enter into, exercise its rights and comply with its obligations; and

 

8.4.2 to make the documents to which it is a party admissible in evidence in its jurisdiction of incorporation,

 

have been obtained or effected and are in full force and effect.

 

9. INDEMNITY AND TAX GROSS UP

 

9.1 The Company shall indemnify and hold harmless the Holder from and against and in respect of all losses suffered or incurred by the Holder and any reduction in the value of the Notes held by the Holder, arising out of or in connection with tax, stamp duty, registration fees or other similar costs.

 

9.2 All amounts set out, or expressed to be payable under this Instrument shall be deemed to be exclusive of any VAT or similar service charge (“Charge”) and if any amount is chargeable on any supply then the Company shall pay to the Holder (in addition to and at the same time as paying the consideration) an amount equal to the Charge.

 

4 -

 

 

10. U.S. SECURITIES ACT OF 1933

 

10.1 The Company nor any of its affiliates nor any person acting on behalf of any of them has engaged or will engage in any directed selling efforts (as such term is defined in Regulation S promulgated under the United States Securities Act of 1933, as amended (the “Securities Act”)) with respect to the Notes.

 

10.2 The Company nor any of its affiliates nor any person acting on behalf of any of them has made offers or sales of securities under circumstances that would require registration of the Notes under the Securities Act.

 

11. HOLDER LIABILITIES

 

This Instrument does not confer upon the Holder any liabilities as a shareholder prior to the conversion of the Note.

 

12. HOLDER OPTION

 

The Holder, in its sole discretion, can transfer the Note to a member of the Group and the Company will undertake any action requested to effect the transfer.

 

13. COSTS AND EXPENSES

 

Except as provided otherwise in this Instrument, each Party shall pay the costs and expenses incurred by it in connection with this Instrument.

 

14. COMMUNICATIONS

 

14.1 Communications under this Instrument shall be in English in writing and delivered (i) by hand or sent by recorded delivery post (or airmail, if the destination is outside the country of origin) to its registered address or (ii) by email as set out below:

 

Holder
Email address: minglis@tekcapital.com
Company
Email address: info@lucyd.co

 

14.2 No press releases or any other forms of communication to third parties, which mention both Parties, shall be released without the prior written consent and approval of the Holder.

 

15. ENTIRE AGREEMENT

 

15.1 This Instrument constitutes the entire agreement between the Parties and supersedes and extinguishes all previous drafts, agreements, arrangements and understandings between them, whether written or oral, relating to its subject matter.

 

15.2 Each Party acknowledges that in entering into this Instrument it does not rely on, and shall have no remedies in respect of, any representation or warranty (whether made innocently or negligently) that is not set out in this Instrument. No Party shall have any claim for innocent or negligent misrepresentation based upon any statement in this Instrument.

 

5 -

 

15.3 Nothing in this Clause shall limit or exclude any liability for fraud.

 

16. VARIATION

 

No variation, amendment or modification of this Instrument shall be effective unless it is in writing and signed by or on behalf of each Party.

 

17. ASSIGNMENT

 

The Company may not assign or transfer its rights and/or obligations under this Instrument without the prior written consent from the Holder.

 

18. NO WAIVER

 

No failure or delay by a Party to exercise any right or remedy provided under this Instrument or by law shall constitute a waiver of that or any other right or remedy, nor shall it preclude or restrict the further exercise of that or any other right or remedy. No single or partial exercise of such right or remedy shall preclude or restrict the further exercise of that or any other right or remedy.

 

19. RIGHTS AND REMEDIES

 

Except as expressly provided in this Instrument, the rights and remedies provided under this Instrument are in addition to, and not exclusive of, any rights or remedies provided by law.

 

20. SEVERANCE

 

20.1 If any court or competent authority finds that any provision of this Instrument (or part of any provision) is invalid, illegal or unenforceable, that provision or part-provision shall, to the extent required, be deemed to be deleted, and the validity and enforceability of the other provisions of this Instrument shall not be affected.

 

20.2 If any invalid, unenforceable or illegal provision of this Instrument would be valid, enforceable and legal if some part of it were deleted, the provision shall apply with the minimum modification necessary to make it legal, valid and enforceable.

 

21. ARBITRATION

 

Any dispute arising from or in connection with this Instrument (including a dispute relating to the existence, exercise, validity or termination of this Instrument or the consequences of its nullity or any non-contractual obligation arising out or in connection with this Instrument) shall be referred to and finally resolved by arbitration under the Arbitration Rules of the London Court of International Arbitration (LCIA) by a sole arbitrator with the seat of arbitration in London under the English language.

 

22. GOVERNING LAW

 

This Instrument and any non-contractual obligations arising out of or in connection with it shall be governed by and construed in accordance with English Law.

 

6 -

 

 

EXECUTED

 

SIGNED as a DEED  
By INNOVATIVE EYEWEAR INC  
  /s/ Harrison Gross

 

Witness: /s/ Konrad Dabrowski  
Name: Konrad Dabrowski  

 

7 -

 

SCHEDULE 1

 

Certificate

 

INNOVATIVE EYEWEAR INC (THE “COMPANY”)

 

USD $[●] UNSECURED CONVERTIBLE LOAN NOTES

 

Certificate No ……………………….

Amount USD $ ……………….

 

Issued pursuant to the By Laws of the Company.

 

Dated [●]

 

THIS IS TO CERTIFY THAT [●] of [●] is/are the registered holder(s) of USD $[●] of the USD $[●] Convertible Loan Notes (the “Loan Notes”) constituted by an Instrument entered into by the Company on [●] (the “Instrument”) and issued with the benefit of, and subject to the provisions contained in the Instrument.

 

Where the context permits, terms defined in the Instrument shall have the same meaning when used in this Certificate.

 

This Certificate has been executed as a deed and delivered on the date set out above.

  

SIGNED as a DEED

By INNOVATIVE EYEWEAR INC

   
     

 

Witness:    
Name:    
Address:    
Occupation:    

 

8 -

 

 

Exhibit 10.5

 

THIS INTERCOMPANY LOAN AND DEBT TRANSFER AGREEMENT is made effective on 1st June 2021

 

BETWEEN

 

(1) Innovative Eyewear Inc (“Company”); and

 

(2) Lucyd Ltd (“Lucyd”).

 

(3) Tekcapital plc (“Tek”).

 

(4) Tekcapital Europe Ltd (“EUR”).

 

(5) Tekcapital LLC (“LLC”).

 

IT IS AGREED as follows:

 

1. DEFINITIONS

 

Debt” means the debt of USD $387,328 which is owed to Lucyd, Tek, EUR or LLC on behalf of the Company.

 

2. DEBT

 

The Parties confirm that Lucyd, Tek, EUR or LLC incurred costs, expenses and facilitated payments on behalf of the Company. This Agreement is to reflect the intercompany loans and to transfer the Debt to the Company. The Parties confirm that Lucyd is entitled to repayment of the Debt which is owed by the Company.

 

3. INTEREST

 

Unless otherwise agreed by the Company and Lucyd, no interest shall be payable on the amount of the Debt outstanding.

 

4. REPAYMENT

 

The Debt (together with all interest accrued thereon and other amounts due or owing to Lucyd in connection with the Debt) shall be repayable by the Company upon the demand of Lucyd at any time or as otherwise agreed between the Company and Lucyd.

 

5. PREPAYMENT

 

The Company may prepay the whole or any part of the Debt (together with interest accrued thereon and any other amounts due or owing to Lucyd at such time) at any time unless otherwise agreed.

 

6. PAYMENTS

 

Unless required by law and unless the Company and Lucyd agree otherwise, all payments made by the Company hereunder shall be made free and clear of and without any deduction for or on account of any tax, set-off or counterclaim.

 

7. VARIATION

 

This Agreement may only be varied by a document signed by both the Company and Lucyd.

 

1 -

 

8. ASSIGNMENT

 

This Agreement is personal to the Parties and no Party shall assign, transfer, mortgage, charge, subcontract, declare a trust of or deal in any other manner with any of its rights and obligations under this Agreement without the prior written consent of the other Party (such consent not to be unreasonably withheld or delayed).

 

9. AUTHORITY

 

The Parties declare that they each have the right, power and authority and have taken all action necessary to execute and deliver, and to exercise their rights and perform their obligations under this Agreement.

 

10. NO WAIVER

 

No failure or delay by a Party to exercise any right or remedy provided under this Agreement or by law shall constitute a waiver of that or any other right or remedy, nor shall it preclude or restrict the further exercise of that or any other right or remedy. No single or partial exercise of such right or remedy shall preclude or restrict the further exercise of that or any other right or remedy.

 

11. SEVERANCE

 

11.1 If any court or competent authority finds that any provision of this Agreement (or part of any provision) is invalid, illegal or unenforceable, that provision or part-provision shall, to the extent required, be deemed to be deleted, and the validity and enforceability of the other provisions of this Agreement shall not be affected.

 

11.2 If any invalid, unenforceable or illegal provision of this Agreement would be valid, enforceable and legal if some part of it were deleted, the provision shall apply with the minimum modification necessary to make it legal, valid and enforceable.

 

12. COUNTERPARTS

 

This Agreement may be executed in any number of counterparts, and this has the same effect as if the signatures on the counterparts were on a single copy of the document.

 

13. GOVERNING LAW AND JURISDICTION

 

13.1 This Agreement and any non-contractual obligations arising out of or in connection with it shall be governed by English Law.

 

13.2 The courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim arising out of this Agreement.

2 -

 

 

AS WITNESS the hands of the duly authorised representatives of the parties hereto the day and year first before written.

 

Signed by:  
   
 
For and on behalf of Innovative Eyewear Inc  
   
Signed by:  
   
 
For and on behalf of Lucyd Ltd  
   
Signed by:  
   
 
For and on behalf of Tekcapital Plc  
   
Signed by:  
   
   
 
For and on behalf of Tekcapital Europe Ltd  
   
Signed by:  
   
 
For and on behalf of Tekcapital LLC  

 

3 -

 

 

Exhibit 10.6

 

EXECUTIVE EMPLOYMENT AGREEMENT

 

THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is made effective as of August 11, 2021 (the “Effective Date”), and entered into by and between Innovative Eyewear, Inc. (the “Company”), and Harrison Gross (the “Executive”), each a “Party,” or, collectively, the “Parties.”

 

WHEREAS, the Company wishes to employ Executive on the terms set forth in this Agreement; and

 

WHEREAS, Executive wishes to become employed on the terms set forth herein.

 

NOW, THEREFORE, in consideration of the mutual promises contained herein and other good and valuable consideration, the receipt and sufficiency of which are acknowledged, the Parties agree as follows:

 

1. Employment Term.

 

The Company agrees to employ the Executive for term of three (3) years beginning on the Effective Date. Executive’s employment shall terminated on the third anniversary of the Effective Date unless the Parties otherwise agree in writing. The period of time between the Effective Date and the termination of the Executive’s employment shall be referred as the “Term.”

 

2. Position and Duties.

 

a) Title/Duties. The Company hereby agrees to employ the Executive to serve as Chief Executive Officer (“CEO”) of the Company.

 

b) Board Service. During the Term, the Board shall nominate and renominate Executive to be elected to the Company’s Board of Directors (the “Board”). Executive shall not receive any additional compensation beyond that set forth in this Agreement for service on the Board. Upon the termination of Executive’s employment for any reason, Executive agrees to resign immediately from the Board and from any and all other offices of the Company, or of any Company affiliate, that Executive holds.

 

c) Duties/Reporting Relationships. As CEO of the Company, the Executive shall: (i) report to the Board; and (ii) be responsible for the general management of the affairs of the Company and shall have all authorities and responsibilities commensurate with the duties, authorities and responsibilities of persons in similar capacities in similarly sized companies, and such other duties, authorities, and responsibilities as may reasonably be assigned to the Executive by the Board.

 

d) Full-Time Commitment/Policies. Throughout the Executive’s employment, the Executive shall devote substantially all of his professional time to the performance of his duties of employment with the Company (except as otherwise provided herein) and shall faithfully and industriously perform such duties. The Executive will be required to comply with all Company policies as may exist and be in effect from time to time.

 

 

 

e) Executive Representations. The Executive represents and warrants to the Company that he is under no obligation or commitments, whether contractual or otherwise, that are inconsistent with his obligations under this Agreement. The Executive represents and warrants that he will not use or disclose, in connection with his employment by the Company, any trade secrets or proprietary information or intellectual property in which the Executive or any other person has any right, title or interest and that his employment by the Company as contemplated by this Agreement will not infringe or violate the rights of any other person.

 

3. Compensation and Benefits.

 

a) Base Salary. In consideration for his work under the terms of this Agreement, the Company shall pay to the Executive a base salary (“Base Salary”) at a rate of $85,800.00 (Eighty- Five Thousand Eight Hundred Dollars) per year in equal monthly installment on the last day of each month of the Term, or more frequently, in accordance with the regular payroll practices of the Company. On January 1, 2022, the Company shall increase Executive’s Base Salary to $150,000.00 (One Hundred Fifty Thousand Dollars). The Base Salary shall be subject to such deductions and withholdings as are required by law and otherwise elected by the Executive. If the Term ends other than on the last day of a month the last Base Salary payment shall be pro-rated based on the number of days in the month that have passed as of the date of termination.

 

b) Discretionary Bonus. The Board may choose in the exercise of its sole discretion to grant Executive an annual bonus in an amount to be determined in its sole discretion.

 

c) Grant of Options. On the date this Agreement is executed, the Company shall grant Executive an option to purchase 100,000 (One Hundred Thousand) shares of common stock of the Company (the “Option”) at a strike price equal to the fair market price of such common shares on the date of grant. The Option shall vest at the rate of 1/36th per month for thirty-six months. The Option shall be subject to the terms of the Innovative Eyewear, Inc. Equity Incentive Plan (the “Equity Plan”) and any share grant agreement provided by the Equity Plan. Executive shall be responsible for all income taxes imposed as a result of such grant except the Company’s share of FICA taxes.

 

d) Benefits. Executive shall be eligible for any fringe benefits offered by the Company on the same terms and conditions as other executives. The Company reserves the right, in its sole discretion, to amend or terminate any employee benefit plan in accordance with applicable law.

 

e) Paid Time Off. Executive shall be entitled to two weeks of paid vacation in accordance with the Company’s policies and to those paid holidays recognized by the Company. In addition to vacation days, Executive will be eligible to accrue and use paid sick time in accordance with Company policy. The Company shall not pay Executive for accrued and unused vacation or sick days when Executive’s employment terminates for any reason.

 

4. Termination of Employment.

 

a) Notice of Termination. A party may terminate Executive’s employment by giving written notice of such termination in accordance with the notice provisions of this Agreement. Termination will become effective upon a party’s receipt of notice of termination.

 

2

 

b) Termination For Cause, due to Death, or Disability; Resignation without Good Reason. In the event the Executive’s employment hereunder is terminated by the Company for Cause (as defined below), by Executive without Good Reason (as defined below), or by reason of the Executive’s death or Disability (as defined below), then (i) the Company shall pay to the Executive the Base Salary earned through the date of termination; (ii) the Company shall reimburse the Executive for any expenses incurred through the date of termination for which the Executive is entitled to reimbursement; (iii) the Executive’s rights under any benefit plans, programs, or arrangements of the Company shall be determined in accordance with the provisions thereof; and (iv) Executive’s right with respect to the Option shall be determined by the Equity Plan (the items in subparagraphs (i) – (v) referred to hereinafter as the “Accrued Amounts”).

 

c) Termination without Cause; Resignation For Good Reason. In the event the Executive’s employer is terminated by the Company without Cause, or Executive resigns for Good Reason, then: (i) the Company shall provide the Executive with the Accrued Amounts; and (ii) Executive shall be entitled to payment of Base Salary for the balance of the Term; and (iii) if Executive timely elects to continue any group health insurance benefits to which he or his family are entitled under the Consolidated Omnibus Reconciliation Act or any applicable state law (collectively “COBRA”) the Company shall reimburse Executive for any COBRA premiums Executive pays for the duration of Executive’s COBRA coverage. Executive’s right to receive such benefits is subject to the requirement that Executive execute a general release of claims in favor of the Company, its affiliates, and its respective officers and directors, in the form reasonably determined by the Company (the “Release”) and such Release becoming effective within forty- five (45) days following the Termination Date (such 45-day period, the “Release Execution Period”). The Release shall not be mutual.

 

d) Cause. The term “Cause” means (i) the gross and willful misconduct on the part of the Executive in connection with the performance of his duties and responsibilities; (ii) the Executive’s material breach of any material provision of this Agreement; (iii) commission by Executive of fraud, embezzlement, misrepresentation or an act of dishonesty in connection with his duties hereunder; (iv) Executive’s conviction of, or a plea of “guilty” or “no contest” to, a felony, or a misdemeanor involving moral turpitude, whether arising under the laws of the United States or any state thereof; or (v) Executive’s willful and repeated refusal or failure to follow specific, lawful, and reasonable written directions of the Board.

 

e) Notice and Cure of Cause Condition. Except for a failure, breach, or refusal which, by its nature, cannot reasonably be expected to be cured, the Executive shall have ten (10) days from the delivery of written notice by the Company within which to cure any acts constituting Cause; provided, however, that, if the Company reasonably expects irreparable injury from a delay of ten (10) days, the Company may give the Executive notice of such shorter period within which to cure as is reasonable under the circumstances, which may include the termination of the Executive’s employment without prior notice and with immediate effect. The Company may place the Executive on paid leave for up to thirty (30) days while it is determining whether there is a basis to terminate the Executive’s employment for Cause. Any such action by the Company will not constitute Good Reason for Executive’s resignation.

 

3

 

 

f) Good Reason. The term “Good Reason” means (i) the Company’s material breach of any material provision of this Agreement; (ii) material diminution in Executive’s title, position, duties, responsibilities, or compensation, without Executive’s prior written consent; or (iii) the Company requires Executive to relocate his office location to a location more than 35 (thirty-five) miles from the address Executive has provided for notice purposes in this Agreement without the Executive’s prior written consent.

 

g) Notice and Cure of Good Reason Condition. In order to resign for Good Reason, Executive must give the Company written notice of the Good Reason condition within ninety (90) calendar days of when the Good Reason condition first arises, allow the Company thirty (30) days to cure the Good Reason condition, and resign within forty-five (45) days after giving the Company written notice of the Good Reason condition.

 

h) Disability. Either Party may terminate the Executive’s employment hereunder due to disability (“Disability”) if the Executive is unable, due to a mental or physical injury, illness or disorder, to perform the essential functions, duties and responsibilities of his position hereunder, after reasonable accommodation has been made for him for a period of more than one hundred twenty (120) days during any consecutive three hundred and sixty-five (365) day period.

 

5. Business Expenses. Upon presentation of reasonable substantiation and documentation as the Company may specify from time to time, the Executive shall be reimbursed in accordance with the Company’s expense reimbursement policy, for all reasonable out-of-pocket business expenses incurred and paid by the Executive during the Term and in connection with the performance of the Executive’s duties hereunder. To the extent the Executive is provided with the use of the Company’s credit or charge card for purposes of business expenses, such credit or charge card shall not be used to incur any personal (non-business-related) expenses; any personal expenses inadvertently charged to such card shall be reimbursed immediately by the Executive to the Company.

 

6. Confidentiality and Intellectual Property.

 

a) Confidential Information. The Executive acknowledges that the Executive will occupy a position of trust and confidence. The Company, from time to time, may disclose to the Executive, and the Executive will require access to and may generate confidential and proprietary information (no matter how created or stored) concerning the business practices, products, services, and operations of the Company which is not known to their competitors or within their industry generally and which is of great competitive value to them, including, but not limited to: (i) Trade Secrets, inventions, mask works, ideas, concepts, drawings, materials, documentation, procedures, diagrams, specifications, models, processes, formulae, source and object codes, data, software, programs, other works of authorship, know-how, improvements, discoveries, developments, designs and techniques; (ii) information regarding research, development, products, marketing plans, market research and forecasts, bids, proposals, quotes, business plans, budgets, financial information and projections, overhead costs, profit margins, pricing policies and practices, accounts, processes, planned collaborations or alliances, licenses, suppliers and customers; (iii) operational information including deployment plans, means and methods of performing services, operational needs information, and operational policies and practices; and (iv) any information obtained by the Company from any third party that the Company treats or agrees to treat as confidential or proprietary information of the third party (collectively, “Confidential Information”). The Executive acknowledges and agrees that Confidential Information includes Confidential Information disclosed to the Executive prior to entering into this Agreement.

 

4

 

 

b) Trade Secrets.Trade Secrets” means any information, including any data, plan, drawing, specification, pattern, procedure, method, computer data, system, program or design, device, list, tool, or compilation, that relates to the present or planned business of the Company and which: (i) derives economic value, actual or potential, from not being generally known to, and not readily ascertainable by proper means to, other persons who can obtain economic value from their disclosure or use; and (ii) is the subject of efforts that are reasonable under the circumstances to maintain their secrecy. To the extent that the foregoing definition is inconsistent with a definition of “trade secret” under applicable law, the latter definition shall control.

 

c) Restrictions On Use and Disclosure of Confidential Information. The Executive recognizes that the Company’s business interests require the full protection of their respective Confidential Information. The Executive agrees during his employment and after his employment ends, the Executive will hold the Confidential Information in strict confidence and will neither use the information nor disclose it to anyone, except to the extent necessary to carry out the Executive’s responsibilities as an employee of the Company or as specifically authorized in writing by a duly authorized officer of the Company. The Parties agree that the restrictions in this Section will not apply to any portion of the Confidential Information which: (i) was known to the public prior to its disclosure to the Executive; (ii) becomes generally known to the public subsequent to disclosure to the Executive through no wrongful act of the Executive; or (iii) the Executive is required to disclose by applicable law, regulation or legal process (provided, if permitted, that the Executive provides the Company with prior notice of the contemplated disclosure and cooperates with the Company at its expense in seeking to protect such information). Nothing in this Agreement shall be deemed to prohibit the Executive from disclosing any concerns about suspected unlawful conduct to any proper government authority subject to proper jurisdiction. This provision shall survive the termination of the Executive’s employment for so long as the Company maintains the secrecy of the Confidential Information and the Confidential Information has competitive value; and to the extent such information is otherwise protected by statute for a longer period, for example and not by way of limitation, the Defend Trade Secrets Act of 2016 (“DTSA”), then until such information ceases to have statutory protection.

 

d) Defend Trade Secrets Act. Misappropriation of a Trade Secret of the Company in breach of this Agreement may subject the Executive to liability under the DTSA, entitle the Company to injunctive relief, and require the Executive to pay compensatory damages, double damages, and attorneys’ fees to the Company. Notwithstanding any other provision of this Agreement, the Executive hereby is notified in accordance with the DTSA that the Executive will not be held criminally or civilly liable under a federal or state law for the disclosure of a trade secret that is made in confidence to a federal, state or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. If the Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, the Executive may disclose the trade secret to the Executive’s attorney and use the trade secret information in the court proceeding, provided that the Executive must file any document containing the trade secret under seal, and must not disclose the trade secret, except pursuant to court order.

5

 

e) Ownership of Inventions. All ideas, data, deliverables, reports, work products, innovations, improvements, know-how, inventions, designs, developments, techniques, methods and other results of the Executive’s employment with the Company (in draft and final forms), and all related documentation (such as, but not limited to, notes, records, documents, drawings, and designs), which the Executive makes, conceives, reduces to practice, or develops in whole or in part, either alone or jointly with others, in connection with his services to the Company or which relate to any Confidential Information (collectively, the “Inventions”) will be the sole and exclusive property of the Company , and will be considered “works made for hire” pursuant to the United States Copyright Act (17 U.S.C. Section 101). The Executive hereby assigns to the Company or its designees all of the Executive’s right, title and interest in and to all of the foregoing without compensation. To the extent the Executive has any “moral rights” in the Inventions which are not assignable by law, the Executive hereby waives any such moral rights relating to the Inventions, including any and all rights of identification of authorship and any and all rights of approval, restriction or limitation on use or subsequent modifications. The Executive further represents that, to the best of the Executive’s knowledge and belief, none of the Inventions that the Executive creates will violate or infringe upon any right, patent, copyright, trademark or right of privacy, or constitute libel or slander against or violate any other rights of any person, firm or corporation, and that the Executive will use the Executive’s commercially reasonable efforts to prevent any such violation.

 

7. Covenants Not To Solicit or Compete.

 

a) Non-Solicitation of Personnel. During the Executive’s employment with the Company and for a period of twelve (12) months following the termination of the Executive’s employment (the “Restricted Period”), the Executive shall not, directly or indirectly, solicit, induce, recruit or encourage any Protected Personnel of the Company to leave their employment, or end their engagement with the Company, to provide services for the Executive or any other person, business, or organization. “Protected Personnel” means: (i) any person currently employed or engaged as an independent contractor by the Company; and (ii) any former employee or independent contractor of the Company, for a period of three (3) months after termination of such employee’s employment, or independent contractor’s engagement, with the Company.

 

b) Non-Competition. During the Term, and during the Restricted Period, Executive shall not, anywhere within the United States, either as principal, agent, employee, consultant, partner, officer, director, shareholder, or in any other individual or representative capacity, own (more than 5%), manage, finance, operate, control, or otherwise engage or participate in any manner or fashion in, a business that is involved in the invention, production, marketing, or sale of eyeglasses that incorporate technology into their frames or lenses.

 

8. Return of Property. On the date of the Executive’s termination of employment with the Company for any reason (or at any time prior thereto at the Company’s request), the Executive shall return all property belonging to the Company, the Company, or their affiliates and not retain any copies, including, but not limited to, any keys, access cards, badges, laptops, computers, cell phones, wireless electronic mail devices, USB drives, other equipment, documents, reports, files, and other property provided by or belonging to the Company or the Company. Executive shall also deliver all usernames, passcodes, or other login credentials needed for access to any electronic documents, websites, accounts, devices, or computer systems of the Company.

6

 

9. Survival of Provisions. The obligations contained in Sections 6, 7, and 8 shall survive the termination of the Executive’s employment with the Company and shall be fully enforceable thereafter.

 

10. Notices. For the purposes of this Agreement, notices, demands and all other communications provided for in the Agreement shall be in writing and shall be deemed to have been given when delivered by email with return receipt requested, upon the obtaining of a valid return receipt from the recipient, by hand or mailed by nationally recognized overnight delivery service, addressed to the Parties’ addresses specified below or to such other address as any Party may have furnished to the other in writing in accordance herewith, except that notices of change of address shall be effective only upon receipt:

 

To the COMPANY:

 

Innovative Eyewear, Inc.

Board of Directors

c/o Konrad Dabrowski, CFO

8101 Biscayne Blvd.

Miami, Florida 33138

 

With a copy (which shall not constitute notice) to:

 

Barry I. Grossman, Esq.

Ellenoff Grossman & Schole LLP

1345 Avenue of the Americas

New York, NY 10105

Email: bigrossman@egsllp.com

 

To the Executive:

 

Mr. Harrison Gross

 

At the address on the most recent Form W-4 Executive has filed with the Company.

 

11. Tax Matters.

 

a) Withholding. The Company may withhold from any and all amounts payable under this Agreement or otherwise such federal, state and local taxes as may be required to be withheld pursuant to any applicable law or regulation.

 

7

 

 

b) Code Section 409A. The payments described in this Agreement are intended either to comply with the requirements of Code Section 409A, to the extent they are subject to Code Section 409A, or to be exempt from such requirements, regulations and guidance (where an exemption is available), and will be construed accordingly. Notwithstanding any other provision of this Agreement, the Parties agree that the Company has the right, to the extent the Company deems necessary or advisable, in its sole discretion, to unilaterally amend this Agreement to ensure that the payments hereunder comply with Section 409A. The Company is not responsible for, and makes no representation or warranty whatsoever in connection with the tax treatment hereunder, and the Executive should consult his own tax advisor, including without limitation the applicability of Code Section 409A as to the tax effect of amounts payable to the Executive under this Agreement. In any case, the Executive shall be solely responsible and liable for the satisfaction of all taxes and penalties that may be imposed on the Executive in connection with this Agreement (including any taxes and penalties under Code Section 409A), and neither the Company nor any of its affiliates shall have any obligation to indemnify or otherwise hold the Executive harmless from any or all of such taxes or penalties.

 

12. Assignment. The Executive may not assign any part of the Executive’s rights or obligations under this Agreement. The Executive agrees and hereby consents that the Company may assign this Agreement to a third party that acquires or succeeds to the Company’s business, that the provisions hereof are enforceable against the Executive by such assignee or successor in interest, and that this Agreement shall become an obligation of, inure to the benefit of, and be assigned to, any legal successor or successors to the Company.

 

13. Headings. Titles or captions of sections or paragraphs contained in this Agreement are intended solely for the convenience of reference, and shall not serve to define, limit, extend, modify, or describe the scope of this Agreement or the meaning of any provision hereof. The language used in this Agreement is deemed to be the language chosen by the Parties to express their mutual intent, and no rule of strict construction will be applied against any person.

 

14. Severability. The provisions of this Agreement are severable. The unenforceability or invalidity of any provision or portion of this Agreement in any jurisdiction shall not affect the validity, legality or enforceability of the remainder of this Agreement, it being intended that all rights and obligations of the Parties hereunder shall be enforceable to the full extent permitted by applicable law.

 

15. Governing Law; Venue. This Agreement, the rights and obligations of the Parties hereto, and any claims or disputes relating thereto, shall be governed by and construed in accordance with the laws of the State of Florida (without regard to its conflicts of laws provisions). Except as provided in Section 16 (Arbitration) of this Agreement, the Parties consent to the personal jurisdiction of the State of Florida and further agree to the exclusive jurisdiction of the courts of the State of Florida located in Miami-Dade County and the United States District Court for the Southern District of Florida, as applicable, in connection with, or incident to, any dispute, claim, case, controversy or matter arising out of or relating to Executive’s employment or this Agreement, to the exclusion of the courts of any other state, territory or country. The Parties knowingly, willingly, and voluntarily, WAIVE ALL RIGHT TO TRIAL BY JURY in any such proceedings.

 

8

 

 

16. Arbitration. Any dispute, controversy, or claim arising out of or relating to this Agreement, its enforcement, arbitrability, or interpretation, or because of an alleged breach, default, or misrepresentation in connection with any of its provisions and Executive’s employment with the Company, including any alleged violation of statute, common law or public policy, shall be submitted to final and binding arbitration before the American Arbitration Association (“AAA”) to be held in Miami, Florida, before a single arbitrator, in accordance with then-current AAA Employment Arbitration Rules. The arbitrator shall issue a written opinion stating the essential findings and conclusions on which the arbitrator’s award is based. The Company will pay the arbitrator’s fees and arbitration expenses and any other costs unique to the arbitration hearing (recognizing that each side bears its own deposition, witness, expert and attorney’s fees and other expenses to the same extent as if the matter were being heard in court). If, however, any party prevails on a statutory claim that affords the prevailing party attorneys’ fees and costs, then the arbitrator may award reasonable attorneys’ fees and costs to the prevailing party. Any dispute as to who is a prevailing party and/or the reasonableness of any fee or costs shall be resolved by the arbitrator.

 

________By initialing here, Executive acknowledges he has read this paragraph and agrees with the arbitration provision herein.

 

17. Waiver; Modification. No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by the Executive and a duly authorized officer of the Company. No waiver by either Party hereto at any time of any breach by the other Party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such other Party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.

 

18. Recitals; Entire Agreement. The Recitals are hereby incorporated into this Agreement. This Agreement sets forth the entire agreement of the Parties with respect to the subject matter contained herein and supersedes any and all prior agreements or understandings between the Executive and the Company with respect to the subject matter hereof. No agreements, inducements or representations, oral or otherwise, express or implied, with respect to the subject matter hereof have been made by either Party which are not expressly set forth in this Agreement and the Transfer Agreement.

 

19. Counterparts. This Agreement may be executed in counterparts, and each executed counterpart shall have the efficacy of a signed original and may be transmitted by facsimile or email. Each copy, facsimile copy, or emailed copy of any such signed counterpart may be used in lieu of the original for any purpose.

 

[Signature Page Follows]

9

 

IN WITNESS WHEREOF, the Parties hereto have executed this Executive Employment Agreement effective as of the date first written above.

 

INNOVATIVE EYEWEAR, INC.

 

By: /s/ Konrad Dabrowski  
Name:  Konrad Dabrowski  
Title: CFO  

 

EXECUTIVE

 

/s/ Harrison Gross

 

Harrison Gross

 

10

 

 

Exhibit 10.7

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 
 

 

 

 

 

 

Exhibit 10.8

 

INNOVATIVE EYEWEAR INC CONSULTING SERVICES AGREEMENT

 

Parties Consultant Name Frank Rescigna
Company Name Innovative Eyewear Inc
Dates Consultant Start Date 5/1/21
Consultant End Date 12/31/21 (contract may be extended for additional 12 month periods with mutual agreement, in writing, between Consultant and Company).
  Consulting fee

Base fee: $6,000 monthly, for duration of contract (billed as $3,000 bi-weekly)

 

Commissions: Consultant will be paid 3.5% of any wholesale sales generated and received, paid at the end of each month, for the duration of their engagement with the company.

 

Quota & Bonus: Consultant will be provided a $50,000 bonus upon successful completion of the projected sales quota of $8,000,000. Consultant will also receive 100,000 vested stock options upon reaching quota. The total exercise price for all of the options is $1. Vested options may be exercised at any time while engaged by the Company or within 90 days following the last date Consultant is engaged by the Company. Based on the recent completed equity crowdfund, the approximately value of these options, if vested, based on the current valuation would be $100,000. Please note share price of Innovative Eyewear, Inc. may be worth more or less than the current valuation, over time, based upon Company performance, marketplace economic conditions and a wide variety of other factors.

 

Consultant to be reimbursed for pre-approved travel and sales expenses.

Consultant working title Sales Director - Eyewear Channels
Description Lead generation and management of key accounts.

Consultant will provide the following services to Innovative Eyewear:

-Seek new wholesale clients to carry Lucyd eyewear among the sporting goods, hearables and cellular accessory retail market.

-Maintain client accounts

-Inform, update and manage company sales processes

-Assist in marketing and company material preparation

-Assist in enhancing our offerings and presentations to the optical market

-When appropriate, meet with clients in person.

-Participate in a weekly Zoom call and a monthly meeting in the Lucyd office in Miami.

  Hours of work Consultant free to work on their own schedule, but is expected to take all reasonable efforts necessary to achieve the quota.

 

 

 

  Performance Review

Every six months, Innovative Eyewear management will conduct a semi-annual review with consultant to discuss performance, goals, areas of improvement, feedback, and compensation. This performance review will also cover contract extension and will take place 30 days before the end of contract cycle.

  Benefits

Provision of glasses: Company will provide prescription eyewear to consultant and his immediate family if needed. ($80 co-pay for progressive lenses). Consultant must provide Company with the eyeglass prescription at their own expense.

Termination Cancellation by either party for any reason

15 calendar days’ notice. Upon termination + 15 days’ notice period, consulting fee and commissions going forward (not already earned) will be discontinued.

Confidential Information

Consultant is under a general obligation to protect Company confidential and business information for the duration of engagement plus three years.

Warranty Standard Terms

All Innovative Eyewear (IE) and IE client confidential information may not be disclosed to any other party. Confidential information shared with Consultant by IE must be maintained as confidential by Consultant for three years following the term of this Agreement.

Dispute Resolution  

Any dispute, controversy or claim arising out of or in connection with this Term Sheet, concerning the Consultant’s engagement or the termination thereof shall be resolved by final and binding arbitration before one arbitrator designated by the American Arbitration

 

Association, pursuant to the then prevailing rules of the AAA for the resolution of consultancy disputes in Miami, Florida; whose decision shall be final and binding and subject to confirmation in a court of competent jurisdiction. Each Party shall share the costs and expenses incurred in connection with any Arbitration.

Confidentiality  

This Consulting Agreement is confidential between the parties and the terms may not be disclosed to others.

Governing Law and

Jurisdiction

  Miami-Dade, Florida

 

1 Note: After the evaluation period, Company will decide at its sole discretion whether to offer consultant an additional consulting engagement.

   

/s/ Harrison Gross   /s/ Frank Rescigna

Harrison Gross, CEO

For and on behalf of Innovative Eyewear

8101 Biscayne Blvd, Suite 705, Miami, Fl 33138

Tel: 305-200-3450

 

Frank Rescigna

For and on behalf of consultant

Address: 3914 Kismet PKWY W, Cape Coral FL, 33993

Email: rescigna@hotmail.com

Tel: 2392466565

 

 

 

Exhibit 10.9

 

THIS AMENDMENT AGREEMENT is dated 10th August 2021 and made between:

 

(1) INNOVATIVE EYEWEAR, INC., a corporation organised and existing under the State of Florida (“Company”); and

 

(2) FRANK RESCIGNA with email rescigna@hotmail.com (“Consultant”).

 

IT IS AGREED as follows:

 

1. DEFINITIONS AND INTERPRETATION

 

1.1 Definitions

In this Agreement:

 

Original Agreement” means the original consultancy agreement dated 5/1/21 between the Company and the Consultant.

 

1.2 Incorporation of defined terms
(a) Unless a contrary indication appears, a term defined in the Original Agreement has the same meaning in this Agreement.

 

(b) The principles of construction set out in the Original Agreement shall have effect as if set out in this Agreement.

 

1.3 Third party rights

A person who is not a party to this Agreement has no right to enforce or to enjoy the benefit of any term of this Agreement.

 

2. AMENDMENT

 

In consideration of $1 to be payable by the Company to the Consultant then with effect from the date of the Original Agreement the Consulting fee section in the Original Agreement will be amended as set out below:

 

Quota & Bonus: Consultant will be provided a $50,000 bonus upon successful completion of the projected sales quota of $8,000,000. Consultant will also receive 100,000 vested stock options upon reaching quota. The exercise price for each stock option is $1 per share. Vested options may be exercised at any time while engaged by the Company or within 90 days following the last date Consultant is engaged by the Company. Based on the recent completed equity crowdfund, the approximately value of these options, if vested, based on the current valuation would be $100,000. Please note share price of Innovative Eyewear, Inc. may be worth more or less than the current valuation, over time, based upon Company performance, marketplace economic conditions and a wide variety of other factors.

 

3. CONTINUITY

 

The provisions of the Original Agreement shall, save as amended by this Agreement, continue in full force and effect.

 

4. COUNTERPARTS

 

This Agreement may be executed in any number of counterparts, and this has the same effect as if the signatures on the counterparts were on a single copy of this Agreement.

 

5. GOVERNING LAW

 

This Agreement and any non-contractual obligations arising out of or in connection with it shall be governed by and construed in accordance with the State of Florida.

 

 

 

 

SIGNATURES

 

INNOVATIVE EYEWEAR, INC.

 

Officer

 

/s/ Harrison Gross

 

 

FRANK RESCIGNA

 

/s/ Frank Rescigna

 

 

 

 

 

Exhibit 10.10

 

2021 Equity Incentive Plan

 

General

 

Prior to the consummation of this offering, we plan to adopt an equity incentive plan (the “2021 Equity Incentive Plan”) which will provide for the grant of incentive stock options and non-qualified stock options to purchase shares of our common stock and other types of awards. The general purpose of the 2021 Equity Incentive Plan is to provide a means whereby eligible employees, officers, non-employee directors and other individual service providers develop a sense of proprietorship and personal involvement in our development and financial success, and to encourage them to devote their best efforts to our business, thereby advancing our interests and the interests of our stockholders. By means of the 2021 Equity Incentive Plan, we seek to retain the services of such eligible persons and to provide incentives for such persons to exert maximum efforts for our success and the success of our subsidiaries.

 

Description of the 2021 Omnibus Equity Incentive Plan

 

The following description of the anticipated principal terms of the 2021 Equity Incentive Plan is a summary and is qualified in its entirety by the full text of the 2021 Equity Incentive Plan.

 

Administration.    The 2021 Equity Incentive Plan will be administered by the Board or by one or more committees to which the board of directors delegates such administration (as applicable, the “Incentive Plan Administrator”). Subject to the terms of the 2021 Equity Incentive Plan, the Incentive Plan Administrator will have the authority to (a) determine the eligible individuals who are to receive awards under the 2021 Equity Incentive Plan, (b) determine the terms and conditions of awards granted under the 2021 Equity Incentive Plan, (c) determine performance criteria and the achievement of such criteria, (d) accelerate the vesting or exercisability of, payment for or lapse of restrictions on, awards and (e) make all other decisions related to the 2021 Equity Incentive Plan and awards granted thereunder. The Incentive Plan Administrator may also delegate to one or more senior officers of the Company the authority to grant awards, subject to terms and conditions determined by the Incentive Plan Administrator and within the limitations of Section 16 of the Exchange Act.

 

Types of Awards.    The 2021 Equity Incentive Plan provides for the grant of stock options, which may be incentive stock options (“ISOs”) or nonqualified stock options (“NSOs”), stock appreciation rights (“SARs”), restricted shares, restricted stock units (“RSUs”) and other cash-based, equity-based or equity-related awards that the Incentive Plan Administrator determines are consistent with the purpose of the 2021 Equity Incentive Plan and the interests of the Company, or collectively, awards.

 

Share Reserve.    The number of shares of Common Stock that may be issued under the 2021 Equity Incentive Plan is equal to the sum of (x)] [__________] shares plus (y) the annual increase in shares described below.

 

On the first day of each calendar year during the term of the 2021 Equity Incentive Plan, beginning on January 1, 2022 and continuing until (and including) January 1, 2031, the aggregate number of shares of Common Stock that may be issued under the 2021 Equity Incentive Plan will automatically increase by a number equal to the lesser of (a) five percent (5%) of the total number of shares of the Common Stock issued and outstanding shares on December 31 of the calendar year immediately preceding the date of such increase and (b) a number of shares of the Common Stock determined by the Board.

 

 

 

 

If options, stock appreciation rights, restricted stock units or any other awards are forfeited, cancelled or expire before being exercised or settled in full, the shares subject to such awards will again be available for issuance under the 2021 Equity Incentive Plan. If stock appreciation rights are exercised or restricted stock units are settled, only the number of shares actually issued upon exercise or settlement of such awards will reduce the number of shares available under the 2021 Equity Incentive Plan. If restricted shares or shares issued upon exercise of an option are reacquired by the Company pursuant to a forfeiture provision, repurchase right or for any other reason, then such shares will again be available for issuance under the 2021 Equity Incentive Plan. Shares applied to pay the exercise price of an option or satisfy withholding taxes related to any award will again become available for issuance under the 2021 Equity Incentive Plan. To the extent an award is settled in cash, the cash settlement will not reduce the number of shares available for issuance under the 2021 Equity Incentive Plan.

 

Shares issued under the 2021 Equity Incentive Plan may be authorized but unissued shares or treasury shares. As of the date hereof, no awards have been granted under the 2021 Equity Incentive Plan.

 

Incentive Stock Option Limit.    No more than [ ] shares of Common Stock may be issued under the 2021 Equity Incentive Plan upon the exercise of ISOs.

 

Annual Limitation on Compensation of Non-Employee Directors.    The grant date fair value of awards granted to each non-employee director during any fiscal year of the Company may not exceed $[________] (on a per-director basis). This limit is increased to $[________] in the fiscal year a non-employee director is initially appointed or elected to the Board. The Board may make exceptions to such limit for a non-employee chairperson or, in extraordinary circumstances, for other non-employee directors, provided the non-employee director receiving such additional compensation does not participate in the decision to award such compensation. Compensation paid to an individual for services as an employee or consultant and awards granted in lieu of cash retainers or other fees will not count towards these limitations.

 

Eligibility.    Employees (including officers), non-employee directors and consultants who render services to the Company or a parent, subsidiary or affiliate thereof (whether now existing or subsequently established) are eligible to receive awards under the 2021 Equity Incentive Plan. ISOs may only be granted to employees of the Company or a parent or subsidiary thereof (whether now existing or subsequently established).

 

International Participation.    The Incentive Plan Administrator has the authority to implement sub-plans (or otherwise modify applicable grant terms) for purposes of satisfying applicable foreign laws, conforming to applicable market practices or for qualifying for favorable tax treatment under applicable foreign laws, and the terms and conditions applicable to awards granted under any such sub-plan or modified award may differ from the terms of the 2021 Equity Incentive Plan. Any shares issued in satisfaction of awards granted under a sub-plan will come from the 2021 Equity Incentive Plan share reserve.

 

Repricing.    The Incentive Plan Administrator has full authority to reprice (reduce the exercise price of) options and stock appreciation rights or to approve programs in which options and stock appreciation rights are exchanged for cash or other equity awards on terms the Incentive Plan Administrator determines.

 

Stock Options.    A stock option is the right to purchase a certain number of shares of stock at a fixed exercise price which, pursuant to the 2021 Equity Incentive Plan, may not be less than 100% of the fair market value of Common Stock on the date of grant. Subject to limited exceptions, an option may have a term of up to 10 years and will generally expire sooner if the optionee’s service terminates. Options will vest at the rate determined by the Incentive Plan Administrator. An optionee may pay the exercise price of an option in cash, or, with the administrator’s consent, with shares of stock the optionee already owns, with proceeds from an immediate sale of the option shares through a broker approved by us, through a net exercise procedure or by any other method permitted by applicable law.

 

2

 

 

Stock Appreciation Rights.    A stock appreciation right provides the recipient with the right to the appreciation in a specified number of shares of stock. The Incentive Plan Administrator determines the exercise price of stock appreciation rights granted under the 2021 Equity Incentive Plan, which may not be less than 100% of the fair market value of Common Stock on the date of grant. Subject to limited exceptions, a stock appreciation right may have a term of up to 10 years and will generally expire sooner if the recipient’s service terminates. SARs will vest at the rate determined by the Incentive Plan Administrator. Upon exercise of a SAR, the recipient will receive an amount in cash, stock, or a combination of stock and cash determined by the Incentive Plan Administrator, equal to the excess of the fair market value of the shares being exercised over their exercise price.

 

Tax Limitations on Incentive Stock Options.    The aggregate fair market value, determined at the time of grant, of the Common Stock with respect to ISOs that are exercisable for the first time by an optionholder during any calendar year under all of the Company’s stock plans may not exceed $100,000. Options or portions thereof that exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of the Company’s total combined voting power or that of any of the Company’s affiliates unless (a) the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant and (b) the term of the ISO does not exceed five years from the date of grant.

 

Restricted Stock Awards.    Shares of restricted stock may be issued under the 2021 Equity Incentive Plan for such consideration as the Incentive Plan Administrator may determine, including cash, services rendered or to be rendered to the Company, promissory notes or such other forms of consideration permitted under applicable law. Restricted shares may be subject to vesting, as determined by the Incentive Plan Administrator. Recipients of restricted shares generally have all of the rights of a shareholder with respect to those shares, including voting rights, however any dividends and other distributions on restricted shares will generally be subject to the same restrictions on transferability and forfeitability as the underlying shares.

 

Restricted Stock Units.    A restricted stock unit is a right to receive a share, at no cost to the recipient, upon satisfaction of certain conditions, including vesting conditions, established by the Incentive Plan Administrator. RSUs vest at the rate determined by the Incentive Plan Administrator and any unvested RSUs will generally be forfeited upon termination of the recipient’s service. Settlement of restricted stock units may be made in the form of cash, stock or a combination of cash and stock, as determined by the Incentive Plan Administrator. Recipients of restricted stock units generally will have no voting or dividend rights prior to the time the vesting conditions are satisfied and the award is settled. At the Incentive Plan Administrator’s discretion and as set forth in the applicable restricted stock unit agreement, restricted stock units may provide for the right to dividend equivalents which will generally be subject to the same conditions and restrictions as the restricted stock units to which they pertain.

 

Other Awards.    The Incentive Plan Administrator may grant other awards based in whole or in part by reference to Common Stock and may grant awards under other plans and programs that will be settled with shares issued under the 2021 Equity Incentive Plan. The Incentive Plan Administrator will determine the terms and conditions of any such awards.

 

Changes to Capital Structure.    In the event of certain changes in capitalization, including a stock split, reverse stock split or stock dividend, proportionate adjustments will be made in the number and kind of shares available for issuance under the 2021 Equity Incentive Plan, the limit on the number of shares that may be issued under the 2021 Equity Incentive Plan as ISOs, the number and kind of shares subject to each outstanding award and/or the exercise price of each outstanding award.

 

Corporate Transactions.    If the Company is party to a merger, consolidation or certain change in control transactions, each outstanding award will be treated as described in the definitive transaction agreement or as the Incentive Plan Administrator determines, which may include the continuation, assumption or substitution of an outstanding award, the cancellation of an outstanding award after an opportunity to exercise or the cancellation of an outstanding award in exchange for a payment equal to the value of the shares subject to such award less any applicable exercise price. In general, if an award held by a participant who remains in service at the effective time of a change in control transaction is not continued, assumed or substituted, then the award will vest in full, and for awards subject to one or more performance-based vesting conditions that have not yet been satisfied, such performance-based vesting conditions shall be deemed achieved at 100% of target levels.

 

3

 

 

Change of Control.    The Incentive Plan Administrator may provide, in an individual award agreement or in any other written agreement with a participant, that the award will be subject to acceleration of vesting and exercisability in the event of a change of control or in connection with a termination of employment in connection with or following a change in control.

 

Transferability of Awards.    Unless the Incentive Plan Administrator determines otherwise, an award generally will not be transferable other than by beneficiary designation, a will or the laws of descent and distribution. The Incentive Plan Administrator may permit transfer of an award in a manner consistent with applicable law.

 

Amendment and Termination.    The Incentive Plan Administrator may amend or terminate the 2021 Equity Incentive Plan at any time. Any such amendment or termination will not affect outstanding awards. If not sooner terminated, the 2021 Equity Incentive Plan will terminate automatically 10 years after its adoption by the Board. Shareholder approval is not required for any amendment of the 2021 Equity Incentive Plan, unless required by applicable law, government regulation or exchange listing standards.

 

Certain Federal Income Tax Aspects of Awards Under the Incentive Plan

 

This is a brief summary of the U.S. federal income tax aspects of awards that may be made under the 2021 Equity Incentive Plan based on existing U.S. federal income tax laws as of the date of this this prospectus. This summary covers only the basic tax rules. It does not describe a number of special tax rules, including the alternative minimum tax and various elections that may be applicable under certain circumstances. It also does not reflect provisions of the income tax laws of any municipality, state or foreign country in which a holder may reside, nor does it reflect the tax consequences of a holder’s death. Therefore, no one should rely on this summary for individual tax compliance, planning or decisions. Participants in the 2021 Equity Incentive Plan should consult their own professional tax advisors concerning tax aspects of awards under the 2021 Equity Incentive Plan. The discussion below concerning tax deductions that may become available to the Company under U.S. federal tax law is not intended to imply that the Company will necessarily obtain a tax benefit or asset from those deductions. The tax consequences of awards under the 2021 Equity Incentive Plan depend upon the type of award. Changes to tax laws following the date of this joint proxy statement/consent solicitation statement/prospectus could alter the tax consequences described below.

 

Incentive Stock Options.    No taxable income is recognized by an optionee upon the grant or vesting of an ISO, and no taxable income is recognized at the time an ISO is exercised unless the optionee is subject to the alternative minimum tax. The excess of the fair market value of the purchased shares on the exercise date over the exercise price paid for the shares is includable in alternative minimum taxable income.

 

If the optionee holds the purchased shares for more than one year after the date the ISO was exercised and more than two years after the ISO was granted (the “required ISO holding periods”), then the optionee will generally recognize long-term capital gain or loss upon disposition of such shares. The gain or loss will equal the difference between the amount realized upon the disposition of the shares and the exercise price paid for such shares. If the optionee disposes of the purchased shares before satisfying either of the required ISO holding periods, then the optionee will recognize ordinary income equal to the fair market value of the shares on the date the ISO was exercised over the exercise price paid for the shares (or, if less, the amount realized on a sale of such shares). Any additional gain will be a capital gain and will be treated as short-term or long-term capital gain depending on how long the shares were held by the optionee.

 

4

 

 

Nonqualified Stock Options.    No taxable income is recognized by an optionee upon the grant or vesting of an NSO, provided the NSO does not have a readily ascertainable fair market value. If the NSO does not have a readily ascertainable fair market value, the optionee will generally recognize ordinary income in the year in which the option is exercised equal to the excess of the fair market value of the purchased shares on the exercise date over the exercise price paid for the shares. If the optionee is an employee or former employee, the optionee will be required to satisfy the tax withholding requirements applicable to such income. Upon resale of the purchased shares, any subsequent appreciation or depreciation in the value of the shares will be treated as short-term or long-term capital gain or loss depending on how long the shares were held by the optionee.

 

Restricted Stock.    A participant who receives an award of restricted stock generally does not recognize taxable income at the time of the award. Instead, the participant recognizes ordinary income when the shares vest, subject to withholding if the participant is an employee or former employee. The amount of taxable income is equal to the fair market value of the shares on the vesting date(s) less the amount, if any, paid for the shares. Alternatively, a participant may make a one-time election to recognize income at the time the participant receives restricted stock in an amount equal to the fair market value of the restricted stock (less any amount paid for the shares) on the date of the award by making an election under Section 83(b) of the Code.

 

Restricted Stock Unit Awards.    In general, no taxable income results upon the grant of an RSU. The recipient will generally recognize ordinary income, subject to withholding if the recipient is an employee or former employee, equal to the fair market value of the shares that are delivered to the recipient upon settlement of the RSU. Upon resale of the shares acquired pursuant to an RSU, any subsequent appreciation or depreciation in the value of the shares will be treated as short-term or long-term capital gain or loss depending on how long the shares were held by the recipient.

 

Stock Appreciation Rights.    In general, no taxable income results upon the grant of a SAR. A participant will generally recognize ordinary income in the year of exercise equal to the value of the shares or other consideration received. In the case of a current or former employee, this amount is subject to withholding.

 

Section 409A.    The foregoing description assumes that Section 409A of the Code does not apply to an award. In general, options and stock appreciation rights are exempt from Section 409A if the exercise price per share is at least equal to the fair market value per share of the underlying stock at the time the option or stock appreciation right was granted. RSUs are subject to Section 409A unless they are settled within two and one half months after the end of the later of (a) the end of the Company’s fiscal year in which vesting occurs or (b) the end of the calendar year in which vesting occurs. Restricted stock awards are not generally subject to Section 409A. If an award is subject to Section 409A and the provisions for the exercise or settlement of that award do not comply with Section 409A, then the participant would be required to recognize ordinary income whenever a portion of the award vested (regardless of whether it had been exercised or settled). This amount would also be subject to a 20% U.S. federal tax in addition to the U.S. federal income tax at the participant’s usual marginal rate for ordinary income.

 

5

 

 

Exhibit 10.11

 

SALES REPRESENTATION AGREEMENT

 

This agreement is effective on the 4th day of March 2021 effective immediately between D. Landstrom Associates, Inc., a Minnesota company (“Representative”), located at 5555 W 78th Suite #L, Minneapolis, MN 55439 and INNOVATIVE EYEWEAR, INC. (“Manufacturer”) located 66 W Flagler St, #900 Miami, FL 33130 (address).

 

RECITALS

 

WHEREAS, the Manufacturer owns or is the manufacturer of all products produced by INNOVATIVE EYEWEAR, INC.

 

WHEREAS, the Representative has knowledge of such products and the Customers (as defined below) that would likely purchase Manufacturer’s Products (as defined below);

 

WHEREAS, the parties are desirous of entering into this Agreement whereby Representative agrees to solicit offers from Customers to purchase Products on behalf of Manufacturer and Manufacturer agrees to pay Representative for its services on the terms and conditions set forth herein; and

 

NOW THEREFORE, in consideration of the mutual promises contained herein the parties agree as follows:

 

1. Appointment. Manufacturer hereby appoints Representative as its independent, exclusive Representative in the Territory for the sole purpose of promoting and soliciting offers on behalf of the Manufacturer for the purchase of the Products from Customers. Representative hereby accepts its appointment as the Manufacturer’s representative with the exclusive right to solicit offers on behalf of Manufacturer to purchase the Products in the Territory. Representative and Manufacturer recognize and acknowledge that Representative’s solicitation efforts for the purchase of the Products shall be limited to the Territory so that Representative will be able to devote sufficient resources in the Territory to develop sales. Representative agrees that it will not solicit offers for the purchase of the Products outside the Territory, nor knowingly solicit offers for the sales of the Products to Customers who intend to sell the Products outside the Territory, without the prior written consent of an authorized representative of Manufacturer.

 

2. Definitions. The following words shall have the following meanings when used in this Agreement:

 

2.1 “Customers” shall mean all existing and prospective customers in the Territory which have been identified in writing by Representative to Manufacturer.

 

2.2 “Gross Sales” shall mean the gross sales of the Products sold by Manufacturer to Customer through Representative.

 

1

 

 

2.3 “Prices” shall mean Manufacturer’s then-current prices for the Products for which Representative shall solicit offers from Customers on behalf of Manufacturer to purchase under this Agreement as may be provided by Company to Representative from time to time, and as initially set forth in Schedule A, attached hereto.

 

2.4 “Product” or “Products” shall mean the product(s) manufactured by the Manufacturer for which the Representative has been engaged by Manufacturer hereunder, as may be provided from time to time, and as initially set forth on Schedule A, attached hereto.

 

2.5 “Purchase Order” shall mean any document received by Manufacturer from a Customer offering to purchase the Product(s).

 

2.6 “Territory” shall mean all retail operations defined in “Schedule A”.

 

3. Obligations of the Representative and Manufacturer.

 

3.1 Obligations of the Representative.

 

Representative shall solicit offers on behalf of Manufacturer from Customers to purchase the Products subject, however, to Manufacturer’s acceptance of any such offer which shall not be unreasonably withheld or delayed.

 

3.2 Obligations of the Manufacturer.

 

The Manufacturer agrees to accept all offers presented to it in good faith and agrees to pay Representative Commissions as set forth in Section 4 below on all Products sold to Customers identified by Representative during the Term of this Agreement and for all purchase orders received for a period of one hundred eighty (180) days thereafter.

 

4. Commissions.

 

As consideration for completing the obligations stated above, the Representative shall be entitled to a fee equal to five percent (5 %) of the net sales of the Products sold to all accounts listed under “Schedule A” under “Customers”. Such fee shall be paid to the Representative within ten (10) days of the Manufacturer’s receipt of payment from the Customer. No commission shall be due unless the Manufacturer sells the Products to the Customer and the Customer pays the Manufacturer.

 

2

 

 

5. Termination of Agreement.

 

Manufacturer may not terminate this Agreement during the initial term from March 4th 2021 through March 4th 2026 unless Manufacturer has “good cause” (as defined below) and after the initial term has ended on March 6th 2026 agreement will auto-renew for a period of 1 year each year beginning on March 4th 2026 and each year thereafter unless agreement is terminated by Manufacturer (as defined below):

 

5.1 Manufacturer has given written notice setting forth the reason(s) for the termination at least ninety (90) days in advance of termination; and

 

5.2 Representative fails to correct the reasons stated for termination in the notice within sixty (60) days of receipt of the notice.

 

5.3 “Good cause” means a material breach of one or more provisions of this Agreement and includes, but is not limited to:

 

(1) assignment for the benefit of creditors or similar disposition of the assets of the Representative’s business;

 

(2) the voluntary abandonment of the business by the Representative as determined by a totality of the circumstances;

 

(3) conviction or a plea of guilty or no contest to a charge of violating any law relating to the Representative’s business;

 

(4) failure to forward customer payments, if applicable, to the Manufacturer.

 

5.4 Notwithstanding the foregoing, a notice of termination is effective immediately upon receipt where the alleged grounds for termination are the reasons set forth in Section 5.3 clauses (1) to (4) above.

 

6. Rights Upon Termination.

 

In the event this Agreement is terminated, the Representative is entitled to be paid on all sales purchase orders received by customer(s) for a period of 180 days as to which the Representative would have been entitled to commission pursuant to the provisions of this Agreement, made prior to the date of termination of the Agreement or the end of the notification period, whichever is later, regardless of whether the Products have been actually shipped. Payment of commissions due the Representative shall be paid in accordance with the terms of this Agreement.

 

7. Independent Contractor.

 

It is expressly agreed that the Representative is not an agent or employee of the Manufacturer and has no authority to act for or on behalf of the Manufacturer or to bind the Manufacturer to any contract or in any other matter. Representative shall not express or imply the contrary to third parties.

3

 

 

8. Confidentiality.

 

Representative and the Manufacturer agree not to disclose at any time during this Agreement or within one (1) year thereafter, any nonpublic business, sales, manufacturing, confidential, proprietary, and valuable trade secret information of the other. This shall not apply to the disclosure of Customer after the twelve-month period mentioned above has expired.

 

9. Governing Law.

 

This Agreement shall be governed by the laws of the State of Minnesota.

 

10. Arbitration.

 

(a) The sole remedy for Manufacturer who alleges a violation of any provision of this Agreement is to submit the matter to arbitration. The Representative may also submit a matter to arbitration, or in the alternative, at its option prior to the arbitration hearing, the Representative may bring the Representative’s claims in a court of law, and in that event the claims of all parties must be resolved in that forum. In the event the parties do not agree to an arbitrator within 30 days after the Representative demand’s arbitration in writing, either party may request the appointment of an arbitrator from the American Arbitration Association. The parties agree to be bound by the arbitration. The cost of an arbitration hearing must be borne equally by both parties unless the arbitrator determines a more equitable distribution.

 

(b) The decision of any arbitration hearing is final and binding on the Representative and the Manufacturer. The district court shall, upon application of a party, issue an order confirming the decision.

 

11. Indemnification.

 

Each party agrees to indemnify and hold the other harmless from any liability, claims, suits, demands, and all expenses and costs arising out of the performance of the party’s work hereunder that are caused in whole or in part by the party’s negligent act or omission.

 

12. Miscellaneous.

 

12.1 If any provision of this Agreement shall for any reason be held invalid or unenforceable, such invalidity or unenforceability shall not affect any other provision hereof but this agreement shall be construed as if such invalid or unenforceable provision had never been contained herein.

 

12.2 Neither party may assign its obligations hereunder without the prior written consent of the other which shall not be unreasonably withheld or delayed.

4

 

 

12.3 The provisions here constitute the entire agreement between the parties and any change, amendment, or modification must be in writing and executed by an authorized representative of both parties.

 

IN WITNESS WHEREOF, this Agreement has been executed and is effective as of the day and year first above written.

 

D. Landstrom Associates, Inc.   INNOVATIVE EYEWEAR, INC.
     
By: /s/ Shean Ferrell                                  By: /s/ Harrison Gross                               
Its: Shean Ferrell   Harrison Gross
Its: CEO and Director
     
Date: 7/8/2021   Date: 7/8/21

 

5

 

 

Schedule A

 

“U.S. Customer’s”

  

· Target Stores & Target.com

· Best Buy Stores & Bestbuy.com
· Walmart Stores & Walmart.com
· ShopHQ
· Heartland America

 

“Products”

· Products to include:
o All products produced by INNOVATIVE EYEWEAR, INC. and affiliated entities

 

6

 

 

Exhibit 10.12

 

 

CANADIAN INDEPENDENT DISTRIBUTION AND
INDEPENDENT CONTRACTOR AGREEMENT

 

This Agreement is made and entered into this day of June 30, and year of 2021, by and between Innovative Eyewear Inc. (“Innovative Eyewear”), a Florida Corporation with offices located at 8101 Biscayne Blvd UNIT 705, North Miami, FL 33181, and 8 Points Inc, a subsidiary of Marca Eyewear Distribution Inc (“IC”) with offices located at 51 Barkdale Way, Whitby ON L1N0G1.

 

NOW, THEREFORE, in consideration of the mutual covenants described in this Agreement, INNOVATIVE EYEWEAR appoints IC as the *Exclusive Distributor for Optical/Retail Sales in Canada, and IC accepts such appointment for the purpose of selling INNOVATIVE EYEWEAR’s products through all appropriate and approved retail distribution channels, with the following terms and conditions:

 

*Exclusivity may be revoked if IC does not meet minimum purchase commitment as outlined in Schedule 11B11

 

1. TERM

 

a. This Agreement will become effective on July 1, 2021, and will continue in effect until December 31,2024 unless terminated earlier pursuant to the provisions of this Agreement.

 

2. PERFORMANCE OF SERVICES

 

a. IC agrees to perform the services (“Services”) of providing maximum market penetration and a minimum monthly/annual sales commitment and target to maintain said Exclusivity for Canada. Innovative Eyewear may add, change, or delete these Services upon ninety (90) days’ prior written notice to IC. IC will determine the method, details, and means of performing the Services. IC will determine the order and sequence of the tasks IC performs, as well as the number of hours and the particular hours necessary to perform the Services. IC may, at IC’s own expense and sole discretion, employ such assistants as IC deems necessary to perform the Services. INNOVATIVE EYEWEAR will not employ, control, direct, or supervise IC, or IC’s assistants, or employees in the performance of those Services.

 

3. RELATIONSHIP CREATED

 

a. Neither IC nor any employees of IC are employees of INNOVATIVE EYEWEAR for any purpose whatsoever. IC is an independent contractor and operates IC’s Distribution business without intervention from INNOVATIVE EYEWEAR and for IC’s own accounts. INNOVATIVE EYEWEAR is interested only in the Sales and Service results obtained by IC, who shall have sole control of the manner and means of performing under this Agreement in accordance with industry and Company business and ethical standards. IC shall have the right to promote, solicit orders for, sell and/or market other goods, wares, and/or services manufactured or supplied by others, with exception to like product and technologies. Except as expressly set forth in this Agreement, INNOVATIVE EYEWEAR shall not have the right to require IC to conform to any fixed or minimum number of hours devoted to IC’s selling effort, follow prescribed itineraries, or do anything else which would jeopardize the independent contractor relationship between INNOVATIVE EYEWEAR and IC.

 

Innovative Eyewear, Inc. 101 Biscayne Blvd, Suite 705, Miami, FL 33138

1

 

 

b. IC, having acknowledged that IC is an independent contractor and not an employee of INNOVATIVE EYEWEAR, hereby waives any rights to assert claims for benefits, wages, pension and any, and all claims under local, state and federal laws dealing with an employment relationship and agrees to indemnify and hold INNOVATIVE EYEWEAR harmless for any such claim made upon INNOVATIVE EYEWEAR by any individual or agency with respect to or arising out of the relationship of Innovative Eyewear and IC.

 

4. PRICING

 

a. Innovative Eyewear will offer its current products to Marca Group at $62 USD. All future releases will endeavor to be calculated similarly which is approximately 80% to 82% of wholesale cost. If however, IC has supplier price increases, it may at its sole discretion increase the wholesale price of new models to reflect these increases.

 

b. INNOVATIVE EYEWEAR shall have the right to change the set forth costs upon thirty (30) days written notice. Innovative Eyewear will continue to monitor market conditions and may change the rates at any time, solely at the discretion of Innovative Eyewear. Innovative Eyewear will notify IC in advance of any changes.

 

5. TERRITORY DEFINED

 

a. The Territory for IC shall be the area set forth as Canada and its provinces.

 

6. SALES ORDER ACCEPTANCE

 

a. All sales orders are subject to acceptance by INNOVATIVE EYEWEAR and, when accepted, shall be considered a contract directly between the customer and INNOVATIVE EYEWEAR. Upon acceptance of the order, INNOVATIVE EYEWEAR shall be responsible for shipping the products in bulk to Marca Groups warehouse, on a schedule TBD between Marca and Innovative Eyewear. INNOVATIVE EYEWEAR reserves the right to decline any order solicited or taken by IC and to discontinue sale of any products prior to such acceptance or to cancel any order either in whole or in part without incurring any liability to IC for the payment of commissions or expenses.

 

7. SAMPLE FRAME INVENTORY

 

a. IC hereby acknowledges that INNOVATIVE EYEWEAR will provide IC with sample eyewear frames and cases necessary to promote INNOVATIVE EYEWEAR’s products and IC agrees that all sample eyewear frames furnished by INNOVATIVE EYEWEAR are for the sole purpose of soliciting orders and shall remain the exclusive property of INNOVATIVE EYEWEAR. IC agrees to take good care of the sample frames and will not store them in a car overnight. If temporarily kept in a car during the day, the frames must be locked in the trunk or luggage compartment and the vehicle must be alarmed if so equipped. Under no circumstances may sample frames be sold by IC to other parties.

 

Innovative Eyewear, Inc. 101 Biscayne Blvd, Suite 705, Miami, FL 33138

2

 

 

b. IC further acknowledges responsibility to keep INNOVATIVE EYEWEAR advised of any changes or modifications to the written sample inventory furnished by INNOVATIVE EYEWEAR, and that it shall be conclusively presumed that all frames listed in the inventory are in IC’s current possession unless IC notifies INNOVATIVE EYEWEAR in writing of any authorized changes. All sample frames shall be returned promptly, upon the termination of IC’S services. Under no circumstances will IC have the right to withhold sample frames that INNOVATIVE EYEWEAR requests IC to return, and IC understands and agrees that IC’s financial responsibility for the sample frames shall be totally independent of any obligation INNOVATIVE EYEWEAR may have to IC without limitation.

 

8. IC OBLIGATIONS

 

a. Best Efforts - IC agrees to use IC’s best efforts to achieve the agreed minimum purchases (below) and other service results desired by INNOVATIVE EYEWEAR, and to devote sufficient time to perform the Services effectively.

 

i. 2021 Minimum: 500 units monthly/2,500 units by year end
ii. 2022 Minimum: 2000 units monthly/24,000 units annually
iii. 2023 Minimum: 4000 units monthly/48,000 units annually

 

b. Equipment and Supplies - IC agrees to operate under IC’s own business name, (Marca Group) separate and apart from that of INNOVATIVE EYEWEAR, and to operate and maintain its own separate office for the performance of the services. IC further agrees to provide any tools that may be necessary to the performance of the services including, but not limited to, office equipment, transportation, and supplies. In the event any supplies or equipment are furnished or leased by INNOVATIVE EYEWEAR to IC including, but not limited to, sample frames, Point of Purchase material, customer lists, and sales analysis reports, such supplies and equipment shall remain the property of INNOVATIVE EYEWEAR and shall be returned to INNOVATIVE EYEWEAR upon request, or upon the termination of IC’s affiliation with INNOVATIVE EYEWEAR. IC shall be responsible for loss or damage to any such supplies or equipment.

 

Expenses and Liabilities - IC shall be responsible for all the expenses incurred while performing services hereunder including, without limitation, travel expenses, business cards, telephone, sample insurance, and all related business expenses. IC agrees to provide copies of all created product marketing expenses and invoices as well as copies of all actual media placements monthly.

 

9. BAD DEBTS

 

a. IC shall be liable for bad debts and may be held liable for collection charges incurred if IC defaults in payments to INNOVATIVE EYEWEAR, as outlined in (Schedule “C”)

 

Innovative Eyewear, Inc. 101 Biscayne Blvd, Suite 705, Miami, FL 33138

3

 

  

10. WORKER’S COMPENSATION INSURANCE

 

a. IC agrees to provide workers’ compensation insurance to cover IC and any of IC’s employees and agents, and agrees to hold harmless and indemnify Innovative Eyewear and its predecessors, successors in interest, assigns, parent and subsidiary organizations, affiliates, and partners, and its past, present, and future officers, directors, shareholders, agents, and employees, and their heirs and assigns, for any and all past, present, or future claims, demands, obligations, or causes of action, whether based on tort, contract, or other theories of recovery arising out of any injury, disability, or death of IC or their employees or agents. IC is responsible for ensuring that INNOVATIVE EYEWEAR has on file a current copy of such policy.

 

11. TAXES & LICENSES

 

a. IC acknowledges sole responsibility to pay all applicable taxes, including estimated taxes, incurred because of the compensation paid by INNOVATIVE EYEWEAR to IC for the Services under this Agreement, and will indemnify and hold INNOVATIVE EYEWEAR harmless with respect thereto. INNOVATIVE EYEWEAR shall not be responsible for paying or withholding any taxes on behalf of IC including, but not limited to, federal, state, or local income taxes, FlCA, FUTA, disability taxes, or unemployment taxes. IC represents and warrants that IC has and will continue to comply with all applicable laws and regulations regarding business permits or licenses required to perform IC’s services hereunder.

 

12. LIABILITY INSURANCE

 

a. IC shall maintain, always during the term of this Agreement, at IC’s expense, general comprehensive liability, and property damage liability insurance of at least Five Hundred Thousand Dollars (USD $500,000.00) to protect against any, and all liability for occurrences incidental to all of IC’s activities, services, and operations under this Agreement, whether these occurrences occur on or off INNOVATIVE EYEWEAR’s premises. IC is responsible for ensuring that INNOVATIVE EYEWEAR has on file a current copy of such policy.

 

13. LIMITATION OF AUTHORITY

 

a. IC acknowledges that, as an independent contractor, IC has no authority to enter into contracts or agreements on behalf of Innovative Eyewear. Innovative Eyewear will have no authority to commit IC in any matter, cause, or thing whatever, or to use IC’s name in any way, except as authorized by this Agreement. In no event shall this Agreement be construed as creating a partnership between the parties.

 

Innovative Eyewear, Inc. 101 Biscayne Blvd, Suite 705, Miami, FL 33138

4

 

  

14. CONFIDENTIAL INFORMATION

 

a. INNOVATIVE EYEWEAR has and will develop, compile and own certain proprietary techniques and confidential information that have great value in its business (collectively “Confidential Information”).

 

i. Confidential Information includes not only information disclosed by INNOVATIVE EYEWEAR to IC during IC’s providing services, but also information developed or learned by IC while providing Services under this Agreement. Confidential Information is to be broadly defined. Confidential Information also includes all information that has or could have commercial value or other utility in the business in which INNOVATIVE EYEWEAR is engaged, or in which it contemplates engaging. Confidential Information also includes all information of which the unauthorized disclosure could be detrimental to the interests of INNOVATIVE EYEWEAR, regardless of if such information is identified as Confidential Information by INNOVATIVE EYEWEAR.

 

a) By example and without limitation, Confidential Information includes trademark and patent details, technological information, specific customer and supplier information, sales and market analyses, financial information, methods of business operations, and methods of distribution and sale.

 

b) IC always agrees that during or after the term of this Agreement to hold in trust, keep confidential, and not publish, disclose, or otherwise disseminate to any third party or make any use of the Confidential Information of INNOVATIVE EYEWEAR except with INNOVATIVE EYEWEAR’s prior written approval, and only to the extent necessary to perform the Services under this Agreement. IC further agrees not to cause the transmission, removal, or transport of Confidential Information from INNOVATIVE EYEWEAR’s principal place of business at Miami, Florida, or such other place of business specified by INNOVATIVE EYEWEAR, without prior written approval of INNOVATIVE EYEWEAR. These prohibitions also apply to IC’s employees, agents, and subcontractors, if any, and IC agrees to take all reasonable measures to prevent them from using or disclosing INNOVATIVE EYEWEAR’s Confidential Information. IC acknowledges that they are aware that the unauthorized disclosure of Confidential Information of INNOVATIVE EYEWEAR may be highly prejudicial to INNOVATIVE EYEWEAR’s interests, an invasion of privacy and an improper disclosure of trade secrets.

 

c) Upon termination of this Agreement, IC shall return any Confidential Information in lC’S possession to INNOVATIVE EYEWEAR and IC further agrees that they will protect the value of the Confidential Information, Trademarks, Patents, Technologies, and Inventions of INNOVATIVE EYEWEAR and will prevent their use, misappropriation, or disclosure. IC will not disclose or use, for IC’S benefit (or the benefit of any third party) or to the detriment of Innovative Eyewear any Confidential Information.

 

d) IC specifically agrees that these provisions shall survive the termination of this Agreement. If, IC breaches or threatens to breach any of the provisions of this Section, INNOVATIVE EYEWEAR shall be entitled to injunctive relief, enjoining, and restraining such breach or threat of breach. INNOVATIVE EYEWEAR shall also be entitled to immediate termination of its obligation to make any further payment under this Agreement and may seek any other damages or remedies available under law, in equity or by statute.

 

Innovative Eyewear, Inc. 101 Biscayne Blvd, Suite 705, Miami, FL 33138

5

 

 

15. CONFLICT OF INTEREST

 

a) IC hereby warrants that there is no conflict of interest between IC’S current employment or other activities, if any, and the activities to be performed pursuant to this Agreement. IC hereby represents and warrants that they are not a party to any agreement, contract or understanding, and that no facts or circumstances exist which would restrict or prohibit them from undertaking or performing any of their obligations under this Agreement. The foregoing representation and warranty shall remain in effect throughout the term of this Agreement. IC shall advise INNOVATIVE EYEWEAR immediately if a conflict of interest arises in the future.

 

16. TRADEMARKS/PATENTS/INTELLECTUAL PROPERTY

 

a) IC acknowledges that the patents, trademarks, and trade names which are associated with Innovative Eyewear’s Intellectual Properties, including, Technologies, Products, Trademarks, Patents, and future ideas, are the exclusive property of INNOVATIVE EYEWEAR. IC shall not, both during the term of this Agreement and following termination of this Agreement, perform or acquiesce in any action which could diminish the value or distinctiveness of the trademarks or trade names or use any confusingly similar trademarks or trade names or in any way trade upon or use the name or good will of INNOVATIVE EYEWEAR.

 

b) IC shall execute any documents or perform any act which INNOVATIVE EYEWEAR may reasonably require to protect INNOVATIVE EYEWEAR’s rights hereunder. Upon termination of this Agreement for any reason, IC will immediately discontinue all uses of INNOVATIVE EYEWEAR’s corporate name, trademarks, or trade names, and shall immediately discontinue any representation, direct or indirect, that IC is or was a representative of Innovative Eyewear. This provision shall survive termination of this Agreement.

 

17. TERMINATION

 

a) Either party may terminate this Agreement, without any reason, by giving ninety (180) days prior written notification to the other party. However, IC may only terminate this agreement if all amounts owed to INNOVATIVE EYEWEAR as of the date of termination have been paid in full. Additionally, INNOVATIVE EYEWEAR may terminate this Agreement for any of the following reasons, if they are not cured within (10) days of issuance of written notice to IC:

 

(a) breach of any of the terms of this Agreement.

 

(b) IC’s conviction of a felony.

 

(c) misconduct by IC or their employees related to the business of Innovative Eyewear.

 

(d) non-performance of service, may include, but not only:

 

· Bad Debt Issues
· Non-Achievement of committed to Minimum Purchases
· Service Issues or misuse of brand that devalues brand

 

Innovative Eyewear, Inc. 101 Biscayne Blvd, Suite 705, Miami, FL 33138

6

 

 

18. NOTICES

 

a) All notices hereunder shall be in writing and shall be sent by certified mail return receipt requested, or via fax, to the party’s respective address herein above stated, or at such other address as may hereafter be designated by the party, in accordance with this section. All notices shall be deemed effective upon actual receipt, or five days after mailing if applicable, whichever is sooner.

 

19. JURISDUCTION AND GOVERNING LAW

 

a) This Agreement and the terms hereof shall be governed by and construed under the laws of the State of Florida, which the parties agree shall be the exclusive forum for the resolution of any claim arising hereunder.

 

20. SEVERABILITY

 

a) The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision.

 

21. MODIFICATION

 

a) This Agreement may only be changed, modified, or amended by a written document signed by both parties hereto.

 

22. NO WAIVER

 

a) The failure of either party to enforce any provision of this Agreement on one or more occasions shall not constitute a waiver and shall have no effect on the subsequent enforceability of that provision or any other provision of this Agreement.

 

21. ENTIRE AGREEMENT

 

a) The foregoing terms constitute the entire agreement of the parties, and accurately reflect the relationship between the parties which has been continuously in effect from the date IC first commenced performing Services for INNOVATIVE EYEWEAR.

 

Innovative Eyewear, Inc. 101 Biscayne Blvd, Suite 705, Miami, FL 33138

7

 

 

IN WITNESS WHEREOF, the parties have hereunto set their respective hands as of the day and year first set forth above.

  

8 Points Inc (a subsidiary of Marca Group Distribution Inc)

 

Fernando Silva

 

/s/ Fernando Silva

 

 

Date: 7/2/21

  

Innovative Eyewear, INC.

 

Harrison Gross

 

/s/ Harrison Gross

 

 

Date 7/2/21

Innovative Eyewear, Inc. 101 Biscayne Blvd, Suite 705, Miami, FL 33138

8

 

 

SCHEDULES

 

SCHEDULE “A”

 

DESCRIPTION OF SERVICES: (IC will perform services, which shall include, but shall not be limited to the following):

 

DESCRIPTION OF SERVICES:

 

*(IC will perform services, which shall include, but shall not be limited to the following):

 

· Sales of INNOVATIVE EYEWEAR’s products into retail distribution by servicing potential purchasers and by generating new business within the Territory.
· Handling of all account inquiries on sales made pursuant to this Agreement.
· INNOVATIVE EYEWEAR needs to receive all Canadian returns on a timely basis. Currently, IC will organize his customer returns such that all returns will be shipped in bulk to INNOVATIVE EYEWEAR’s distribution center in Miami, Florida.
· Innovative Eyewear will provide marketing activities to support the sales of all the collections sold by the IC in the territory.
· IC will provide logistic service to distribute the product in the territory served by the IC, including 10 reps covering all provinces, internal customer service and warehousing and shipping, as well as after purchase care to customer.

 

SCHEDULE “

 

SCHEDULE “B”

 

MINIMUM S

 

· 2021 Minimum: 500 units monthly/2,500 units by year end
· 2022 Minimum: 2000 units monthly/24,000 units annually
· 2023 Minimum: 4000 units monthly/48,000 units annually

 

SCHEDULE “C”

 

TERMS

 

· Initial Stock Order: Payment at time of shipping
· Weekly Orders: All weekly orders in a fiscal month will be accumulated and invoiced at the end of that month. Payment on monthly orders will have a net 30-day term.
o As annual minimums increase, both parties will meet before next fiscal year to discuss terms and/or adjustments and justifications.
· Non-or Late Payment: If IC does not make payments as scheduled and becomes over 120 days in the rears, Innovative Eyewear, has the rights to stop shipping IC, remove exclusivity, and/or serve IC a Breach of Contract.

 

Innovative Eyewear, Inc. 101 Biscayne Blvd, Suite 705, Miami, FL 33138

9

 

 

Exhibit 14.1

 

CODE OF ETHICS

OF

INNOVATIVE EYEWEAR, INC.

 

1. Introduction

 

The Board of Directors (the “Board”) of Innovative Eyewear, Inc.(the “Company”) has adopted this code of ethics (this “Code”), as amended from time to time by the Board and which is applicable to all of the Company’s directors, officers and employees. To the extent this Code requires a higher standard than required by commercial practice or applicable laws, rules or regulations, the Company adheres to these higher standards.

 

This Code applies to all of our directors, officers and employees. We refer to all Company executive and subordinate officers and employees covered by this Code as “Company employees” or simply “employees,” unless the context otherwise requires. In this Code, we refer to our principal executive officer, principal financial officer, principal accounting officer and controller, or persons performing similar functions, as our “principal financial officers.”

 

This Code is intended to supplement, and not replace, the various guidelines and documents that the Company has prepared on specific laws, rules, regulations and policies that all officers, directors and employees of the Company should be aware of, such as the Company’s Employee Handbook and Insider Trading Policy.

 

It is the Company’s policy that all Company directors, officers and employees:

 

promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;

 

promote the full, fair, accurate, timely and understandable disclosure in reports and documents that the Company files with, or submits to, the Securities and Exchange Commission (the “SEC”), as well as in other public communications made by or on behalf of the Company;

 

promote compliance with applicable governmental laws, rules and regulations;

 

deter wrongdoing; and

 

require prompt internal reporting of breaches of, and accountability for adherence to, this Code.

 

This Code may be amended and modified by the Board. In this Code, references to the “Company” means Innovative Eyewear, Inc. and, in appropriate context, the Company’s subsidiaries, if any.

 

2. Honest, Ethical and Fair Conduct

 

Each person owes a duty to the Company to act with integrity. Integrity requires, among other things, being honest, fair and candid. Deceit, dishonesty and subordination of principle are inconsistent with integrity. Service to the Company should never be subordinated to personal gain or advantage.

 

Each person must:

 

act with integrity, including being honest and candid while still maintaining the confidentiality of the Company’s information where required or when in the Company’s interests;

 

observe all applicable governmental laws, rules and regulations;

 

comply with the requirements of applicable accounting and auditing standards, as well as Company policies, in order to maintain a high standard of accuracy and completeness in the Company’s financial records and other business-related information and data;

 

adhere to a high standard of business ethics and not seek competitive advantage through unlawful or unethical business practices;

 

deal fairly with the Company’s customers, suppliers, competitors and employees;

 

1

 

 

refrain from taking advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation of material facts or any other unfair-dealing practice;

 

protect the assets of the Company and ensure their proper use;

 

until such time as such person ceases to be an officer or director of the Company, to first present to the Company for its consideration, prior to presentation to any other entity, any business opportunity suitable for the Company, subject to any pre-existing fiduciary or contractual obligations such officer may have or as otherwise set forth in the prospectus related to the Company’s initial public offering; and

 

avoid conflicts of interest, wherever possible, except as may be allowed under guidelines or resolutions approved by the Board (or the appropriate committee of the Board) or as disclosed in the Company’s public filings with the SEC.

 

A conflict of interest can arise whenever an officer, director or employee, take action or have an interest that prevents that person from performing their Company duties and responsibilities honestly, objectively and effectively. Anything that would be a conflict for a person subject to this Code also will be a conflict for that person’s family members. For purposes of the Code, “family members” includes your spouse or life-partner, siblings, parents, aunts, uncles, nieces, nephews, cousins, in-laws and children whether such relationships are by blood or adoption. Examples of conflict of interest situations include, but are not limited to, the following:

 

any significant ownership interest in any supplier or customer;

 

any consulting or employment relationship with any supplier, customer or competitor of the Company;

 

serving on a board of directors or trustees or on a committee of any entity (whether profit or not-for-profit) whose interests reasonably would be expected to conflict with those of the Company;

 

the receipt of any money, non-nominal gifts or excessive entertainment from any entity with which the Company has current or prospective business dealings;

 

selling anything to the Company or buying anything from the Company, except on the same terms and conditions as comparable officers or directors are permitted to so purchase or sell;

 

any other financial transaction, arrangement or relationship (including any indebtedness or guarantee of indebtedness) involving the Company; and

 

any other circumstance, event, relationship or situation in which the personal interest of a person subject to this Code interferes — or even appears to interfere — with the interests of the Company as a whole.

 

3. Corporate Opportunities

 

As an officer, director or employee of the Company, you have an obligation to advance the Company’s interests when the opportunity to do so arises. If you discover or are presented with a corporate opportunity through the use of corporate property or information or because of your position with the Company, you should first present the corporate opportunity to the Company before pursuing the opportunity in your individual capacity. No officer, director or employee may use corporate property, information or his or her position with the Company for personal gain or compete with the Company while employed by or associated with the Company.

 

You should disclose to your supervisor the terms and conditions of each business opportunity covered by this Code that you wish to pursue. Your supervisor will contact the Company’s Chief Legal Officer and the appropriate management personnel to determine whether the Company wishes to pursue the business opportunity. If the Company waives its right to pursue the business opportunity, you may pursue the business opportunity on the same terms and conditions as originally proposed and consistent with the other ethical guidelines set forth in this Code.

 

2

 

 

4. Confidential Information

 

Officers, directors and employees have access to a variety of confidential information regarding the Company. Confidential information includes all non-public information that might be of use to competitors, or, if disclosed, harmful to the Company or its counterparties, collaborators, customers or suppliers. Officers, directors and employees have a duty to safeguard all confidential information of the Company or third parties with which the Company conducts business, except when disclosure is authorized or legally mandated. Unauthorized disclosure of any confidential information is prohibited. Additionally, officers, directors and employees should take appropriate precautions to ensure that confidential or sensitive business information, whether it is proprietary to the Company or another company, is not communicated within the Company except to employees and directors who have a need to know such information to perform their responsibilities for the Company. An officer’s, director’s and employee’s obligation to protect confidential information continues after he or she leaves the Company. Unauthorized disclosure of confidential information could cause competitive harm to the Company or its counterparties, collaborators, customers or suppliers and could result in legal liability to you and the Company. Any questions or concerns regarding whether disclosure of Company information is legally mandated should be promptly referred to the Company’s Chief Executive Officer.

 

5. Competition and Fair Dealing

 

Officers, directors and employees should not take unfair advantage of anyone through manipulation, concealment, abuse of privileged information, misrepresentation of material facts or any other unfair-dealing practice. Officers, directors and employees should maintain and protect any intellectual property licensed from licensors with the same care as they employ with regard to Company-developed intellectual property.

 

6. Disclosure

 

The Company strives to ensure that the contents of and the disclosures in the reports and documents that the Company files with the SEC and other public communications shall be full, fair, accurate, timely and understandable in accordance with applicable disclosure standards, including standards of materiality, where appropriate. Each person must:

 

not knowingly misrepresent, or cause others to misrepresent, facts about the Company to others, whether within or outside the Company, including to the Company’s independent registered public accountants, governmental regulators, self-regulating organizations and other governmental officials, as appropriate; and

 

in relation to his or her area of responsibility, properly review and critically analyze proposed disclosure for accuracy and completeness.

 

In addition to the foregoing, the Chief Executive Officer and Chief Financial Officer of the Company and each subsidiary of the Company (or persons performing similar functions), and each other person that typically is involved in the financial reporting of the Company must familiarize himself or herself with the disclosure requirements applicable to the Company as well as the business and financial operations of the Company.

 

Each person must promptly bring to the attention of the Chairman of the Board any information he or she may have concerning (a) significant deficiencies in the design or operation of internal and/or disclosure controls that could adversely affect the Company’s ability to record, process, summarize and report financial data or (b) any fraud that involves management or other employees who have a significant role in the Company’s financial reporting, disclosures or internal controls.

 

7. Compliance

 

It is the Company’s obligation and policy to comply with all applicable governmental laws, rules and regulations. All directors, officers and employees of the Company are expected to understand, respect and comply with all of the laws, regulations, policies and procedures that apply to them in their positions with the Company. Employees are responsible for talking to their supervisors to determine which laws, regulations and Company policies apply to their position and what training is necessary to understand and comply with them.

 

Directors, officers and employees are directed to specific policies and procedures available to persons they supervise.

 

3

 

 

8. Protection and Use of Company Assets

 

Employees should protect the Company’s assets and ensure their efficient use for legitimate business purposes only and not for any personal benefit or the personal benefit of anyone else. Theft, carelessness and waste have a direct impact on the Company’s financial performance. The use of Company funds or assets, whether or not for personal gain, for any unlawful or improper purpose is prohibited. Employees should be aware that Company property includes all data and communications transmitted or received to or by, or contained in, the Company’s electronic or telephonic systems. Company property also includes all written communications. Employees and other users of this property should have no expectation of privacy with respect to these communications and data. Employees may not copy, retrieve, modify or forward copyrighted materials, except with permission or as a single copy to reference only. Transmission of customer information should be encrypted as applicable. To the extent permitted by law, the Company has the ability, and reserves the right, to monitor all electronic and telephonic communication. These communications may also be subject to disclosure to law enforcement or government officials

 

9. Reporting and Accountability

 

The Board is responsible for applying this Code to specific situations in which questions are presented to it and has the authority to interpret this Code in any particular situation. The Company requires that officers, directors and employees disclose any situation that reasonably would be expected to give rise to a conflict of interest. If you suspect that you have a situation that could give rise to a conflict of interest, you must report it in writing to the Chairman of the Board. Any person who becomes aware of any existing or potential breach of this Code is required to notify the Chairman of the Board promptly. Failure to do so is, in and of itself, a breach of this Code.

 

Specifically, each person must:

 

Notify the Chairman of the Board promptly of any existing or potential violation of this Code.

 

Not retaliate against any other person for reports of potential violations that are made in good faith.

 

The Company will follow the following procedures in investigating and enforcing this Code and in reporting on the Code:

 

The Board will take all appropriate action to investigate any breaches reported to it.

 

Upon determination by the Board that a breach has occurred, the Board (by majority decision) will take or authorize such disciplinary or preventive action as it deems appropriate, after consultation with the Company’s General Counsel (or outside counsel), up to and including dismissal or, in the event of criminal or other serious violations of law, notification of the SEC or other appropriate law enforcement authorities.

 

No person following the above procedure shall, as a result of following such procedure, be subject by the Company or any officer or employee thereof to discharge, demotion suspension, threat, harassment or, in any manner, discrimination against such person in terms and conditions of employment.

 

It is Company policy that any officer, director or employee who violates this Code will be subject to appropriate discipline, which may include termination of employment or, in the case of a director, a request that such director resign from the Board of Directors. This determination will be based upon the facts and circumstances of each particular situation. If you are accused of violating this Code, you will be given an opportunity to present your version of the events at issue prior to any determination of appropriate discipline, if any. Officers, directors and employees who violate the law or this Code may expose themselves to substantial civil damages, criminal fines and prison terms. The Company may also face substantial fines and penalties and may incur damage to its reputation and standing in the community. Your conduct as a representative of the Company, if it does not comply with the law or with this Code, can result in serious consequences for both you and the Company.

 

10. Policy Against Retaliation

 

The Company prohibits retaliation against an officer, director or employee who, in good faith, seeks help or reports known or suspected violations. If an officer, director or employee believes that they have been retaliated against, he or she should speak with the Human Resources Director. Any reprisal or retaliation against an employee because the employee, in good faith, sought help or filed a report will be subject to disciplinary action, including potential termination of employment.

 

4

 

 

11. Waivers and Amendments

 

Any waiver (defined below) or an implicit waiver (defined below) from a provision of this Code for the principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions or any amendment (as defined below) to this Code is required to be disclosed in a current report on Form 8-K filed with the SEC. In lieu of filing a current report on Form 8-K to report any such waivers or amendments, the Company may provide such information on its website and if it keeps such information on the website for at least 12 months and discloses the website address as well as any intention to provide such disclosures in this manner in its most recently filed Annual Report on Form 10-K.

 

A “waiver” means the approval by the Company’s Board of a material departure from a provision of the Code. An “implicit waiver” means the Company’s failure to take action within a reasonable period of time regarding a material departure from a provision of the Code that has been made known to an executive officer of the Company. An “amendment” means any amendment to this Code other than minor technical, administrative or other non-substantive amendments hereto.

 

12. Insider Information and Securities Trading

 

The Company’s directors, officers or employees who have access to material, non-public information are not permitted to use that information for share trading purposes or for any purpose unrelated to the Company’s business. It is also against the law to trade or to “tip” others who might make an investment decision based on inside company information. For example, using non-public information to buy or sell the Company shares, options in the Company shares or the shares of any Company supplier, customer or competitor is prohibited. The consequences of insider trading violations can be severe. These rules also apply to the use of material, nonpublic information about other companies (including, for example, our customers, competitors and potential business partners). In addition to directors, officers or employees, these rules apply to such person’s spouse, children, parents and siblings, as well as any other family members living in such person’s home. All of the Company’s directors, officers and employees must familiarize themselves with the Company’s Insider Trading Policy.

 

13. Financial Statements and Other Records

 

All of the Company’s books, records, accounts and financial statements must be maintained in reasonable detail, must appropriately reflect the Company’s transactions and must both conform to applicable legal requirements and to the Company’s system of internal controls. Unrecorded or “off the books” funds or assets should not be maintained unless permitted by applicable law or regulation. All Company records must be complete, accurate and reliable in all material respects.

 

Records should always be retained or destroyed according to the Company’s record retention policies. In accordance with those policies, in the event of litigation or governmental investigation, please consult the board of directors or the Company’s counsel.

 

14. Improper Influence on Conduct of Audits

 

No director or officer, or any other person acting under the direction thereof, shall directly or indirectly take any action to coerce, manipulate, mislead or fraudulently influence any public or certified public accountant engaged in the performance of an audit or review of the financial statements of the Company or take any action that such person knows or should know that if successful could result in rendering the Company’s financial statements materially misleading. Any person who believes such improper influence is being exerted should report such action to such person’s supervisor, or if that is impractical under the circumstances, to any of our directors.

 

5

 

 

Types of conduct that could constitute improper influence include, but are not limited to, directly or indirectly:

 

Offering or paying bribes or other financial incentives, including future employment or contracts for non-audit services;

 

Providing an auditor with an inaccurate or misleading legal analysis;

 

Threatening to cancel or canceling existing non-audit or audit engagements if the auditor objects to the Company’s accounting;

 

Seeking to have a partner removed from the audit engagement because the partner objects to the Company’s accounting;

 

Blackmailing; and

 

Making physical threats. 

 

15. Anti-Corruption Laws

 

The Company complies with the anti-corruption laws of the countries in which it does business, including the U.S. Foreign Corrupt Practices Act (FCPA). Directors, officers and employees will not directly or indirectly give anything of value to government officials, including employees of state-owned enterprises or foreign political candidates. These requirements apply both to Company employees and agents, such as third party sales representatives, no matter where they are doing business. If you are authorized to engage agents, you are responsible for ensuring they are reputable and for obtaining a written agreement to uphold the Company’s standards in this area.

 

16. Violations

 

All directors, officers and employees have a duty to report any known or suspected violation of this Code, including violations of the laws, rules, regulations or policies that apply to the Company. Violation of this Code is grounds for disciplinary action up to and including termination of employment. Such action is in addition to any civil or criminal liability which might be imposed by any court or regulatory agency.

 

17. Gifts and Entertainment

 

The giving and receiving of gifts can be a common business practice. Appropriate business gifts and entertainment are welcome courtesies designed to build relationships and understanding among business partners. Gifts and entertainment, however, should not compromise, or appear to compromise, your ability to make objective and fair business decisions. In addition, it is important to note that the giving and receiving of gifts are subject to a variety of laws, rules and regulations applicable to the Company’s operations. These include, without limitation, laws covering the marketing of products, bribery and kickbacks. You are expected to understand and comply with all laws, rules and regulations that apply to activities you engage in when acting on the Company’s behalf.

 

It is your responsibility to use good judgment in this area. As a general rule, you may give or receive gifts or entertainment to or from collaborators, customers or suppliers only if the gift or entertainment is infrequent, modest, intended to further legitimate business goals, in compliance with applicable law, and provided the gift or entertainment would not be viewed as an inducement to or reward for any particular business decision. All gifts and entertainment expenses should be properly accounted for on expense reports.

 

If you conduct business in other countries, you must be particularly careful that gifts and entertainment are not construed as bribes, kickbacks or other improper payments.

 

You should make every effort to refuse or return a gift that is beyond these permissible guidelines. If it would be inappropriate to refuse a gift or you are unable to return a gift, you should promptly report the gift to your supervisor. Your supervisor will bring the gift to the attention of the Chief Legal Officer, who may require you to donate the gift to an appropriate community organization. If you have any questions about whether it is permissible to accept a gift or something else of value, contact your supervisor or a principal financial officer for additional guidance.

 

Note: Gifts and entertainment may not be offered or exchanged under any circumstances to or with any employees of the United States or any foreign government or state, city, provincial or local governments. If you have any questions about this policy, contact your supervisor or the Company’s Chief Legal Officer for additional guidance.

 

6

 

 

18. Other Policies and Procedures

 

Any other policy or procedure set out by the Company in writing or made generally known to employees, officers or directors of the Company prior to the date hereof or hereafter are separate requirements and remain in full force and effect.

 

19. Inquiries

 

This Code is not intended to be a comprehensive rulebook and cannot address every situation that you may face. If you feel uncomfortable about a situation or have any doubts about whether it is consistent with the Company’s ethical standards, seek help. All inquiries and questions in relation to this Code or its applicability to particular people or situations should be addressed to the Company’s Secretary, or such other compliance officer as shall be designated from time to time by the Company.

 

20. Conclusion

 

This Code contains general guidelines for conducting the business of the Company consistent with the highest standards of business ethics. If you have any questions about these guidelines, please contact your supervisor or the Company’s Chief Legal Officer. The Company expects all of its employees and directors to adhere to these standards.

 

This Code, as applied to the Company’s principal financial officers, shall be our “code of ethics” within the meaning of Section 406 of the Sarbanes-Oxley Act of 2002 and the rules promulgated thereunder.

 

This Code and the matters contained herein are neither a contract of employment nor a guarantee of continuing Company policy. The Company reserves the right to amend, supplement or discontinue this Code and the matters addressed herein, without prior notice, at any time.

 

7

 

 

PROVISIONS FOR CHIEF EXECUTIVE OFFICER AND SENIOR FINANCIAL OFFICERS

 

The Chief Executive Officer and all senior financial officers, including the Chief Financial Officer and principal accounting officer, are bound by the provisions set forth therein relating to ethical conduct, conflicts of interest, and compliance with law. In addition to the Code, the Chief Executive Officer and senior financial officers are subject to the following additional specific policies:

 

1. Act with honesty and integrity, avoiding actual or apparent conflicts between personal, private interests and the interests of the Company, including receiving improper personal benefits as a result of his or her position.

 

2. Disclose to the Board (and the Chief Executive Officer in the case of a senior financial officer) any material transaction or relationship that reasonably could be expected to give rise to a conflict of interest.

 

3. Perform responsibilities with a view to causing periodic reports and documents filed with or submitted to the SEC and all other public communications made by the Company to contain information that is accurate, complete, fair, objective, relevant, timely and understandable, including full review of all annual and quarterly reports.

 

4. Comply with laws, rules and regulations of federal, state and local governments applicable to the Company and with the rules and regulations of private and public regulatory agencies having jurisdiction over the Company.

 

5. Act in good faith, responsibly, with due care, competence and diligence, without misrepresenting or omitting material facts or allowing independent judgment to be compromised or subordinated.

 

6. Respect the confidentiality of information acquired in the course of performance of his or her responsibilities except when authorized or otherwise legally obligated to disclose any such information; not use confidential information acquired in the course of performing his or her responsibilities for personal advantage.

 

7. Share knowledge and maintain skills important and relevant to the needs of the Company, its stockholders and other constituencies and the general public.

 

8. Proactively promote ethical behavior among subordinates and peers in his or her work environment and community.

 

9. Use and control all corporate assets and resources employed by or entrusted to him or her in a responsible manner.

 

10. Not use corporate information, corporate assets, corporate opportunities or his or her position with the Company for personal gain; not compete directly or indirectly with the Company.

 

11. Comply in all respects with the Company’s Code.

 

12. Advance the Company’s legitimate interests when the opportunity arises.

 

The Board will investigate any reported violations and will oversee an appropriate response, including corrective action and preventative measures. Any officer who violates this Code will face appropriate, case specific disciplinary action, which may include demotion or discharge.

 

Any request for a waiver of any provision of this Code must be in writing and addressed to the Chairman of the Board. Any waiver of this Code will be disclosed promptly on Form 8-K or any other means approved by the SEC.

 

It is the policy of the Company that each officer covered by this Code shall acknowledge and certify to the foregoing annually and file a copy of such certification with the Chairman of the Board of Directors.

 

8

 

 

ACKNOWLEDGEMENT

 

I have read and understand the foregoing Code. I hereby certify that I am in compliance with the foregoing Code and I will comply with the Code in the future. I understand that any violation of the Code will subject me to appropriate disciplinary action, which may include demotion or discharge.

 

Dated:   

 

Name:   

 

Signature:   

 

Title:   

 

9

 

Exhibit 23.1

 

 

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the inclusion in this Amendment No. 1 to the Registration Statement on Form S-1 of Innovative Eyewear, Inc. (the “Company”) of our report dated October 12, 2021, related to the financial statements of the Company as of and for the periods ended December 31, 2020 and 2019 and to the reference to us under the heading “Experts” in this Amendment No. 1 to the Registration Statement.

 

 

 

Tampa, Florida

January 10, 2022

 

 

cbh.com

 

 

 

 

Exhibit 99.1

 

INNOVATIVE EYEWEAR, INC.

AUDIT COMMITTEE CHARTER

 

I. Purpose.

 

The purpose of the Audit Committee (the “Committee”) of the Board of Directors (the “Board”) of Innovative Eyewear, Inc. (the “Company”) is to assist the Board with oversight of the Company’s accounting and financial reporting processes and the audit of the Company’s financial statements.

 

The primary role of the Committee is to oversee the Company’s financial reporting and disclosure process. To fulfill this obligation, the Committee relies on: (i) the Company’s named executive officers and their employee designees (referred to herein as “management”) for the preparation and accuracy of the Company’s financial statements; (ii) both management and the Company’s personnel responsible for establishing effective internal controls and procedures to ensure the Company’s compliance with accounting standards, financial reporting procedures and applicable laws and regulations; and (iii) the Company’s independent auditors for an unbiased, diligent audit or review, as applicable, of the Company’s financial statements and the effectiveness of the Company’s internal controls. The members of the Committee are not employees of the Company and are not responsible for conducting the audit or performing other accounting procedures.

 

II. Membership.

 

The Committee shall consist of three or more directors. Each member of the Committee shall be “independent” in accordance with the requirements of Rule 10A-3 of the Securities Exchange Act of 1934 and the rules of the Nasdaq Stock Market. No member of the Committee can have participated in the preparation of the Company’s financial statements at any time during the past three years.

 

Each member of the Committee must be financially literate and able to read and understand fundamental financial statements, including the Company’s balance sheet, income statement and cash flow statement. At least one member of the Committee must have past employment experience in finance or accounting, requisite professional certification in accounting or other comparable experience or background that leads to financial sophistication. At least one member of the Committee must be an “audit committee financial expert” as defined in Item 407(d)(5)(ii) of Regulation S-K. A person who satisfies this definition of audit committee financial expert will also be presumed to have financial sophistication.

 

The members of the Committee shall be appointed by the Board and shall serve for such term or terms as the Board may determine or until earlier resignation, removal or death. The Board may remove any member from the Committee at any time with or without cause.

 

III. Duties and Responsibilities.

 

The Committee shall have the following authority and responsibilities:

 

A. To: (i) select and retain an independent registered public accounting firm to act as the Company’s independent auditors for the purpose of auditing the Company’s annual financial statements, books, records, accounts and internal controls over financial reporting; (ii) set the compensation of the Company’s independent auditors; (iii) oversee the work done by the Company’s independent auditors; and (iv) terminate the Company’s independent auditors, if necessary in the Committee’s determination.

 

 

 

 

B. To select, retain, compensate, oversee and terminate, if necessary, any other registered public accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for the Company.

 

C. To (i) approve all audit engagement fees and terms (with the power to sign any engagement letter providing for the same on behalf of the Company) and (ii) pre-approve all audit and permitted non-audit and tax services that may be provided by the Company’s independent auditors or other registered public accounting firms, and establish policies and procedures for the Committee’s pre-approval of permitted services by the Company’s independent auditors or other registered public accounting firms on an on-going basis.

 

D. At least annually, to obtain and review a report by the Company’s independent auditors that describes: (i) the accounting firm’s internal quality control procedures; (ii) any material issues raised by the most recent internal quality control review, peer review or Public Company Accounting Oversight Board (“PCAOB”) review or inspection of the firm or by any other inquiry or investigation by governmental or professional authorities in the past five years regarding one or more audits carried out by the firm and any steps taken to deal with any such issues; and (iii) all relationships between the firm and the Company; and to discuss with the independent auditors this report and any relationships or services that may impact the objectivity and independence of the auditors.

 

E. At least annually, to evaluate the qualifications, performance and independence of the Company’s independent auditors, including an evaluation of the lead audit partner; and to assure the regular rotation of the lead audit partner at the Company’s independent auditors and consider regular rotation of the accounting firm serving as the Company’s independent auditors.

 

F. To review and discuss with the Company’s independent auditors: (i) the auditors’ responsibilities under generally accepted auditing standards and the responsibilities of management in the audit process; (ii) the overall audit strategy; (iii) the scope and timing of the annual audit; (iv) any significant risks identified during the auditors’ risk assessment procedures; and (v) when completed, the results, including significant findings, of the annual audit.

 

G. To review and discuss with the Company’s independent auditors: (i) all critical accounting policies and practices to be used in the audit; (ii) all alternative treatments of financial information within generally accepted accounting principles (“GAAP”) that have been discussed with management, the ramifications of the use of such alternative treatments and the treatment preferred by the auditors; and (iii) other material written communications between the auditors and management.

 

H. To review and discuss with the Company’s independent auditors and management: (i) any audit problems or difficulties, including difficulties encountered by the Company’s independent auditors during their audit work (such as restrictions on the scope of their activities or their access to information); (ii) any significant disagreements with management; and (iii) management’s response to these problems, difficulties or disagreements; and to resolve any disagreements between the Company’s auditors and management.

 

I. To review with management and the Company’s independent auditors: (i) any major issues regarding accounting principles and financial statement presentation, including any significant changes in the Company’s selection or application of accounting principles; (ii) any significant financial reporting issues and judgments made in connection with the preparation of the Company’s financial statements, including the effects of alternative GAAP methods; and (iii) the effect of regulatory and accounting initiatives and off-balance sheet structures on the Company’s financial statements.

 

2

 

 

J. To inform the Company’s independent auditors as requested as to the Committee’s understanding of the Company’s relationships and transactions with related parties that are significant to the Company; and to review and discuss with the Company’s independent auditors the auditors’ evaluation of the Company’s identification of, accounting for, and disclosure of its relationships and transactions with related parties, including any significant matters arising from the audit regarding the Company’s relationships and transactions with related parties.

 

K. To review with management and the Company’s independent auditors: (i) the adequacy and effectiveness of the Company’s internal controls, including any significant deficiencies or material weaknesses in the design or operation of, and any material changes in, the Company’s internal controls; (ii) any special audit steps adopted in light of any material control deficiencies; (iii) any fraud involving management or other employees with a significant role in such internal controls; (iv) the independent auditors’ attestation (as required) of the report on internal controls and the required management certifications to be included in or attached as exhibits to the Company’s Annual Report on Form 10-K or quarterly report on Form 10-Q, as applicable.

 

L. To review and discuss with the Company’s independent auditors any other matters required to be discussed by applicable requirements of the PCAOB and the Securities and Exchange Commission (“SEC”).

 

M. To review and discuss with the Company’s independent auditors and management the Company’s annual audited financial statements (including the related notes), the form of audit opinion to be issued by the auditors on the financial statements and the disclosure under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” to be included in the Company’s Annual Report on Form 10-K before such Form 10-K is filed, and recommend to the Board whether the audited financial statements should be included in the Company’s Form 10-K and whether the Form 10-K should be filed with the SEC.

 

N. To produce the audit committee report required to be included in the Company’s annual or other proxy statements.

 

O. To review and discuss with the Company’s independent auditors and management the Company’s quarterly financial statements and the disclosure under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” to be included in the Company’s Quarterly Report on Form 10-Q before such Form 10-Q is filed; and to review and discuss the Form 10-Q for filing with the SEC.

 

P. To recommend to the Board policies for the Company’s hiring of employees or former employees of the Company’s independent auditors.

 

Q. To establish and oversee Company procedures for the receipt, retention and treatment of complaints received about the Company regarding accounting, internal accounting controls or auditing matters, or instances of fraud or unlawful conduct, and for the confidential, anonymous submission by Company employees of concerns regarding such matters.

 

R. To review and discuss with management the material risks faced by the Company and the policies, guidelines and process by which management assesses and manages the Company’s risks, including the Company’s major financial risk exposures and the steps management has taken to monitor and control such exposures.

 

3

 

 

S. To oversee the Company’s compliance with applicable laws and regulations and to review and oversee the Company’s policies, procedures and programs designed to promote and monitor such legal and regulatory compliance.

 

T. To review with the Company’s legal counsel, legal and regulatory matters, including legal cases against or regulatory investigations of the Company that could have a significant impact on the Company’s financial statements.

 

U. To review, approve and oversee any transaction between the Company and any related person (as defined in Item 404 of Regulation S-K promulgated by the SEC) and any other potential conflict of interest situations on an ongoing basis, in accordance with Company policies and procedures, and to develop policies and procedures for the Committee’s approval of related party transactions.

 

IV. Outside Advisors.

 

The Committee shall have the authority, in its sole discretion, to retain and obtain the advice and assistance of independent outside counsel and such other advisors as it deems necessary to fulfill its duties and responsibilities under this Charter. The Committee shall set the compensation, and oversee the work, of any outside counsel and other advisors.

 

The Committee shall receive appropriate funding from the Company, as determined by the Committee in its capacity as a committee of the Board, for the payment of compensation to the Company’s independent auditors, any other accounting firm engaged to perform services for the Company, any outside counsel and any other advisors to the Committee.

 

V. Structure and Operations

 

The Board shall designate a member of the Committee as the chairperson. The Committee shall meet at least four (4) times a year at such times and places as it deems necessary to fulfill its responsibilities. The Committee shall report to the Board on its discussions and actions, including any significant issues or concerns that arise at its meetings, and shall make recommendations to the Board as appropriate. The Committee is governed by the same rules regarding meetings (including meetings in person or by telephone or other similar communications equipment), action without meetings, notice, waiver of notice, and quorum and voting requirements as are applicable to the Board as provided for in the Company’s bylaws, as amended and/or restated from time to time.

 

The Committee shall meet separately, and periodically, with management and representatives of the Company’s independent auditors, and shall invite such individuals to its meetings as it deems appropriate, to assist in carrying out its duties and responsibilities. However, the Committee shall meet regularly without such individuals present.

 

The Committee shall review this Charter at least annually and recommend any proposed changes to the Board for approval.

 

4

 

 

VI. Delegation of Authority.

 

The Committee shall have the authority to delegate any of its responsibilities, along with the authority to take action in relation to such responsibilities, to one or more subcommittees as the Committee may deem appropriate in its sole discretion.

 

VII. Performance Evaluation.

 

The Committee shall conduct or otherwise participate in/respond to an annual evaluation of the performance of its duties under this Charter and shall present, or otherwise participate in, the results of the evaluation to the Board. The Committee shall conduct this evaluation in such manner as it deems appropriate.

 

# # #

 

 

5

 

Exhibit 99.2

 

CHARTER OF THE COMPENSATION COMMITTEE

OF THE BOARD OF DIRECTORS

OF INNOVATIVE EYEWEAR, INC.

 

AS ADOPTED [     ], 2022

 

I. Purpose

 

The Compensation Committee (“Committee”) of the Board of Directors (“Board”) of Innovative Eyewear, Inc., a Florida corporation (“Company”), is appointed by the Board to: (a) assist the Board in discharging its responsibilities relating to the compensation of the Company’s directors and executive officers; and (b) produce an annual report on executive officer compensation for inclusion in the Company’s annual proxy statement, in accordance with applicable rules and regulations. The Committee shall undertake those specific duties and responsibilities enumerated below, and such other duties as the Board may from time to time prescribe. All powers of the Committee are subject to the restrictions designated in the Company’s bylaws and by applicable law, each as amended and/or restated from time to time.

 

II. Committee Membership

 

Committee members shall be appointed by the Board and shall serve until their respective successors are duly elected and qualified or until their earlier resignation, disqualification, retirement, death or removal. Committee members may be removed at any time by the Board. Committee members may resign from the Committee at any time without resigning from the Board.

 

The Committee shall consist of no fewer than two (2) members of the Board. Each member of the Committee shall meet the independence requirements of the Nasdaq Stock Market (“Nasdaq”), the definition of a “non-employee director” under Rule 16b-3 under the Securities Exchange Act of 1934, as amended, the requirements of Section 162(m) of the Internal Revenue Code for “outside directors,” and any other applicable regulatory requirements.

 

III. Structure and Meetings

 

The Committee shall conduct its business in accordance with this Charter, the Company’s bylaws (as amended and/or restated from time to time) and any direction by the Board. The Board may appoint a member of the Committee to serve as the chairperson of the Committee (“Chair”); if the Board does not appoint a Chair, the Committee members may designate a Chair by their majority vote. The Chair will set the agenda for Committee meetings and conduct the proceedings of those meetings.

 

The Committee shall meet from time to time at a time and place to be determined by the Chair, with meetings to occur, or actions to be taken by unanimous written consent, when deemed necessary or desirable by the Committee or its Chair. Members of the Committee may participate in a meeting of the Committee by means of conference call or similar communications equipment by means of which all persons participating in the meeting can hear each other, and such participation shall constitute presence in person at such meeting.

 

The Chair will preside at each meeting and will set the agenda of items to be addressed at each meeting. The Chair (or other member designated by the Chair or the Committee in the Chair’s absence) shall regularly report to the full Board on the proceedings and any actions that the Committee takes. The Committee will maintain written minutes of its meetings, which minutes will be maintained with the books and records of the Company.

 

 

 

 

As necessary or desirable, the Chair may invite any director, officer or employee of the Company, or other persons whose advice and counsel are sought by the Committee, to be present at the meetings of the Committee, consistent with the maintenance of confidentiality of compensation discussions. The Company’s Chief Executive Officer (or President, if the President is then serving as the principal executive officer of the Company) (“CEO”) should not be present during voting or deliberations on the CEO’s compensation.

 

IV. Committee Authority and Responsibilities

 

The Committee shall:

 

4.1 Review and approve the Company’s compensation programs and arrangements applicable to its executive officers, including without limitation salary, incentive compensation, equity compensation and perquisite programs, and amounts to be awarded or paid to individual officers under those programs and arrangements, or make recommendations to the Board regarding approval of the same. Without limiting the generality of the foregoing, the Committee shall review and approve all other employment-related contracts, agreements or arrangements between the Company and its officers and all other contracts, agreements or arrangements under which compensatory benefits are awarded or paid to, or earned or received by, the Company’s officers, including, without limitation, employment, severance, change of control and similar agreements or arrangements.

 

4.2 Determine the objectives of the Company’s executive officer compensation programs, identify what the programs are designed to reward, and modify (or recommend that the Board modify) the programs as necessary and consistent with such objectives and intended rewards.

 

4.3 Ensure appropriate corporate performance measures and goals regarding executive officer compensation are set and determine the extent to which they are achieved and any related compensation earned.

 

4.4 Consistent with the foregoing, at least annually review and approve the Company’s goals and objectives relevant to CEO compensation, evaluate the CEO’s performance in light of such goals and objectives, and determine and approve the CEO’s compensation level based on this evaluation. In determining the long-term incentive component of the CEO’s compensation, the Committee will consider the Company’s performance and the value of similar incentive awards received by CEOs at companies of comparable size and comparable industries.

 

4.5 Review and approve any new equity compensation plan or any material change to an existing plan where stockholder approval has not been obtained.

 

4.6 Review and approve any stock option award or any other type of equity-based or equity-linked award as may be required for complying with any tax, securities, or other regulatory (including Nasdaq) requirement, or otherwise determined to be appropriate or desirable by the Committee or Board.

 

4.7 If required, review and discuss with the Company’s named executive officers and their employee designees (referred to herein as “management”) the “Compensation Discussion and Analysis” required to be included in the Company’s annual proxy statement or Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “Commission”), and recommend to the Board whether to include such “Compensation Discussion and Analysis” in such proxy statement or annual report.

  

2

 

 

4.8 Produce a Committee report on executive officer compensation, as required to be included in the Company’s annual proxy statement or Annual Report on Form 10-K filed with the Commission.

 

4.9 Review and discuss any compensation-related disclosures that may be required in the Company’s annual proxy statement or Annual Report on Form 10-K regarding such risks.

 

4.10 Oversee the Company’s submissions to a stockholder vote on executive compensation matters, including advisory votes on executive compensation and the frequency of such votes, incentive and other executive compensation plans, and amendments to such plans. Review the results of stockholder votes on executive compensation matters and to the extent the Committee determines it appropriate to do so, take such results into consideration in connection with the review and approval of executive officers compensation. Discuss with management the appropriate engagement with stockholders and proxy advisory firms in response to such votes.

 

4.11 Perform such other functions and have such other powers consistent with this Charter, the Company’s bylaws and applicable law as the Committee or the Board may deem appropriate.

 

V. Performance Evaluation

 

The Committee shall annually review and assess the adequacy of this Charter and recommend any proposed changes to the Board for approval. The Committee shall also perform an annual evaluation of its own performance, which shall compare the performance of the Committee with the requirements of this Charter. The performance evaluation by the Committee shall be conducted in such manner as the Committee deems appropriate. The report to the Board may take the form of an oral report by the Chair or any other member of the Committee designated by the Committee to make this report.

 

VI. Committee Resources; Assessing Advisor Independence

 

The Committee shall have the resources and authority appropriate to discharge its duties and responsibilities, including the authority to select, retain and terminate independent legal counsel and other experts or consultants, as it deems appropriate, without seeking approval of the Board or management, including the authority to approve the fees payable to such counsel, experts or consultants and any other term of retention. The Committee also shall have the sole authority to retain and and/or replace, as needed, compensation consultants to provide independent advice to the Committee, and the sole authority to approve such consultants’ fees and other terms and conditions of retention. The Company shall provide for appropriate funding for the payment of administrative expenses of the Committee that are necessary or appropriate in carrying out its duties. The Committee may select a compensation consultant, legal counsel or other adviser to the Committee only after taking into consideration all factors relevant to that person’s independence from management, including the following:

 

6.1 The provision of other services to the Company by the person that employs the compensation consultant, legal counsel or other adviser;

 

6.2 The amount of fees received from the Company by the person that employs the compensation consultant, legal counsel or other adviser, as a percentage of the total revenue of the person that employs the compensation consultant, legal counsel or other adviser;

 

3

 

 

6.3 The policies and procedures of the person that employs the compensation consultant, legal counsel or other adviser that are designed to prevent conflicts of interest;

 

6.4 Any business or personal relationship of the compensation consultant, legal counsel or other adviser with a member of the Committee;

 

6.5 Any securities of the Company owned by the compensation consultant, legal counsel or other adviser; and

 

6.6 Any business or personal relationship of the compensation consultant, legal counsel, other adviser or the person employing the adviser with an executive officer of the Company.

 

The Committee shall conduct the independence assessment with respect to any compensation consultant, legal counsel or other adviser that provides advice to the Committee, other than: (i) in-house legal counsel; and (ii) any compensation consultant, legal counsel or other adviser whose role is limited to the following activities for which no disclosure would be required under Item 407(e)(3)(iii) of Regulation S-K promulgated by the Commission: consulting on any broad-based plan that does not discriminate in scope, terms, or operation, in favor of executive officers or directors of the Company, and that is available generally to all salaried employees; or providing information that either is not customized for the Company or that is customized based on parameters that are not developed by the compensation adviser, and about which the compensation advisor does not provide advice.

 

Nothing herein requires a compensation consultant, legal counsel or other compensation adviser to be independent, only that the Committee consider the enumerated independence factors before selecting or receiving advice from a compensation consultant, legal counsel or other compensation adviser. The Committee may select or receive advice from any compensation consultant, legal counsel or other compensation adviser it prefers, including ones that are not independent, after considering the six independence factors outlined above.

 

Nothing herein shall be construed: (1) to require the Committee to implement or act consistently with the advice or recommendations of the compensation consultant, legal counsel or other adviser to the Committee; or (2) to affect the ability or obligation of the Committee to exercise its own judgment in fulfillment of its duties.

 

VII. Impact of Charter

 

This Charter does not change or augment the obligations of the Company, the Board, the Committee or its directors or management under the federal or state securities laws or create new standards for determining whether the Board, the Committee or the Company’s directors or management have fulfilled their duties, including fiduciary duties, under applicable law.

 

VIII. Disclosure of Charter

 

This Charter will be made available on the Company’s website.

 

# # #

 

4

 

 

Exhibit 99.3

 

CHARTER OF THE NOMINATING AND CORPORATE GOVERNANCE COMMITTEE OF THE BOARD OF DIRECTORS OF

INNOVATIVE EYEWEAR, INC.

 

ADOPTED: [ ], 2022

 

I. Authority and Purpose

 

The Nominating and Corporate Governance Committee (“Committee”) of the Board of Directors (“Board”) of Innovative Eyewear, Inc., a Florida corporation (the “Company”), is appointed by the Board to carry out the responsibilities delegated by the Board relating to the Company’s director nominations process and procedures, developing and maintaining the Company’s corporate governance policies and any related matters required by the federal securities laws. The Committee shall undertake those specific duties and responsibilities listed below and such other duties as the Board may from time to time prescribe. All powers of the Committee are subject to the restrictions designated in the Company’s bylaws and by applicable law, each as amended and/or restated from time to time.

 

II. Membership

 

A. The Committee shall consist of three (3) or more directors serving on the Board. A majority of the members of the Committee shall be “independent” as defined under the rules of the U.S. Securities and Exchange Commission, the NASDAQ Stock Market or any other securities exchange on which any of the Company’s securities are listed.

 

B. The members of the Committee shall be appointed by the Board from time to time. The members of the Committee shall serve for such term or terms as the Board may determine or until earlier resignation, death or other termination of service on the Board. The Board may remove any member from the Committee at any time with or without cause.

 

III. Duties, Authority and Responsibilities

 

The Committee shall have the following authority and responsibilities:

 

A. To determine the qualifications, qualities, skills, and other expertise required to be a director and to develop, and recommend to the Board for its approval, criteria to be considered in selecting nominees for director, which criteria shall include diversity on the Board (the “Director Criteria”).

 

B. To identify and screen individuals qualified to become members of the Board, consistent with the Director Criteria. The Committee shall consider any nominations of director candidates validly made by Company stockholders in accordance with applicable laws, rules and regulations and the provisions of the Company’s charter documents.

 

C. To select and approve the nominees for director to be submitted to a stockholder vote at each annual meeting of stockholders, including, without limitation, reviewing and evaluating the performance of incumbent directors whose term of office is scheduled to expire at the next annual meeting of shareholders.

 

D. To review the structure and duties of the Board’s committees (including monitoring the functions and operations of all Board committees) and to make recommendations to the Board as to which directors should serve on such committees.

 

 

 

 

E. If a vacancy on the Board and/or any Board committee occurs, to identify and recommend to the Board candidates to fill such vacancy either by election by stockholders or appointment by the Board.

 

F. To assess actual or potential conflicts of interest regarding Board members, candidates for service on the Board and the Company’s officers and employees, including, without limitation, whether such conflicts would impair the independence of the subject director or director candidate.

 

G. To assess (in conjunction with the Audit Committee of the Board as required or appropriate) related party transactions involving the Company and any director, officer or employee of the Company.

 

H. To oversee the annual board evaluation process.

 

I. To develop and monitor the Board’s succession plans for the Company’s senior executive officers.

 

J. To oversee the diversity of the members of the Board.

 

K. To annually review and recommend changes to this Charter for consideration by the full Board.

 

L. To ensure directors are properly on-boarded through an orientation program.

 

M. To review and discuss with management the Company’s required or other public disclosure regarding the operations of the Committee and director independence, and to recommend that this disclosure be, included in the Company’s proxy statement or annual report on Form 10-K, as applicable.

 

N. To monitor compliance with the Company’s Code of Ethics (the “Code”), to investigate any alleged breach or violation of the Code and to enforce the provisions of the Code.

 

O. To take on any other matters and take on any actions that may, from time to time, be delegated to the Committee by the Board.

 

IV. Outside Advisors

 

The Committee shall have the authority, in its sole discretion, to select, retain and obtain the advice of a director search firm as necessary to assist with the execution of its duties and responsibilities as set forth in this Charter. The Committee shall set the compensation, and oversee the work, of the director search firm. The Committee shall have the authority, in its sole discretion, to retain and obtain the advice and assistance of outside legal counsel and such other advisors as it deems necessary to fulfill its duties and responsibilities under this Charter. The Committee shall set the compensation, and oversee the work, of its outside legal counsel and other advisors. The Committee shall receive appropriate funding from the Company, as determined by the Committee in its capacity as a committee of the Board, for the payment of compensation to its outside consultants, legal counsel and any other advisors.

 

V. Structure and Operations

 

A. The Board shall designate a member of the Committee as the Chairperson. The Committee shall meet at least two (2) times a year at such times and places as it deems necessary to fulfill its responsibilities. The Committee shall report regularly to the Board regarding its actions and make recommendations to the Board as appropriate. The Committee is governed by the same rules regarding meetings (including meetings in person or by telephone or other similar communications equipment), action without meetings, notice, waiver of notice, and quorum and voting requirements as are applicable to the Board.

 

2

 

 

B. A majority of the membership of the Committee shall constitute a quorum, and all actions of the Committee shall require the affirmative vote of a majority of the membership of the Committee. Committee members shall not simultaneously serve on more than two other public companies.

 

C. The Committee shall have the authority to conduct or authorize investigations into any matter within the scope of its responsibilities as it shall deem appropriate, including the authority to request any director, officer, employee or advisor of the Company, or other persons whose advice and counsel are sought by the Committee, to meet with the Committee or any advisors engaged by the Committee.

 

D. The Committee shall review this Charter at least annually and recommend any proposed changes to the Board for approval.

 

VI. Delegation of Authority

 

The Committee shall have the authority to delegate any of its responsibilities, along with the authority to take action in relation to such responsibilities, to one or more subcommittees as the Committee may deem appropriate in its sole discretion.

 

VII. Impact of Charter

 

This Charter does not change or augment the obligations of the Company, the Board, the Committee or its directors or management under the federal or state securities laws or create new standards for determining whether the Board, the Committee or the Company’s directors or management have fulfilled their duties, including fiduciary duties, under applicable law.

 

VIII. Performance Evaluation

 

The Committee shall annually review and assess the adequacy of this Charter and recommend any proposed changes to the Board for approval. The Committee shall also perform an annual evaluation of its own performance, which shall compare the performance of the Committee with the requirements of this Charter. The performance evaluation by the Committee shall be conducted in such manner as the Committee deems appropriate. The report to the Board may take the form of an oral report by the Chair or any other member of the Committee designated by the Committee to make this report.

 

IX. Delegation of Duties

 

In fulfilling its responsibilities, the Committee shall be entitled to delegate any or all of its responsibilities to a subcommittee of the Committee, to the extent consistent with the Company’s certificate of incorporation, bylaws and applicable law and rules of markets in which the Company’s securities then trade.

 

X. Disclosure of Charter

 

This Charter will be made available on the Company's website.

 

# # #

  

3